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ABSTRACT
Cells communicate to drive all biological processes during organismal
development, homeostasis, and disease. Communication, or signaling, is carried out
through an orchestration of complex sequential molecular interactions. A signal is
typically initiated by an extracellular cue binding to a receptor on the cell membrane,
which induces an intracellular response, resulting ultimately in cellular phenotypes such
as growth, proliferation, migration, apoptosis or survival. Adaptor proteins are critical
to signal transduction, as they facilitate the formation of protein complexes that
transduce signals. CT10 regulator of kinase (CRK) and CRK-like (CRKL) form a
family of adaptors that facilitate complex formation during developmental signaling,
bridging phosphorylated tyrosine residues on membrane localized proteins with
downstream signaling molecules. We previously identified Discoidin, CUB, and LCCL
domain-containing 2 (DCBLD2), a protein with similar structure to the neuronal
guidance receptors neuropilins, as an interactor of CRK adaptors. DCBLD1 and
DCBLD2 constitute a family of type-I transmembrane orphan receptors that play roles
in development and cancer. How DCBLD proteins modulate cellular processes
including proliferation, migration, and growth on a molecular scale are unknown.
This dissertation begins by further characterizing the interactions between CRK
adaptors and DCBLD family members. We identify the cytoplasmic tyrosine kinases
FYN and ABL as regulators of the DCBLD/CRKL interaction. FYN- and ABL-driven
DCBLD1 and 2 tyrosine, serine, and threonine phosphorylation sites and the resulting
changes in protein interactors are quantified with multiple quantitative mass
spectrometry approaches.
Next, we identify a mechanism by which DCBLD2 serves as a scaffold for
signaling pathways initiated by the receptor tyrosine kinases PDGFRβ and insulin
receptor (INSR), and alters downstream signaling events and cell proliferation. We find
that activation of both receptors induces DCBLD2 tyrosine phosphorylation at multiple
sites including CRKL binding sites, and demonstrate direct phosphorylation of
DCBLD2 by PDGFRβ and ABL.
Finally, we describe an original way to predict how bridging molecules find
targets to facilitate signaling complex formation. This “in silico proteomics” approach
uses publicly available webtools to predict and prioritize CRK adaptor interactions. Our
approach identified known CRK-interactors, including DCBLD2, as well as many
novel interactors, several of which we have biochemically validated. We further
extended our approach to incorporate any modified motif-driven binding interaction to
empower the signaling community in their studies of a wide array of signaling systems.
Together, this dissertation expands our understanding of cellular signaling
mechanisms by delineating DCBLD receptor signaling and by predicting and
characterizing many novel signaling interactions dependent on post-translationally
modified motifs, particularly those involving the critical and versatile CRK family
adaptors.
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CHAPTER 1: THE DCBLD RECEPTOR FAMILY: EMERGING SIGNALING
ROLES IN DEVELOPMENT, HOMEOSTASIS AND DISEASE
1.1. Dissertation Overview
This dissertation begins with a seminal review of the discoidin, CUB, and
LCCL domain-containing (DCBLD) receptor family in Chapter 1, which was published
in Biochemical Journal in 2019 (Schmoker, Ebert et al. 2019). This review is preceded
by a short section (1.2) that provides background on our interest in studying these
proteins. In addition to providing a comprehensive description of the history and known
function of DCBLD proteins, the review covers some of the published empirical data
presented in later research Chapters 2 and 5 (Schmoker, Weinert et al. 2017, Schmoker,
Driscoll et al. 2018).
Research Chapters 2-4 focus on characterizing the DCBLD/CRKL-SH2
interaction, as well as DCBLD signaling in general. Chapter 2 characterizes the
interaction between the CT10 regulator of kinase-like (CRKL) SRC homology 2 (SH2)
domain and DCBLD1 and DCBLD2, describing the identification of tyrosine kinases
FYN and ABL as important regulators of these interactions. Chapter 3 presents a
quantitative phosphorylation site analysis of the full intracellular domains of DCBLD1
and 2 using mass spectrometry, mapping serine, threonine, and tyrosine
phosphorylation sites regulated by FYN and ABL. In addition, the general interactome
as well as FYN- and ABL-regulated interactors of DCBLD proteins are identified
through a quantitative proteomics screen. One class of proteins identified as ABL-
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regulated DCBLD interactors, 14-3-3 proteins, are shown to directly interact with
DCBLD1 and DCBLD2. Chapter 4 characterizes the interface between DCBLD2 and
the receptor tyrosine kinases (RTKs) platelet-derived growth factor receptor β
(PDGFRβ) and insulin receptor (INSR), monitoring DCBLD2 tyrosine phosphorylation
downstream of RTK/ligand interactions, as well as the effect of high DCBLD2
expression on downstream MAPK phosphorylation and cell proliferation.
Research Chapter 5 returns to the original proteomics screen that identified the
DCBLD2/CRKL-SH2 interaction and describes a bioinformatics-based approach to
predict and prioritize protein-protein interactions dependent on post-translationally
modified motifs. This in silico screen overcomes certain caveats of functional
proteomics screens and can serve as a complement to functional proteomics screens.
Chapter 6 is composed of a discussion of the work presented in this dissertation,
synthesizing our current knowledge of DCBLD signaling, both in the context of CRK
adaptor signaling and outside the realm of CRK signaling.
The appendix contains an article describing a comparison of CRK- and CRKLSH2 interactors in a neuronal cell line via functional proteomics. This research was
conducted in collaboration with 12 undergraduate students in an advanced biology
laboratory course at the University of Vermont in 2019.
A few supplementary figures and tables are included in the appendix. Large
supplementary files are available on the publisher’s website for published chapters or
will be provided upon request.
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1.2. The CRK family of adaptor proteins
The CT10 regulator of kinase (CRK) family of signaling adaptors are encoded
by two genes and are composed of CRKI, CRKII (arising from alternative splicing of
CRK) and CRK-like (CRKL). CRK and CRKL were first discovered from the related
viral oncogene v-CRK found in an avian sarcoma virus (Mayer, Hamaguchi et al.
1988). v-CRK possesses domains that are homologous to domains originally identified
in the non-receptor tyrosine kinase SRC, and include one SRC homology 2 (SH2)
domain, which binds phosphorylated tyrosine residues in YXXP motifs, and one SH3
domain, which binds proline-rich motifs, most strongly within PXXPXK motifs. The
oncogene is a fusion between the viral gag protein, which localizes v-CRK
constitutively to the membrane, with an SH2 and SH3 domain (Figure 1).
gag

SH2

SH3 SH3
v-Crk
Crk I
Crk II

CrkL

Figure 1. Domain structure of CRK adaptor proteins.
Common protein interacting domains indicated. Regulatory tyrosines in CRKII and CRKL, Y221
and Y207, are in YXXP motifs and engage the SH2 domain intramolecularly.

Of the CRK family of adaptors normally expressed in metazoan cells, CRKI is
most similar in structure to v-CRK (Figure 1). CRKI is composed of one SH2 and one
3

SH3 domain and, like v-CRK, has oncogenic properties (Sriram and Birge 2010).
CRKII and CRKL both possess a second C-terminal SH3 domain (Figure 1), which is
not thought to bind cellular effector proteins, and may serve to promote
homodimerization (Harkiolaki, Gilbert et al. 2006). The linker sequence between these
two SH3 domains contains a regulatory tyrosine (Figure 1) that, when phosphorylated,
engages the SH2 domain intramolecularly, preventing CRKII and CRKL from binding
pYXXP-containing interactors (Takino, Tamura et al. 2003). For the remainder of this
dissertation, all references to the protein CRK are referring to CRKII for simplicity.
As adaptor proteins, CRK family members facilitate protein complex formation
at hubs of cellular signaling in a variety of cell processes fundamental to both
development and cancer, including cell migration, proliferation, growth, and survival
(Birge, Kalodimos et al. 2009). Once a YXXP tyrosine residue becomes
phosphorylated at or near the membrane, CRK adaptors are recruited, transporting
constitutively bound SH3 cargo to the membrane. These cargo proteins are commonly
guanine nucleotide exchange factors (GEFs), such as C3G, SOS, or DOCK1 (Feller
2001), and their localization to the membrane activates signaling downstream of the
associated GTPase. The specific cargo proteins brought to the membrane depend
largely on the expression of various CRK/CRKL SH3 interactors within a given cell
type at a given time.
One such pathway is activated by the secreted protein Reelin in migrating
neurons in the developing brain (Figure 2A) (Park and Curran 2008, Feng and Cooper
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2009). Reelin binds to its receptors ApoER2 or VLDLR on the surface of migrating
neurons, clustering receptors and activating constitutively bound SRC family kinases
(SFKs) inside the cell. Active SFKs phosphorylate YXXP tyrosine residues on the
receptor bound scaffolding protein disabled-1 (DAB1), which recruits CRK or CRKL.
C3G is a dominant SH3-bound cargo brought to the DAB1 scaffold, the small G protein
RAP1 and its downstream signaling. Conditional loss of CRK and CRKL in the
developing nervous system leads to phenotypes similar to the loss of Reelin, Reelin
receptors, or DAB1 (Falconer 1951, Howell, Hawkes et al. 1997, Trommsdorff,
Gotthardt et al. 1999, Yip, Kronstadt‐O'Brien et al. 2007).
CRK family members can also be involved in RTK signaling (Figure 2B)
(Birge, Kalodimos et al. 2009). A ligand bound to the extracellular domain of a RTK
dimerizes multiple RTK molecules, inducing transphosphorylation of the kinase within
the activation loop. The RTK can then either directly or indirectly, through the
activation of downstream tyrosine kinases, such as SFKs or ABL, phosphorylate
tyrosine residues within YXXP motifs on the receptor itself or nearby proteins, leading
to the membrane recruitment of CRK/CRKL complexes.
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Reelin signaling
A
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RTK signaling

C Focal adhesion dynamics
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Actin
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Figure 2. Signaling mechanisms involving CRK adaptor proteins.
A) CRK adaptors in Reelin signaling in the developing brain B) Receptor tyrosine kinase (RTK)
signaling C) CRK adaptors in focal adhesion dynamics.

CRK and CRKL are also important regulators of focal adhesion dynamics
(Figure 2C) (Iwahara, Akagi et al. 2004, Antoku and Mayer 2009, Birge, Kalodimos et
al. 2009). CRK adaptors are recruited to focal adhesion complexes via YXXP motifs
phosphorylated by SFKs and focal adhesion kinase (FAK) on the scaffolding protein
CAS (also BCAR1). Notably, CAS possesses 16 YXXP motifs that could potentially
become phosphorylated and recruit multiple CRK/CRKL complexes. This could serve
to either to rapidly maximize cellular phenotypes downstream of a particular GTPase, if
all recruited CRK/CRKL complexes bring the same SH3 cargo, or to diversify
signaling, based on the SH3 interactors expressed in a particular cell type at a particular
time.
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Since the discovery of v-CRK, approximately 25 proteins have been identified
as pYXXP-dependent interactors of the CRK family of adaptors (Table 9). However,
there are many reasons to hypothesize that there exist many CRK- and CRKL-SH2
domain interactors that have not yet been identified. First is the ubiquitous expression
of CRK adaptors and their diverse signaling roles. Second is the abundance of YXXP
motifs. Scansite 4.0 (Obenauer, Cantley et al. 2003) currently lists 107,843 proteins in
the human Ensembl database (which includes isoforms including splice variants),
within which 60,406 YXXP sites are found. Lastly, PhosphoSitePlus
(phosphositeplus.org, (Hornbeck, Zhang et al. 2014)) has curated over 27,000 YXXP
motifs which have been experimentally shown to be phosphorylated on tyrosine across
model mammals. For these reasons, a former undergraduate student in the lab
conducted a proteomics screen that aimed to identify SFK-driven interactors of the
CRKL-SH2 domain in 293 cells. In addition to the known CRKL-SH2 interactor CAS,
a novel SFK-dependent interactor, DCBLD2 was identified. Like CAS, DCBLD2
possesses an enrichment of YXXP motifs within a disordered scaffolding region on its
intracellular domain. DCBLD2 has similar extracellular domain structure to
neuropilins, which are important co-receptors for class III semaphorins and VEGF in
neuronal and endothelial cell migration (Neufeld, Cohen et al. 2002). For these reasons,
we investigated the DCBLD2/CRKL-SH2 in a series of studies outlined in subsequent
research chapters. The following review article is a seminal review of DCBLD family
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members, synthesizing the field’s understanding of DCBLD function at the molecular
level as well as the cellular and organismal phenotypic level in 2019.
1.3. Abstract
The discoidin, CUB, and LCCL domain-containing (DCBLD) receptor family is
composed of the type-I transmembrane proteins DCBLD1 and DCBLD2 (also ESDN
and CLCP1). These proteins are highly conserved across vertebrates and possess
similar domain structure to that of neuropilins, which act as critical co-receptors in
developmental processes. Although DCBLD1 remains largely uncharacterized, the
functional and mechanistic roles of DCBLD2 are emerging. This review provides a
comprehensive discussion of this presumed receptor family, ranging from structural and
signaling aspects to their associations with cancer, physiology, and development.
1.4. Abbreviations
ADAM, a disintegrin and metalloprotease; CAEC, coronary artery endotheial
cell; CASMC, coronary artery smooth muscle cell; CLCP1, CUB, LCCL-homology,
and coagulation factor V/VIII-homology domains 1; CRK(L), CT10 regulator of
kinase(-like); CUB, complement C1r/C1s, Uegf, and the Bmp1; DCBLD1/2, discoidin,
CUB, and LCCL domain-containing 1/2; EC, endothelial cell; EGF, epithelial growth
factor; EGFR, epithelial growth factor receptor; ER, endoplasmic reticulum; ESDN,
endothelial smooth muscle cell-derived neuropilin-like; HEK, human embryonic
kidney; HGF, hepatocyte growth factor; HUVEC, human umbilical vein endothelial
cell; IGF, insulin-like growth factor; IGFR, insulin-like growth factor receptor; IR,
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insulin receptor; ISV, intersegmental vessel; LCCL, Limulus clotting factor C, Coch5b2, and Lgl1; MO, morpholino; NFκB, nuclear factor kappa B; NT5E, 50nucleosidase ecto; PDGF, platelet-derived growth factor; PDGFR, platelet-derived
growth factor receptor; PPARγ, peroxisome proliferator-activated receptor gamma;
RGC, retinal ganglion cell; RHBDL2/4, Rhomboid-related protein 2/4; RTK, Receptor
tyrosine kinase; SEMA4B, Semaphorin 4B; SFK, SRC family kinase; SH2, SRC
Homology 2; TM, transmembrane; TNFα, tumor necrosis factor alpha; VEGF, vascular
endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VSMC,
vascular smooth muscle cell; WT, wild type.
1.5. Introduction: cloning and early work
The discoidin, CUB, and LCCL domain-containing (DCBLD) receptor family is
comprised of two paralogous type-I transmembrane proteins, DCBLD1 and DCBLD2,
which are conserved across vertebrates. DCBLD2 was first characterized in two
separate cloning experiments almost 20 years ago (Kobuke, Furukawa et al. 2001,
Koshikawa, Osada et al. 2002), however, the function of the DCBLD family is not yet
fully delineated. To date, DCBLD2, also endothelial and smooth muscle cell derived
neuropilin-like protein (ESDN) and CUB, LCCL-homology, and coagulation factor
V/VIII-homology domains protein 1 (CLCP1), is the better-studied family member and,
necessarily, will be the primary focus of the functional and mechanistic discussion
herein. This review synthesizes the current understanding of the DCBLD protein family
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and offers interpretations of the complexities concerning the functional biology and
mechanistic signaling these proteins have been observed to modulate.
Kobuke, et al. were the first to describe cloning of the novel cDNA ESDN
(DCBLD2) from human, mouse, and rat coronary arterial endothelial and smooth
muscle cells (CAECs and CASMCs) using a signal sequence trap method in yeast
(Kobuke, Furukawa et al. 2001). They were interested in characterizing novel proteins
that entered the secretory pathway of CAECs and CASMCs and identified ESDN,
among other novel transmembrane and secreted proteins. Further analysis in cultured
vascular smooth muscle cells (VSMCs) revealed a robust upregulation of ESDN mRNA
in response to stimulation with the homodimeric BB isoform of the platelet-derived
growth factor (PDGF-BB) and, to a lesser degree, with fetal calf serum (Kobuke,
Furukawa et al. 2001), which suggested that this protein may play a role in cell growth
and proliferative processes.
Shortly thereafter, Koshikawa, et al. cloned a cDNA they named CLCP1
(DCBLD2) from highly metastatic lung cancer cells (Koshikawa, Osada et al. 2002).
They first identified upregulation of the gene at the RNA level in a highly metastatic
lung cancer cell line (LNM35) relative to a low-metastatic clone (N15) of the LNM35
parental line. Additionally, they identified increased CLCP1 expression in several
clinical lung cancer cases, with particularly strong expression in lymph node metastases
in comparison to normal tissue (Koshikawa, Osada et al. 2002). This group went on to
look at possible extracellular cues important in the metastatic abilities of LNM35 cells
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using a phage display assay and identified a binding peptide with homology to a portion
of the semaphorin domain of SEMA4B (Nagai, Sugito et al. 2007). The authors
hypothesized that the extracellular domains of CLCP1 and SEMA4B could interact and
that together they might modulate tumor progression (Nagai, Sugito et al. 2007). They
demonstrated an interaction between CLCP1 and both SEMA4B-Fc and full-length
SEMA4B by co-immunoprecipitation, and observed an increase in CLCP1
ubiquitylation and a decrease in fully modified CLCP1 levels induced by SEMA4B-Fc
co-expression (Nagai, Sugito et al. 2007).
This early work set the foundation for investigations into the functional and
mechanistic roles of DCBLD2 (Sadeghi, Esmailzadeh et al. 2007, Aten, Redmond et al.
2013, Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Li, Jung et al. 2016, Schmoker,
Weinert et al. 2017). The observed interaction with SEMA4B, which serves as a local
repulsive cue in axon guidance and vascular development, presented the possibility that
DCBLD2 might be involved in neuronal pathfinding and angiogenic processes, as well
as tumorigenesis and the progression of certain cancers.
1.6. Structural features and conservation
DCBLD1 and DCBLD2 amino acid sequences are highly conserved across
vertebrates (Figure 3A,B and Figure 4A,B) (Apweiler, Bairoch et al. 2004, Larkin,
Blackshields et al. 2007, Goujon, McWilliam et al. 2010). Presumed DCBLD homologs
in a handful of invertebrates have been curated in the Uniprot (uniprot.org) and NCBI
(ncbi.nlm.nih.gov) protein databases (Apweiler, Bairoch et al. 2004, Geer, Marchler-
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Bauer et al. 2009), although the length and domain structure of these proteins deviate
substantially from vertebrate sequences (Table 1). Many of the invertebrate sequences
do not possess the extracellular domains or the transmembrane region common to
canonical vertebrate sequences, suggesting that DCBLD1/2 vertebrate function may not
be conserved in these species.
Table 1. Invertebrate DCBLD-related sequences.
Curated by NCBI (ncbi.nlm.nih.gov) (Geer, Marchler-Bauer et al. 2009) and Uniprot (uniprot.org)
(Apweiler, Bairoch et al. 2004).

Protein
length (AA)

Signal
peptide

Domains

Status

48

-

FV/FVIII

fragment

Stylophora pistillata

265

yes

FV/FVIII

complete

DCBLD2

Stylophora pistillata

583

-

2 x FV/FVIII, SEUL-type lectin

complete

DCBLD2

Exaiptasia pallida

165

-

-

complete

KXJ07036

DCBLD2

Exaiptasia pallida

170

-

-

complete

A0A0A9XIF2

JAG19759

DCBLD2

Lygus hesperus

149

-

-

fragment

F7BAJ6

-

uncharacterized
protein

Ciona intestinalis

799

yes

CUB, LCCL, FV/FVIII, TM

complete

A0A1W2W0D7

-

DCBLD2

Ciona intestinalis

1018

yes

CUB, LCCL, FV/FVIII, TM

complete

Uniprot ID

GeneBank ID

Gene Name

Invertebrate Species

A0A2B4R494

PFX11619

DCBLD1

Stylophora pistillata

A0A2B4RZ56

PFX21608

DCBLD2

A0A2B4R6B1

PFX13181

-

KXJ17924

-

Full-length human sequences of DCBLD1 and DCBLD2 span 715 and 775
amino acids, respectively. Each family member possesses a signal sequence, followed
by CUB, LCCL, and Coagulation Factor V/VIII type-C (also Discoidin) domains
(Figure 3C and Figure 4C) (Apweiler, Bairoch et al. 2004, Nielsen 2017). A single-pass
transmembrane region precedes the intracellular C-terminal scaffolding domain.
Although the intracellular region does not possess any currently described modular
domains, it contains several phosphorylation, acetylation, and ubiquitylation sites
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(Figure 5) as well as SH2 domain-binding motifs (Aten, Redmond et al. 2013,
Schmoker, Weinert et al. 2017). DCBLD domain structure closely resembles that of
neuropilins, transmembrane proteins that possess two CUB and discoidin domains, and
act as co-receptors for class 3 semaphorins and growth factors in axon guidance and
angiogenesis (Nakamura and Goshima 2002, Geretti, Shimizu et al. 2008).
Conservation of DCBLD1 and DCBLD2 domain structure in canonical and
isoformic protein products is shown across representative vertebrates in Figure 3C and
Figure 4C. The human DCBLD2 signal peptide is composed of 66 amino acids and is
the longest signal sequence in the human proteome (Resch, Hiss et al. 2011). Resch, et
al. characterized distinct domains within the DCBLD2 signal peptide that exhibit
different functionality: a N-terminal domain, a transition region, and a C-terminal
domain. The C-domain acts as a fully functional signal peptide, possessing the
characteristic sequence of positively-charged amino acids followed by a hydrophobic
stretch and a polar C-terminus, and alone is a sufficient target to the secretory pathway
(Resch, Hiss et al. 2011). Interestingly, the N-domain, in the absence of its C-terminal
region, targets proteins to the mitochondria. It remains unknown whether the N-domain
is biologically cleaved, thereby freeing it for alternative functions, or if in some cases it
shuttles DCBLD2 to the mitochondria. The N-domain is also required for
glycosylation, suggesting that it plays a role in DCBLD2 maturation (Resch, Hiss et al.
2011). Although non-mammlian vertebrates possess shorter signal sequences with
lengths closer to the average signal peptide length (22 amino acids in humans (Resch,
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Hiss et al. 2011)), mammalian DCBLD2 signal sequences are remarkably long and
highly conserved (Figure 4A,C). This would suggest that the mammalian signal peptide
may have a unique functionality that has not yet been fully characterized.
Following the signal peptide are the CUB and the LCCL domains, which are
conserved in canonical vertebrate sequences (Figure 3C and Figure 4C). CUB domains
(~110 AAs) are represented in many developmentally-regulated extracellular and
plasma membrane-associated proteins, including components of the complement
cascade, adhesive molecules, proteases, and certain growth factors (Bork and
Beckmann 1993, Fredriksson, Li et al. 2004). Although the functional role of the CUB
domain is not yet fully delineated, it is thought to facilitate protein–protein or protein–
carbohydrate interactions. For example, in the C and D isoforms of PDGF, the CUB
domain serves to sterically inhibit PDGF-C and -D binding partners from interacting
with the growth factor domain before the CUB domain is cleaved by a regulatory
protease (Fredriksson, Li et al. 2004). The DCBLD1/2–CUB domain could similarly
prevent binding of extracellular interactors prior to cleavage of the extracellular
domain. The two CUB domains of neuropilins are involved in Semaphorin binding
(Villoutreix and Miteva 2016), suggesting that DCBLD2–CUB domain might be
involved in the DCBLD2/SEMA4B interaction. The LCCL domain (~100 AAs) is,
similarly, poorly characterized, although this module is thought to be involved in
structural integrity and immune function, specifically in binding lipid A of the
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endotoxin lipopolysaccharide (Trexler, Bányai et al. 2000, Liepinsh, Trexler et al. 2001,
Vásárhelyi, Trexler et al. 2014).
The third conserved domain located N-terminal to the transmembrane region is
the Coagulation Factor V/VIII type C, or Discoidin, domain. This ~150 AA module is
found within membrane and extracellular proteins, including discoidin domain receptor
tyrosine kinase (DDR) family members, which are involved in focal adhesion
dynamics, proliferation, and extracellular matrix degradation (Vogel, Abdulhussein et
al. 2006). Although the function of this domain is similarly unknown, it shares
homology with regions of Factors V and VIII that are required for anionic phospholipid
binding (KaneWH 1988, Foster, Fulcher et al. 1990). The Discoidin domain is,
interestingly, not conserved in rodent DCBLD1 (Figure 3C), suggesting that it either is
not essential to the conserved function of this gene, or other rodent proteins (e.g.
DCBLD2) may otherwise functionally compensate. The discoidin domains of
neuropilins have been shown to bind growth factors of the VEGF family and other
heparin binding proteins (Vander Kooi, Jusino et al. 2007, Villoutreix and Miteva
2016), suggesting that this domain may similarly interface with secreted factors, either
in direct contribution to growth factor receptor signaling, or by an alternative
mechanism.
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H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

MVPGARGGGALARAAGRGLL-ALLLAVSAPLRLQAEELGDGCGHLVTYQDSGTMTSKNYPGTYPNHTVCEKTITVPKGKRLILRLGDLDIESQTCASDYLLFT--SS--SDQYGPYCGSM
MVPGARGGGALARAAGPGLL-ALLLAVSAPLRLQAEELGDGCGHLVTYQDSGTMTSKNYPGTYPNHTVCEKTITVPKGKRLILRLGDLDIESQTCASDYLLFT--SS--SDQYGPYCGSM
---------MGTGAGGPSVL-ALLFAVCAPLRLQAEELGDGCGHIVTSQDSGTMTSKNYPGTYPNYTVCEKIITVPKGKRLILRLGDLNIESKTCASDYLLFS--SA--TDQYGPYCGSW
---------MGTGAGGPGVL-ALLFAVCAPLRLQAEELGDGCGHIVTSQDSGTMTSKNYPGTYPNYTVCEKIITVPKGKRLILRLGDLNIESKTCASDYLLFS--SA--TDQYGPYCGSW
MAPGR---GICWAQPVTEILALLGICVTIPPLLVAETLGDGCGHVMLYEESGTLTSKNYPGTYPNQTLCKITLKVQTGKSLYIMLADVDIESRDCESAYLKIFKGTS--SEEIASYCGDQ
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H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio
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ANGVLSRDGSLSDKRFLFTSNGCSRSLSFEP-DGQIRASSSWQSVNESGDQVHWSPGQARLQDQGPSWASGDSSNNHKPREWLEIDLGEKKKITGIRTTGSTQSNFNFYVKSFVMNFKNN
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LVFAGMGIFAAFRKKKKKGSPYGSAEAQKTDCWKQIKYPFARHQSAEFTISYDNEKEMTQKLDLITSDMA-DYQQPLMIGTGTVTRKGSTFRPMDTDAEEAGVSTDAGGHYDCPQRAGRH
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LLLTGTGIFAICRKKKKKGNPFVSAEAQKTGCWKQIKYPFARHQSAEFTISYDNEKEMTQKLDLITSDMA-DYQQPLMIGTGTVTRKGSTFRPMDTDTEEARVNTEASSHYDCPHRPGRH
VLMAGVC-FCATRSRKLKTEAYKSPEEQNGGCWKPLDQPIVRQQSTEFIISYNNDKDPPQKFDLGKCDME-DYQQPAMIGTGLVTRKGSTFKPMDTDTKETPGSLEIENHYACPHR-NRH
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EYALPLAPPEPEYATPIVERHVLRAHTFSAQSGYRVPGPQPGHKHSLSSGGFSP-VAGVGAQDGDYQRPHS----AQPADRGYDRPKAVSALATESGHPDSQKPPTHPGTSDSYSAPRDC
EYALPLAPPEPEYATPIVERHLLRAHTFSAQSGYRVPGPQPGHKHSLSSGGFSP-VAGVGAQDGDYQRPHS----AQPADRGYDRPKAVSAFATESGHSDSQKPPTHPGTSDSYSAPRDC
EYALPLTHSEPEYATPIVERHLLRAHTFSTQSGYRVPGPRPTHKHSHSSGGFPP-ATGAT-QVESYQRPAS----PKPVGGGYDKPAA-SSFLD-SRDPASQS-QMTSGGDDGYSAPRNG
EYALPLTHSEPEYATPIVERHLLRAHTFSTQSGYRVPGPRLTHKHSLSSGGFPP-AAGAT-QIESYQRPAS----PKPVGGGYDKPAAASSFLD-SGDPASQS-QMTSGGNDGYSAPRNG
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QYALPLTNQEPEYATPIIERHAFRKDPFIPDASYSVPGVVLNKSPSFRAVEGGNCRKVIGGLAGGYQTPQVKPDRGNSPEDIYDSPKIRKAVV--LNGPEYQRPQIKSQDQECYSTPRDC
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LTPLNQTAMTALL-------------LTPLNQTAMTALL-------------LAPLNQTAMTALL-------------LAPLNQMAVTALL-------------LKAINQTAITSLL-------------VRLPFSGLRPDPEGSRSEPEGSSSDGS

SS

CUB

LCCL

FV/FVIII

TM

Intracellular

Extracellular

N- SS

TM
CUB

LCCL

FV/FVIII

-C
Q8N8Z6
Q8N8Z6-2

Human

H2QTM8
K6ZUP1

Chimpanzee

Q9D4J3
Mouse
Q9D4J3-2
D. rerio
X. tropicalis
H. sapiens
P. troglodytes
M. musculus
R. norvegicus

100
39.29
42.94
42.79
45.01
44.51

100
52.48 100
52.62 99.44 100
48.70 77.53 77.93 100
49.20 78.37 78.77 94.23

D3ZfM7

Rat

F1QGI1
A2BDL4

100

Zebrafish

Q4V8Y8

K9J7Z0

Frog

Figure 3: Multiple sequence alignments, conservation, and domain structure of the DCBLD1
protein in vertebrate species.
A) Alignments and B) percent conservation of canonical DCBLD1 sequences across representative
vertebrates (H. sapiens, P. troglodytes, M. musculus, R. norvegicus, X. tropicalis, D. rerio) were
constructed using ClustalOmega (Larkin, Blackshields et al. 2007, Goujon, McWilliam et al. 2010).
Regions of the alignment that are part of conserved domains are indicated. C) Domain structure of
all DCBLD1 isoforms of representative vertebrates in the UniprotKB database (uniprot.org)
(Apweiler, Bairoch et al. 2004). SS = signal sequence, TM = transmembrane.
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R. norvegicus
X. tropicalis
D. rerio

MASRAVVRARRCPQCPQVRAAAAAPAWAALPLSRS--LPPCSNSSSFSMPLFLLLLLVLLLLLEDAGAQQGDGCGHTVLGPESGTLTSINYPQTYPNSTVCEWEIRVKMGERVRIKFGDF
MASRAVVRARRCPQCPQVRAAAAAPAWAALPLSRS--LPPCSNSSSFSMPLFLLLLLVLLLLLEDAGAQQGDGCGHTVLGPESGTLTSINYPQTYPNSTVCEWEIRVKMGERVRIKFGDF
MASRAPLRAARSPQGPGGPAAPAATGRAALPSAGCCPLPPGRNSS--SRPR---LLLLLLLLLQDAGGQQGDGCGHTVLGPESGTLTSINYPHTYPNSTVCEWEIRVRTGERIRIKFGDF
MASRAPLRAARSPQDPGGRAAPAATGRAPLPSAGWCPLPPGRNSS--SRPR---LLLLLLLLLPDAGAQKGDGCGHTVLGPESGTLTSINYPHTYPNSTVCKWEIRVKTGERIRIKFGDF
-------------------------------------METG--GMVSRRLAWLLSGCVVSLLLGATEAQKGDGCGYTVMGPESGTLTSMNYPQTYPNNTVCEWDIHVKPGKRILIKFGDF
-------------------------------MDAS--VMVGRG--TGGAALFILIVFIVLLGARSSRAQKGDGCGHTVLGVGSGSLASLGYPQSYPSQSVCEWEISVTAGHKVLVRIADL

SS

CUB

H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

DIEDSDSCHFNYLRIYNGIGVSRTEIGKYCGLGLQMNHSIESKGNEITLLFMSGIHVSGRGFLASYSVIDKQDLITCLDTASNFLEPEFSKYCPAGCLLPFAEISGTIPHGYRDSSPLCM
DIEDSDSCHFNYLRIYNGIGVSRTEIGKYCGLGLQMNHSIESKGNEITLLFMSGIHVSGRGFLASYSVIDKQDLITCLDTASNFLEPEFSKYCPAGCLLPFAEISGTIPHGYRDSSPLCM
DIEDSDYCHLNYLKIFNGIGVSRTEIGKYCGLGLQMNQSIESKGSEVTVLFMSGTHAAGRGFLASYSVIDKEDLITCLDTVSNFLEPEFSKYCPAGCLLPFAEISGTIPHGYRDSSPLCM
DIEDSDYCHLNYLKIFNGIGVSRTEIGKYCGLGLQMNQSIESKGSEITVLFMSGIHASGRGFLASYSVIDKQDLITCLDTVSNFLEPEFSKYCPAGCLLPFAEISGTIPHGYRDSSPLCM
DIENSDSCHSSYVRIYDGVRESRTEIAKYCGSAVQLESLIESRTNKVTVQFMSGTHISGRGFLASYSTANKTDLITCLEKASHFSEPEYSKYCPAGCMTPFGEISGTIPLGYRDSSSLCM
DID-TNNCQVSYLRLYNGIGPGRTEIVKFCGSKEWKDVVIKSEGHQVTVQFMSGPHHNGRGLFLSYTNSQHTDLITCLEKGEHFSEAEFSKFCPAGCLIDFGEVSGTIPHGYRDSSPLCL

H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

AGVHAGVVSNTLGGQISVVISKGIPYYESSLANNVTSVVGHLSTSLFTFKTSGCYGTLGMESGVIADPQITASSVLEWTDHTGQENSWKPKKARLKKPGPPWAAFATDEYQWLQIDLNKE
AGVHAGVVSNTLGGQISVVISKGIPYYESSLANNVTSVVGHLSTSLFTFKTSGCYGTLGMESGVIADPQITASSVLEWTDHTGQENSWKPKKARLKKPGPPWAAFATDEYQWLQIDLNRE
AGIHAGVVSNVLGGQISIVISKGTPYYESSLANNVTSTVGYLSASLFTFKTSGCYGTLGMESGVIADPQITASSALEWTDHMGQENSWTAEKARLRKPGPPWAAFATDEHQWLQIDLNKE
AGIHAGVVSDVLGGQISVVISKGTPYYESSLANNVTSMVGYLSTSLFTFKTSGCYGTLGMESGVIADPQITASSVLEWTDHMGQENSWKPEKARLRKPGPPWAAFATDEHQWLQIDLNKE
AGVHAGVVSNILGGQINVVISKGIHFYEGSLANNITSKVGSLSSTLFTFKTSGCYGTLGMESGVIPDAQINSSSFLEWTDNTGQNNAWKAERARLKKQGPPWVASFSNELQWLQIDLSKL
AGIHAGVLSNTLGGQISVVSSKGIPHYESSLANNVTSVPGNLSPSLFTFKTSGCYGTLGLESGVVSDSQITASSEWEWGGHGKQPTVWGPTGARLKTPGRPWAAANSDTKEWIQVDLKKE

H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

KKITGIITTGSTMVEHNYYVSAYRILYSDDGQKWTVYREPGVEQDKIFQGNKDYHQDVRNNFLPPIIARFIRVNPTQWQQKIAMKMELLGCQFIPKGRPPKLTQPPPPRNSNDLKNTTAP
KKITGIITTGSTMVEHNYYVSAYRILYSDDGQKWTVYREPGVEQDKIFQGNKDYHQDVRNNFLPPIIARFIRVNPTQWQQKIAMKMELLGCQFIPKGRPPKLTQPPPPRNSNDLKNTTAP
KKITGIVTTGSTMIEHSYYVSAYRVLYSDDGQRWTVYREPGVDQDKIFQGNKDYHKDVRNNFLPPIIARFIRVNPVQWQQKIAMKVELLGCQFTLKGRLPKLT--PPPRNGNNLRNTTAR
KKITGIVTTGSTLIEHNYYVSAYRVLYSDDGQKWTVYREPGAAQDKIFQGNKDYHKDVRNNFLPPIIARFIRVNPVQWQQKIAMKVELLGCQFTLKGRLPKLTQPPPPRNSNNLKNTTVH
KKITGIITTGSTMDKFNYYVSSYKIAYSEDGIKWTVYRLFSEDQDKVFQGNIDYNQEVRNNFI-PIVARFVKIHPLQWHQKIAMKVELLGCQIITVP--PKLTITEGP-----------KKITGITTTGSTLPEYQFYVSAYEVLYSHDGQQWKTYQEVGSDKNKIFQGNTHYLQEVRNNFIPPIEARFLRICPLQWHQRIALKMELLGCQPHAAR--PRIFHPGP-------------

H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

PKIAKGRAPKFTQPLQPRSS-NEFPAQTEQTTASPDIRNTTVTPNVTKDVALAAVLVPVLVMVLTTLILILVCAWHWRNRKKKTEGTYDLPYWDRAGWWKGMKQFLPAKAVDHEETPVRY
PKIAKGRAPKFTQPLQPRSS-NEFPAQTEQTTASPDIRNTTVTPNVTKDVALAAVLVPVLVMVLTTLILILVCAWHWRNRKKKTEGTYDLPYWDRAGWWKGMKQFLPAKAVDHEETPVRY
PKLGKGRAPKFTQVLQPRSR-NELPVQPAETTTTPDIKNTTVTPSVTKDVALAAVLVPVLVMALTTLILILVCAWHWRNRKKKTEGAYDLPHWDRAGWWKGMKQLLPAKSVDHEETPVRY
PKLG--RAPKFTQALQPRSR-NDLPLLPAQTTATPDVKNTTVTPSVTKDVALAAVLVPVLVMALTTLILILVCAWHWRNRKKKAEGTYDLPHWDRAGWWKGVKQLLPAKSVEHEETPVRY
-------------VLKPRANNNNSGVRHDKTTFPPEIKNTTVTPTISKDLPLVTILVPVLVMALTSIILILVCAWHCRNRKKKAEGTYDLPYWDRAGWWKGMKQFLPAKSAEHEETPVRY
---------------APPRRKSTTPPAQDRTTHTPNIRNSTMPPHSHDEVALVAVLVPVLVVVLTTPVLVMVCSWLWKNRKS-PEVTYDLPHWERTVWWKSMKQLLPSKLDG--EDCVRY

H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

SSS-EVNHLSPREVTTVLQADSAEYAQPLVGGIVGTLHQRSTFKPEEGKEAGYADLDPYNSPGQEVYHAYAEPLPITGPEYATPIIMDMSGHPTTSVGQPSTSTFKATGNQPPPLVGTYN
SSS-EVNHLSPREVTTVLQADSAEYAQPLVGGIVGTLHQRSTFKPEEGKEAGYADLDPYNSPGQEVYHAYAEPLPITGPEYATPIIMDMSGHPTTSVGQPSTSTFKATGNQPPPLVGTYN
STS-EVSHLSAREVTTVLQADSAEYAQPLVGGIVGTLHQRSTFKPEEGKEAGYADLDPYNSPMQEVYHAYAEPLPVTGPEYATPIVMDMSGHPTASVGLPSTSTFKTAGTQPHALVGTYN
SNS-EVSHLSPREVTTVLQADSAEYAQPLVGGIVGTLHQRSTFKPEEGKEASYADLDPYNAPVQEVYHAYAEPLPVTGPEYATPIVMDMSGHSTASVGLPSTSTFRTAGNQPPALVGTYN
SSC-EVGRARPREVATMLQTESAEYAQPLVGGAMGTLHQRSTFKPEEGKEPGYADLDSYTNPDDAIYHAYAEPLPTNGPEYATPIIMDMSGHPVGPMGLPSTSTFKVTGSQAPPLVGTYN
SSTARVDHQRP-------RVEPAEYAQPLVTGNMASLGQRSTFKPEEADVPEYDAPI-----PPEHYHAYAEPLPASGTEYAMPIMIDRANHLSGGT-----LPFR------------GR

H. sapiens
P. troglodytes
M. musculus
R. norvegicus
X. tropicalis
D. rerio

TLLSRTDSCSSAQAQYDTPKAGKPGLPAPDELVYQVPQSTQEVSGAGRDGECDVFKEIL
TLLSRTDSCSSAQAQYDTPKAGKPGPPAPDELVYQVPQSTQEVSGAGRDGECDVFKEIL
TLLSRTDSCSSGQAQYDTPKGGKSA-ATPEELVYQVPQSTQELSGAGRDEKFDAFKEIL
TLLSRTDSCSSGQAQYDTPKGGKPA-AAPEELVYQVPQSTQEASGAGRDEKFDAFKETL
KLLSRTDSSASTQVLYDTPKGTQ-GVCAAEEMVYQVPQCVPQQTASRDVPP-------GLVTQTDSSQSANSAYDTPKITSDQATPTEGQLYQVPQN--------------------
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Figure 4. Multiple sequence alignments, conservation, and domain structure of the DCBLD2
protein in vertebrate species.
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A) Alignments and B) percent conservation of canonical DCBLD2 sequences across representative
vertebrates (H. sapiens, P. troglodytes, M. musculus, R. norvegicus, X. tropicalis, D. rerio) were
constructed using ClustalOmega (Larkin, Blackshields et al. 2007, Goujon, McWilliam et al. 2010).
Regions of the alignment that are part of conserved domains are indicated. C) Domain structure of
all DCBLD2 isoforms of representative vertebrates in the UniprotKB database (uniprot.org)
(Apweiler, Bairoch et al. 2004). Domain size is proportional to relative amino acid lengths, as
annotated by UniprotKB. Signal sequences (SS) are separated from the mature protein with a
dotted line. SSs that were not annotated in UniprotKB were predicted using SignalP 4.1 (Nielsen
2017) (dotted outlines). SS = signal sequence, TM = transmembrane.

Several splice variants exist for both DCBLD1 and DCBLD2 (uniprot.org;
Figure 3C and Figure 4C) (Apweiler, Bairoch et al. 2004), some of which could have
interesting functional implications. In mice, there is a DCBLD1 isoform with no CUB
domain, which could act to prevent important CUB-mediated interactions, as well as a
DCBLD2 isoform with no extracellular region (Figure 3C and Figure 4C).
Interestingly, zebrafish Dcbld1 splice variants include Dcbld1–CUB and Dcbld1–
CUB–TM species, and a Dcbld2 splice variant possessing only the CUB and Discoidin
domains (Figure 3C and Figure 4C). The signal peptide remains intact in these species;
therefore, these variants are presumed secretory pathway targets. These isoforms
suggest an important mechanism that links extracellular CUB-mediated interactions to
intracellular signal transduction. This could either be achieved by removing the
potential for CUB-mediated interactions, as in the mouse variant, or by removing the
potential for intracellular signal transduction stimulated through CUB domain
interactions, as in zebrafish variants. The DCBLD1 CUB domain could act as a
paracrine signal, and the zebrafish isoforms could promote signaling through an
unknown Dcbld1/2–CUB receptor.
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Figure 5. Experimentally observed post-translational modifications (PTMs) of DCBLD1 and
DCBLD2.
Sites of PTMs are indicated by the amino acid position along each protein sequence, and numbers
indicate the number of high and low-throughput experiments, conducted either by Cell Signal
Technology or curated from the literature, obtained from the PhosphoSitePlus (Hornbeck, Zhang
et al. 2014) database on August 22, 2018. Observed PTMs include phosphorylation (Ph, yellow),
ubiquitylation (Ub, light blue), and acetylation (Ac, dark blue). Due to the high abundance of
observed phosphorylation sites on DCBLD1 and DCBLD2, the number of experimentally
identified phosphorylation sites are only included if > 5, although all ubiquitylation and acetylation
identifications are included.

In addition, the zebrafish Dcbld1–CUB–TM isoform has an abbreviated
intracellular domain that terminates after the first intracellular tyrosine, similar to
human and chimpanzee isoforms with stop codons that falls directly before the first
CRK/CRKL–SH2 binding motif (pYXXP) in the canonical sequence (Figure 3C).
These variants would prevent scaffolding of intracellular binding partners important in
DCBLD1/2 signaling, and thus are predicted to act as dominant negatives to interfere
with DCBLD signaling and reduce the binding potential of intracellular interactors.
Secreted forms may serve as either dominant negative species that bind ligands in non19

functional complexes, or conceivably as paracrine factors capable of forward or
“reverse” signaling when considering semaphorins such as SEMA4B.
1.7. Expression and localization
1.7.1. Expression profile
Currently available RNA-seq data generated by the Human Protein Atlas project
(www.proteinatlas.org) (Pontén, Jirström et al. 2008) demonstrate that DCBLD2
exhibits generally higher expression levels than DCBLD1 (Figure 6). Of the represented
tissues, DCBLD2 transcripts were concentrated most in reproductive and muscle tissue,
as well as the parathyroid gland (Figure 6A). DCBLD1 transcripts were present at
relatively lower concentrations, with highest transcripts-per-million (TPM) found in the
parathyroid gland, placenta, and gallbladder. Of the queried cell types, DCBLD2 was
represented at similar or higher levels than DCBLD1 and was most highly expressed in
glioma (U-87 MG) and myoblast (LHCN-M2) cell lines (Figure 6B). DCBLD2 tissueand cell-specific expression analyses have also been published by several investigative
groups (Table 2) (Kobuke, Furukawa et al. 2001, Koshikawa, Osada et al. 2002,
Yoshida, Han et al. 2006, O'Connor, Salles et al. 2009, Nie, Guo et al. 2013, Li, Jung et
al. 2016). These studies similarly demonstrate high DCBLD2 expression in
reproductive and muscle tissues, as well as muscle-derived cell types.
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A

B
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Figure 6. DCBLD1 and DCBLD2 expression levels across A) tissues and B) cell types, and
Expression of C) DCBLD1 and D) DCLBD2 in normal tissue and tumors.
A-B) Tile plots display DCBLD1 and DCBLD2 RNA transcripts per million (TPM) detected from
human tissues and cell types by RNA sequencing conducted as part of the Human Protein Atlas
project (www.proteinatlas.org) (Pontén, Jirström et al. 2008). C-D) Tile plots display DCBLD1 and
DCBLD2 RNA transcripts per million (TPM) detected from human tissues and cell types by RNA
sequencing conducted as part of the Cancer Genome Atlas (TCGA) Research Network
(http://cancergenome.nih.gov) accessed through Gepia (http://gepia.cancer-pku.cn/) (Tang, Li et al.
2017).

DCBLD2 is expressed highly in proliferating cells in culture and is upregulated
in vivo following vascular injury (Sadeghi, Esmailzadeh et al. 2007), suggesting its
expression is tightly regulated in developmental and repair processes. DCBLD2
expression in a variety of human fetal tissues has been described (Koshikawa, Osada et
al. 2002), although there is little data describing developmental expression patterns of
DCBLD family members. Modulated DCBLD1 and DCBLD2 expression levels are
associated with several types of cancer (Table 3) (Koshikawa, Osada et al. 2002,
Autiero, De Smet et al. 2005, Chen, Low et al. 2007, Nagai, Sugito et al. 2007, Hofsli,
Wheeler et al. 2008, Kim, Lee et al. 2008, Orso, Penna et al. 2008, Orso, Corà et al.
2010, Lan, Hsiung et al. 2012, Osella-Abate, Novelli et al. 2012, Pagnotta, Laudanna et
al. 2013, Feng, Lopez et al. 2014, Seow, Matsuo et al. 2016, Kikuta, Kubota et al. 2017,
Raman, Maddipati et al. 2018, Yang, Stueve et al. 2018). Currently available
DCBLD1/2 RNA-seq data generated by the Cancer Genome Atlas (TCGA) Research
Network (http://cancergenome.nih.gov) is included in Figure 6D,C, which compare
expression of DCBLD family members in tumors to that in normal tissue (Tang, Li et
al. 2017). Given the proliferative phenotypes and links to cancer, the developmental

22

role of DCBLD proteins will likely become important subjects of study and, therefore,
necessitates further investigation into developmental expression patterning.

Table 2. Expression of DCBLD2 protein and mRNA in tissue and cell types.
Data were compiled from low-throughput studies reported in primary literature.

HIGHEST EXPRESSION
Heart
Skeletal muscle, heart,
testis

OTHER TISSUES/CELL TYPES
brain, lung, spleen, stomach, small
intestine, colon, kidney, testis
pancreas, kidney, liver, placenta*,
brain, colon*, small intestine,
ovary*, prostate*

SPECIES

AGE

ORGANISM

REFERENCE

TISSUE/CE
LL

mRNA

-

rat

(Kobuke, Furukawa et al.
2001)

Tissue

mRNA

Adult

human

(Koshikawa, Osada et al.
2002)

Tissue
Tissue

Heart

lung, brain, kidney, adrenal gland

mRNA

Fetal

human

(Koshikawa, Osada et al.
2002)

Nervous system

-

mRNA

18-72 hpf

zebrafish

(Ballif, Ebert, unpublished)

Tissue

Heart, lung, aorta

brain, spleen, stomach, kidney,
skeletal muscle, liver

protein

-

mouse

(Nie, Guo et al. 2013)

Tissue

-

liver, muscle

protein

18-20 wk

mouse

(Li, Jung et al. 2016)

Tissue

Megakaryocytes

erythrocytes, HUVECs

mRNA

-

human

CASMCs

hCAECs, HeLa

mRNA

-

rat, human

DRG neurons

-

mRNA

e15.5

mouse
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(O'Connor, Salles et al.
2009)
(Kobuke, Furukawa et al.
2001)
(Yoshida, Han et al. 2006)

Cell
Cell
Cell

Table 3. Associations of DCBLD family members with cancer.
Data were compiled from primary literature reports.
CANCER TYPE

FAMILY
MEMBER

LUNG
ADENOCARCINOMA

CELL TYPE STUDIED

PHENOTYPE/ASSOCIATION

MOLECULAR INSIGHTS

ROS1,
DCBLD1

clinical specimens

Associated with EGFR mutations

N/A

GLIOMA

DCBLD1ROS1

clinical specimens

Highly expressed

N/A

MYXOFIBROSARCOMA

DCBLD2

clinical specimens

Associated with invasive properties

N/A

LUNG CANCER

DCBLD2

clinical specimens, A549

Promotes cell motility

may interact with SEMA4B

NEUROENDOCRINE

DCBLD2

clinical specimens

Involved in invasion, progression,
metastasis

N/A

GLIOMA

DCBLD2

U87, SNB19

HEAD AND NECK
CANCER

DCBLD2

PCI-158

Required for EGFR-drivien
tumoigenesis; Associated with poor
prognosis
Required for EGFR-drivien
tumoigenesis; Associated with poor
prognosis

EGFR-mediated pTyr750
facilitates TRAF6-mediated
Akt activation
EGFR-mediated pTyr750
facilitates TRAF6-mediated
Akt activation

GASTRIC CANCER

DCBLD2

clinical specimens, SNU016, SNU-601, SNU-620,
SNU-638 (others?)

Inhibits colony formation and
invasion

High promotor methylation

COLORECTAL
CANCER

DCBLD2

clinical specimens, HT29,
RKO

Reduced in distant metastases;
Associated with good prognosis

PPARγ and TNF-α signaling
regulate NT5E and DCBLD2
levels

MELANOMA

DCBLD2

clinical specimens, HeLa

High levels associated with
decreased migration

Expression repressed by
AP2-alpha

CERVICAL CANCER

DCBLD2

A431

N/A

PANCREATIC CANCER

DCBLD2

clinical specimens

Associated with poor survival,
vascular invasion, and an
aggressive squamous subtype

pTyr target downstream of
EGF-signaling
Part of a 5-gene signature
with ADM, ASPM, E2F7, and
KRT6A

REFERENCE
(Lan, Hsiung
et al. 2012,
Seow, Matsuo
et al. 2016)
(Yang, Stueve
et al. 2018)
(Kikuta,
Kubota et al.
2017)
(Koshikawa,
Osada et al.
2002, Nagai,
Sugito et al.
2007)
(Hofsli,
Wheeler et al.
2008)
(Feng, Lopez
et al. 2014)
(Feng, Lopez
et al. 2014)
(Kim, Lee et al.
2008)
(Pagnotta,
Laudanna et
al. 2013)
(Orso, Penna
et al. 2008,
Orso, Corà et
al. 2010,
Osella-Abate,
Novelli et al.
2012)
(Chen, Low et
al. 2007)
(Raman,
Maddipati et
al. 2018)

1.7.2. Subcellular localization
The DCBLD family are a class of type-I transmembrane proteins that are
thought to localize to the plasma membrane, however, there is a lack of reproducible,
robust experimental evidence clearly demonstrating their subcellular localization.
Koshikawa, et al. described plasma membrane localization of transiently-expressed
DCBLD2 in A549 cells via immunofluorescence (Koshikawa, Osada et al. 2002), and
the same research group later replicated these findings following proteasome inhibition
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with MG-132 (Nagai, Sugito et al. 2007). Similarly, immunohistochemistry of
DCBLD2 in clinical myxofibrosarcoma specimens revealed plasma membrane
localization (Kikuta, Kubota et al. 2017). Kobuke, et al. also examined DCBLD2
localization by immunofluorescence in COS7 cells transiently-transfected with
DCBLD2-FLAG and observed strong fluorescence at the cell membrane using both
anti-FLAG as well as antibodies raised against peptides within the CUB and FV/FVIII
extracellular domains of DCBLD2 (Kobuke, Furukawa et al. 2001).
In HUVECs, Nie, et al. observed a strong signal of endogenous DCBLD2 at the
plasma membrane, the endoplasmic reticulum, and the perinuclear space; however,
there was also significant staining throughout the cytoplasm. It is possible that this
staining indicates sequestration or trafficking in vesicles. Interestingly, the localization
at the plasma membrane appeared to be non-uniform (Nie, Guo et al. 2013), suggesting
that DCBLD2 could be integrated into lipid micro-domains and possibly involved in
polarizing processes. Li, et al. observed fluorescence of endogenous DCBLD2 in
VSMCs that was primarily localized to vesicles (Li, Jung et al. 2016). They detected a
small degree of membrane localization, apparent in concentrated patches, although the
published images suggest less of a polarization effect than that observed by Nie, et al.
1.7.3. Post-translational modifications and processing
The human DCBLD2 protein has a predicted molecular weight of ~80 kDa
based on its amino acid sequence, although it regularly displays an effective molecular
weight of ~130 kDa via SDS-PAGE (Nagai, Sugito et al. 2007, Aten, Redmond et al.
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2013, Schmoker, Weinert et al. 2017). A significant portion of this reduced
electrophoretic mobility was shown to be the result of glycosylation (Nagai, Sugito et
al. 2007). Commonly, two protein bands of different molecular weight (110 and 130
kDa) are observed with antibodies to a C-terminal epitope tag (Kobuke, Furukawa et al.
2001, Nagai, Sugito et al. 2007). A third species of ~100 kDa, although less frequently
reported, is prominently observed when cells expressing DCBLD2 are treated with the
proteasome inhibitor MG-132 (Nagai, Sugito et al. 2007), suggesting that this variant is
more susceptible to degradation.
Intracellular phosphorylation will likely emerge as an important regulator of
DCBLD1/2 biological function. With no enzymatic activity, these transmembrane
proteins are hypothesized to act as scaffolds for the formation of signaling hubs at the
plasma membrane. Large-scale mass spectrometric studies curated at PhosphoSitePlus
(phosphositeplus.org) (Hornbeck, Zhang et al. 2014) have revealed high spectral counts
of tyrosine phosphorylation, as well as the identification of ubiquitylation and
acetylation sites (Figure 5). The most well-characterized DCBLD2 phosphorylation site
is Tyr750. This site has been identified as a direct substrate of the receptor tyrosine
kinase (RTK) EGFR using an in vitro kinase assay (Feng, Lopez et al. 2014), and has
been shown to be phosphorylated downstream of EGF and hyperactive EGFR (Chen,
Low et al. 2007, Feng, Lopez et al. 2014). Activity of ABL and the SFK FYN has also
been shown to induce DCBLD2 tyrosine phosphorylation (Aten, Redmond et al. 2013,
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Schmoker, Weinert et al. 2017), although direct phosphorylation of DCBLD2 by these
cytoplasmic kinases has yet to be demonstrated.
In addition to functional regulation via glycosyl and phosphoryl modification,
DCBLD2 has recently been identified as a novel substrate of the serine protease
RHBDL2 (Johnson, Březinová et al. 2017). Catalyzing proteolysis of extracellular
domains of transmembrane proteins localized at the plasma membrane, RHBDL2 is a
key positive regulator of EGF signaling (Adrain, Strisovsky et al. 2011) and its activity
is implicated in wound healing and cancers of the airway and digestive tract (Cheng,
Wu et al. 2011, Cheng, Lai et al. 2014, Lastun, Grieve et al. 2016). Johnson, et al.
demonstrated that the ~80 kDa RHBDL2-cleaved DCBLD2 product was detectable in
the growth medium and not in the cell lysate, when both proteins were ectopically
expressed in HEK293-ET cells (Johnson, Březinová et al. 2017). Using mass
spectrometry and site-directed mutagenesis, the authors identified the cleavage site as
Ala531, which falls directly N-terminal to the DCBLD2 transmembrane domain
(Figure 7B). They demonstrated that transiently transfected DCBLD2 was cleaved by
endogenous RHBDL2, but not by ADAM metalloproteases, in HeLa cells and HEK
cells, respectively. In addition, they identified DCBLD2 as a substrate of the ER
membrane protease RHBDL4 (Lastun, Grieve et al. 2016, Wunderle, Knopf et al. 2016)
when co-expressed in HEK cells (Johnson, Březinová et al. 2017), which may play a
role in degradation of misfolded DCBLD2 at the endoplasmic reticulum (Figure 7C).
The identification of DCBLD2 as an RHBDL2 substrate presents interesting functional

27

implications; DCBLD2 ectodomain shedding could modulate cell-cell contact or the
released product could possess altered bioactivity, functioning as an autocrine or
paracrine signal.
1.8. Alteration of DCBLD2 gene function
DCBLD2 has been shown to have both inhibitory and activating effects on cell
proliferation and migration, supporting the mounting evidence that the function of
DCBLD2 is highly specific to its cellular environment (Kobuke, Furukawa et al. 2001,
Sadeghi, Esmailzadeh et al. 2007, Guo, Nie et al. 2009, O'Connor, Salles et al. 2009,
Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Li, Jung et al. 2016).
1.8.1. Phenotypes at the cellular level
In a mouse model of graft arteriosclerosis, the DCBLD2 protein co-localizes
with proliferative cells (Sadeghi, Esmailzadeh et al. 2007). Sadeghi, et al. demonstrated
that siRNA-mediated knockdown (KD) of DCBLD2 increased proliferation of vascular
smooth muscle cells (VSMCs), while overexpression had a reciprocal effect (Sadeghi,
Esmailzadeh et al. 2007). Robust evidence of the inhibitory effect of DCBLD2 on
PDGF-BB-driven proliferation of VSMCs was shown by Guo, et al., who observed a
~7-fold increase in PDGF-BB-induced VSMC proliferation in the presence of DCBLD2
siRNA, as well as a more subtle increase in PDGF-BB-induced VSMC migration (Guo,
Nie et al. 2009). Given the robust upregulation of DCBLD2 expression following
PDGF-BB treatment observed in early work by Kobuke and colleagues (Kobuke,
Furukawa et al. 2001), and the apparent inhibitory effect of DCBLD2 on PDGF-
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induced proliferation, upregulation of DCBLD2 could be an important negative
feedback loop that decreases the rate of PDGF-driven proliferation and migration at
later time-points.
In addition to PDGF-driven processes, DCBLD2 has been found to modulate
phenotypic effects of other mitogens and growth factors, including insulin, vascular
endothelial growth factor (VEGF), and epidermal growth factor (EGF) (Nie, Guo et al.
2013, Feng, Lopez et al. 2014, Li, Jung et al. 2016). Li et al. observed increased
insulin-induced proliferation and migration in mouse-derived DCBLD2 knock-out
(Dcbld2-/-) VSMCs (Li, Jung et al. 2016). In contrast, overexpression of DCBLD2
promoted VEGF-driven proliferation and migration in human umbilical vein
endothelial cells (HUVECs), and proliferation was inhibited in cells transfected with
DCBLD2 siRNA (Nie, Guo et al. 2013). Although no investigations into the phenotypic
effects of other RTK ligands have been made in normal cell lines, DCBLD2 is required
for EGF- and hyperactive EGFR-driven cell growth, proliferation, and migration in a
variety of cancer cell lines, including those derived from glioma, head-and-neck cancer
(HNC), lung cancer, and melanoma (Feng, Lopez et al. 2014).
1.8.2. Organismal level knockout and knockdown
Nie, et al. generated global and endothelial cell (EC)-specific Dcbld2-/- mice by
homologous recombination resulting in deletion of the Dcbld2 promotor region and
exon 1 (Nie, Guo et al. 2013). These mice exhibit impaired neovascularization in adult
mice following both injury and exogenous VEGF administration and, more subtly,
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impaired developmental angiogenesis. The authors observed less severe phenotypes in
EC-specific knockout mice than in the global knockout, which was likely due to
compensation by non-EC DCBLD2 or other proteins (Nie, Guo et al. 2013). Although
DCBLD2 has been shown to exhibit an inhibitory effect on PDGF-BB-induced
proliferation in smooth muscle cells (Sadeghi, Esmailzadeh et al. 2007, Guo, Nie et al.
2009), cellular crosstalk could be an important factor in the phenotypic effects of
DCBLD2 during vascular development and regeneration. The fact that these mice are
viable suggest that DCBLD1 could be compensating for the loss of DCBLD2 gene
function, which could also explain the lack of severity in phenotypes. In addition to
studying the effects of gene alteration in mice, Nie, et al. investigated the
developmental role of Dcbld2 in zebrafish vasculogenesis using morpholino (MO)induced dcbld2 KD. They demonstrated that dcbld2 KD resulted in decreased
anastomosis of intersegmental vessels (ISVs), a process in which VEGF-A signaling
plays a central role (Nie, Guo et al. 2013).
Li, et al. went on to explore the effects of DCBLD2 on insulin-related signaling
in the global knockouts, and reported improved insulin sensitivity in Dcbld2-/- mice
relative to wild type (WT) mice. Dcbld2-/- mice exhibited significantly lower blood
glucose levels in the course of both glucose and insulin tolerance testing regardless of
whether they were fed a normal or high fat diet, despite no differences in secreted
insulin levels (Li, Jung et al. 2016). The enhanced glucose metabolism in Dcbld2-/mice coupled with the proliferative effects observed in VSMCs derived from Dcbld2-/-
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mice suggests that DCBLD2 negatively affects insulin signaling proximal to the insulin
receptor (INSR).
O’Connor, et al. identified Dcbld2 as a novel platelet membrane protein in a
functional genomics screen in zebrafish and demonstrated increased thrombus surface
area in dcbld2 KD fish, suggesting that Dcbld2 plays an inhibitory role in thrombus
formation (O'Connor, Salles et al. 2009).

Vascular repair and angiogenesis are concerted processes that require
heterocellular crosstalk between endothelial and smooth muscle cells, and similar
mechanisms function in neuronal developmental, as well as tumorigenic and metastatic
processes. The dynamic phenotypic effects observed in the regulation of DCBLD2
expression are likely due to differential environment-specific modifications and/or
expression of interacting partners. DCBLD2 is likely differentially phosphorylated or
otherwise post-translationally modified downstream of various mitogens and growth
factors, resulting in the association/dissociation of different intracellular signaling
molecules that ultimately affect RTK signaling in distinct ways.
The negative regulatory effects of DCBLD2 on glucose uptake and thrombus
formation present DCBLD2 as a potential therapeutic target in individuals in which
these processes are compromised. Impaired angiogenesis in Dcbld2-/- mice and dcbld2
KD zebrafish indicates that there may be a broader developmental role of DCBLD2 that
remains as yet unexplored. For example, signaling mechanisms that govern
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angiogenesis are similarly central to proper nervous system development (Zacchigna,
de Almodovar et al. 2007, Eichmann and Thomas 2013). It will be important to utilize
these available models to query the developmental role of DCBLD2, as this will not
only continue to unravel the complexities of and complications associated with
developmental processes, but will also inform potential targets to combat cancers in
which progression relies on overexpression or suppression of this gene.
1.9. Role in Cancer and Disease
As has been discussed of the roles of DCBLD family members in normal
cellular processes, their roles in cancers likewise appear highly environment-specific.
The observed activating and inhibitory roles of DCBLD1 and DCBLD2 in
tumorigenesis and progression are summarized in Table 3 (Koshikawa, Osada et al.
2002, Autiero, De Smet et al. 2005, Chen, Low et al. 2007, Nagai, Sugito et al. 2007,
Hofsli, Wheeler et al. 2008, Kim, Lee et al. 2008, Orso, Penna et al. 2008, Orso, Corà et
al. 2010, Lan, Hsiung et al. 2012, Osella-Abate, Novelli et al. 2012, Pagnotta,
Laudanna et al. 2013, Feng, Lopez et al. 2014, Seow, Matsuo et al. 2016, Kikuta,
Kubota et al. 2017, Raman, Maddipati et al. 2018, Yang, Stueve et al. 2018). DCBLD
family members have also been associated with various physical abnormalities.
Increased DCBLD2 levels are linked to enlarged Heschyl’s gyrus (Cai, Fonteijn et al.
2014) and nasal polyposis in asthmatics (Park, Kim et al. 2012, Pasaje, Bae et al. 2012).
Increased DCBLD1 levels are associated with COPD and emphysema (Sakornsakolpat,
Morrow et al. 2018).
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1.9.1. DCBLD2 expression is suppressed by AP-2α in invading cells of melanomic
origin
Regulation of DCBLD2 expression by members of the AP-2 family of
transcription factors (TFs) has been characterized in cervical and breast
adenocarcinoma, breast ductal carcinoma, and melanoma (Orso, Penna et al. 2008,
Orso, Corà et al. 2010, Osella-Abate, Novelli et al. 2012). AP-2 TFs are known to be
involved in progression of certain cancers and have been shown to play both inhibitory
(Hilger-Eversheim, Moser et al. 2000, Ruiz, Pettaway et al. 2004) and oncogenic
(Bosher, Williams et al. 1995) roles. Orso, et al. demonstrated that knockdown of AP2 and AP-2 is associated with increased cell proliferation at early stages of tumor
growth, and reduced migration and invasion in breast (MDA-MB-435 and MDA-MB231) and cervical (HeLa) adenocarcinoma lines (Orso, Penna et al. 2008). In AP-2deficient HeLa cells, they observed a significant increase in DCBLD2 mRNA levels,
and this effect was reversed by AP-2 overexpression (Orso, Penna et al. 2008). The
observed ~5-fold increase in migration of DCBLD2-deficient HeLa cells (Orso, Penna
et al. 2008) indicates that DCBLD2 could either inhibit cell migration or act in
promotion of cell adhesive properties. They later demonstrated that AP-2 binds
directly to the DCBLD2 promotor and acts as a transcriptional repressor of DCBLD2
expression (Orso, Corà et al. 2010).
Like DCBLD2, the AP-2 family is known to play important roles in
embryogenic processes, including modulation of cell proliferation, differentiation, and
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apoptosis. This mechanism of DCBLD2 repression in invasive malignant cells could be
similarly involved in dynamic modulation of cell migration during development.
1.9.2. DCBLD2 expression is associated with good prognosis in colorectal cancer
Pagnotta, et al. found that high levels of DCBLD2 expression coupled with low
NT5E expression in colorectal cancer (CRC) was a robust predictor of patient survival,
with 100% of the patients in the study surviving after 5 years (Pagnotta, Laudanna et al.
2013). Upregulation of NT5E is known to be important in tumor invasion and
metastasis (Zhang 2012). Pagnotta, et al. identified NT5E as a novel target gene of the
TNF/NFB inflammatory cascade in HEK293T cells (Pagnotta, Laudanna et al.
2013). PPAR, a nuclear receptor that represses cell growth and promotes
differentiation in epithelial cells (Pancione, Sabatino et al. 2010, Sabatino, Fucci et al.
2012) and is a known tumor suppressor via negative regulation of NFB (Remels,
Langen et al. 2009, Scirpo, Fiorotto et al. 2015), was found to also negatively regulate
NT5E expression (Pagnotta, Laudanna et al. 2013). The authors treated stable cell lines
derived from both colon carcinoma (RKO cells), which possess low levels of PPAR,
and colorectal adenocarcinoma (HT29 cells), which possess high levels of PPAR, with
TNF and found an increase in NT5E expression and a reciprocal decrease in
DCBLD2 expression in RKO cells, but not in HT29 cells (Pagnotta, Laudanna et al.
2013). When these same cells lines were treated with the PPAR agonist, DCBLD2
protein levels were dramatically increased in HT29 cells, but not in RKO cells
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(Pagnotta, Laudanna et al. 2013). These findings suggest that PPAR activity either
prevents degradation of DCBLD2 or directly interferes with TNF signaling.
Together with the observed AP-2-induced transcriptional repression of
DCBLD2 as well as the observed increase in DCBLD2 mRNA levels downstream of
PDGF signaling, the dynamic modulation of DCBLD2 levels by TNF/NFB and
alternatively by PPAR further underlines the importance of high regulation of
DCBLD2 expression, and likely of DCBLD2 protein stability, in distinct signaling
mechanisms governing cellular functions important both in developmental and in
oncogenic and metastatic processes.
1.9.3. DCBLD1 and DCBLD2 associations with EGFR-driven tumorigenesis and
progression
Although high levels of DCBLD2 can have inhibitory effects on tumorigenesis
and progression in some malignant cell types, DCBLD family members are also
associated with oncogenic properties in other cancers, including glioma, lung
adenocarcinoma, myxofibrosarcoma, neuroendocrine cancer, and head and neck cancer
(Table 3).
DCBLD2 was identified as a phosphotyrosine target downstream of EGFinduced activation of EGFR in a cervical cancer cell line (A431) (Chen, Low et al.
2007). DCBLD2 co-expression has also been shown to be important for hyperactive
EGFR-driven tumorigenesis in gliomas and head-and-neck cancers (HNCs) through a
DCBLD2 pTyr750-dependent mechanism of AKT activation (Feng, Lopez et al. 2014).
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Analysis of clinical specimens of gliomas and HNCs revealed that high levels of
pTyr1172 EGFR and pTyr750 DCBLD2 were severely correlated with decreased
patient survival (Feng, Lopez et al. 2014).
1.10. Signaling
The signaling roles of DCBLD1 and DCBLD2 in normal and diseased states
remain largely undefined, although a handful of publications provide insight into the
potential biological mechanisms involving this protein family (Figure 7) (Nagai, Sugito
et al. 2007, Guo, Nie et al. 2009, Aten, Redmond et al. 2013, Nie, Guo et al. 2013,
Feng, Lopez et al. 2014, Li, Jung et al. 2016, Johnson, Březinová et al. 2017,
Schmoker, Weinert et al. 2017).
1.10.1. Interface with receptor tyrosine kinases (RTKs)
The majority of publications investigating molecular interactors involving
DCBLD family members and their potential avenues of mechanistic signaling focus on
the interplay between DCBLD2 and the receptor tyrosine kinases EGFR, VEGFR,
PDGFR, and INSR. DCBLD2 co-expression has been shown to have both positive and
negative effects on signaling downstream of growth factors and hormones (Guo, Nie et
al. 2009, Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Li, Jung et al. 2016), however,
the specific mechanisms by which DCBLD2 differentially affects RTK-mediated
signaling are poorly understood.
Intracellular signaling following RTK activation involves differential activation
of a subset of generally conserved pathways, although the mechanisms of activation
36

and regulation can be highly variable across RTK families (Marshall 1995, Simon
2000, Lemmon and Schlessinger 2010). This may contribute to some of the observed
differences in DCBLD2-mediated RTK modulation. In general, a ligand binds to the
extracellular domain of a RTK, inducing dimerization and autophosphorylation within
the receptor’s intracellular domain, leading to the activation of downstream signaling
via complex formation surrounding intracellular phosphorylation sites of RTKs and/or
their substrates. RTK tyrosine phosphorylation can recruit and activate ubiquitin
ligases, leading to internalization of the receptor, from which RTKs are either recycled
to the plasma membrane or degraded. Determinants in receptor fate include protein
interactors, such as co-receptors, which can regulate the level and type of receptor
ubiquitylation.

Figure 7. Molecular interactions and signaling of DCBLD family members.
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A) SEMA4B increases ubiquitylation of DCBLD2, leading to degradation of plasma membrane
localized DCBLD2 (Nagai, Sugito et al. 2007). This likely occurs through an interaction between
the SEMA4B and DCBLD2 extracellular domains, leading to DCBLD2 intracellular
phosphorylation and the recruitment of E3 ubiquitin ligases. B) RHBDL2 activity releases the
DCBLD2 extracellular region, either allowing this cleaved protein to act as a paracrine signal or to
prevent DCBLD2 signaling through a ligand-binding mechanism (Johnson, Březinová et al. 2017).
C) DCBLD2 is a substrate of the endoplasmic reticulum (ER) localized protease RHBDL4
(Johnson, Březinová et al. 2017), likely as a result of misfolded DCBLD2. D) Extracellular ligand
binding clusters DCBLD2 molecules, leading to activation of constitutively-bound FYN and,
subsequently, cytosolic ABL (Aten, Redmond et al. 2013, Schmoker, Weinert et al. 2017). Both
kinases are stabilized via their SH2 domain at DCBLD2 FYN-/ABL-mediated pTyr sites.
CRK/CRKL are recruited to DCBLD2 pYXXP motifs, bringing with them unknown CRK/CRKLSH3 interactors (Aten, Redmond et al. 2013, Schmoker, Weinert et al. 2017). This mechanism
could conceivably be activated by SEMA4B (A). E) ABL-mediated DCBLD1 tyrosine
phosphorylation leads to the recruitment of CRK/CRKL to DCBLD1 pYXXP sites (Schmoker,
Weinert et al. 2017). Stimuli for ABL activation in this context are unknown. F) PDGF-BB binding
to PDGFR leads to upregulation of DCBLD2 expression and, subsequently, of the PDGFR
negative regulator c-Cbl (Kobuke, Furukawa et al. 2001, Guo, Nie et al. 2009). DCBLD2 could
recruit other negative regulators to or titrate positive regulators away from PDGFR. G) DCBLD2
promotes VEGFR2 internalization and downstream signaling through direct binding (Nie, Guo et
al. 2013). DCBLD2 could scaffold positive regulators of VEGFR2 signaling or titrate away
VEGFR2 phosphatases. H) DCBLD2 attenuates insulin signaling through a direct interaction with
INSR (Li, Jung et al. 2016). DCBLD2 alters the ratio of bound INSR negative regulators c-Cbl and
NEDD4, likely through the complexation of regulatory proteins (Li, Jung et al. 2016). For example,
the recruitment of cytoplasmic tyrosine kinases would increase phosphorylation of members within
the INSR complex, increasing the recruitment rate of negative regulators. I) Active EGFR
phosphorylates DCBLD2 at Tyr750, which resides within the preferred binding motif of TRAF6
(PXEXXpY) (Feng, Lopez et al. 2014). Membrane-recruited TRAF6 is autoubiquitylated and
activated, leading to TRAF6-mediated AKT ubiquitylation and translocation to the membrane,
where it is activated via phosphorylation of Thr308 and Ser473 (Feng, Lopez et al. 2014).

Drawing from the first description of DCBLD2, which reported its upregulation
during vascular remodeling and in response to PDGF-BB treatment in VSMCs
(Kobuke, Furukawa et al. 2001), Guo, et al. investigated the potential role of DCBLD2
in modulating signaling of PDGFRß, the primary VSMC receptor for PDGF-BB (Guo,
Nie et al. 2009). Following DCBLD2 siRNA-mediated knockdown, they observed a
subtle increase in PDGF-BB-induced activation of ERK1/2, SRC and, more robustly,
PDGFRß (Guo, Nie et al. 2009).
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Guo, et al. went on to show that DCBLD2 can alter the ratio of receptor boundto-unbound PDGF-BB, demonstrating that DCBLD2 KD increased the total amount of
PDGF-BB bound to VSMCs without affecting PDGFRß levels (Guo, Nie et al. 2009).
While it remains unclear whether this effect is through a direct interaction between
DCBLD2 and PDGFRß or indirectly via secondary messengers, these data suggest that
DCBLD2 interacts with PDGFRß or other PDGF-BB receptors to reduce the total
amount of bound ligand. The observed increase in bound PDGF-BB is most likely
attributed to increased surface levels of PDGF-BB receptors in the absence of
DCBLD2. This particular hypothesis has been tested (Guo, Nie et al. 2009), however,
the published results were inconclusive. The mechanism of the observed DCBLD2mediated decrease in bound PDGF-BB is not likely achieved by effecting a
conformation of PDGFRß that inhibits ligand binding regions from interacting with
PDGF-BB, as the receptor-ligand dissociation constant remained unaltered in WT and
DCBLD2 KD VSMCs (Guo, Nie et al. 2009). It remains possible that full-length
DCBLD2 is involved in intercellular interactions with PDGF-BB receptors or, given
the recent report that RHBDL2 mediates DCBLD2 ectodomain shedding (Johnson,
Březinová et al. 2017), the released ectodomain could compete for PDGF-BB receptor
binding sites. RHBDL2, is upregulated during wound healing and angiogenesis, and is
known to play important roles in the migratory and proliferative properties of
keratinocytes and endothelial cells (Cheng, Wu et al. 2011, Noy, Swain et al. 2016).
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In addition to investigating the effects of DCBLD2 on ligand binding, Guo, et
al. demonstrated a subtle decrease in PDGFRß ubiquitylation in the presence of
DCBLD2 siRNA and investigated whether DCBLD2 KD had an effect on the
expression of the E3 ubiquitin ligase c-Cbl, an important negative regulator of PDGFRß
(Joazeiro, Wing et al. 1999). They demonstrated that both c-Cbl protein and mRNA
were decreased by levels similar to DCBLD2 following siRNA-mediated DCBLD2 KD
(Guo, Nie et al. 2009). Although the implications of this relationship require further
investigation, it is possible that DCBLD2 promotes the expression of c-Cbl, thereby
indirectly modulating PDGFRß degradation and decreasing PDGFRß surface levels
(Figure 7F).

This group went on to create a Dcbld2-/- mouse, described above, and
investigated the effect of Dcbld2 knockout (KO) on the signaling of other RTKs. Nie,
et al. investigated the effect of Dcbld2 KO on VEGF signaling, given the similarity in
domain structure of DCBLD2 to that of neuropilins as well as the known role of Nrp1
as a co-receptor of VEGF165 with VEGFR2 (Soker, Takashima et al. 1998). In murine
lung endothelial cells (MLECs) derived from WT and Dcbld2-/- mice, they found that
Dcbld2 KO prevented VEGF-induced phosphorylation of eNOS, indicating that AKT
signaling was impaired in the absence of DCBLD2 (Nie, Guo et al. 2013). Further
investigation into signaling downstream of VEGF revealed a dramatic reduction in
VEGFR-induced ERK1/2 and AKT phosphorylation, with a more subtle effect on p38
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activity (Nie, Guo et al. 2013). This inconsistency with the observed effect on signaling
downstream of PDGFRß further supports the context-dependent nature of the effect of
DCBLD2 on RTK signaling.
In HUVECs, Nie, et al. (Nie, Guo et al. 2013) observed a modest DCBLD2
siRNA-mediated decrease in VEGF-induced VEGFR2 autophosphorylation of
Tyr1054/1059 in the kinase domain, Tyr1175, which regulates AKT and ERK1/2
signaling via SHB and PLC binding, respectively, and Tyr1214, which has been
implicated in CDC42/p38 activation (Olsson, Dimberg et al. 2006, Simons, Gordon et
al. 2016). This suggests that DCBLD2 could either promote VEGFR2 dimerization by
interacting with the receptor or its ligand, or prevent the complexation of VEGFR2 with
its negative regulators, such as phosphatases (Corti and Simons 2017) and VE-cadherin
(Rahimi and Kazlauskas 1999, Lampugnani, Orsenigo et al. 2006). They tested this
latter hypothesis in MLECs and found a subtle increase in levels of VEGFR2-bound
PTP1B, TCPTP, VE-cadherin in Dcbld2-/- cells (Nie, Guo et al. 2013). In addition, they
were able to marginally recover MAPK, Akt, and VEGFR2 phosphorylation by
knocking down expression of PTP1B and TCPTP in Dcbld2-/- cells, but not to the level
of activity observed in WT cells (Nie, Guo et al. 2013).
Internalization is a key step in VEGFR2 signaling post-ligand binding, and is
facilitated by EphrinB2 (Sawamiphak, Seidel et al. 2010) and potentially additional
interacting partners. DCBLD2 could play a role in the recruitment of positiveregulatory signaling molecules to the membrane that reduce binding of VEGFR2 to
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regulators that prevent receptor internalization, such as titrating away VEGFR2
phosphatases, or DCBLD2 could directly interact with VEGFR2 to promote its
internalization (Figure 7G). Nie, et al. observed co-immunoprecipitation of the two
transmembrane proteins (Nie, Guo et al. 2013), although it was not determined whether
this was through a direct interaction or as part of a larger signaling complex. VEGFR2
internalization is also negatively regulated by VEGFR1, which can titrate VEGF away
from VEGFR2 (Shibuya 2006, Failla, Carbo et al. 2018). It would be interesting to
investigate whether, like PDGFRß, DCBLD2 could affect VEGF binding to its
receptors, and whether DCBLD2 co-expression or knockdown could affect the ratio of
VEGF bound to VEGFR1 and VEGFR2. Interestingly, Nie, et al. did not find any
evidence of reduced c-Cbl expression in Dcbld2-/- MLECs (Nie, Guo et al. 2013),
which suggests that the observed effect of DCBLD2 on c-Cbl expression in smooth
muscle cells is indirect and is not a factor in endothelial cells. Alternatively, knocking
out DCBLD2 could allow for the development of compensatory mechanisms that
would be observed in the transient knockdown of gene expression.
c-Cbl is a known negative regulator of VEGFR2 signaling, promoting
degradation of the receptor (Duval, Bédard-Goulet et al. 2003, Rahimi 2009). However,
VEGFR2 requires internalization for proper signaling (Lampugnani, Orsenigo et al.
2006, Sawamiphak, Seidel et al. 2010), and the presence of Nrp-1 as a co-receptor
promotes sequestration in specific vesicles, altering the signaling output and preventing
VEGFR2 degradation (Ballmer-Hofer, Andersson et al. 2011). In environments rich in
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VEGFR2 and DCBLD2, DCBLD2 could similarly promote VEGFR2 signaling for a
specific output.

In addition to the alteration of VEGFR2 signaling in Dcbld2-/--derived ECs, Li,
et al. investigated the effect of Dcbld2 KO on insulin receptor (INSR) signaling (Li,
Jung et al. 2016). In liver and muscle tissue excised from Dcbld2-/- mice, insulininduced ERK1/2 and AKT activity was increased in Dcbld2-/- over WT mice (Li, Jung
et al. 2016). Li, et al., reported a subtle increase in INSR phosphorylation in Dcbld2-/liver, muscle and VSMCs (Li, Jung et al. 2016). More robustly, the authors observed a
marked increase of INSR ubiquitylation in Dcbld2-/- liver and muscle tissue in a manner
that was independent of insulin stimulation (Li, Jung et al. 2016), suggesting that
DCBLD2 constitutively inhibits INSR ubiquitylation. DCBLD2 could alter the
association of adaptors and regulatory proteins that modulate INSR phosphorylation
and activity, however, these would likely be constitutively bound if they were to affect
INSR ubiquitylation in unstimulated cells. Given the importance of ubiquitylation in
INSR activation and downstream signaling (Kishi, Mawatari et al. 2007), Li, et al.
focused on the potential for a DCBLD2-mediated interaction between INSR and the
adaptor proteins Grb10 and APS, which bring the INSR-regulatory E3 ubiquitin ligases
Nedd4 and c-Cbl to the membrane (Li, Jung et al. 2016).
In liver and muscle tissue excised from Dcbld2-/- mice, Li, et al. observed a
subtle increase and reciprocal decrease in INSR-associated APS/c-Cbl and
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Grb10/Nedd4, respectively (Li, Jung et al. 2016). More definitive findings were in the
combined effect of Dcbld2 KO and Grb10 or APS knockdown in VSMCs. A dramatic
increase in insulin-induced INSR activity in WT VSMCs in the absence of Grb10 was
observed (Li, Jung et al. 2016), which is consistent with the known negative regulatory
effect of Grb10 on INSR activity (Desbuquois, Carré et al. 2013). Strikingly, this
increase in INSR phosphorylation was abolished in Dcbld2-/- VSMCs treated with
GRB10 siRNA (Li, Jung et al. 2016). This suggests that the effect of DCBLD2 on
insulin receptor signaling is complex and is not simply explained by the promotion of
the Grb10/INSR complex and inhibition of the APS/INSR complex. Both the
Grb10/Nedd4 complex and DCBLD2 are presumed negative regulators of insulin
signaling, and yet DCBLD2 was required for INSR activation in the absence of Grb10
(Li, Jung et al. 2016). APS siRNA-mediated KD did reduce insulin-induced INSR
phosphorylation, although this appeared to be independent of DCBLD2 expression (Li,
Jung et al. 2016). Grb10 is known to attenuate INSR signaling by binding to multiple
phosphotyrosine residues that serve as docking points for downstream effectors of
insulin signaling via the Grb10 SH2 and BPS domains (Desbuquois, Carré et al. 2013).
Additionally, Grb10 prevents substrates from engaging with the binding pocket of the
INSR kinase domain by acting as a pseudo-substrate INSR inhibitor (Desbuquois,
Carré et al. 2013). DCBLD2 could act as a scaffold for cytoplasmic tyrosine kinases of
INSR, increasing the rate of INSR tyrosine phosphorylation, signal propagation, and
INSR downregulation.
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Although Grb10 and, to a lesser degree, APS, KD in Dcbld2 null cells have
potent and distinct effects on INSR activity, these INSR/adaptor interactions likely do
not explain the change in the observed insulin-independent INSR ubiquitylation state in
Dcbld2-/- cells (Li, Jung et al. 2016). Recruitment of these SH2 domain-containing
adaptors and their E3 ubiquitin ligase cargo requires insulin-induced tyrosine
phosphorylation of INSR (He, Rose et al. 1998, Liu, Kimura et al. 2002). Membrane
translocation of Grb10 or APS could also be mediated by DCBLD2 tyrosine
phosphorylation, which would bring the E3 ligase cargo in close proximity to INSR,
given the reported insulin-independent complexation of INSR and DCBLD2 (Li, Jung
et al. 2016). Conceivably, the loss of DCBLD2 expression could free available
adaptor/E3 ligase complexes or other INSR positive regulators that normally interact
with DCBLD2. In this manner, DCBLD2 could modulate insulin signaling by titrating
away certain positive regulators of INSR. For example, c-Cbl is a known negative
regulator of INSR through ubiquitin-mediated receptor internalization and degradation
(Ahmed, Smith et al. 2000, Sehat, Andersson et al. 2008), however, c-Cbl also directly
participates in and promotes glucose uptake in parallel to the canonical IRS/PI3K/AKT
pathway (Liu, Kimura et al. 2002, Liu, DeYoung et al. 2003). c-Cbl is recruited to the
INSR complex via APS where it is tyrosine-phosphorylated (Liu, Kimura et al. 2002).
c-Cbl can then migrate with the associated CAP to lipid rafts, leading to the recruitment
of CRK/C3G to c-Cbl phosphotyrosine residues, activation of TC10, and translocation
of the GLUT4 complex to the membrane for glucose transport (Liu, Kimura et al. 2002,
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Liu, DeYoung et al. 2003). The recruitment of cytoplasmic kinases (e.g. SFKs) to the
DCBLD2 intracellular scaffold downstream of insulin/INSR binding could promote
phosphorylation and c-Cbl-mediated ubiquitylation of downstream effectors, thereby
altering the pool of c-Cbl involved in positive vs. negative regulation of glucose uptake
(Figure 7H).

The signaling interface between DCBLD2 and EGFR, characterized in glioma
and HNC cell lines, has produced robust biochemical evidence. However, the particular
signaling pathway explored may not be a conserved mechanism, as it requires a
mammalian-specific TRAF6 binding motif (PXEXXY; Figure 4A). Feng, et al.
demonstrated that EGFR, activated through EGF-binding or mutation-induced
hyperactivity, phosphorylates DCBLD2 Tyr750, near its C-terminus, recruiting the E3
ubiquitin ligase TRAF6 (Feng, Lopez et al. 2014, Schmoker, Weinert et al. 2017).
Upon binding to the DCBLD2 PXEXXpY motif containing the EGFR substrate
tyrosine, the TRAF6 ubiquitin ligase is activated, inducing AKT ubiquitylation and
ultimately resulting in AKT activation via ubiquitin-mediated translocation of AKT to
the plasma membrane (Yang, Wang et al. 2009). Interestingly, they demonstrated that
DCBLD2 pTyr750 is not induced by HGF or PDGF-A in variety of cell types (343T,
SNB19, PCI-15B, A375), further supporting the evidence of DCBLD2 contextdependent phosphorylation and signaling. Whether additional DCBLD2 tyrosine
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residues are phosphorylated in these cell lines downstream of EGF, HGF, and PDGF-A,
as well as directly by the EGFR, remains to be determined.
1.10.2. Signaling via SFKs and Abl
In addition to RTK-dependent signaling, there is evidence to suggest that
DCBLD1 and DCBLD2 might participate in RTK-independent signaling. DCBLD
proteins are known to act as scaffolds for the SRC homology 2 (SH2) domain of the
ubiquitously-expressed adaptor protein CRKL which, along with its homolog CRK,
plays central roles in cytoskeletal and focal adhesion dynamics, among many other
fundamental cellular processes (Feller 2001). The CRK/CRKL-SH2 domain binds
phosphorylated tyrosine residues in YXXP motifs, which is the preferred substrate
motif of several receptor and non-receptor tyrosine kinases, including ABL and SFKs
(Schmoker, Driscoll et al. 2018). The interaction between DCBLD proteins and CRKL
requires SFK- and/or ABL-induced phosphorylation of intracellular tyrosine residues
within YXXP motifs (Aten, Redmond et al. 2013, Schmoker, Weinert et al. 2017),
although it remains formally possible that other kinases are also involved. Whether this
interaction is dependent or independent of RTK signaling remains unexplored.
The DCBLD2/CRKL-SH2 interaction was first described by Aten, et al., and
emerged from a proteomics screen that aimed to identify SFK-induced binding partners
of the CRKL-SH2 domain in HEK293 cells. They demonstrated that SFKs and FYN,
specifically, could induce DCBLD2 to bind the CRKL-SH2 domain, and that this
interaction required phosphorylation of at least one of the seven intracellular YXXP
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motifs within the DCBLD2 sequence (Aten, Redmond et al. 2013). In addition, they
identified the FYN-SH2 domain as novel pYXXP-dependent DCBLD2 interactor
(Aten, Redmond et al. 2013), suggesting a possible mechanism by which FYN could be
stabilized in its active conformation upon binding to DCBLD2 pTyr residues. In
support of an RTK-independent mechanism of DCBLD2 signaling, they demonstrated
that DCBLD2 tyrosine phosphorylation could be induced by adding a DCBLD2
ectodomain-specific antibody (Aten, Redmond et al. 2013), thereby clustering the
transmembrane proteins. Possessing no intracellular kinase domain, DCBLD2
phosphorylation upon receptor clustering would require a constitutively-bound kinase
or other regulatory protein normally in an inactive state that, upon clustering, could
autophosphorylate/autoactivate and either directly phosphorylate/modify DCBLD2
and/or lead to the recruitment of other tyrosine kinases to the membrane. While this
evidence of a potential RTK-independent pathway is interesting and likely important,
an extracellular ligand that can induce DCBLD2 dimerization has yet to be discovered.
Schmoker, et al. described a similar and yet differentially regulated interaction
between DCBLD1 and CRKL. Although FYN kinase activity was sufficient to induce a
subtle DCBLD1/CRKL-SH2 interaction, the effect of FYN on DCBLD2/CRKL-SH2
binding was more robust (Schmoker, Weinert et al. 2017). Further, the effect of FYN
co-expression on induction of the DCBLD1/CRKL-SH2 interaction was much weaker
than the induction by H2O2 treatment (Schmoker, Weinert et al. 2017), which increases
cellular levels of tyrosine phosphorylation by endogenous kinases. This suggested that

48

another kinase was involved in mediating this interaction, and lead to the identification
of ABL as non-receptor tyrosine kinase that could mediate the interaction between
DCBLD1/2 and the CRKL-SH2 domain (Schmoker, Weinert et al. 2017). ABL was
shown to be more important for the DCBLD1/CRKL-SH2 interaction while DCBLD2
was equally induced to bind the CRKL-SH2 domain by FYN and ABL (Figure 7D,E)
(Schmoker, Weinert et al. 2017). These findings were further supported by the mapping
and quantification of FYN- and ABL-induced tyrosine phosphorylation sites using
mass spectrometry, which demonstrated that ABL was the primary kinase of DCBLD1,
while FYN and ABL were found to phosphorylate both common and distinct YXXP
and non-YXXP DCBLD2 tyrosine residues (Schmoker, Weinert et al. 2017). As was
demonstrated for the FYN-SH2 domain by Aten, et al. (Aten, Redmond et al. 2013), the
ABL-SH2 domain was found to bind to DCBLD2 in a pYXXP-dependent manner
using site-directed mutagenesis (Figure 7D) (Schmoker, Weinert et al. 2017).

As both FYN and ABL can be activated downstream of RTKs, phosphorylation
of DCBLD1 and DCBLD2 by these non-RTKs is likely also a factor in RTK signaling.
Although the interface of DCBLD2 with RTKs is likely important in developmental
and tumorigenic processes, it will be interesting to explore the implications of nonRTK-related DCBLD2 signaling defined by the binding of an as of yet unknown
ligand. The increased ubiquitylation state of DCBLD2 observed with co-expression of
SEMA4B coupled with the loss of the highest molecular weight variant of DCBLD2
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(Nagai, Sugito et al. 2007) suggests that SEMA4B could be a ligand of DCBLD2. This
highest molecular weight variant was shown to be the product of glycosylation and
could represent the fraction of fully matured DCBLD2 that is localized at the plasma
membrane, which is degraded in the presence of SEMA4B (Figure 7A) (Nagai, Sugito
et al. 2007). SEMA4B-mediated clustering of DCBLD2 could activate bound SFKs,
leading to phosphorylation of DCBLD2 tyrosine residues and the recruitment of
CRK/CRKL (Figure 7D), as well as negative regulatory molecules including ubiquitin
ligases. As the induction of signaling related to DCBLD1 phosphorylation has yet to be
explored, it will be important to determine whether DCBLD1 is similarly activated by
RTKs or whether DCBLD1 phosphorylation can be achieved by DCBLD1 clustering.
1.11. Future Perspectives and Outlook
The body of investigations into the DCBLD receptor family discussed here
reveal that cellular context is highly influential in determining the outcomes of
DCBLD2 expression and signaling, at both the cellular and organismal levels.
Temporal regulation of DCBLD2 action is achieved through modulating expression and
stability of the scaffolding receptor, although the precise function of DCBLD2, and
whether DCBLD1 expression is similarly regulated, remains unknown. The dynamic
crosstalk between ECs, SMCs, pericytes, and fibroblasts governed by receptor/ligand
interactions during angiogenesis and neovascularization facilitates the migration and
proliferation of these cell types at precise time-points. Similar interactions are essential
to proper neuronal migration and pathfinding, as well as cancer cell invasion and
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metastasis (Autiero, De Smet et al. 2005, Carmeliet and Tessier-Lavigne 2005,
Klagsbrun and Eichmann 2005, Raimondi and Ruhrberg 2013). The implications of
DCBLD2 in blood vessel (Kobuke, Furukawa et al. 2001, Sadeghi, Esmailzadeh et al.
2007, Nie, Guo et al. 2013), and in tumorigenesis and metastasis (Koshikawa, Osada et
al. 2002, Chen, Low et al. 2007, Nagai, Sugito et al. 2007, Hofsli, Wheeler et al. 2008,
Feng, Lopez et al. 2014, Kikuta, Kubota et al. 2017, Raman, Maddipati et al. 2018),
suggest that its functions, likely involving receptor/ligand interactions, are similarly
conserved throughout these processes.
Known DCBLD2 molecular interactors are closely related to those of
neuropilins in their angiogenic roles. Neuropilins (Nrps) bind Class III semaphorins and
VEGF165 in tandem with and separately from VEGFR2 (Anil Karihaloo 2005). Nrp1
acts as a co-receptor for VEGFR2 and enhances the VEGF165/VEGFR2 interaction (Gu,
Limberg et al. 2002, Soker, Miao et al. 2002), while the SEMA3A/Nrp1 interaction
prevents VEGF form binding the Nrp1/VEGFR2 complex (Parker, Xu et al. 2012,
Palodetto, Duarte et al. 2017). SEMA4B binds to DCBLD2 and induces its
ubiquitylation and, presumably, its degradation, suggesting that SEMA4B acts to
attenuate DCBLD2 action (Nagai, Sugito et al. 2007). SEMA4B could act as a
repulsive cue by inducing DCBLD2 degradation in migrating cells, thereby affecting
focal adhesions or cytoskeletal dynamics. SEMA4B is known to potently inhibit AKTdriven metastasis of non-small cell lung cancers (Jian, Zhao et al. 2015), indicating a
potential link to the role of DCBLD2 downstream of EGFR in aberrant AKT signaling.
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DCBLD2 also modulates VEGF-induced VEGFR2 activation, although it is not yet
known whether this occurs through a co-receptor mechanism or otherwise.
During angiogenic migration, endothelial tip cells extend lamellopodia toward a
VEGF gradient to stimulate VEGFR2 signaling, and secrete PDGF-BB to recruit
PDGFRß-expressing pericytes and SMCs. DCBLD2 promotes growth factor-mediated
signaling, proliferation, and growth in ECs through VEGF/VEGFR2, while attenuating
the same processes in SMCs through PDGF-BB/PDGFRß (Guo, Nie et al. 2009, Nie,
Guo et al. 2013). However, a population of RTKs are expressed within a given cell
type, therefore, the action of DCBLD2 on the signaling of a specific RTK within a
specific cell type may not be a sufficient representation of DCBLD2 function. This is
further complicated by our evolving understanding of the promiscuity of growth
factor/RTK interactions, such as PDGF/VEGFR and VEGF/PDGFR interactions
(Rolny, Nilsson et al. 2006, Ball, Shuttleworth et al. 2007, Mamer, Chen et al. 2017).
Although DCBLD2 was found to decrease PDGFRß signaling in SMCs (Guo, Nie et al.
2009), the effect on the signaling of PDGFRß or of other RTKs in ECs was not
considered. DCBLD2 could play a role in determining the fate of cells within a
population migrating toward a permissive signal; for example, DCBLD2 could promote
VEGFR2 signaling in cells in close proximity to concentrated VEGF while attenuating
signaling through other RTKs within the same cell type.
The binding of different ligands to RTKs is known to modulate the amount of
time a signal is propagated and, therefore, the phenotypic outcome of the receptor-
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ligand interaction. Co-receptors also influence these interactions by altering receptor
conformation, post-translational modifications and protein-protein interactions, and
therefore downstream signaling events. DCBLD2 could act as a co-receptor for certain
RTKs, to alter the phenotypic outcome of the signal. Internalization of VEGFR,
PDGFRß, EGFR, NGF, FGF, and TGFß receptors is known to promote their signaling
from endosomal compartments (Wiley and Burke 2001, Suyama, Shapiro et al. 2002,
Wang, Pennock et al. 2004, Bryant, Wylie et al. 2005, Sigismund, Woelk et al. 2005,
Lampugnani, Orsenigo et al. 2006, Chen 2009), while INSR is thought to signal
predominately at the cell surface, although some evidence of INSR endosomal
signaling has been reported (Wiley and Burke 2001). Although the evidence of cellular
environment and molecular context surrounding DCBLD2/RTK interactions are
variable across studies, the unifying features, either implied or explicitly demonstrated,
include DCBLD2-mediated regulation of i) expression/association of RTK-regulators
including phosphatases and ubiquitin ligases, and ii) surface levels of RTKs, which can
either promote or attenuate downstream signaling. Our current understanding of the
DCBLD2/RTK interface implies that DCBLD2 could affect receptor fate postinternalization, potentiating RTK membrane recycling, degradation, or vesicular
sequestration.
Although there remains much to uncover surrounding the characterization of
DCBLD1/2 signaling and the resulting functional implications, the preliminary
investigations discussed here demonstrate the importance of this understudied receptor
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family in modulating the phenotypic outcomes of several well-studied systems. Future
studies will need to focus on distinguishing ligand induced DCBLD2 signaling from its
interface with RTK signaling, and to determine whether these mechanisms are
conserved in DCBLD1 functionality. Given the conservation of these protein sequences
among vertebrates, and their apparent roles in fundamental biological processes,
DCBLD1 and DCBLD2 will likely emerge as important subjects of study in
understanding vertebrate development, and in the improvement of therapeutic agents to
combat progression of certain cancers.
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CHAPTER 2: DYNAMIC MULTI-SITE PHOSPHORYLATION BY FYN AND
ABL DRIVES THE INTERACTION BETWEEN CRKL AND THE NOVEL
SCAFFOLDING RECEPTORS DCBLD1 AND DCBLD2
2.1. Abstract
Discoidin, CUB, and LCCL Domain-containing (DCBLD) 2 is a neuropilinlike transmembrane scaffolding receptor with known and anticipated roles in vascular
remodeling and neuronal positioning. DCBLD2 is also upregulated in several cancers
and can drive glioblastomas downstream of activated Epidermal Growth Factor
Receptor. While a few studies have shown either a positive or negative role for
DCBLD2 in regulating growth factor receptor signaling, little is known about the
conserved signaling features of DCBLD family members that drive their molecular
activities. We previously identified DCBLD2 tyrosine phosphorylation sites in
intracellular YXXP motifs that are required for the phosphorylation-dependent binding
of the signaling adaptors CRK and CRKL (CT10 regulator of kinase and CRK-Like).
These intracellular YXXP motifs are highly conserved across vertebrates and between
DCBLD family members. Here, we demonstrate that, as for DCBLD2, DCBLD1
YXXP motifs are required for CRKL-SH2 binding. We report SRC family kinases
(SFKs) and ABL differentially promote the interaction between the CRKL-SH2
domain and DCBLD1 and DCBLD2, and while SFKs and ABL each promotes
DCBLD1 and DCBLD2 binding to the CRKL-SH2 domain, the effect of ABL is more
pronounced for DCBLD1. Using high performance liquid chromatography coupled
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with tandem mass spectrometry, we quantified phosphorylation at several YXXP sites
in DCBLD1 and DCBLD2, mapping site-specific preferences for SFKs and ABL.
Together these data provide a platform to decipher the signaling mechanisms by which
these novel receptors drive their biological activities.
2.2. Abbreviations
Proper neurodevelopment requires precise temporal and spatial regulation of a
complex array of signaling molecules, the regulation of which remains largely
uncharacterized. CT10 regulator of kinase (CRK) and
2.3. Introduction
Proper neurodevelopment requires precise temporal and spatial regulation of a
complex array of signaling molecules, the regulation of which remains largely
uncharacterized. CT10 regulator of kinase (CRK) and CRK-like (CRKL) are
ubiquitously expressed intracellular signaling adaptors critical to neuronal positioning
in the embryonic brain, as well as to many fundamental cellular processes such as
proliferation, differentiation, apoptosis, and focal adhesion dynamics (Feller 2001,
Nakamura, Komiya et al. 2002, Ballif, Arnaud et al. 2004, Chodniewicz and Klemke
2004, Park and Curran 2014). CRK and CRKL each possess a single SRC homology 2
(SH2) domain that binds to phosphorylated tyrosine residues in YXXP motifs, linking
signaling molecules harboring such motifs with downstream effectors bound to the
CRK and CRKL SH3 domains.
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Previously, we reported a proteomics screen for novel SRC Family Kinase
(SFK) substrates that, when phosphorylated, would bind to the CRKL SH2 domain
(Aten, Redmond et al. 2013). This screen identified the transmembrane protein
Discoidin, CUB, and LCCL domain-containing 2 (DCBLD2; also endothelial and
smooth muscle cell-derived neuropilin-like, ESDN) as a novel phosphotyrosinedependent CRKL-SH2 binding partner. DCBLD2 possesses a similar ectodomain
structure to that of neuropilins, critical co-receptors for guidance cues in neuronal
pathfinding. The seven YXXP motifs residing within the intracellular sequence of
DCBLD2 are highly conserved among vertebrates, and are essential for the
phosphorylation-dependent binding of DCBLD2 to the CRKL SH2 domain.
Furthermore, it was determined that SFKs were sufficient for, but not the only tyrosine
kinases capable of, inducing the interaction of DCBLD2 with CRKL. Our initial study
also identified four specific sites on DCBLD2 of regulated tyrosine phosphorylation,
three of which were in YXXP motifs (Aten, Redmond et al. 2013).
DCBLD2 has been reported to be involved in vasculature remodeling (Kobuke,
Furukawa et al. 2001, Sadeghi, Esmailzadeh et al. 2007, Nie, Guo et al. 2013, Feng,
Lopez et al. 2014) and insulin sensitivity (Li, Jung et al. 2016), and is also upregulated in a variety of cancers (Koshikawa, Osada et al. 2002, Kim, Lee et al. 2008,
Osella-Abate, Novelli et al. 2012). While relatively little is known about the specific
molecular mechanisms by which DCBLD2 transduces or modulates signals, DCBLD2
has been shown to both positively and negatively regulate receptor tyrosine kinase
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(RTK) signaling (Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Li, Jung et al. 2016).
DCBLD2-deficient mice show lower blood glucose levels and increased insulininduced activation of MAPK and AKT (Li, Jung et al. 2016). In cultured vascular
smooth muscle cells, DCBLD2 knockdown similarly shows an increase in PDGFinduced stimulation of MAPK (Guo, Nie et al. 2009). These data suggest that
DCBLD2 might normally inhibit RTK signaling. However, VEGF-dependent
activation of MAPK in DCBLD2-deficient mice is reduced, suggesting a single mode
of action is insufficient to describe how DCBLD2 regulates RTK signaling. One way
by which DCBLD2 might regulate insulin and PDGF signaling is by altering the levels
of ubiquitin ligases in complex with RTKs as was shown for the insulin receptor (IR).
This in turn can regulate the ubiquitination, internalization and degradation of RTKs
and therefore their signaling capacity (Guo, Nie et al. 2009, Li, Jung et al. 2016). In
VEGF signaling, DCBLD2 was shown to reduce the binding of tyrosine phosphatases
to the VEGFR and this may be how DCBLD2 increases VEGF signaling to MAPK
(Nie, Guo et al. 2013).
In the mechanisms described above, the roles of DCBLD2 tyrosine
phosphorylation were not explored. However, in the case of oncogenic EGFR
signaling, DCBLD2 was shown to be phosphorylated at Tyr750 thereby activating a
TRAF6-AKT pathway (Feng, Lopez et al. 2014). TRAF6 binding to DCBLD2
requires phosphorylation of Tyr750 in a PxEXXY motif (Feng, Lopez et al. 2014).
This motif at Tyr750 is conserved in DCBLD2 across many, but not all vertebrates.
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On the other hand, a more striking motif conservation is embodied by DCBLD2’s
seven intracellular YXXP motifs. These YXXP motifs are not only highly conserved
among DCBLD2 orthologs, but they are also highly conserved in their related paralog,
DCBLD1, which harbors eight YXXP motifs (Figure 8). While to date almost all
studies involving DCBLD2 have importantly focused on the interaction of DCBLD2
with RTKs, we have proposed that the clustering of DCBLD proteins by unknown
ligands could be an important RTK-independent mechanism of DCBLD signaling
(Aten, Redmond et al. 2013). In order to understand how these conserved motifs might
participate in non-RTK or RTK signaling pathways it is important to establish the
contribution of specific kinases to the phosphorylation of specific YXXP motifs on
DCBLD proteins. In this study we used biochemical methods and several quantitative
mass spectrometry approaches to characterize the phosphorylation of DCBLD proteins
by the non-receptor tyrosine kinases of the SRC and ABL families, both known to
specifically target YXXP motifs (Ballif, Carey et al. 2007), and both known to be
activated by both RTK-dependent and RTK-independent signaling mechanisms
(Pendergast 2002, Bromann, Korkaya et al. 2004, Roskoski 2005, Colicelli 2010,
Greuber, Smith-Pearson et al. 2013). We also evaluated how well phosphorylation by
SFKs and ABL family kinases induces the interaction of DCBLD proteins with the
SH2 domain of CRKL. Our results uncovered distinct site-specific differences in the
regulation of DCBLD1 and 2 by SFKs and ABL kinases.
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Figure 8. DCBLD1 and DCBLD2 YxxP sites are conserved across vertebrates and family
members.
Domain structure, YxxP motif locations (blue), and alignments of transmembrane (green)
through C-terminal sequences of (A) DCBLD1 and (B) DCBLD2 from four model vertebrates (Hs
= human, Mm = mouse, Rn = rat, Dr = zebrafish) are shown below with percent identity of amino
acids tabulated in (C). Further, five YxxP sites are conserved between human DCBLD1 and
DCBLD2 (D).

2.4. Experimental
2.4.1. Multiple sequence alignments
Multiple sequence alignments were constructed with the UniProt Align tool
(EMBL-EBI, Cambridge, United Kingdom; SIB Swiss Institute of Bioinformatics,
Geneva, Switzerland; Protein Information Resource, Washington, DC, USA).

70

Conservation of intracellular amino acids and YXXP motifs was examined across
representative model vertebrates: DCBLD1 homo sapiens (Hs, Q8N8Z6), mus
musculus (Mm, Q9D4J3), rattus norvegicus (Rn, D3ZFM7), danio rerio (Dr F1QGI1);
DCBLD2 Hs (Q96PD2), Mm (Q91ZV3), Rn (Q91ZV2), Dr (B0S5V9).
2.4.2. Materials
Penicillin/Streptomycin 100X solution and Dulbecco’s Modified Eagle
Medium (DMEM) were obtained from Mediatech (Manassas, VA, USA). SILAC
media and kanamycin sulfate were acquired from Thermo Scientific (Waltham MA,
USA), and fetal bovine serum (FBS), dialyzed FBS for SILAC experiments, and
cosmic calf serum (CCS) were purchased from Hyclone (Logan, Utah, USA). Heavy
labeled L-arginine (13C6, 15N4) and L-lysine (13C6, 15N2) were obtained from
Cambridge Isotope Laboratories Inc. (Tewksbury, MA, USA), and unlabeled Larginine (12C6, 14N4) and L-lysine (12C6, 14N2) were purchased from MP Biomedicals
(Santa Ana, CA, USA). The ProFection® Mammalian Transfection System kit for
calcium phosphate transfections and the trypsin used in enzymatic digests prior to LCMS/MS analysis were from Promega (Madison, WI, USA). Calf Intestinal
Phosphatase (CIP) was obtained from New England Biolabs (Ipswich, MA, USA).
The SFK inhibitor SRC-1 was purchased from EMD-Calbiochem (Billerica, MA,
USA) and Imatinib (STI571), the ABL-specific inhibitor, was acquired from
Selleckchem (Houston, TX, USA). The BSA standard for Bradford assays and the
Bradford Reagent were obtained from Amresco Life Sciences, LLC. (Cleveland, OH,
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USA). For the development of Western blots, enhanced chemiluminescence (ECL)
reagents were purchased from Pierce (Rockford, IL, USA), and x-ray film was from
Denville scientific (Metuchen, NJ, USA). Synthetic stable isotope-labeled peptide
standards (SL peptides) were from Cell Signaling Technologies (Danvers, MA, USA).
Packing material used for HPLC was 5 µm C18-coated silica beads, 200 Å pore size,
purchased from Michrom Bioresources Inc. (Auburn, CA, USA). Nitrocellulose
membranes were from GVS Life Sciences (Sanford, ME, USA). All additional
reagents were purchased from Sigma (St. Louis, MO, USA) unless otherwise noted.
2.4.3. Plasmids
Mammalian expression constructs for full-length DCBLD2 (Hs) and DCBLD1
(Mm) in pCMV6-Entry, tagged with Flag and Myc sequences at C-termini, were
obtained from Origene (#RC224483 and #MR206887 respectively; Rockville, MD,
USA). Wild-type (WT) FYN (Mariotti, Kedeshian et al. 2001) and kinase dead
(K299M) FYN (Mariotti, Kedeshian et al. 2001) plasmids in pRK5-Entry were
acquired from AddGene (Cambridge, MA, USA). The human c-ABL construct, with a
C-terminal Flag tag was kindly gifted by A. Howe (U. of Vermont), originally
constructed in the Kufe lab (Harvard Medical School) (Cao, Leng et al. 2003).
DCBLD2 mutant constructs: DCBLD2-Y1F (Tyr750Phe), DCBLD2-Y3F
(Tyr750Phe, Tyr732Phe, Tyr565Phe), and DCBLD2-Y7F (Tyr750Phe, Tyr732Phe,
Tyr677Phe, Tyr666Phe, Tyr655Phe, Tyr621Phe, Tyr565Phe) were described
previously (Aten, Redmond et al. 2013). The C-terminal Myc- and Flag-tagged
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DCBLD1 WT and mutant DCBLD1-Y8F (Tyr540Phe, Tyr578Phe, Tyr589Phe,
Tyr600Phe, Tyr621Phe, Tyr652Phe, Tyr665Phe, and Tyr696Phe) constructs in
pCMV6 vectors were synthesized by Bio Basic Inc. (Markham, ON). The bacterial
expression plasmids encoding the fusion of glutathione S-transferase with the CRKLSH2 domain (GST-CRKL-SH2) and GST-ABL-SH2 were kindly gifted by A.
Imamoto (U. of Chicago) and S. Kornbluth (Duke U.), respectively.
2.4.4. Antibodies
The mouse α-Flag (M2) antibody (Ab) and Affinity Gel were from Sigma and
the free Ab was used for Western blotting at a concentration of 0.5 µg/mL. Cell
Signaling Technologies Inc. (Danvers, MA, USA) was the source of the following
antibodies, used at the indicated dilution or concentration: α-Flag (M2, rabbit mAb;
1:1000), α-FYN (rabbit mAb; 1:2000), α-SRC (rabbit mAb; 1:2000), α-pTyr416-SRC
(rabbit mAb; 1:5000), α-pTyr412-ABL (rabbit mAb; 1:1000), α-alpha-tubulin
(1:1000), and α-pan-actin (0.1 µg/mL). The rabbit α-ABL antibody (K-12, 0.2 µg/mL)
was from Santa Cruz Biotechnology (Dallas, TX, USA). The α-phosphotyrosine
(4G10; 1:1000) was from EMD Millipore (Billerica, MA, USA) and the α-Myc (9E10;
1:1000) was obtained from American Type Tissue Collection (Manassas, VA, USA).
All primary antibodies were diluted in 1.5% BSA in Tris-Buffered Saline (0.9% NaCl,
0.4% Tris-HCl, and 0.1% Tris-base) with 0.05% Tween 20 (TBS-T) and containing
0.005% sodium azide. Horseradish peroxidase (HRP)-conjugated secondary antibodies
were obtained from EMD Millipore and used at the following concentrations: goat α-
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mouse IgG-HRP (1:5,000), light-chain-specific goat α-mouse IgG-HRP (1:10,000) and
goat α-rabbit IgG-HRP (1:15,000). All secondary antibodies were diluted in TBS-T.
2.4.5. Cell culture, transfection, inhibitors, stimulation, and cell lysis
Adenovirus early region transformed HEK 293 cells were cultured in DMEM
supplemented with 5% each of FBS and CCS, 50 U/mL penicillin, and 50 μg/mL
streptomycin at 37 ˚C in 5% atmospheric CO2. For experiments involving stable
isotope labeling of amino acids in cell culture (SILAC), HEK 293 cells were cultured
in labeled (heavy) or unlabeled (light) growth medium for at least one week prior to
transfection to ensure full incorporation of stable isotopes into proteins. SILAC media,
lacking L-lysine and L-arginine were supplemented with 10% dialyzed FBS and
antibiotics as stated above, 60 mg/L unlabeled L-proline, 100 mg/L of L-lysine either
unlabeled or labeled (13C6, 15N2), and 100 mg/L of L-arginine either unlabeled or
labeled (13C6, 15N4).
HEK 293 cells were grown to 60% of confluence prior to transfection via
calcium phosphate precipitation. The following amount of plasmid was transfected per
10 cm dish: wild type and mutant DCBLD1 and DCBLD2 (6 µg), wild type FYN (1.5
µg), kinase-dead FYN (2.5 µg), and wild type c-ABL (2 µg). Six hours posttransfection, cells were washed with phosphate-buffered saline (PBS) and returned to
full medium overnight before lysis. Cells treated with inhibitors received 2 µM SRC-1
and/or 20 µM STI571 in dimethyl sulfoxide (DMSO) for 15 min at standard culture
conditions, prior to stimulation with 8.8 mM H2O2 (15 min, with or without inhibitor
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treatment). Cells were placed on ice immediately following H2O2 stimulation and
washed with PBS (4 ˚C) prior to lysis in Brain Complex Lysis Buffer (BCLB: 25 mM
Tris pH 7.2, 137 mM NaCl, 10% glycerol, 1% igepal, 25 mM NaF, 10 mM
Na2H2P2O7, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/mL
each leupeptin and pepstatin-A). Lysates were centrifuged and the supernatant was
reserved and stored at -20 ˚C for further analysis.
2.4.6. Immunoprecipitation, Western blotting and SDS-PAGE
Protein concentration was determined using an Eppendorf BioPhotometer Plus
(Eppendorf; Hamburg, Germany) with BSA standards. For immunoprecipitations,
normalized lysates (103 µg total protein in 750 µL) were incubated with α-Flag
Affinity Gel (10 µL of a 50 % slurry in BCLB) overnight, rocking at 4 ˚C. The beads
were washed four times with BCLB, after which bound proteins were eluted and
denatured in 25 µL sample buffer (150 mM Tris pH 6.8, 2% SDS, 5% βmercaptoethanol, 7.8% glycerol, 0.25 ng/mL bromophenol blue) at 95 ˚C for 5 min.
For Western blotting of whole cell lysates, samples were denatured in sample buffer
and 15 µg total protein was loaded per lane. Immunoprecipitations, pull-downs, whole
cell lysates, and phosphatase assays were separated on 10% acrylamide gels (30% w/v
and 37.5:1 acrylamide:bis-acrylamide) with 4.2% acrylamide stacking gels. Current
was maintained at 20 mA and 30 mA per gel through the stacking and separating
layers, respectively. Following separation, proteins were either transferred to a
nitrocellulose membrane for Western blotting or stained with Coomassie for mass
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spectrometric analysis. Transfers to nitrocellulose membranes were in a submersible
transfer unit at 4 ˚C (400 mA for 2 hours) in 1.13% glycine, 0.25% Tris-base and 20%
methanol. Membranes were stained with a reversible Ponceau stain (0.5% Ponceau
and 1% acetic acid in H2O) to assess total protein levels and were then blocked with
5% non-fat dry milk in TBS-T. Primary antibody solutions were incubated overnight
at 4 ˚C. Membranes were then washed three times with TBS-T and incubated with
HRP-conjugated secondary antibody solution for three hours at 25 ˚C. After three final
washes in TBS-T, membranes were briefly incubated in ECL reagents and exposed to
x-ray film.
2.4.7. Phosphatase assay
Anti-Flag resin was added to cell extracts containing 1 mg of protein in 500 µL
BCLB as described above. After washing three times with BCLB and once with PBS,
the resin from each immunoprecipitation was divided equally into two separate tubes
and drained. Resins were resuspended in 50 µL Calf Intestinal Phosphatase (CIP)
Buffer (100 mM NaCl, 1 mM Tris-HCl pH 8.0, 10 mM MgCl2, 1 mM 1,4dithiothreitol) with or without 2.5 units of CIP, after which all samples were incubated
at 37 ˚C on a dry block for 3 hours. Proteins were eluted and denatured at 95 ˚C after
the addition of 4x protein sample buffer. Denatured proteins were prior subjected to
SDS-PAGE and Western blotting.
2.4.8. GST-CRKL-SH2 pull-down assay
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To generate GST-CRKL-SH2-conjugated glutathione beads, 50 mL cultures of
Luria Broth (LB; 0.5% Tryptone, 0.5% yeast extract, 171 mM NaCl) containing 50
µg/mL ampicillin were inoculated with E. Coli harboring a plasmid encoding GSTCRKL-SH2 and incubated overnight at 37 ˚C, shaking at 250 rpm. This initial culture
was then spiked into 500 mL LB with ampicillin, and incubation was continued for 2
hours, at which time expression was induced by the addition of isopropyl β-D-1thiogalactopyranoside (IPTG) to 1 mM, followed by an additional 4 hours of
incubation. Cultures were then centrifuged at 4 ˚C (6,000 x g, 20 min). The
supernatants were decanted and the pellets were stored at -20 ˚C. Pellets were
resuspended in 10 mL Bacterial Lysis Buffer (BLB; 100 mM EDTA, 1 mM PMSF, 10
µg/mL each leupeptin and pepstatin-A in PBS). Cells were sonicated in six 30 sec
intervals, intermitted with equal rest periods on ice, after which 1 mL of 10% Triton
X-100 was added. Lysates were mixed and centrifuged at 4 ˚C (12,000 x g, 20 min)
and pellets were discarded. Glutathione resin (300 µL of a 50% slurry in BLB) was
added to the GST-CRKL-SH2-enriched supernatant and rocked overnight at 4 ˚C.
Beads were washed three times in BLB, once in BCLB, and twice in PBS and then
stored in PBS at 4 ˚C. For pull-down assays, HEK 293 cell lysates were rocked with
15 µL GST-CRKL-SH2-conjugated glutathione beads (30% slurry in PBS) at 4 ˚C.
Beads were washed three times with BCLB and proteins were eluted and denatured in
25 µL of sample buffer at 95 ˚C for 5 min prior to analysis via SDS-PAGE and
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Western blotting. GST-ABL-SH2-conjugated beads were obtained using the protocol
outlined above, after which the purified protein was eluted with 10 mM glutathione.
2.4.9. Peptide preparation, mass spectrometry, data analysis and statistics
Bands containing immunoprecipitated proteins of interest were excised from
Coomassie-stained acrylamide gels, diced to 1 mm cubes and transferred to separate
microcentrifuge tubes. Gel pieces were washed with HPLC-grade H2O and then destained in 50 mM ammonium bicarbonate (NH4HCO3) and 50% acetonitrile (MeCN)
at 37 ˚C for 30 minutes. De-stain was then removed and gel pieces were dehydrated in
100% MeCN. On ice, dried gel pieces were rehydrated in 25 µL of 12 ng/µL
sequencing grade modified trypsin in 50 mM NH4HCO3. After a 20-minute incubation
at 4 ˚C, an additional 25–50 µL of 50 mM NH4HCO3 were added to submerge gel
pieces, followed by overnight incubation at 37 ˚C. After centrifugation, supernatants
were transferred to new microcentrifuge tubes. Remaining peptides were extracted
from gel pieces with the addition of 50% MeCN, 2.5% formic acid (FA). Supernatants
were combined with the initial tryptic digest supernatants, and gel pieces were
dehydrated in 100% MeCN. The final extraction was combined with the previous two
extractions and peptides were dried in a speed-vac.
Peptides were resuspended in 2.5% MeCN / 0.15% FA (Solvent A) and
separated on a reverse-phase HPLC column (length=12 cm x 100 µm) packed in house
with 5 µm C18 beads (pore size=200 Å) prior to analysis via a linear ion trap-orbitrap
(LTQ-Orbitrap Discovery; resolution=3x104, scan speed=1 Hz) mass spectrometer
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fitted with a Finnigan Surveyor Pump Plus and Micro AS autosampler (Thermo
Electron; San Jose, CA, USA) and controlled with Xcalibur™ 2.1 Software (Thermo
Fisher Scientific, Inc.; Waltham, MA, USA). Following a 15 min loading phase (flow
rate=100 µL/min) onto the C18 column in Solvent A, peptides were eluted using a 0–
50% gradient of Solvent B (99.85% MeCN, 0.15% FA) over 38 min and
electrosprayed (2.1 kV) into the mass spectrometer. This gradient was followed by 7
min at 100% Solvent B before a 10 min equilibration in 100% Solvent A.
The precursor scan (360–1700 m/z) was followed by ten low energy collisioninduced dissociation (CID) tandem mass spectra. CID spectra were acquired for the
top two most abundant ions in the precursor scan (dynamic exclusion settings: repeat
count=2, repeat duration=30 sec, exclusion list size=100, exclusion duration=60 sec,
exclusion width= ±1.5 m/z), followed by eight targeted scans for DCBLD1 or
DCBLD2 peptides of interest (Table 12 and Table 13). Target mass isolation windows
were set to ±1.6 m/z for z of +2, and 0.9 m/z for z of +3. All mass spectra were
obtained in centroid with precursor ion spectra acquired in the orbitrap and fragment
ion spectra in the linear ion trap.
SEQUEST searches were performed using a forward and reverse 2011 Uniprot
Human Protein database requiring tryptic peptides and permitting the following
modifications: phosphorylation of serine, threonine and tyrosine (+79.9663 Da),
oxidation of methionine (+15.9949 Da), and acrylamidation of cysteine (+71.0371
Da). Mass additions in experiments employing isotopically labeled residues were as
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follows: heavy lysine (+8.0142 Da) and arginine (+10.0083 Da) in SILAC analyses,
and heavy leucine (+7.0172 Da) and valine (+6.0138 Da) when using SL peptides.
Peptides were manually quantified in Xcalibur using the precursor scan
monoisotopic peak intensities averaged across full width at half maximum (FWHM) of
the elution window. In the case of SILAC and SL peptides, the heavy-to-light ratio
(H:L) or L:H of monoisotopic peak intensities, for SILAC or SL quantification
respectively, were determined. Ratios were normalized to reference peptides of
DCBLD1 or DCBLD2 that were not found modified (Table 14A,B). For SILAC
experiments, kinases were co-expressed with DCBLD proteins in cells grown in
medium supplemented with stable-isotope labeled arginine and lysine and paired with
a light culture expressing the DCBLD proteins alone. In the case of WT FYN /
DCBLD(X) co-expression, the corresponding light culture possessed kinase-dead
(KD) FYN co-transfected with DCBLD(X). Inhibitors were applied to the light
cultures prior to H2O2-stimulation and paired with heavy cultures subjected to H2O2stimulation alone. Heavy and light samples were immunoprecipitated separately and
eluted proteins were combined as heavy and light pairs before SDS-PAGE.
Each set of SL peptides or label-free (LF) experiments had six conditions with
three replicates for each condition as follows: a) mock, b) DCBLD(X), c) DCBLD(X)
with H2O2, d) DCBLD(X) with WT FYN or SRC-1/H2O2, e) DCBLD(X) with c-ABL
or STI571/H2O2, f) DCBLD(X) with WT FYN/c-ABL or SRC-1/STI571/H2O2.
Approximately 300 fmol of each SL peptide (Table 13A) were spiked into tryptic
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peptide samples. These included peptides corresponding to the tryptic peptides
harboring unphosphorylated and phosphorylated DCBLD2 peptides, as well as a
DCBLD2 peptide (GFLASYSVIDK) that was not found post-translationally modified
as a reference for relative DCBLD2 levels. The L:H value for this reference peptide
was used to normalize all L:H ratios from SL peptides (Table 14B). In label-free (LF)
quantification, approximate local noise levels were subtracted from monoisotopic
intensities and then divided by the average ion intensities of reference peptides (Table
14A,B). Reference intensities in this method were obtained from an average of three
unmodified peptides (LNSNEVTVLFK, GSHYFEEK, and DIAGDISGNTK for
DCBLD1; IYNGIGVSR, NNFLPPIIAR, and FTQPLQPR for DCBLD2; m/z tabulated
in Table 14A,B) regularly identified in each LC-MS/MS run.
To quantify changes in phosphorylation in the presence of H2O2, kinases, or
inhibitors, normalized L:H (SL peptides) or LF intensities were divided by the
condition in which we predicted to find to the maximum signal per peptide. It was
predicted that the maximum number of unphosphorylated peptides would be found in
the unstimulated condition, and that of phosphorylated peptides would be observed in
the co-expression of FYN and c-ABL with DCBLD(X) in kinase expression
experiments, or in the H2O2-stimulated condition in the case of inhibitor treatments.
Changes in the number of observed ions across conditions were reported as a percent
relative to the condition that would yield the predicted maximum. The percent change
relative to the treatment deemed the predicted max was determined as described
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above. Two and three trials were conducted for each condition with DCBLD1 and
DCBLD2, respectively.
Quantified changes in phosphorylation state among experimental conditions
were analyzed for significance with a one-way ANOVA test. The Tukey-HSD (P <
0.05) was used to compare each experimental condition to the others. Methods of SL
peptides and LF quantification for a given peptide and experimental condition were
compared using a t-test (P < 0.05), with the exception of Tyr565. Four distinct
methods of quantification were considered for the peptide harboring Tyr565 due to
alternative cleavage patterns and the use of both SL and LF methods, necessitating the
use of a Tukey-HSD (P < 0.05) analysis. The four methods used to quantify
phosphorylation at this site were compared using a one-way ANOVA and Tukey-HSD
(P < 0.05). Statistical analyses were performed in JMP Pro 12 Statistical Software
(SAS Institute, Cary, NY, USA).
2.5. Results
2.5.1. DCBLD1 and DCBLD2 YXXP motifs are highly conserved across
vertebrates
Previously, we identified tyrosine phosphorylation sites in YXXP motifs
within the DCBLD2 intracellular domain and found that these motifs were essential
for the phosphorylation-dependent binding of the signaling adaptor CRKL (Aten,
Redmond et al. 2013). Figure 8 displays the extracellular domain structure, including
CUB, LCCL, and FV/FVIII domains, as well as intracellular tyrosines in YXXP
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motifs within human DCBLD1 and DCBLD2. Also shown are multiple sequence
alignments of the TM domain through the C-terminus for each family member across
model vertebrates. Percent identity of the intracellular sequences of each protein for
the aligned species is shown in Figure 8C. Both paralogs have eight YXXP motifs, all
of which are intracellular with the exception of one from DCBLD2. Importantly, while
the overall conservation of the intracellular domains of DCBLD1 and 2 between
mammals and zebrafish deviate considerably (~40% identity), the same number of
intracellular YXXP motifs can be found across the aligned sequences with only one
YXXP position in zebrafish falling out of alignment (Figure 8A). A similar analysis of
the TM through C-terminal domains of human DCBLD1 and 2 was conducted to
examine sequence and motif conservation within the protein family. While there
appears to be little homology between other intracellular amino acid sequences, five
YXXP sites between DCBLD1 and 2 are conserved (Figure 8D). This striking
conservation of YXXP motifs suggests that this feature is essential for the specific
signaling roles inherent to this novel family of proteins. Indeed, we previouslyreported the importance of DCBLD2 YXXP motifs in the interaction with the CRKLSH2 domain (Aten, Redmond et al. 2013). This initial discovery led us to investigate if
the paralog DCBLD1 might also show a reversible interaction with the CRKL-SH2
domain and to determine the relative contribution of the non-receptor tyrosine kinases
of the ABL and SFK family in the phosphorylation of specific DCBLD1 and DCBLD2
YXXP motifs.

83

2.5.2. DCBLD1 binds the CRKL-SH2 domain upon induction of tyrosine
phosphorylation
One way to acutely induce tyrosine phosphorylation on cellular substrates by
endogenous kinases is to inhibit tyrosine phosphatases by treating cells with H2O2
(Zick and Sagi-Eisenberg 1990). We previously reported that H2O2 induced tyrosine
phosphorylation of DCBLD2 YXXP sites and thereby facilitated the binding of
DCBLD2 with the CRKL-SH2 domain (Aten, Redmond et al. 2013). To determine
whether DCBLD1 is also tyrosine-phosphorylated in a regulated manner, a
phosphatase assay was conducted. Flag-tagged DCBLD1 and DCBLD2 (Figure 9A)
were expressed in HEK 293 cells, and cells were H2O2-stimulated prior to lysis. α-Flag
immunoprecipitations (IPs) of the extracts were incubated with or without calf
intestinal phosphatase (CIP). Regulated tyrosine phosphorylation on DCBLD1 and
DCBLD2 was demonstrated following immunoblotting for phosphotyrosine (Figure
9B), given H2O2-stimulated tyrosine phosphorylation observed in the WCE was lost
when CIP was incubated with the immune complexes. We next tested if H2O2-induced
tyrosine phosphorylation on DCBLD1 would render it capable of binding to the
CRKL-SH2 domain. A GST-CRKL-SH2 pull-down (PD) was performed with lysates
from untreated and H2O2-stimulated cells expressing either DCBLD1 or DCBLD2.
Both paralogs showed H2O2-induced binding to the CRKL-SH2 domain (Figure 9C).
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Figure 9. DCBLD1 is reversibly tyrosine phosphorylated and binds the CRKL-SH2 domain
following stimulation by H2O2 and FYN.
(A) Schematic of DCBLD family member expression constructs used in this study. (B) H2O2
stimulation of HEK 293 cells stimulates endogenous tyrosine kinases to phosphorylate DCBLD1
and DCBLD2. DCBLD1-Flag and DCBLD2-Flag were immunoprecipitated from transfected
cells, which had been left untreated or stimulated with H2O2 for 20 min prior to lysis. Immune
complexes were incubated with or without calf intestinal phosphatase (CIP; “*” denotes antibody
cross-reaction with CIP) before analysis via SDS-PAGE and Western blotting for antiphosphotyrosine. Arrows indicate signals from antibody aggregates in the anti-pY and anti-Flag
panels of the IP. A light-chain-specific secondary antibody was used to resolve the DCBLD1 signal
from that of the heavy chain. Contributed by Bryan Ballif. (C) H2O2 stimulation of HEK 293 cells
induces DCBLD1 and DCBLD2 to bind to the CRKL-SH2 domain. Pulldown assays (upper
panels) using GST-CRKL-SH2 were performed on whole cell extracts (lower panels) from cells
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expressing Flag-tagged DCBLD(X) and stimulated with or without H2O2 for 20 min as indicated.
The antibodies used for each blot are indicated. The Ponceau stain of the blot prior to anti-Flag
immunoblotting is shown to indicate the relative levels of GST-CRKL-SH2 in the pulldowns.
Contributed by Jaye Weinert. (D) FYN induces DCBLD family members to bind to the CRKLSH2 domain. Pulldown assays were conducted as described in (B) above. Pulldown assays were
stained with Ponceau followed by immunoblotting with anti-Flag. Whole cell extract blots were
with the indicated antibodies. The anti-pSRC antibody is cross-reactive will active SFKs including
FYN. Contributed by Kyle Kellet.

2.5.3. YXXP sites are necessary for the interaction of human DCBLD1 with the
CRKL-SH2 domain
The initial expression construct we were able to obtain for DCBLD1, and the
one we characterize in detail below, was derived from mouse. Interestingly, rodent
DCBLD1 sequences are smaller than other vertebrate orthologs as they lack the
FV/FVIII portion of the ectodomain. To validate whether human DCBLD1 also
showed stimulus-dependent binding to the CRKL-SH2 domain, and to determine if the
intracellular YXXP motifs were essential for this interaction, we obtained an
expression construct for human DCBLD1 as well as a mutant with all intracellular
YXXP motifs mutated to FXXP motifs (DCBLD1 Y8F). WT DCBLD1, but not
DCBLD1 Y8F exhibited regulated binding to the CRKL-SH2 domain in response to
H2O2 stimulation (Figure 10). These results demonstrate that both human and mouse
DCBLD1 orthologs show a similar reversible interaction with the CRKL-SH2 domain
and establishes the necessity of the DCBLD1 YXXP sites for the CRKL-SH2
interaction.
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Figure 10. YxxP motifs in human DCBLD1 are required for H2O2-induced binding to the CRKLSH2 domain. GST-CRKL-SH2 pull-down assays comparing human DCBLD1-Flag WT and
human DCBLD1-Flag Y8F.
HEK 293 cells transfected with the indicated constructs were either left untreated or stimulated
with H2O2 for 20 minutes prior to lysis and pulldown assays from the clarified extracts. The
immunoblot of the pulldown assays was first stained with Ponceau to visualize levels of the GSTCRKL-SH2 domain. This was followed by blotting with anti-Flag. Levels of the DCBLD1-Flag
proteins were determined by immunoprecipitation and immunoblotting of the immune complexes
following their separation by SDS-PAGE. Whole cell extracts were subjected to SDS-PAGE and
immunoblotting with anti-phosphotyrosine to verify the effect of H2O2 stimulation.

2.5.4. FYN and ABL variably induce DCBLD1 and DCBLD2 to bind the CRKLSH2 domain
Our previous characterization of the DCBLD2-CRKL interaction demonstrated
that co-expression of the SFK FYN was sufficient to induce DCBLD2 to bind to the
CRKL-SH2 domain (Aten, Redmond et al. 2013). This led us to examine the effect of
FYN activity on the DCBLD1-CRKL interaction. We found that co-expression of
DCBLD1 with active FYN, but not kinase-dead FYN, was sufficient to induce
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DCBLD1 binding to the CRKL-SH2 domain in a pull-down assay (Figure 9D).
However, the relative amount of DCBLD2 that FYN induced to bind to the CRKLSH2 domain was far higher than the amount of DCBLD1 that FYN induced to bind to
the CRKL-SH2 domain (Figure 9D).
The ABL kinase family (ABL and Arg) demonstrate high specificity for
tyrosine residues in YXXP motifs (Ballif, Carey et al. 2007, Colicelli 2010).
Therefore, the effect of SRC-1 (Tian, Cory et al. 2001), a SFK inhibitor, was
compared to that of an ABL-specific inhibitor (STI571) (Nagar 2007), on the
interaction of DCBLD1 and DCBLD2 with the CRKL-SH2 domain to determine
whether the activity of endogenous SFKs and/or ABL is necessary for this interaction.
Prior to lysis, cells were treated for 15 min with 2 µM SRC-1, 20 µM STI571, or both
inhibitors prior to H2O2 stimulation to investigate whether the presence of SFK or
ABL inhibitors counteracted the effect of tyrosine phosphatase inhibition on the pulldown assay. Appropriate inhibitor concentrations were determined from a titration in
which endogenous SFK and ABL activities were monitored after treatments of
increasing concentrations of SRC-1 and STI571, individually (Figure 39). This was
paired with a CRKL-SH2 pull-down assay using extracts of DCBLD2-transfected
HEK 293 cells in order to determine whether the ABL-specific inhibitor would
dampen the binding interaction, as was previously observed with SRC-1 (Aten,
Redmond et al. 2013). The 2 µM SRC-1 treatment sufficiently reduced the fraction of
active SRC (pTyr416), however, we did not attempt to increase inhibitor dose to
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eliminate SFK activity due the observed reduction in active ABL (pTyr412) following
treatment (Figure 11A). Sanguinetti et al (Sanguinetti, Haiming et al. 2003) reported
that SFKs (FYN specifically) play a role in ABL activation in response to reactive
oxygen species, which may account for the decrease in ABL activity upon SFK
inhibition. Although the DCBLD2-CRKL interaction was somewhat affected by the 2
µM SRC-1 and 5, 10, and 20 µM STI571, each inhibitor alone was not sufficient to
eliminate the binding of DCBLD2 to the CRKL-SH2 domain, suggesting that more
than one kinase is capable of mediating the DCBLD2-CRKL interaction. We
hypothesized that simultaneous inhibition of SFKs and ABL may be sufficient to
eliminate or significantly reduce this interaction. Additionally, we observed an
increase in endogenous ABL activity and, to a lesser extent, SFK activity upon H2O2
stimulation alone in DCBLD2-transfected cells over control cells (Figure 39A), which
was eliminated with the DCBLD2-Y7F mutant (Figure 39B). We hypothesized that
this increase in ABL activity above that in untransfected cells stimulated with H2O2
was the result of a phosphorylation-dependent binding interaction between the ABLSH2 domain and at least one of the DCBLD2 YXXP motifs. Therefore, we compared
the binding capacity of a GST-ABL-SH2 fusion protein with immunoprecipitated
DCBLD2-WT and DCBLD2-Y7F (Figure 39C). Significantly higher levels of the
GST-ABL-SH2 fusion protein bound DCBLD2-WT following H2O2 treatment, as
observed in the anti-GST panel of the IP, suggesting that phosphorylated YXXP
motifs are required for the DCBLD2-ABL-SH2 interaction to occur. These data
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suggest that phosphorylation of DCBLD2 YXXP sites elevate ABL activity through a
binding interaction between pYXXP motifs and the ABL-SH2 domain, maintaining
the kinase in a catalytically active conformation.
We then tested the combined effect of SRC-1 (2 µM) and STI571 (20 µM)
treatment on the binding of CRKL-SH2 to DCBLD1 and DCBLD2 (Figure
11A,B). SRC-1 significantly reduced the DCBLD1-CRKL-SH2 interaction in
comparison to H2O2 stimulation alone, but did not reduce binding to the baseline
levels observed in the unstimulated condition. However, STI571 was sufficient to
reduce binding to baseline levels. Combined treatment of SRC-1 and STI571
eliminated the interaction, suggesting that SFK and ABL activities both promote
the DCBLD1-CRKL-SH2 interaction. Similarly, while inhibition of SFKs and
ABL alone were not sufficient to disrupt the DCBLD2-CRKL-SH2 interaction
(Figure 11B), the combination of SRC-1 and STI571 significantly reduced the
binding. The residual binding upon application of both inhibitors may be due to the
incomplete inhibition of SFKs in this experiment, observable in the α-pSRC
(Tyr416) blot (Figure 11B).
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Figure 11. SFKs and ABL are necessary and sufficient to induce DCBLD1 and DCBLD2 to bind
to the CRKL-SH2 domain.
Pulldown assays were performed from extracts of DCBLD1- and DCBLD2-transfected cells as
described in the legend to Figure 9 above. (A) DCBLD1 binding was reduced upon treatment with
the SFK inhibitor (SRC-1). However, the ABL-specific inhibitor (STI571) more strongly
disrupted the interaction. The application of both inhibitors abolished the interaction. (B) No
significant reduction in the binding between DCBLD2 and the CRKL-SH2 domain was observed
in response to either inhibitor alone. However, the application of both inhibitors strongly reduced
the DCBLD2-CRKL-SH2 interaction. To determine whether these kinases were sufficient to
induce this interaction, FYN and c-ABL were co-transfected with (C) DCBLD1 or (D) DCBLD2.
While FYN was able to induce a small degree of binding between the CRKL-SH2 domain and
DCBLD1, ABL was superior in this regard. Figure C and D were contributed by Jaye Weinert.
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Upon establishing that activities of endogenous SFKs and ABL are necessary
for the H2O2-induced interaction between the CRKL-SH2 domain and DCBLD
proteins, ABL co-expression with DCBLD1 and DCBLD2 was investigated to
determine sufficiency while using FYN as a positive control as established in Figure
9D. Figure 11C,D display the CRKL-SH2 pull-downs from extracts of cells coexpressing c-ABL and DCBLD1 or DCBLD2. Here, the Myc epitope tags were
employed for immunoblotting for DCBLD proteins, as the c-ABL construct used also
possesses a Flag tag and c-ABL-Flag runs at the approximate MW of DCBLD2-MycFlag. The pull-down assay from lysates containing DCBLD1 revealed intense
phosphorylation by ABL in the whole cell extract (WCE), consistent with the strong
signal from the α-Myc blot in the CRKL-SH2 pull-down. Although the specific
activities of FYN and ABL are not identical in this system, it appeared that the effect
of FYN co-expression was reduced relative to H2O2 stimulation or ABL in inducing
DCBLD1 and DCBLD2 to bind to CRKL-SH2. Interestingly, co-expression of
DCBLD proteins with ABL significantly reduced the mobility of both DCBLD family
members in SDS-PAGE. This could be the result of dramatically higher levels of
phosphorylation on DCBLD proteins generally, ABL-specific phosphorylation events,
or additional ABL-specific modifications. FYN and ABL both can drive DCBLD
family members to bind to the CRKL-SH2 domain. However, these kinases
demonstrate preferences with the binding of DCBLD1 more strongly affected by ABL,
suggesting that SFKs and ABL differentially target DCBLD protein YXXP sites.

92

2.5.5. SFKs and ABL differentially phosphorylate DCBLD1 and DCBLD2 at
distinct tyrosine phosphorylation sites
In order to identify sites that may be differentially regulated by SFKs and
ABL, we immunoprecipitated DCBLD1 or DCBLD2 from HEK 293 cell lysates under
kinase active or inhibited conditions and monitored the phosphorylation of several of
the eight DCBLD1 and seven DCBLD2 intracellular YXXP sites using targeted liquid
chromatography (LC) tandem mass spectrometry (MS/MS). We also monitored the
DCBLD2 peptide harboring Tyr715, a non-YXXP tyrosine residue, as this site was
found phosphorylated in a previous analysis (Aten, Redmond et al. 2013). Taking a
three-pronged approach for quantification, we were able to monitor changes in
phosphorylation at three YXXP sites for each DCBLD protein while comparing the
effectiveness of quantitative LC-MS/MS methodologies (Figure 40). Full amino acid
sequences and coverage maps for DCBLD1 and DCBLD2 can be found in Figure 41.
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Figure 12. Schematic of sample preparation for SILAC quantification and representative example
of quantification by LC-MS/MS.
Cells grown in media supplemented with either light or heavy lysine and arginine were
transfected with DCBLD(X)–Flag in kinase inactive/inhibited (light) or active (heavy) conditions.
Post-IP, heavy and light immune complex pairs were combined and analyzed via LC-MS/MS to
determine relative abundance of phosphopeptide ions between each state. Heavy-to-light ratios
(H:L) of monoisotopic peak intensities were normalized to DCBLD(X) peptides that were found
not to be modified (loading control).

SILAC was used as an initial survey of differential phosphorylation (Figure
12). HEK 293 cells were grown in SILAC media supplemented with heavy or light
arginine and lysine for at least five doublings prior to transfection,
immunoprecipitation, and SDS-PAGE. Bands containing DCBLD1 or DCBLD2 were
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excised, subjected to tryptic digestion, and analyzed via LC-MS/MS. Heavy-to-light
(H:L) ratios were calculated from monoisotopic peak intensities averaged across
elution windows to quantify differential phosphorylation (Table 4,Table 15). Three
YXXP sites were identified from each molecule, as well as DCBLD2 Tyr715. While
using mouse DCBLD1 and human DCBLD2, the numbering used throughout is for
human family members.

Table 4. SILAC identifies tyrosine phosphorylation sites on DCBLD1 and DCBLD2 differentially
regulated by SFKs and ABL.
As indicated, heavy conditions either possessed a co-expressed kinase when paired with a light
unstimulated condition, or H2O2 stimulation alone when paired with a light inhibitor treatment
followed by H2O2 stimulation. The identified phosphotyrosine (Y#)-containing peptides and the
number of the phosphorylated residue (human numbering) are indicated on the left. For each
phosphopeptide and each condition the H:L ratios (fold change) are listed.
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Taken from the four SILAC pairings not involving kinase inhibitors
(unstimulated paired with (i) H2O2-stimulation, (ii) FYN co-expression, (iii) ABL coexpression, or (iv) FYN and ABL co-expression) we detected phosphorylation of
Tyr589, Tyr600, and Tyr621 in YXXP sites on DCBLD1 and all were dominantly
phosphorylated by ABL. When ABL was co-expressed with DCBLD1 alone or in
combination with FYN, phosphorylation of all three tyrosines were induced between
16 and over 100-fold. None of these sites was observed phosphorylated by FYN coexpression alone (Table 4). H2O2-stimulation only induced measurable amounts of
Tyr600 phosphorylation on DCBLD1, rendering the use of inhibitors in tandem with
H2O2 only informative for this site. Nonetheless, a twelve-fold decrease in H2O2induced phosphorylation was observed at Tyr600 with the ABL-specific inhibitor,
further demonstrating that ABL activity is important in the phosphorylation of Tyr600
(Table 4). Notably, each of these phosphorylation sites has complications when
quantifying them based on the tryptic peptides that harbor these sites. As regards
Tyr589 and Tyr600, each of these sites falls within one tryptic peptide such that
singly- and doubly phosphorylated combinations are possible. Nevertheless, strong
ABL-dependent increases were observed for each permutation (Table 4). For
phosphorylation of Tyr621, its quantification was complicated given it falls directly Nterminal to an arginine. It is well known that modified amino acids near tryptic
cleavage sites can locally decrease trypsin’s proteolytic activity. In this case, we were
able to measure Tyr621 phosphorylation only on a larger tryptic peptide, which was
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not cut after Arg622. Consistent with a phosphorylation-dependent effect on tryptic
activity, this larger peptide was not observed without ABL co-expression. Given its
absence, we used a local signal-to-noise calculation and found this larger
phosphopeptide was increased by more than 100-fold by ABL (Table 4). Furthermore,
the fully tryptic unphosphorylated peptide identified in these experiments was reduced
by 54% when c-ABL was expressed suggesting the percentage of Tyr621
phosphorylation occupancy was also 54% (Table 15).
In SILAC quantification of DCBLD2 YXXP motif phosphorylation, coexpression of FYN and ABL together generally gave similar increases to H2O2
stimulation (Table 4). When the kinases were expressed individually with DCBLD2,
FYN was able to induce a more than 25-fold higher level of Tyr565 phosphorylation
than ABL and approximately a four-fold higher increase of phosphorylation at Tyr621.
On the other hand, ABL induced a higher level of phosphorylation than FYN at
Tyr715 and Tyr750 (17-fold and six-fold respectively). In general, the difference
between H2O2 stimulation alone and in the presence of inhibitors was not strong
except in the case where SRC-1 was able to reduce phosphorylation of Tyr565 over
fifty-fold (Table 4). This was consistent with the approximately 50-fold
phosphorylation induction by FYN at this site. STI571 did reduce phosphorylation of
Tyr565, Tyr621, Tyr715, and Tyr750 between four- and ten-fold, but the magnitudes
of the changes for Tyr715 and Tyr750 might have been expected to be higher given
ABL induced the phosphorylation of these sites 56- and 21-fold respectively (Table 4).
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However, the expression of c-ABL is likely more aggressive than the endogenous
ABL being inhibited by STI571.
Our SILAC comparisons provided an initial baseline survey, but we next
turned to label-free (LF) quantification of monoisotopic ion intensities for more rapid
replication. This was accompanied by the use of synthetic stable isotope-labeled
peptide standards (SL peptides) corresponding to select DCBLD2 tryptic peptides. The
chosen peptides harbored phosphorylated or unphosphorylated Tyr565, Tyr715, and
Tyr750. We selected these peptides given that, on the one hand tryptic peptides
containing phosphorylated Tyr715 and Tyr750 were readily detected, and on the other
hand the tryptic peptide containing phosphorylated Tyr565 was more challenging to
detect, due in part to the RKKK sequence creating a “ragged” N-terminal side of the
tryptic peptide. The SL peptides that were chosen harboring Tyr565 had a single
missed cleavage, KTEGTYDLPWDR, as this peptide would likely be a fraction of the
fully-tryptic peptide and we found it in a previous study (Aten, Redmond et al. 2013).
This SL peptide also allowed us to determine whether the cleavage site preference of
trypsin at the N-terminus was condition-dependent or whether accurate changes in
phosphorylation could be measured by monitoring just one of the “ragged end”
peptides. To do so we compared SL peptide quantifications with LF quantification of
peptide ions for KTEGTYDLPWDR and TEGTYDLPWDR individually or using their
summed intensities from a single LC-MS/MS run.
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Figure 13. Schematic of sample preparation for quantification using either label-free methods or
stable isotope-labeled synthetic reference peptides (SL peptides).
Also shown are representative examples of quantification for these two methods by LC-MS/MS.
DCBLD2-containing, or control bands were excised from Coomassie-stained gels post-IP from
kinase active or inactive/inhibited states. Following in-gel tryptic digestion peptides were analyzed
via LC-MS/MS. Label free quantification was achieved by normalizing noise-subtracted
monoisotopic peak intensities to loading control peptides for comparison across experimental
conditions. SL peptides were spiked into digested native peptides prior to LC-MS/MS.
Monoisotopic ratios of native-to-synthetic standard peptides were normalized to reference peptide
ratios for comparison across conditions. Heavy and light pairs were confirmed from
fragmentation spectra and chromatographic retention time (RT).

Figure 13 displays a schematic of the LF and SL peptide addition methods (see
method section for full details). Bands containing the protein of interest were excised
from Coomassie-stained gels and digested with trypsin prior to targeted LC-MS/MS
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scans for phosphorylated and unphosphorylated YXXP-containing peptides. LF
quantification was achieved by normalizing the noise-subtracted, monoisotopic
intensities of control peptides within DCBLD1 or DCBLD2. These control peptides
showed no signs of being modified and therefore served as “loading controls” and
allowed direct comparisons of ion intensities across experimental conditions. For
quantification using internal standards, the DCBLD2 SL peptides listed above as well
as a loading control reference SL peptide were spiked into the native peptide samples
just prior to LC-MS/MS analysis. Ratios of native-to-standard monoisotopic peaks of
targeted sites were normalized to those of the loading controls for comparison across
experimental conditions. Heavy and light pairs were further confirmed through manual
comparison of fragmentation ion spectra (Figure 42).Figure 14 displays the LF and SL
peptide quantification results for DCBLD2 Tyr565, Tyr621, Tyr715, and Tyr750
(Table 5A,B). Phosphopeptides (red) are plotted as a percent relative to the FYN/cABL condition for kinase co-expression experiments or to H2O2 stimulation when
inhibitors were used. Unphosphorylated peptides (blue) were normalized to the
unstimulated condition regardless of treatment. Y-axes for unphosphorylated peptides
were inverted to best visualize the shift in phosphorylation state of the given peptide.
Clusters of bars represent different quantification methods for a given condition.
Significant differences between conditions were determined by a one-way ANOVA
and Tukey HSD, and are either indicated (* for P < 0.05, ** for P < 0.01) or are
tabulated in Table 16. For the method comparison, a one-way ANOVA and Tukey
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HSD analysis was used in the case of DCBLD2 Tyr565 (>2 methods), while a simple
t-test was employed with DCBLD2 Tyr715 and Tyr750 (2 methods) (Table 17).
Significant differences among quantification methods are designated by blue bars
(triangle for P < 0.05). Additional DCBLD2 phospho-tyrosine residues that were
identified, but not quantified, are listed in Table 18, and include Tyr569, Tyr649,
Tyr655, Tyr663 and Tyr677. Tyr569 was not observed in adequate trials to obtain
complete quantification of its phosphorylation state, suggesting it is either not highly
phosphorylated or it ionizes poorly. The other four sites were on the same tryptic
peptide, which was only identified in one LC-MS/MS run.
Table 5. Quantification of DCBLD1 and DCBLD2 tyrosine phosphorylation with label-free (LF)
and SL peptides (SL).
Tabulated averages of normalized phosphorylated peptide and unphosphorylated peptide ion
intensities as graphed in Figure 14. Phosphorylated peptide ion intensities were normalized
(boxed values) either to dual co-expression of FYN and c-ABL (in kinase co-expression studies) or
H2O2 stimulation (in inhibitor treatment studies). Unphosphorylated peptide ion intensities were
normalized to the unstimulated condition in all cases. Tabulated values for each DCBLD family
member and the sets of conditions are as follows: kinase co-expression studies with (A) DCBLD2
and (B) DCBLD1 and inhibitor studies with (C) DCBLD2 and (D) DCBLD1.
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Figure 14. Site-specific quantification of SFK- and ABL-dependent changes in tyrosine
phosphorylation of DCBLD1 and DCBLD2 by label-free (LF) or SL peptides.
Phosphorylated peptide intensities (red) were normalized to the co-transfection of FYN and cABL in kinase co-expressed conditions, and H2O2 stimulation for inhibitor treatments.
Unphosphorylated peptide ion intensities (blue) were normalized to the unstimulated condition,
and the y-axes were inverted to visualize the shift in phosphorylation state. Error bars indicate
the standard error of the mean. Column clusters display measurements for the same peptide and
condition using different quantification methods. Significance between conditions, indicated by *
(P < 0.05) or ** (P < 0.01), was determined with a one-way ANOVA with a post-hoc Tukey HSD
(n=3 biological replicates, Table 16). Blue bars and triangles indicate significant differences
between quantification methods (P < 0.05) using either a student’s t-test for a two-method
comparison, or the ANOVA/Tukey HSD for more than two methods (Table 17). The
quantification of four DCBLD2 phosphorylation sites are shown in (A-H), including one nonYxxP site. The quantification of three DCBLD1 sites are shown in I-L (n=2 biological replicates
and individual data points are provided). Phosphorylation at DCBLD2 Tyr565 was quantified in
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alternative cleavage states individually, as well as in sum (K/TEGYDLPYWDR) as described in
the methods.

Significant changes in the phosphorylation state of Tyr565 (Figure 14A,B)
were observed in FYN-active conditions; the abundance of the unphosphorylated
peptide decreased relative to the unstimulated condition, with a corresponding increase
in the abundance of the phosphopeptide. Further, co-transfection of FYN and c-ABL
resulted in an increased intensity of the phosphopeptide relative to c-ABL alone,
which was not significantly different from the unstimulated state, suggesting that FYN
may be the primary kinase of Tyr565. This was corroborated by a decrease in Tyr565
phosphorylation in the presence of SRC-1, while STI571 was not able to reduce
phosphorylation to the level of the unstimulated condition (Figure 14B). No
statistically significant differences were observed in the phosphorylation state of
Tyr621 (Figure 14C,D), as there was high variability among conditions when analyzed
as a group. However, FYN alone demonstrated a strong reduction in phosphorylation
levels in comparison to ABL. Phosphorylation of the non-YXXP Tyr715 (Figure
14E,F) was induced by both FYN and ABL, although more strongly by ABL. The
inhibitor studies showed that individually the SFK and ABL inhibitors were sufficient
to significantly reduce Tyr715 phosphorylation relative to H2O2 stimulation. Further,
application of SRC-1 and STI571 together reduced the phosphorylation state beyond
that of STI571 alone, suggesting that both FYN and ABL are involved in the
phosphorylation of Tyr715. Tyr750 (Figure 14G,H) demonstrated significantly higher
phosphorylation levels by H2O2 stimulation and by co-expression of ABL compared to
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co-expression of FYN. This, together with the ~60% decrease in intensity of the
unphosphorylated peptide in the ABL-active condition, indicates that ABL is the
primary kinase of Tyr750.
Given that we found FYN and ABL preferentially phosphorylate Tyr565 and
Tyr750 respectively, we asked if the loss of these sites would have important
functional consequences on the FYN- or ABL-induced binding of DCBLD2 to the
CRKL-SH2 domain. We made use of tyrosine-to-phenylalanine mutant DCBLD2
expression constructs (Figure 9A) (Aten, Redmond et al. 2013), where a DCBLD2Y1F construct harbored a Tyr750Phe mutation, and a DCBLD2-Y3F mutant harbored
Tyr565Phe, Tyr732Phe and Tyr750Phe. The DCBLD2-Y7F construct had tyrosine-tophenylalanine mutations at all seven intracellular YXXP motifs. Analyses using these
constructs, in tandem with the phospho-tyrosine quantification by mass spectrometry,
were helpful in specifying which tyrosine residues are most important in the FYN- or
ABL-mediated DCBLD2-CRKL-SH2 interaction. The DCBLD2-Y1F construct
showed little reduction in binding induced by either kinase (Figure 15) demonstrating
that phosphorylation at Tyr750 was not strictly required for the DCBLD2-CRKL
interaction induced by FYN or ABL. While DCBLD2-Y3F was induced to bind upon
stimulation by each kinase, the interaction with DCBLD2-Y3F was reduced in
comparison to the DCBLD2-Y1F mutant or WT DCBLD2 (Figure 15). As Tyr732 was
not found to be phosphorylated by FYN or ABL by LC-MS/MS, these analyses
suggest that together Tyr565 and Tyr750 contribute to FYN- and ABL-induced
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binding of DCBLD2 to the CRKL-SH2 domain. As predicted, DCBLD2-Y7F showed
complete loss of FYN- and ABL-induced binding to the CRKL-SH2 domain (Figure
15). The graded loss of CRKL-SH2 binding between DCBLD2 WT, Y1F, Y3F and
Y7F denotes the role of multi-site phosphorylation in this interaction and predicts a
role for avidity in the strength of the interaction.

Figure 15. Several DCBLD2 YxxP Tyr residues contribute to the ability of FYN and ABL to
induce DCBLD2 to bind to CRKL-SH2 domain.
DCBLD2 WT as well as tyrosine-to-phenylalanine point mutants (Y1F, Y3F, and Y7F) were
expressed in cells with or without co-expression of FYN (A) or ABL (B). All DCBLD2 constructs
have both Myc and Flag tags at their C-terminus. Cell extracts were subject to pulldown assays
with GST-CRKL-SH2 or immunoblotting with the indicated antibodies. As the ABL kinase we
are using has a Flag-tag, anti-Myc was used in the immunoblots.
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For DCBLD1 three phosphorylation sites were identified: Tyr621, Tyr589, and
Tyr600. The latter two sites were on the same tryptic peptide. Phosphorylation of
Tyr621 was quantified from the sum of monoisotopic intensities of two cleavage
patterns surrounding this site. As with the SILAC experiments described above, a
decreased preference for cleavage after Arg622 was readily observed when
phosphorylation was found at Tyr621. However, we did identify the presence of the
phosphorylated fully cleaved ion and unphosphorylated ion with one missed cleavage
using targeted precursor ion scans. Raw intensities of the unphosphorylated and
phosphorylated fully cleaved peptides were summed with their uncleaved counterparts
in order to obtain a clear picture of phosphorylation at this site. While the two trials
completed did not permit statistical analysis, FYN did not appear to be the primary
Tyr621 kinase as phosphorylation levels by co-expression of FYN or by H2O2
stimulation were comparably weak. On the other hand, co-expression of ABL alone or
in combination with FYN led to strong increases in phosphorylation, well above that
of H2O2 stimulation (Figure 14I). While treatment with SRC-1 and STI571 resulted in
similar decreases in pTyr621 (Figure 14J), the possibility of ABL activation
downstream of SFKs in the oxidative stress response suggests that the reduction in
signal upon SRC-1 treatment could be due to a reduction in ABL activity. Together
with the kinase expression data, this suggests that ABL is the primary kinase of
Tyr621. The peptide harboring both Tyr589 and Tyr600 was quantified in various
states of phosphorylation; singly phosphorylated peptides were individually quantified
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at each YXXP site, and separately from the doubly phosphorylated peptide. FYN was
able to induce phosphorylation at Tyr600 only, while c-ABL co-expression resulted in
high signal intensity of all three phosphorylation states. Only H2O2 stimulation was
capable of bringing pTyr600-containing peptides to sufficient concentrations to
analyze via LC-MS/MS, complicating quantification with inhibitor treatment. The
complete loss of signal of pTyr600 upon inhibitor treatment, similar to pTyr621,
suggests that the activity of ABL is necessary for phosphorylation at this site.
2.6. Discussion
This study characterized the intracellular tyrosine phosphorylation of the
DCBLD family of transmembrane orphan receptors summarized in the model and data
shown in Figure 16. Our data revealed site-specific regulation of phosphorylation by
ABL and FYN, showing that phosphorylation at multiple tyrosines induces DCBLD
proteins to bind to the CRKL-SH2 domain. Our results are summarized in Figure 16B
and in general find that specific DCBLD1 YXXP sites (Tyr589, Tyr600 and Tyr621)
are strongly targeted by ABL while DCBLD2 YXXP sites are in general targets of
both ABL and FYN. However, ABL demonstrated preferences for DCBLD2 Tyr750
and Tyr715 and FYN had a preference for Tyr565 and likely Tyr655, Tyr666 and
Tyr677. We used our quantitative MS data to calculate the relative induction of
distinct phosphorylation sites of DCBLD1 and DCBLD2 by ABL and FYN (Figure
16B). These ratios describe an approximate fold change of molecules phosphorylated
at a given site under the indicated cellular states.
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Figure 16. Mechanisms of SFK-/ABL-driven phosphorylation of DCBLD proteins and CRKL
recruitment.
(A) ROS-driven phosphorylation model. Generation of ROS following H2O2 treatment of cells in
culture inhibits tyrosine phosphatases, thereby activating SFKs, which in turn activate ABL.
Together, SFKs and ABL contribute to the phosphorylation of DCBLD family members. The
same effect was achieved by co-expression FYN or c-ABL with DCBLD1/2 to determine the
relative contribution of each kinase. (B) Summary depicting the relative site-specific targeting of
ABL and FYN in the tyrosine phosphorylation of DCBLD1 and DCBLD2. Tick marks within the
intracellular domains of DCBLD1 and DCBLD2 indicate tyrosines within YxxP motifs or nonYxxP tyrosines that were found phosphorylated. The relative targeting of each quantified site is
demonstrated by the size of the letter: “A” for ABL or “F” for FYN. The magnitude of the
relative difference is also indicated for each site. (C) Signaling model for SFK-/ABL-driven CRKL
recruitment to DCBLD family scaffolds. In the ligand-mediated clustering model, extracellular
ligand binding clusters DCBLD1/2 and membrane-anchored SFKs, leading to SFK autophosphorylation and activation of kinase activity. Active SFKs then phosphorylate clustered
DCBLD1/2 on intracellular tyrosines, providing a docking site for SFK-SH2 domains to stabilize
the open, active conformation (Aten, Redmond et al. 2013). Active SFKs also phosphorylate ABL
Tyr412, activating ABL kinase activity. ABL-SH2-mediated stabilization leads to increased levels
of DCBLD pYxxP, recruiting CRK/CRKL to bind the DCBLD scaffold via the SH2 domain.
CRK/CRKL-SH3-bound cargo (e.g. C3G) is brought to the membrane through this interaction.
In the co-receptor signaling model, DCBLD1/2 act as co-receptors with growth factor RTKs (e.g.
EGFR). Upon extracellular growth factor (GF) binding, RTK auto-phosphorylate and activate
membrane-anchored SFKs. SFKs phosphorylate DCBLD1/2 co-receptors and ABL, leading to
kinase SH2-mediated stabilization, signal propagation, CRK/CRKL recruitment, and ultimately
to CRK/CRKL-related processes such as cell migration, adhesion, or proliferation. Included
under the figure is a key indicating the color-coding of protein domains.

To our knowledge, this is the first side-by-side comparison of label free
methods to internal standard addition and SILAC in targeted quantification of PTMs.
SL peptide addition holds an advantage over other methods, as the user is provided
with a strong MS2 fingerprint to aid in the identification of low abundance
endogenous peptides harboring PTMs. When relying on a spectral matching algorithm
alone, fragmentation spectra of low abundance peptides may be lost through the
peptide filtration process (e.g. due to low cross-correlation scores using SEQUEST).
In the simple identification or verification of site-specific PTMs that are present in low
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abundances, standard addition would present an advantage over SILAC or LF
methods. However, in the quantification of multiple sites across a variety of conditions
as described here, SL peptides can artificially inflate native-to-standard ratios in cases
where no modified peptide is identified. For such quantitative comparisons, the LF
method is advantageous, as it provides the more accurate representation as minimal-tono signal above the level of noise. Overall, LF and SL quantification yielded similar
results, demonstrating the merits of LF quantification. In low-complexity samples,
such as peptides derived from an immunoprecipitated band as used here, the known
challenges of ion suppression in LF quantification (Fang, Elias et al. 2006) are
minimized. While SILAC quantification has the advantage of providing a side-by-side
comparison of all peptides across 2-3 treatments, we found LF analysis was less
cumbersome and less costly given we were quantifying many samples from several
treatments. However, in large-scale quantification discovery analyses of PTMs across
only a few experimental conditions, SILAC would be a strong choice.
Additional merits of LF quantification over SL peptides include the ability to
quantify different enzymatic cleavage patterns. Using the quantification of DCBLD2
pTyr565 as an example, the summed raw intensities of KTEGTYDLPYWDR and
TEGTYDLPYWDR were not statistically different than the most abundant fully
cleaved peptide. This demonstrates that quantification of the most abundant cleavage
pattern will generally yield an accurate measurement in cases where the PTM falls far
from cleavage sites. However, PTMs close to the enzyme cleavage site can reduce the
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specificity of the enzyme for that site, as was observed with the tryptic cleavage of
DCBLD1 Tyr621, and it may be necessary to sum the intensities of fully cleaved and
miss-cleaved peptides. Using LF methods in such cases allows the investigator
flexibility in quantification post-LC-MS/MS. These findings demonstrate the
importance in choice of quantification method, and the need to consider the peptide
harboring the PTM when determining which method is most appropriate.
Future work will characterize whether phosphorylation of any individual
tyrosine residue reported here is dependent upon phosphorylation of other sites. As we
observed with H2O2 stimulation in DCBLD2-transfected cells, endogenous ABL
activity was maintained above that in untransfected cells stimulated with H2O2 by a
possible binding interaction between the ABL-SH2 domain and at least one of the
DCBLD2 YXXP motifs. This activity was reduced to baseline levels observed in the
mock when all seven YXXP sites were mutated to FXXP (Figure 39). Others have
demonstrated that ABL activity requires binding to phosphotyrosine-containing
proteins through the ABL-SH2 domain (Juang and Hoffmann 1999, Zukerberg,
Patrick et al. 2000, Miyoshi-Akiyama, Aleman et al. 2001). Further, it is hypothesized
that phosphoprotein binding to the SH2 domain is the mechanism of activation for cABL through RTKs, as has been shown with EphB2 and Trk (Yano, Cong et al. 2000,
Hai-Hui, Zisch et al. 2001). Our reported dependence of ABL activity and SH2
domain binding on DCBLD2 pYXXP sites suggests that ABL-directed
phosphorylation of DCBLD2 requires priming of the ABL-SH2 binding site. If
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specific YXXP sites are essential for ABL-SH2 binding, phosphorylation of other sites
could be dependent upon phosphorylation of the ABL-SH2 binding site. It will also be
important to determine whether proteins in addition to CRKL are induced to bind
differentially upon SFK- or ABL-induced phosphorylation.
Our working DCBLD signaling model is summarized in Figure 16C. We have
previously demonstrated antibody-induced phosphorylation of DCBLD2, which
suggests a ligand-mediated clustering mechanism (Figure 16C) (Aten, Redmond et al.
2013). We hypothesize that clustering leads to SFK activation at the membrane and
subsequent ABL activation, either through direct phosphorylation by SFKs or ABLSH2 binding to SFK-directed pYXXP (Hantschel, Nagar et al. 2003, Tanis, Veach et
al. 2003, Hantschel and Superti-Furga 2006, Hossain, Dubielecka et al. 2012), leading
to increased levels of DCBLD1/2 tyrosine phosphorylation and recruitment of
CRK/CRKL. Future work will strive to identify an extracellular ligand that induces
intracellular phosphorylation and CRK/CRKL recruitment. In an alternative signal
transduction mechanism, others have demonstrated growth factor-induced DCBLD2
phosphorylation (Feng, Lopez et al. 2014) and DCBLD2-RTK complex formation
(Nie, Guo et al. 2013). We present a co-receptor signaling mechanism (Figure 16C) in
which growth factor binding to EGFR, a representative growth factor receptor, induces
SFK and ABL activation, as well as DCBLD1/2 phosphorylation and CRK/CRKL
recruitment. It is unknown whether DCBLD1/2 phosphorylation occurs directly via
RTK activity, or indirectly through the activation of non-receptor tyrosine kinases.
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While the biological roles of DCBLD family tyrosine phosphorylation sites
remain to be elucidated, their strong conservation across vertebrates implies they
mediate important signaling events. Our characterization here of the overlapping roles
of SFKs and ABL in DCBLD family phosphorylation and how this multisite
phosphorylation induces CRKL binding provides a framework for further cellular
biochemical studies of this new receptor family.
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CHAPTER 3: FYN AND ABL REGULATE THE INTERACTION NETWORKS
OF THE DCBLD RECEPTOR FAMILY
3.1. Abstract
The Discoidin, CUB, and LCCL domain-containing protein (DCBLD) family
consists of two type-I transmembrane scaffolding receptors, DCBLD1 and DCBLD2,
which play important roles in development and cancer. The non-receptor tyrosine
kinases FYN and ABL are known to drive phosphorylation of tyrosine residues in
YXXP motifs within the intracellular domains of DCBLD family members, which
leads to the recruitment of the SRC homology 2 (SH2) domain of the adaptors CT10
regulator of kinase (CRK) and CRK-like (CRKL). We previously characterized the
FYN- and ABL-driven phosphorylation of DCBLD family YXXP motifs. However, we
have identified additional FYN- and ABL-dependent phosphorylation sites on
DCBLD1 and DCBLD2. This suggests that beyond CRK and CRKL, additional
DCBLD interactors may be regulated by FYN and ABL activity. Here, we report a
quantitative proteomics approach in which we map the FYN- and ABL-regulated
interactomes of DCBLD family members. We found FYN and ABL regulated the
binding of several signaling molecules to DCBLD1 and DCBLD2, including members
of the 14-3-3 family of adaptors. Biochemical investigation of the DCBLD2/14-3-3
interaction revealed ABL-induced binding of 14-3-3 family members directly to
DCBLD2.
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3.2. Abbreviations
CCR2, CC chemokine receptor 2; CCL2, CC chemokine ligand 2; CCR5, CC
chemokine receptor 5; TLC, thin layer chromatography. Ab, antibody; BCLB, brain
complex lysis buffer; BH, Benjamini-Hochberg; BLB, bacterial lysis buffer; BSA,
bovine serum albumin; CID, collision-induced dissociation; CL, confidence limit;
DCBLD1/2, discoidin, CUB, and LCCL domain-containing 1/2; DMEM, Dulbecco’s
modified eagle’s medium; DMSO, dimethyl sulfoxide; ECL, enhanced
chemiluminescence; EGFR, Epidermal Growth Factor Receptor; ERK, extracellular
signal-regulated kinase; ESDN, endothelial smooth muscle cell-derived neuropilin-like;
ESI, electrospray ionization; FA, formic acid; FWHM, full-width half-maximum; GO,
gene ontology; GST, Glutathione S-transferase; HEK, human embryonic kidney; H/L,
heavy-to-light ratio; HPLC, high performance liquid chromatography; HRP,
horseradish peroxidase; IP, immunoprecipitation; IPTG, isopropyl β-D-1thiogalactopyranoside; INSR, Insulin Receptor; KD, kinase-dead; LB, Luria broth; LCMS/MS, liquid chromatography tandem mass spectrometry; MAPK, Mitogen Activated
Protein Kinase; PD, pull-down; PDGFR, Platelet-Derived Growth Factor receptor;
PMSF, phenylmethylsulfonyl fluoride; PPI, protein-protein interaction; PTM, posttranslational modifications; RTK, receptor tyrosine kinase; SD, standard deviation;
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SFK, Src
family kinase; SH2 , Src homology 2; SH3, Src homology 3; SILAC, stable isotope
labeling of amino acids in cell culture; TBS-T, Tris-buffered saline–polysorbate
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(Tween) 20; TM, transmembrane; TRAF6, TNF receptor-associated factor 6; VEGFR,
Vascular Endothelial Growth Factor Receptor; WCE, whole cell extract; WT, wild-type
3.3. Introduction
The Discoidin, CUB, and LCCL domain-containing protein (DCBLD) receptor
family is composed of two single-pass transmembrane proteins that play integral roles
in vertebrate development and disease (Schmoker, Ebert et al. 2019). Both family
members possess CUB, LCCL, and coagulation factor FV/FVIII (Discoidin)
extracellular domains, as well as a cytoplasmic scaffolding region (Schmoker, Ebert et
al. 2019). Although they remain orphan receptors, there is evidence that a class IV
semaphorin, SEMA4B, may be a ligand for DCBLD2 (Nagai, Sugito et al. 2007).
DCBLD2 is also known to modulate signaling of receptor tyrosine kinases (RTKs),
including vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived
growth factor receptor β (PDGFRβ) in blood vessel development and repair (Kobuke,
Furukawa et al. 2001, Guo, Nie et al. 2009, Nie, Guo et al. 2013), insulin receptor
(INSR) in glucose homeostasis (Li, Jung et al. 2016), and epidermal growth factor
receptor (EGFR) in oncogenesis and cancer progression (Koshikawa, Osada et al. 2002,
Feng, Lopez et al. 2014). However, the molecular mechanisms of DCBLD2 action on
RTK signaling are not well understood.
The intracellular scaffolding domains of DCBLD family members harbor seven
(DCBLD2) and eight (DCBLD1) intracellular binding motifs of the SRC homology 2
(SH2) domains of the signaling adaptors CT10 regulator of kinase (CRK) and CRK120

like (CRKL). Binding of the CRK/CRKL-SH2 domain requires tyrosine
phosphorylation within these YXXP motifs, as mutation of all such motifs via tyrosineto-phenylalanine substitutions prevents their phosphorylation and abolishes the SH2mediated DCBLD/CRK(L) interaction (Aten, Redmond et al. 2013, Schmoker, Weinert
et al. 2017). The non-receptor tyrosine kinases FYN and ABL can drive
phosphorylation of tyrosines within these YXXP motifs, thereby inducing the
interaction between DCBLD proteins and the SH2 domain of CRK/CRKL (Schmoker,
Weinert et al. 2017, Schmoker, Ebert et al. 2019). FYN (Lu, Zhu et al. 2009, Zhang,
Fan et al. 2017) and ABL (Plattner, Kadlec et al. 1999) can be activated downstream of
RTKs and in many other signaling pathways. Thus, FYN and ABL activity could
regulate proteins in complex with DCBLD proteins and thereby engage DCBLD
proteins to participate in RTK or other signal transduction mechanisms. To identify and
measure the networks of proteins that dynamically interact with DCBLD family
members dependent on FYN and ABL, we employed affinity chromatography and
quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS).
3.4. Experimental Procedures
3.4.1. Materials
Penicillin/Streptomycin 100X solution and Dulbecco’s Modified Eagle Medium
(DMEM) were obtained from Mediatech (Manassas, VA, USA). DMEM for stable
isotope labeling of amino acids in cell culture (SILAC) and kanamycin sulfate were
acquired from Thermo Scientific (Waltham MA, USA), and fetal bovine serum (FBS),
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dialyzed FBS for SILAC experiments, and cosmic calf serum (CCS) were purchased
from Hyclone (Logan, Utah, USA). Heavy labeled L-arginine (13C6, 15N4) and L-lysine
(13C6, 15N2) were obtained from Cambridge Isotope Laboratories (Tewksbury, MA,
USA), and unlabeled amino acids were purchased from MP Biomedicals (Santa Ana,
CA, USA). The sequencing-grade trypsin used in enzymatic digests prior to LCMS/MS analysis was from Promega (Madison, WI, USA). The BSA standard for
Bradford assays and the Bradford Reagent were obtained from Amresco Life Sciences,
LLC. (Cleveland, OH, USA). Protein G resin was obtained from G-Biosciences (St.
Louis, MO, USA). Protein A resin and enhanced chemiluminescence (ECL) reagents
were purchased from Pierce (Rockford, IL, USA), and x-ray film was from Denville
scientific (Metuchen, NJ, USA). Packing material used for HPLC was purchased from
Michrom Bioresources Inc. (Auburn, CA, USA). Nitrocellulose membranes were from
GVS Life Sciences (Sanford, ME, USA). All additional reagents were purchased from
Sigma (St. Louis, MO, USA) unless otherwise noted.
3.4.2. Plasmids
The mammalian expression construct for full-length human DCBLD2
(RC224483) in pCMV6-Entry, tagged with FLAG and MYC sequences at C-termini,
were obtained from OriGene (Rockville, MD, USA). The C-terminal MYC- and
FLAG-tagged human DCBLD1 construct in pCMV6 vectors was synthesized by Bio
Basic Inc. (Markham, ON). Wild-type (WT) FYN (Mariotti, Kedeshian et al. 2001) and
kinase dead (K299M) FYN (Mariotti, Kedeshian et al. 2001) plasmids in pRK5-Entry
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were acquired from AddGene (Cambridge, MA, USA). The human pRK5-FYN WT
(wild type), pRK5-FYN KD (K299M, kinase dead), and pRK5-FYN ΔSH3 (deletion of
76-141) were acquired from Addgene (Cambridge, MA, USA) (Mariotti, Kedeshian et
al. 2001). The FYN-Y3D mutant (FYN-Y3D), with three tyrosine-to-aspartate
mutations in the SH2 domain (Y185D, Y213D, and Y214D), was previously described
by Weir, et al.(Weir, Mann et al. 2016). The human c-ABL construct, with a C-terminal
Flag tag was kindly gifted by A. Howe (U. of Vermont), originally constructed in the
Kufe lab (Harvard Medical School) (Cao, Leng et al. 2003). The bacterial expression
plasmids encoding the fusion of glutathione S-transferase with 14-3-3β (Addgene #
13276), 14-3-3ε (Addgene # 13279), 14-3-3ε K49E (Addgene # 11945), 14-3-3ζ
(Addgene # 13278), 14-3-3σ (Addgene # 11944) were kind gifts from M. Yaffe (Yaffe,
Rittinger et al. 1997, Brunet, Kanai et al. 2002). The plasmids encoding wild-type
ABL:ER fusion protein (pPLcIV:ER) and the mutant lacking the SH3 domain
(ABL:ER-SH3; pPLXB:ER) were kindly gifted from D. Picard (Jackson, Baltimore
et al. 1993).
3.4.3. Antibodies
The mouse α-Flag (M2) antibody (Ab) and Affinity Gel were from Sigma and
the free Ab was used for Western blotting at a concentration of 0.5 µg/mL. The rabbit
α-GST (1:2000 for Western blotting) was also from Sigma. Cell Signaling
Technologies Inc. (Danvers, MA, USA) was the source of the following antibodies,
used at 1:1000 dilutions: α-FLAG (M2, rabbit mAb), α-MYC (71D10, rabbit mAb), α123

FYN (rabbit polyclonal), α-pTyr416-SRC (D49G4, rabbit mAb), α-α-tubulin (DM1A,
mouse mAb), α-pTyr412-ABL (247C7, rabbit mAb), α-c-ABL (rabbit polyclonal), αRXXpS/pT (110B7E, rabbit mAb), and α-RXXpSXP (rabbit polyclonal). The α-pY
(4G10; 1:1000) was from EMD Millipore (Billerica, MA, USA). For immunoblotting
all primary antibodies were diluted in 1.5% BSA in Tris-Buffered Saline (0.9% NaCl,
0.4% Tris-HCl, and 0.1% Tris-base) with 0.05% Tween 20 (TBS-T) and containing
0.005% sodium azide. Horseradish peroxidase (HRP)-conjugated secondary antibodies
were obtained from EMD Millipore and used at the following concentrations: goat αmouse IgG-HRP (1:5,000), light-chain-specific goat α-mouse and α-rabbit IgG-HRP
(1:10,000), and goat α-rabbit IgG-HRP (1:15,000). All secondary antibodies were
diluted in TBS-T.
3.4.4. Cell culture, transfection, and lysis
Adenovirus early region 1A (E1A)-transformed HEK 293 cells were cultured in
DMEM supplemented with 5% each of FBS and CCS, 50 U/mL penicillin, and 50
μg/mL streptomycin at 37 ˚C in 5% atmospheric CO2. For SILAC experiments HEK
293 cells were cultured in labeled (heavy) or unlabeled (light) growth medium for at
least one week prior to transfection to ensure full incorporation of stable isotopes into
proteins. SILAC media, lacking L-lysine and L-arginine were supplemented with 10%
dialyzed FBS and antibiotics as stated above, and with 60 mg/L unlabeled L-proline,
100 mg/L of L-lysine either unlabeled or labeled (13C6, 15N2), and 100 mg/L of Larginine either unlabeled or labeled (13C6, 15N4).
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HEK 293 cells were grown to 60% of confluence prior to transfection via
calcium phosphate precipitation. The following amount of plasmid was transfected per
10 cm dish: wild type and mutant DCBLD1 (10 µg) and DCBLD2 (6 µg), wild type
and mutant FYN (1.5 µg), and wild type c-ABL (1 µg), WT- or SH3-ABL:ER (4 µg).
Six hours post-transfection, cells were washed with phosphate-buffered saline (PBS)
and returned to full medium overnight before lysis. Cells were placed on ice and
immediately washed with PBS (4 ˚C) prior to lysis in Brain Complex Lysis Buffer
(BCLB: 25 mM Tris pH 7.2, 137 mM NaCl, 10% glycerol, 1% igepal, 25 mM NaF, 10
mM Na2H2P2O7, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10
µg/mL each of leupeptin and pepstatin-A). Lysates were centrifuged and the
supernatant was reserved for immunoprecipitation or immunoblotting.
3.4.5. Immunoprecipitation and SDS-PAGE for immunoblotting
Protein concentration was determined as described above. For
immunoprecipitations, normalized lysates (1 µg/µL) were incubated separately with αFLAG Affinity Gel (10 µL of a 50 % slurry) or the -MYC antibody with a 50/50
mixture of protein A and G resin (20 µL of a 50 % slurry) overnight, rocking at 4 ˚C.
Beads were washed three times with BCLB, after which bound proteins were eluted
and denatured in 25 µL sample buffer at 95 ˚C for 5 min. For whole cell extracts
(WCEs), normalized lysates were denatured in sample buffer (final concentration of
0.75 µg/µL) at 95 ˚C for 5 min. Immunoprecipitations and WCEs (15 µg per well) were
separated on 10% acrylamide gels with 4.2% acrylamide stacking gels, as described
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above. Following separation, proteins were transferred onto nitrocellulose membranes
in a submersible transfer unit at 4 ˚C in 1.13% glycine, 0.25% Tris-base and 20%
methanol. Membranes were stained with a reversible Ponceau stain to assess total
protein levels. Membranes were blocked with 5% non-fat dry milk in TBS-T and
incubated in primary antibody solutions overnight at 4 ˚C. Membranes were then
washed and incubated with HRP-conjugated secondary antibody solution for three
hours at 25 ˚C. Membranes were briefly incubated in ECL reagents and exposed to xray film.
3.4.6. GST-14-3-3 pulldown assays and far-Western blotting
To generate GST-14-3-3-conjugated glutathione beads, 50 mL cultures of Luria
Broth (LB; 0.5% Tryptone, 0.5% yeast extract, 171 mM NaCl) containing 50 µg/mL
ampicillin were inoculated with E. coli harboring a pGEX plasmid encoding GST-14-33, GST-14-3-3, GST-14-3-3K49E, GST-14-3-3, or GST-14-3-3 and incubated
overnight at 37 ˚C, shaking at 215 rpm. This initial culture was then spiked into 500mL LB with ampicillin, and incubation was continued for 2 hours. Expression of GST14-3-3 fusions was induced by the addition of isopropyl β-D-1-thiogalactopyranoside
(IPTG) to 1 mM, followed by an additional 4-5 hours of incubation. Bacteria were
pelleted and stored at -20˚C. Pellets were re-suspended in 10 mL Bacterial Lysis Buffer
(BLB; 100 mM ethylenediaminetetraacetic acid, 1 mM PMSF, 10 µg/mL each
leupeptin and pepstatin-A in PBS). Cells were sonicated in six 30 sec intervals,
intermitted with equal rest periods on ice, after which 1 mL of 10% Triton X-100 was
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added. Lysates were mixed separately and insoluble material was pelleted. Glutathione
resin (400 µL of a 50% slurry in BLB) was added to the supernatant and rocked
overnight at 4˚C. Beads were washed 2X in BLB, 3X in BCLB, and 2X in PBS and
then stored in PBS (~50% slurry) at 4 ˚C. For pull-down assays, cell lysates were
rocked with 20 µL of the 50% slurry of individual GST-14-3-3-conjugated glutathione
beads at 4 ˚C. Beads were washed three times with BCLB and proteins were eluted and
denatured in 25 µL of sample buffer at 95˚C for 5 min prior to analysis via SDS-PAGE
and Western blotting, as described above.
For far-Western blotting, GST-fusion proteins were eluted from the glutathione
resin in 50 mM Tris (pH 7-8), 100 mM NaCl, and 20 mM glutathione for 30 min at 4
˚C while rocking. Following centrifugation, the supernatant was removed and reserved.
The eluent was dialyzed in 25 mM Tris and 50% glycerol in PBS overnight and stored
at -20˚C. Eluted fusion proteins were diluted to a final concentration of approximately
50-100 ng/mL in 1.5% BSA in TBST with 0.005% sodium azide. Western blotting of
α-FLAG or α-MYC immunoprecipitations was carried out as described above, with the
additional incubation of blocked nitrocellulose membranes with diluted GST-fusion
proteins prior to primary antibody incubation (α-GST). Densitometric analyses of αGST and α-FLAG or α-MYC signals were conducted in Photoshop. Mean intensities in
α-GST signals, normalized to α-FLAG/α-MYC signals, were compared in JMP using
an all pairs, Tukey HSD test.
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3.4.7. Immunoprecipitation and SDS-PAGE for mass spectrometry
Protein concentrations were determined using Bradford assays and an Eppendorf
BioPhotometer Plus (Eppendorf; Hamburg, Germany) with BSA standards. For SILAC
immunoprecipitations, normalized lysates (3.5 x 103 µg total protein in 1 mL) from
heavy/light conditions were incubated separately with α-FLAG Affinity Gel (10 µL of
a 50 % slurry) overnight, rocking at 4 ˚C. The beads were washed three times with
BCLB, after which bound proteins were eluted and denatured in 30 µL sample buffer
(150 mM Tris pH 6.8, 2% SDS, 5% β-mercaptoethanol, 7.8% glycerol, 0.25 ng/mL
bromophenol blue) at 95 ˚C for 5 min. Immunoprecipitations were combined (10 µL
each per well) separated on 10% and 15% acrylamide gels (30% w/v and 37.5:1
acrylamide:bis-acrylamide) with 4.2% acrylamide stacking gels. Current was
maintained at 20 mA and 30 mA per gel through the stacking and separating layers,
respectively. Following separation, proteins were stained with Coomassie.
Immunoprecipitations from non-quantitative experiments for LC-MS/MS were carried
out as described above and separated on 10% acrylamide gels (20 µL each per well).
To identify DCBLD2 interactors from zebrafish extracts, adult zebrafish were
anesthetized with tricaine and then chilled in ice water before freezing. Frozen
zebrafish were placed in BCLB and homogenized on ice using a tissue homogenizer
(IKA Works Inc.; Wilmington, NC USA). Insoluble material was pelleted, and the
supernatant was used for immunoprecipitations using resins charged with DCBLD2:
DCBLD2-charged resins were prepared by immunoprecipitating FLAG-tagged
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DCBLD2 constructs from HEK cells expressing DCBLD2 alone or DCBLD2 with
ABL. The immune complexes were washed three times with BCLB and incubated with
zebrafish extracts overnight. The complexes were washed again with BCLB three times
before bound proteins were denatured at 95˚C and analyzed by SDS-PAGE, as
described above. Animal care and use was according to an approved University of
Vermont IACUC protocol by Alicia Ebert.
3.4.8. Peptide preparation and LC-MS/MS methods
Regions were excised from Coomassie-stained acrylamide gels, diced to 1-mm
cubes and transferred to separate microcentrifuge tubes. Gel pieces were washed with
HPLC-grade H2O and then de-stained in 50 mM ammonium bicarbonate (NH4HCO3)
and 50% acetonitrile (MeCN) at 37 ˚C for 30 minutes. De-stain was removed and gel
pieces were dehydrated in 100% MeCN. For protein identification experiments,
proteins were subjected to proteolytic digest with sequencing grade modified trypsin
(10 ng/µL in 50 mM NH4HCO3) overnight at 37 ˚C. After centrifugation, supernatants
were transferred to new microcentrifuge tubes. Remaining peptides were extracted from
gel pieces with the addition of 50% MeCN, 2.5% formic acid (FA). Supernatants were
combined with the initial tryptic digest supernatants, and gel pieces were dehydrated in
100% MeCN. The final extraction was combined with the previous two extractions and
peptides were dried in a speed-vac. For mapping phosphorylation sites on DCBLD
family members, gel bands containing DCBLD proteins were subjected to a short
tryptic digest (4 hours at 37 ˚C) and peptides were extracted as described above. Dried
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peptides were re-suspended in GluC (10 ng/µL in 50 mM NH4HCO3) and incubated for
2 hours at 37 ˚C. The reaction was quenched in FA (2.5% in 50% MeCN), gel pieces
were dehydrated as described above, and doubly digested peptides were dried in a
speed-vac.
Dried peptides were re-suspended in Solvent A (2.5% MeCN, 0.15% formic
acid (FA)) and separated via HPLC (300 nL/min) using the Easy n-LC 1200 prior to
MS/MS analysis on the Q Exactive Plus mass spectrometer fitted with a Nanospray
Flex ion source and supplied with Thermo Xcalibur 4.0 software (instruments and
software from Thermo Fisher Scientific). Chromatography columns (15 cm x 100 µm)
were packed in-house with 2.7 µm C18 packing material (Halo, pore size = 90 Å from
Bruker, Billlerica, MA USA). Peptides were eluted using a 0-50% gradient of Solvent
B (80% MeCN, 0.15% FA) over 60 min and ionized by nanospray ionization (2.2 kV).
This gradient was followed by 10 min at 100% Solvent B before a 15-min equilibration
in 100% Solvent A. The precursor scan (scan range = 360-1700 m/z, resolution =
7.0x104, AGC = 106, maximum IT = 100 ms, lock mass=371.1012 m/z) was followed
by ten higher energy C-trap dissociation (HCD) tandem mass spectra of the top ten ions
in the precursor scan (resolution = 3.5 x 104, AGC = 5.0 x 104, maximum IT = 50 ms,
isolation window = ±1.6 m/z, normalized collision energy = 26%, dynamic
exclusion=30 s).
3.4.9. Mass spectrometry data filtering and statistical analysis
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For PTM-mapping of DCBLD1 and DCBLD2 experiments, raw spectra were searched
for matches within forward and reverse human DCBLD1 and DCBLD2 sequences
using SEQUEST (version 28) with no enzyme indicated, 2 missed cleavages permitted,
a precursor mass tolerance of ± 5 PPM and a fragment ion tolerance of ± 0.006 Da. The
following differential modifications were permitted: phosphorylation of serine,
threonine and tyrosine (+79.9663 Da), ubiquitylation of lysine (+114.0429 Da),
oxidation of methionine (+15.9949 Da), carboxyamidomethylation of cysteine
(+57.0215 Da), and acrylamidation of cysteine (+71.0371 Da). Peptides were then
filtered to remove any cut sites other than after K, R, E, or D, as well as by precursor
mass accuracy (tolerance = ±4 ppm) and cross correlation (XCorr) scores dependent
upon charge state (XCorrz=+1=1.8; XCorr z=+2=2.0; XCorr z=+3=2.2; XCorr z=+4=2.4;
XCorr z=+5=2.6). All identified DCBLD1 and DCBLD2 peptides from the double digest
are available upon request. Label free quantification (previously described in
(Schmoker, Weinert et al. 2017)) was achieved by taking ratios of phosphopeptide
intensities across conditions, normalized to that of loading control peptides within
DCBLD1 (LGGQISVLQR, AAIHAGIIADE, DVAGDISGNMVDGYR,
LQDQGPSWASGDSSNNHKPR) or DCBLD2 (FGDFDIEDSDSC^HFNYLR,
ITGIITTGSTM*VEHNYYVSAYR, KPGPPWAAFATDE, LKKPGPPWAAFATDE).
C^ = Cys carboxyamidomethylation and M* = Met oxidation. The modified DCBLD2
peptides were chosen for use as loading controls due to their high abundance and
comparable intensity changes across conditions to that of the unmodified loading
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controls. We note that these modifications are artifacts from the sample preparation,
rather than post-translational, and therefore the same percentage of these sites should be
modified on these reference peptides across conditions. Average precursor ion
intensities of reference peptides and signal-to-noise ratios in each experimental
condition are tabulated in Table 6. Phosphorylation site localizations were scored using
the ModScore algorithm (Data available upon request) (Beausoleil, Villén et al. 2006).
Table 6. Reference peptide intensity and signal-to-noise (S/N) for DCBLD1 and DCBLD2 label free
quantification.
Average reference peptide intensities were used for normalization purposes to compare
phosphopeptide intensity across experimental conditions. ^ = Cys carbamidomethylation, * = Met
oxidation
DCBLD(X) alone

DCBLD(X) + ABL
Intensity

S/N

DCBLD(X) + FYN

z

Protein

Peptide

Intensity

S/N

2

DCBLD1

E.LGGQISVLQR.K

5.01E+08

16587.2

1.81E+08

8321.4

Intensity
-

S/N
-

2

DCBLD1

K.AAIHAGIIADE.L

1.35E+08

944.8

6.97E+07

1586.6

-

-

2

DCBLD1

R.DVAGDISGNMVDGYR.D

9.17E+07

51.2

3.77E+07

38.6

-

-

3

DCBLD1

R.LQDQGPSWASGDSSNNHKPR.E

4.25E+08

640.8

1.25E+08

320

-

-

3

DCBLD2

K.FGDFDIEDSDSC^HFNYLR.I

2.15E+07

451.9

3.24E+07

490.8

5.75E+06

3

DCBLD2

K.ITGIITTGSTM*VEHNYYVSAYR.I

1.37E+06

197.9

3.04E+06

218.4

2.66E+06

72.9

2

DCBLD2

K.KPGPPWAAFATDE.Y

6.16E+07

1183.5

1.02E+08

1991.5

2.70E+07

607.8

3

DCBLD2

R.LKKPGPPWAAFATDE.Y

3.43E+07

1011.2

7.02E+07

766

1.45E+07

75.4

113.4

For SILAC experiments, raw spectra from three biological replicates were
searched for matches within a forward and reverse human proteome (Uniprot, 2018,
>70,000 entries) using SEQUEST (version 28), requiring tryptic peptides and
permitting 2 missed cleavages and the following differential modifications: heavy
lysine (+8.0142 Da) and arginine (+10.0083 Da), phosphorylation of serine, threonine
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and tyrosine (+79.9663 Da), oxidation of methionine (+15.9949 Da),
carboxyamidomethylation of cysteine (+57.0215 Da), and acrylamidation of cysteine
(+71.0371 Da). Peptides were filtered by precursor mass accuracy (tolerance = ±4
ppm), XCorr scores (XCorrz=+1=1.8; XCorr z=+2=2.0; XCorr z=+3=2.2; XCorr z=+4=2.4;
XCorr z=+5=2.6) and unique Corr (0.15). These parameters resulted in a false
discovery rate (FDR) < 1% calculated as follows: (2 x [# reverse hits])/[# forward hits].
Proteins were considered identified by three or more peptides. Peptide heavy-to-light
ratios (H/L) were calculated using Vista (Bakalarski, Elias et al. 2008) by precursor
maxima. Peptides were considered quantifiable if the signal-to-noise ratio (S/N) of
either the heavy or light peptide was >10 (Bakalarski, Elias et al. 2008). Quantified
proteins were required to have three or more quantifiable peptides. Peptide H/L were
averaged across a given protein to obtain a protein H/L with an associated standard
deviation (SD).
For each experimental condition in a given set (Figure 43), H/L of proteins
present in both experimental and mock conditions were compared (experimental-tomock fold change (E/M)). Those falling 2 standard deviations (SDs) from the mean
E/M were retained in the experimental dataset. All other proteins identified in the mock
condition were removed from each experimental dataset. Proteins that were identified
bound to DCBLD1 or DCBLD2 in all three biological replicates in a given
experimental condition were considered specific interactors. H/L were normalized to
that of DCBLD(X) in a given treatment group before individual protein statistical
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comparisons at 95% confidence to the DCBLD(X) H/L ± SD using a student’s T-test
with a Benjamini-Hochberg (BH) correction. For proteins identified by multiple
isoforms, H/L were averaged across isoforms. H/L and corrected p-values of quantified
specific interactors are available upon request.
For the analysis of DCBLD2 interactors from zebrafish extracts, spectra were
searched against a forward and reverse database of combined zebrafish and human
proteomes (Uniprot). Peptides were filtered with the same parameters for mass
tolerance, XCorr, and unique Corr as described above. Peptides that mapped to
zebrafish proteins were analyzed by the NCBI Protein BLAST tool
(blast.ncbi.nlm.nih.gov (Madden 2013)) to determine whether peptides were unique to
zebrafish or common to human. DCBLD2 interactors identified in the zebrafish
immunoprecipitation are available upon request.
3.4.10. Gene Ontology term enrichment analysis
Gene Ontology (GO) term enrichment analyses of GO Molecular Function, GO
Biological Process, and GO Cellular Compartment were conducted via the Metascape
(metascape.org) platform (Zhou, Zhou et al. 2019). Metascape’s default statistical
parameters were used for the analysis. GO terms were considered enriched in the input
dataset if they possessed a corrected p-value of < 0.05.
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3.5. Results
3.5.1. PTM mapping of DCBLD1 and DCBLD2 reveals novel FYN- and ABLregulated phosphorylation sites
Previously, using a targeted LC-MS/MS approach, we found that the nonreceptor tyrosine kinases FYN and ABL regulated several tyrosine phosphorylation
sites on DCBLD family members (human DCBLD2 and mouse DCBLD1) (Schmoker,
Weinert et al. 2017). Given that we found the tyrosine residues in DCBLD intracellular
YXXP motifs critical to the DCBLD/CRKL-SH2 interaction (Aten, Redmond et al.
2013), our targeted approach in that study focused primarily on the phosphorylation of
YXXP tyrosines. While a few YXXP tyrosines remained refractory to quantification
due to their presence in long tryptic peptides housing multiple potential
phosphorylation sites, several were quantitatively monitored. We found that both FYN
and ABL induced DCBLD2 tyrosine phosphorylation in YXXP motifs. Although both
cytoplasmic kinases induced the phosphorylation of common sites, FYN and ABL
exhibited distinct specificity for certain DCBLD2 YXXP tyrosines (Schmoker, Weinert
et al. 2017). However, ABL, but not FYN, induced YXXP tyrosine phosphorylation of
DCBLD1 (Schmoker, Weinert et al. 2017). Therefore, we conducted a quantitative
proteomics analysis of DCBLD receptor binding proteins in the presence or absence of
either FYN or ABL for DCBLD2 and in the presence or absence of only ABL for
DCBLD1. This approach also afforded us the opportunity to examine in a more
unbiased fashion the phosphorylation of serine, threonine and tyrosine residues outside
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of YXXP motifs, as well as to consider alternative approaches to analyze the previously
unidentifiable or unquantifiable pYXXP-containing peptides in DCBLD proteins. As
these analyses go hand-in-hand, and as differential phosphorylation may reveal
mechanisms behind changing interactomes, we first describe an in-depth
phosphorylation analysis of DCBLD proteins, followed by an analysis of their
interactomes dependent upon ABL and also upon FYN for DCBLD2.
To increase coverage and thereby identify phosphorylation sites not readily
observed in tryptic peptides, we took a more comprehensive approach to map
phosphorylation sites on DCBLD1 (human) and DCBLD2 (human) using a limiting,
double-enzyme digest before LC-MS/MS analysis. DCBLD1 and DCBLD2 were
transiently expressed in 293 cells with and without FYN (DCBLD2 only) or ABL (both
family members). DCBLD proteins were immunoprecipitated (α-FLAG) and subjected
to SDS-PAGE and Coomassie staining. Bands containing DCBLD1 or DCBLD2 were
excised and subjected to a double-enzymatic digest with trypsin, followed by GluC.
Peptides were analyzed by LC-MS/MS and spectra were searched via SEQUEST
against forward and reverse human DCBLD1 or DCBLD2 sequences. No enzyme was
specified in order to expand the database of potential hits and the resulting data was
filtered to include only trypsin and/or GluC cut sites, resulting in a FDR of <1%.
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Figure 17. Differential phosphorylation of DCBLD family members by FYN and ABL.
DCBLD1-FLAG and DCBLD2-FLAG were transiently expressed in 293 cells in the presence and
absence of ABL or FYN. Immunoprecipitates (α-FLAG) from 293 lysates were analyzed by SDSPAGE and Coomassie staining. Bands containing DCBLD1 and DCBLD2 were excised and
subjected to proteolytic digest with Trypsin and GluC prior to analysis via LC-MS/MS. RAW
spectra were searched against DCBLD1 or DCBLD2 sequences. Intensities of quantifiable singly
phosphorylated peptides (S/N >10) were normalized to unmodified loading control peptides for
comparison of relative phosphopeptide intensities across conditions. Relative phosphopeptides
abundance is plotted as a spatially resolved heat map across DCBLD1 and DCBLD2 sequences,
with blue, green, and red gradients displaying phosphoserine (pSer), phosphothreonine (pThr),
and phosphotyrosine (pTyr) abundances, respectively. Unquantifiable phosphorylation sites are
indicated by asterisks (*) of the same colors. Sites identified in multiply phosphorylated peptides in
each condition are indicated with yellow triangles and tabulated in the Supplementary Spectra
(available upon request), but not quantified. Multiple sites present within single peptides were
individually quantified if resolved chromatographically. In cases where similar species were not
chromatographically resolved, proximal sites were quantified together, indicated by dashed boxes.
Notated residues of phosphorylation sites identified in this study that have not yet been curated in
the PhosphoSitePlus (phosphosite.org) database are highlighted in green.
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Several serine, threonine and tyrosine phosphopeptides were identified on both
DCBLD1 and DCBLD2. Singly phosphorylated peptides were quantified by relative
ion intensity across experimental conditions, normalized to loading control peptides
within the DCBLD1 or DCBLD2 sequence. Quantification of individual serine (blue),
threonine (green) and tyrosine (red) phosphorylation sites are represented in a spatially
resolved heat map along DCBLD protein sequences in Figure 17, and in tabulated form
in Table 7. Singly phosphorylated peptides possessing multiple potential S/T/Y
phosphorylation sites that were indistinguishable by fragment ions were quantified
together and surrounded by boxes in Figure 17 (Table 7). Although the specific
phosphorylation sites remained ambiguous, it was still important to show regions where
phosphorylation increased or decreased, as these may represent important regulatory
regions on DCBLD proteins. However, we note that additional targeted studies would
be required to resolve those sites. Unquantifiable sites (S/N < 10) and sites identified in
multiply phosphorylated peptides in each experimental condition are indicated by
asterisks and yellow triangles, respectively (Figure 17). Tables of identified DCBLD1
and DCBLD2 peptides as well as annotated spectra of confirmed phosphorylation sites
are available upon request.
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Table 7. Average ion intensities DCBLD1 and DCBLD2 phosphopeptides.
Average ion intensities of all quantifiable singly phosphorylated peptides identified in label-free
quantification studies for A) DCBLD1 and B) DCBLD2 are tabulated. Intensities of quantifiable
singly phosphorylated peptides (S/N >10) were normalized to unmodified loading control peptides
(Table 6) for comparison of relative phosphopeptide intensities across conditions. Phosphorylated
species that were not resolve chromatographically were quantified together, indicated by multiple
site localizations with one average intensity. These intensities were used to quantify relative changes
in phosphopeptide intensities represented in the heat map in Figure 17.

A
Average Normalized
Intensity
Site(s)

DCBLD1

S488

4.14E+07

9.85E+06

S513

6.52E+07

1.29E+08

Y540

-

8.16E+07

S556

2.03E+08

2.33E+08

Y578

-

3.22E+08

Y589

-

9.91E+07

Y600

3.65E+07

7.12E+08

T602

2.04E+07

-

Y621
S633,
S635,
S636,
S640

9.27E+06

9.12E+08

8.83E+08

1.90E+08

Y652
S657,
Y665

4.57E+06

2.28E+08

-

5.04E+07

S672
S963,
S695,
Y696,
S697

2.16E+06

-

3.89E+06

9.39E+08
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DCBLD1 + ABL

B
Site(s)

Average Normalized Intensity
DCBLD2 +
DCBLD2 +
DCBLD2
ABL
FYN

Y565

-

Y569
T593,
Y597,
S598,
S599,
S600

-

8.42E+07

8.71E+07

S618

-

5.36E+07

1.16E+07

Y621

-

1.45E+08

4.71E+07

Y649

-

1.21E+08

1.39E+07

Y655

-

3.89E+06

5.21E+06

S657
Y663,
Y666

4.35E+06

3.73E+06

5.96E+06

-

1.17E+06

5.22E+07

Y677

-

1.58E+07

3.40E+06

T679

-

2.00E+06

Y715
S724,
S727

-

8.91E+07

5.29E+07

9.58E+07

1.16E+07

4.70E+07

-

6.14E+07

2.02E+07

-

7.63E+05

Y750
T756,
S760

1.09E+07
-

8.35E+07
4.38E+07

-

-

-

Quantification of FYN- and ABL-driven phosphorylation of DCBLD1 Y589,
Y600, and Y621 and DCBLD2 Y565, Y621, Y715 (non-YXXP), and Y750
corroborated previous reports (Aten, Redmond et al. 2013, Schmoker, Weinert et al.
2017). Additional tyrosine resides on both DCBLD1 and DCBLD2 sequences were
further characterized as FYN- and/or ABL- driven phosphorylation sites, including
DCBLD1 YXXP tyrosines Y540, Y578, Y652, Y665 and Y696, DCBLD2 YXXP
tyrosines Y655, Y666 and Y677, and DCBLD2 tyrosines outside CRK/CRKL-SH2
binding motifs Y569, Y597, Y649 and Y663. One DCBLD2 YXXP tyrosine residue,
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Y732, remained undetected. Interestingly, several serine and threonine phosphorylation
sites were found to be differentially regulated by FYN or ABL expression (Figure 17).
A comparison with phosphorylation sites curated on PhosphoSitePlus (phosphosite.org
(Hornbeck, Zhang et al. 2014)) confirmed that several novel phosphorylation sites on
DCBLD1 and DCBLD2 were identified in this study, denoted by green site locations
(Figure 17).
3.5.2. FYN- and ABL-regulated DCBLD interactome defined by quantitative LCMS/MS
With the identification of additional FYN- and ABL-regulated tyrosine, serine, and
threonine phosphorylation sites on DCBLD1 and DCBLD2, our hypothesis was
strengthened that ABL- and FYN-regulated phosphorylation of DCBLD proteins could
alter their binding partners. Therefore, we took a quantitative proteomics approach
using stable isotope labeling of amino acids in cell culture (SILAC) to identify DCBLD
interactors in the presence and absence of active FYN and/or ABL.
Cells were grown in medium containing lysine and arginine with only heavy or
light stable isotopes of carbon (13C or 12C) and nitrogen (15N or 14N) for at least one
week prior to transfection. The constructs were transiently expressed in labeled or
unlabeled 293 cells for the following experimental SILAC pairs: DCBLD1 (light) and
DCBLD1 + ABL (heavy), DCBLD2 (light) and DCBLD2 + ABL (heavy), DCBLD2
(light) and DCBLD2 + FYN (heavy). DCBLD family members were
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immunoprecipitated (α-FLAG) from cell lysates and SILAC pairs were combined prior
to SDS-PAGE analysis and Coomassie staining (Figure 18, Figure 43).
Immunoprecipitations from control SILAC pairs were carried out in order to identify
non-specific proteins bound to immune complexes: Mock (light) and Mock (heavy),
Mock (light) and ABL (heavy), Mock (light) and FYN (heavy). To effectively separate
and identify high and low molecular weight interactors, combined SILAC pairs were
divided across 10% and 15% SDS-PAGE gels (Figure 18, Figure 43). Stained 10% and
15% gels were divided into 8 and 7 regions of molecular weight, respectively, all of
which were individually digested into tryptic peptides and analyzed by LC-MS/MS
(Figure 18). Proteins identified in control conditions were removed from the dataset
unless significantly enriched (95% CL) in an experimental heavy or light condition. All
heavy-to-light ratios (H/Ls) were normalized to those of DCBLD family members prior
to statistical analysis across three experimental replicates. Notably, we observed a
substantial loss of DCBLD1 protein when co-expressed with ABL. Figure 19 shows
unnormalized MS1 spectra of representative DCBLD1 peptides, demonstrating a 10fold decrease of DCBLD1 levels on average in when ABL was co-expressed.
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SILAC proteomics screen
ABL

180
130
12C 14N

Arg/Lys
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13C15N

Arg/Lys
Heavy

DCBLD2

95
DCBLD1

72
IP -FLAG

55
Combine heavy/light pairs
15% SDS-PAGE
(Low MW
interactors)

Coomassie

10% SDS-PAGE
(High MW
interactors)

43
34
10% SDS-PAGE
130
72
55

DCBLD2, ABL
DCBLD1

34
23

Analyzed for
normalization,
only

17

Not analyzed

Relative abundance

10

15% SDS-PAGE

Quantify
heavy-to-light
ratios

m/z

Controls

Excise protein bands
Tryptic digest

LC-MS/MS
SEQUEST search, subtract controls

Figure 18. Schematic illustrating SILAC experimental design for the identification of DCBLD1 and
DCBLD2 interactors.
DCBLD1 and DCBLD2 were transiently expressed with and without FYN and/or ABL in 293 cells
grown in DMEM supplemented with arginine and lysine containing either heavy (13C, 15N) or light
(12C, 14N) stable isotopes of carbon and nitrogen. DCBLD(X)-FLAG constructs were
immunoprecipitated from 293 lysates and heavy and light experimental pairs were combined prior to
SDS-PAGE and Coomassie staining. Immunoprecipitates were split across 10% and 15% acrylamide
gels to maximize separation of high molecular weight proteins (10% SDS-PAGE) while retaining
smaller proteins (15% SDS-PAGE) in the analysis. Each lane was divided into the indicated regions
of molecular weight for analysis. All regions of 10% gels were analyzed for binding partners, while
the 15% gels were only analyzed below 34 kDa to minimize overlap in each dataset. The region
containing DCBLD family members in 15% gels were also analyzed for normalization purposes.
Each region was subjected to tryptic digestion and analyzed via LC-MS/MS. Raw spectra were
searched against a forward and reverse human protein database (Uniprot 2011) with the SEQUEST
algorithm. Proteins identified by three or more peptides within ± 4 ppm of theoretical precursor
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masses and unique delta-correlation scores of 0.15 or higher were considered identified. Proteins
identified in control heavy/light conditions (heavy=Mock, light=Mock; heavy=FYN, light=Mock;
heavy=ABL, light=Mock), denoted by green boxes, were removed from experimental datasets.
Quantifiable peptides possessed summed heavy/light signal-to-noise ratios (S/N) of >20. This
workflow was carried out for three separate experimental replicates.

DCBLD1- and DCBLD2-specific interactors common across replicates are
plotted by their Log2-transformed average H/L in Figure 20A–B. Interestingly, no
interactors were found to dissociate from either DCBLD family member in the presence
of FYN or ABL (Figure 20A–B). Those with significantly different (95% CL) H/Ls are
marked with asterisks (Figure 20A–B). No proteins were induced to bind to the αFLAG resin when FYN was expressed alone. ABL interactors identified in the ABLalone controls are indicated (triangles in Figure 20A–B). Although these proteins were
found to interact with ABL, they were maintained as potential DCBLD2 interactors
given their potential to interact with DCBLD2 via ABL, or uniquely with DCBLD2.
ABL is known to bind DCBLD2 through its SH2 domain (Schmoker, Weinert et al.
2017), which could represent a mechanism by which additional DCBLD2-interacting
proteins could be transported to DCBLD2 phosphotyrosine docking sites for ABL-SH2.
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Figure 19. MS1 spectra of select DCBLD1, 14-3-3ε, and CRKL peptides identified in the DCBLD1
α-FLAG immune complex in each biological replicate.
Light peptides (red) originated from 293 cells transiently expressing DCBLD1 alone, and heavy
peptides (blue) originated from cells expressing ABL alongside DCBLD1. Dashed lines with error
bars (standard error) indicate the average percent of the less abundant peptide in each heavy and
light pair, relative to the base peak, across all peptides for the given protein. Although DCBLD1
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protein levels decrease by an average of 10% with ABL co-expression, 14-3-3ε and CRKL proteins
increase >10% in the DCBLD1 immune complex in the presence of ABL.

The pie charts in Figure 20C indicate the proportion of DCBLD1 and DCBLD2
interactors, separately, with the indicated functional classifications, as presently curated
in the major bioinformatic repositories. Each interactor is represented once. Strikingly,
several adaptor proteins with phosphorylation-dependent binding domains, including
members of the CRK and 14-3-3 protein families, were among the ABL-induced
interactors of both DCBLD1 and DCBLD2, as well as several proteins related to actin
dynamics (Figure 20A–C). Proteins involved in the regulation of ubiquitin
modification, including the E3 ubiquitin ligase c-Cbl, the E3-independent E2 ubiquitinconjugating enzyme (UBE2O), and the C-terminal ubiquitin hydrolase FAF-Y
(USP9Y), were induced to bind to DCBLD1 by ABL (Figure 20A, C). Among the
DCBLD2 interacting partners identified in both FYN and ABL SILAC pairs were three
proteins involved in glycosylation dynamics, calnexin (CANX), UDPglucose:glycoprotein glucosyltransferase 1 (UGGT1), and neutral α-glucosidase
(GANAB), although none exhibited marked changes in binding to DCBLD2 in the
presence of either kinase (Figure 20B–C).
Several cytoplasmic kinases were also found in complex with DCBLD1 and
DCBLD2 (Figure 20C). Serine/threonine kinases of the Ca2+/calmodulin-dependent
protein kinase type-II family CaMK-IIβ and CaMK-IIδ were induced to bind both
DCBLD family members in the presence of ABL (Figure 20A-B). In accordance with
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our previous work that characterized the interaction between DCBLD2 and the FYNSH2 domain (Aten, Redmond et al. 2013), FYN co-immunoprecipitated with DCBLD2
when the two proteins were co-expressed (Figure 20B).
Gene ontology (GO) term enrichment analyses of DCBLD1- and DCBLD2interacting proteins are summarized in Figure 20D,E, revealing the enrichment of terms
related to several signaling mechanisms and biological processes known to involve
DCBLD family members. Full results of GO term enrichment analysis are available
upon request. Several GO terms related to cell motility were enriched among DCBLD1
and DCBLD2 interacting proteins, including GO:0031209 SCAR complex (LogFDR = 11.919 (DCBLD2), -13.886 (DCBLD1)), GO:0016358 dendrite development (LogFDR
= -5.923 (DCBLD2), -3.552 (DCBLD1)), GO:0072673 lamellopodium morphogenesis
(LogFDR = -3.740 (DCBLD2), -3.310 (DCBLD1)), and GO:0030426 growth cone
(LogFDR = -4.206 (DCBLD1)). Also enriched in the DCBLD interactor datasets were
GO terms related to receptor tyrosine kinase signaling, including general terms in the
DCBLD1 dataset (GO:0071363 cellular response to growth factor stimulus (LogFDR =
-4.465) and GO:1990782 protein tyrosine kinase binding (LogFDR = -2.806)), and
more specific terms related to VEGFR and IGFR signaling in the DCBLD2 datasets
(GO:0048010 vascular endothelial growth factor receptor signaling (LogFDR = 7.916) and GO:0005159 insulin-like growth factor receptor binding (LogFDR = -3.818
(DCBLD2)). The association of these newly identified DCBLD interactors with
biological processes related to changes in cell morphology and motility, as well as
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receptor tyrosine kinase (RTK) signaling, has been supported by reports in the literature
concerning the implications of DCBLD family members in cell proliferation and
migration downstream of RTK activation (Kobuke, Furukawa et al. 2001, Koshikawa,
Osada et al. 2002, Nagai, Sugito et al. 2007, Guo, Nie et al. 2009, Nie, Guo et al. 2013,
Feng, Lopez et al. 2014, Li, Jung et al. 2016, Schmoker, Ebert et al. 2019).
Complementary to the phosphorylation site map constructed from the double
enzyme digest and label free quantification described above, heavy-to-light ratios of
DCBLD1 and DCBLD2 post-translational modifications identified in the SILAC
datasets, along with means and standard deviations across replicates where applicable,
are available upon request. Additional sites identified here include DCBLD1 T614,
S619, and S683, as well as DCBLD2 S606 and S720. Phosphorylation of DCBLD1
S619 and DCBLD2 S720 was strongly induced by ABL.
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Figure 20. FYN- and ABL-driven DCBLD1 and DCBLD2 interactors identified through a SILAC
proteomics screen.
A) DCBLD1 and B) DCBLD2 interacting proteins identified in the SILAC LC-MS/MS analysis
described in Figure 18 are plotted by their Log2-tranformed heavy-to-light ratios (H/L) in rank
order. H/L of interactors were normalized to that of DCBLD1 or DCBLD2. Error bars represent the
standard deviation of the mean H/L across three experimental replicates. Interactors exhibiting
significantly increased (95% CL) binding to DCBLD proteins in the presence of FYN or ABL are
denoted with an asterisk. Triangles denote potential ABL interactors. Full peptide tables from each
biological replicate are available upon request. C) General functional classifications of DCBLD1 and
DCBLD2 interactors are outlined in pie charts. Each interactor is represented once. D,E) Gene
Ontology (GO) term enrichment analysis of proteins identified in immune complex with (D)
DCBLD1 and (E) DCBLD2. Uniprot accessions of DCBLD1 and DCBLD2 interactors identified in
the SILAC proteomics screen were uploaded to the Metascape (metascape.org) platform. A GO term
enrichment analysis of GO Molecular Function, GO Biological Process, and GO Cellular
Compartment was conducted using the default statistical settings. Proteins with corrected p-values
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less than 0.05 were considered enriched in the dataset. Negative Log10-transformed corrected pvalues of enriched terms are plotted. Full lists of proteins annotated with enriched terms are
available upon request.

We then asked whether any of the DCBLD2 interacting partners identified in
293 cells were conserved across vertebrate species, and therefore likely serving
important functional roles in vertebrate biology. Several investigations involving the
modulation of DCBLD2 expression have been conducted in the model vertebrate
systems of mouse and zebrafish. DCBLD2 is known to be upregulated in the neointima
of healing vasculature in mice. Further, vascular development and repair are impaired
when DCBLD2 is knocked down in zebrafish and knocked out in mice (Nie, Guo et al.
2013). DCBLD2 is also involved in insulin signaling in mice; DCBLD2-/- mice present
improved insulin sensitivity and glucose uptake (Li, Jung et al. 2016). We chose
zebrafish as a system of study, given their evolutionary distance from humans in
general vertebrate phylogeny, such that DCBLD2 interactions common to zebrafish and
humans would represent those with strong evolutionary conservation. To identify
zebrafish proteins that would interact with human DCBLD2, DCBLD2 was first
immunoprecipitated (α-FLAG) from 293 cells transiently expressing the protein in the
presence or absence of ABL. ABL was chosen given its robustness in inducing
DCBLD2 interactions in the SILAC screen (Figure 20A–B). Immunoprecipitations
were then incubated with zebrafish extracts prior to SDS-PAGE, tryptic digest, and
analysis via LC-MS/MS. Spectra were searched against a combined human and
zebrafish proteome, and unique zebrafish peptides were extracted to distinguish
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zebrafish interactors from human (data available upon request). ABL-induced zebrafish
interactors of DCBLD2 were extracted and compared to ABL-induced DCBLD1 and
DCBLD2 human interactors identified in the SILAC screen (Figure 44). Eight zebrafish
homologs of the human interactors identified in the SILAC screen were detected in
immune complex with DCBLD2 in the presence of ABL, including five members of
the 14-3-3 adaptor family, CaMKIIδ, and the known DCBLD interactors CRK and
CRKL (Figure 44). Although these are not endogenous complexes that were extracted
from fish, the interactions identified in both 293 cells and fish are likely relevant and
signify evolutionarily conserved interactions.
3.5.3. ABL regulates the binding of 14-3-3 adaptor family to DCBLD2
In both SILAC and zebrafish co-immunoprecipitation screens described above,
several members of the 14-3-3 family of adaptor proteins emerged as evolutionarily
conserved ABL-induced DCBLD2 interactors (Figure 20A–B, Figure 44). Members of
the 14-3-3 adaptor are highly conserved across eukaryotes and canonically bind
phosphorylated serine (pS) and phosphorylated threonine (pT) residues in
RXXpS/pTXP (mode 1), RXXXpS/pTXP (mode 2), or C-terminal pS/pTX(X)-CO2(mode 3) motifs (Yaffe, Rittinger et al. 1997, Ottmann C 2007). However, 14-3-3
proteins are also known to bind pS/pT residues outside the canonical motifs and are
capable of binding certain target proteins independent of phosphorylation (Yaffe,
Rittinger et al. 1997, Li, Wang et al. 2011). Central to signal transduction, these homoand heterodimeric proteins are involved in cell cycle regulation, apoptosis, cell growth,
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differentiation, vesicular trafficking, and can regulate the subcellular localization,
activity, or interactors of their target molecules. The identification of several members
of the 14-3-3 family of adaptor proteins in immune complex with DCBLD1 and
DCBLD2 was intriguing, in part because their heavy-to-light ratios suggested these
canonically phosphoserine/phosphothreonine-dependent interactors were induced to
bind DCBLD proteins in the presence of the tyrosine kinase ABL.
To further characterize this interaction, we first purified fusion proteins of
glutathione S-transferase (GST) with select members of the 14-3-3 family (14-3-3β, 143-3σ, 14-3-3ε, 14-3-3ζ) for use in pulldown assays and Western blotting. Members β, ε,
and ζ were first chosen for biochemical validation as representative 14-3-3 members
from the subset identified in the proteomics screen. Although unique peptides were
identified from these three 14-3-3 proteins, several peptides that the SEQUEST
algorithm mapped to select 14-3-3 proteins were common among multiple or all family
members. As there were multiple redundancies of 14-3-3 peptides in human database
used as input for SEQUEST, the H/Ls of common 14-3-3 peptides were manually
quantified separately from peptides that were unique to 14-3-3 family members
identified by SEQUEST. However, the H/Ls were not found to change considerably
when quantified separately. The occurrence of multiple redundant peptides raised the
possibility that additional 14-3-3 family members that were not included in the dataset
obtained from the SEQUEST analysis could also be interacting with DCBLD family
members because they were not represented by unique peptides. Therefore, we chose to
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test an additional family member that was not represented by unique peptides, 14-3-3σ,
for its potential to bind to DCBLD2. Given the strong loss of DCBLD1 protein levels
when it was co-expressed with ABL in the SILAC experiments, we did not attempt to
further investigate this interaction. However, this will be an area of further investigation
once an expression system that can prevent DCBLD1 degradation is established.
To confirm that the purified GST-14-3-3 proteins were functional, resin-bound
fusion proteins were incubated with 293 cell extracts treated with and without calyculin
A, a serine/threonine phosphatase inhibitor. Proteins that bound to the GST-14-3-3X
resin were denatured and subjected to SDS-PAGE and Western blotting for the
canonical (mode-1) 14-3-3 binding motif, RXXpS/pTXP. Pulldowns from these same
extracts with GST alone as well as a GST-14-3-3ε mutant incapable of phosphodependent binding (GST-14-3-3K49E) served as negative controls. All wild-type 14-3-3
fusion proteins exhibited increased binding to RXXpS/pTXP-containing proteins in
extracts from cells treated with calyculin A prior to lysis, while the GST and GST-14-33K49E proteins did not (Figure 45). Wild-type fusion proteins were then incubated with
extracts from 293 cells transiently expressing DCBLD2 with C-terminal FLAG and
MYC tags alone or alongside ABL-FLAG. Pulldowns were subjected to SDS-PAGE
and Western blotting for DCBLD2 (α-MYC; Figure 22A). The MYC tag was used
because ABL was found to also bind to GST-14-3-3 fusion proteins (Figure 46). In
agreement with SILAC ratios obtained from the proteomics screen, DCBLD2 was
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induced to bind to all four GST-14-3-3 fusion proteins when ABL was co-expressed
(Figure 22A).
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Figure 21. 14-3-3 family members bind to DCBLD2 in an ABL-induced manner.
A) DCBLD2-FLAG-MYC was transiently expressed in 293 cells in the presence and absence of
ABL. GST-fusions with 14-3-3σ, 14-3-3ε, and 14-3-3ζ on glutathione resin were incubated with 293
extracts in pulldown assays. Bound proteins were denatured and analyzed by SDS-PAGE and
Western blotting. Ponceau stains display levels of GST-14-3-3(X) and α-MYC blots of the
pulldowns conditions in which DCBLD2 bind to the fusion protein. Immunoprecipitations (IP, αFLAG) show DCBLD2 expression levels. Whole cell extracts (WCEs) show levels of ABL
expression (α-ABL) and the tubulin blot serves as a loading control. B) DCBLD2-FLAG-MYC was
transiently expressed in 293 cells in the presence and absence of ABL. Immunoprecipitations (αMYC) from 293 cell lysates were subject to SDS-PAGE and far-Western blotting with eluted GST14-3-3 fusions proteins, followed by α-GST primary antibodies. Signals in α-GST blots show
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relative levels of GST-fusions interacting with DCBLD2 in the presence and absence of ABL, and
the α-MYC blot displays levels of DCBLD2 protein. C) α-GST signals from (B) were quantified
across three replicates and normalized to DCBLD2 levels using densitometry. Fold changes of
GST-14-3-3 binding in the presence of ABL are plotted. Error bars are representative of three
trials.

Several potential 14-3-3 docking sites (RXXS motifs) are housed within the
DCBLD1 and DCBLD2 intracellular sequences. Several of these sites were found
phosphorylated in the label-free phosphorylation site mapping and in the SILAC screen
(Figure 17, SILAC data available upon request). Because of the loss of DCBLD1
protein upon co-expression with ABL, the DCBLD1/14-3-3 interaction was not further
validated, however, the DCBLD2/14-3-3 interaction was investigated further using
biochemical methods.
To determine whether 14-3-3 family members were binding directly to
DCBLD2, we conducted far-Western blotting assays (Wu, Li et al. 2007). DCBLD2
was immunoprecipitated (α-MYC) from 293 cells expressing each family member with
and without ABL. Immunoprecipitations were subjected to SDS-PAGE, transferred to
nitrocellulose membranes, and incubated with eluted GST-14-3-3 fusion proteins
overnight. Membranes were then subjected to immunoblotting (α-GST) to detect bound
GST-14-3-3 proteins. Fusion proteins bound to the membrane at the same molecular
weight of DCBLD2, suggesting that these interactions are likely direct (Figure 21B).
The far-Western blotting revealed a strongly ABL-induced DCBLD2/14-3-3
interaction, quantified in Figure 21C, in agreement with the SILAC screen and the
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pulldown assays (Figure 20B, Figure 21A). This apparent regulation of a canonically
pS/pT-mediated interaction by a tyrosine kinase suggests that either a serine/threonine
phosphatase is inhibited downstream of ABL activity, or that ABL activation leads to
the subsequent activation of a serine/threonine kinase (Figure 22). It will be important
for future studies to determine whether this interaction relates to known biological roles

T

P

P

S

P

S

P

T

T

P

P

S

P

S

DCBLD2

of DCBLD2, namely, cell proliferation and motility.

Act as an
adaptor to
promote an
interaction

Prevent docking
of other
interactors

?

Abl
Promote or Attenuate DCBLD2-driven proliferative/migratory effects?

Figure 22. Potential ABL-driven implications of the DCBLD2/14-3-3 interaction.
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inhibit a serine/threonine phosphatase, increasing levels of DCBLD2 phosphorylation in 14-3-3
binding motifs. This could recruit 14-3-3 family members to the membrane, to bind multiple motifs
on DCBLD2, preventing docking of other interactors. Alternatively, the binding of a 14-3-3 dimer
to a single binding motif on DCBLD2 could facilitate interactions between DCBLD2 and other 143-3 binding partners. The DCBLD2/14-3-3 interaction could be either activating or inhibitory
toward biological outcomes, such as cell proliferation or migration.
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The DCBLD1/14-3-3 interaction was not further investigated biochemically due
to the 10-fold decrease in DCBLD1 levels when ABL was co-expressed, however, the
SILAC data suggests that the 14-3-3/DCBLD1 interaction increases with ABL coexpression (Figure 19). It remains possible that the observed increase in 14-3-3 binding
in the SILAC experiments could be entirely due to the ABL/14-3-3 interaction (Figure
46), however, 14-3-3 peptides were also observed in the “light” immune complex in
which DCBLD1 was expressed alone. Further investigations into this interaction will
be an area of future study.
3.6. Discussion
The plasma membrane receptors DCBLD1 and DCBLD2 modulate basic cellular
processes that are fundamental to vertebrate development, glucose homeostasis, and the
progression of certain cancers (Kobuke, Furukawa et al. 2001, Koshikawa, Osada et al.
2002, Chen, Low et al. 2007, Nagai, Sugito et al. 2007, Sadeghi, Esmailzadeh et al.
2007, Hofsli, Wheeler et al. 2008, Kim, Lee et al. 2008, Guo, Nie et al. 2009, OsellaAbate, Novelli et al. 2012, Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Topkas, Cai et
al. 2014, Li, Jung et al. 2016, Kikuta, Kubota et al. 2017, Schmoker, Ebert et al. 2019).
DCBLD2 expression affects the activation of downstream MAPKs or AKT following
ligands binding to the receptor tyrosine kinases EGFR, VEGFR2, PDGFRβ, and INSR,
altering phenotypes at the cellular level such as proliferation and migration (Kobuke,
Furukawa et al. 2001, Koshikawa, Osada et al. 2002, Nagai, Sugito et al. 2007, Guo,
Nie et al. 2009, Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Li, Jung et al. 2016,
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Schmoker, Ebert et al. 2019). EGFR and the cytoplasmic tyrosine kinases FYN and
ABL, which can be activated downstream of RTKs, induce phosphorylation of
DCBLD2 intracellular tyrosine residues leading to the recruitment of TNF Receptor
Associated Factor 6 (TRAF6) or CRKL (Aten, Redmond et al. 2013, Feng, Lopez et al.
2014, Schmoker, Weinert et al. 2017). Beyond these interactions, the molecular
mechanisms of the DCBLD/RTK signaling interface that modulate the observed
phenotypic outcomes in development and cancer are not well understood. Here, we
further characterize the FYN- and ABL-regulated interactome of DCBLD family
members, identifying and presenting several candidate protein interactors that could
play roles in DCBLD signaling.
The known DCBLD interactor CRKL was identified in the SILAC screen, along
with its homolog CRK (Figure 20). This was not surprising, as the DCBLD/CRKL
interaction is known to be mediated through the CRKL-SH2 domain, which binds
DCBLD1 and DCBLD2 phosphotyrosine residues in YXXP motifs (Aten, Redmond et
al. 2013, Schmoker, Weinert et al. 2017). The SH2 domains of CRK family members
are highly homologous. Therefore, the ABL-induced DCBLD/CRK interaction is likely
similarly SH2/pYXXP-mediated. Although CRK and CRKL are likely involved in the
proliferative or migratory effects of DCBLD signaling, the biological implications of
this interaction are not yet understood.
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DCBLD1 protein levels decreased considerably when WT ABL was cotransfected (Figure 19). Phosphorylation by or downstream of activation of these
cytoplasmic kinases appears to strongly regulate DCBLD family member degradation
and/or solubility. The SILAC screen identified three ubiquitin-related enzymes that are
recruited to the DCBLD1 scaffold downstream of active ABL, namely, the E3 ubiquitin
ligase c-Cbl, the E3-independent E2 ubiquitin-conjugating enzyme (UBE2O), and the
c-terminal ubiquitin hydrolase FAF-Y (USP9Y) (Figure 20). c-Cbl possesses several
potential interaction-mediating domains within its own sequence, including an SH2-like
domain, but is often also brought to target protein via adaptors and is an important
regulator of cell signaling. UBE2O and USP9Y could similarly contribute to the
positive and negative regulation, respectively, of DCBLD1 ubiquitylation. Although no
ubiquitin linker sequences were identified in the label free or SILAC analyses of
DCBLD1 PTMs, ubiquitin-containing peptides were not targeted in the analyses and
would be relatively rare, given the canonical role of ubiquitin as a degradation signal.
DCBLD1 ubiquitylation could lead either to its proteasome-mediated degradation or
endocytosis and subsequent degradation in lysosomes.
DCBLD2 protein loss was not strongly observed in this study, although we have
previously reported evidence that suggests that FYN, in particular, is capable of
inducing DCBLD2 degradation (Schmoker, Weinert et al. 2017). Indeed, the
deubiquitylating enzyme USP7 was identified in two biological replicates each of the
DCBLD2/ABL and DCBLD2/FYN SILAC pairs (data available upon request),
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however, proteins involved in ubiquitin dynamics were more highly concentrated in
DCBLD1 immune complexes. Given that DCBLD1 levels are much more sensitive to
kinase regulation than DCBLD2, we hypothesize that our ability to find ubiquitinregulating proteins would be greater under conditions when DCBLD1 is being actively
and highly degraded, such as with ABL co-expression. Therefore, that is likely the
reason we found them bound to DCBLD1 at high abundance in the SILAC screen, and
not in DCBLD2 immune complexes. This will be an area of future study, as we would
like to understand how these proteins are getting degraded. We would start
characterizing these interactors of DCBLD1, with the hope that they may help us
determine whether similar pathways are involved with DCBLD2.
It should be noted that the loss of DCBLD1 protein could affect quantification.
The label-free quantification to assess DCBLD1 phosphorylation was conducted with
relatively higher protein levels to ensure that we had adequate intensities on DCBLD1
peptides in order to quantify phosphopeptide abundance. Cell extracts from several
dishes were pooled to obtain signals of DCBLD1 phosphopeptide intensities that met
signal-to-noise cut-offs for accurate label-free quantification. For the SILAC
experiments, less protein was used to reduce non-specific interactors, however, we still
observed DCBLD1 peptides in all conditions that met the S/N cut-offs for
quantification. Although the loss of DCBLD1 complicated biochemical assays that
require lower protein quantities, such as Western blotting, the methods employed for
mass spectrometric analysis of DCBLD1 phosphorylation sites and interacting partners
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permitted strong quantitative measurements. Interestingly, the mouse Dcbld1 construct
that was initially characterize the Dcbld1/CRKL-SH2 interaction was not sensitive to
ABL co-expression (Schmoker, Weinert et al. 2017). While it may be premature to
make conclusions, we hypothesize that this is a difference between the human (use in
the present study) and mouse DCBLD1 proteins, the most apparent difference between
these sequences being the lack of the Discoidin domain in the mouse construct.
In addition, we identified and quantified both known and novel FYN- and/or
ABL-regulated changes in phosphorylation along the intracellular sequence of
DCBLD1 and DCBLD2, several of which are novel phosphorylation sites. The striking
changes in population of serine, threonine, and tyrosine phosphorylation sites in the
presence and absence FYN and ABL suggest that DCBLD signaling is strongly
regulated by these cytoplasmic kinases. This is further supported by the DCBLD/14-3-3
interaction identified in the initial SILAC screen and, for DCBLD2, validated in
biochemical assays as it is likely phosphorylation-dependent in nature. Indeed, several
potential 14-3-3 binding sites (RXXS/T) that reside within DCBLD1 and DCBLD2
sequences were found phosphorylated and variably regulated by ABL (Figure 17).
Phosphorylation of DCBLD1 RXXS serine residues S513, S556, and S657 all increased
in the presence of ABL, although S513 and S556 were also highly phosphorylated
when DCBLD1 was expressed alone (Figure 17). Although the DCBLD1/14-3-3
interaction was not investigated further biochemically due to the loss of protein levels
in the presence of ABL, the normalized SILAC ratios of 14-3-3 proteins in immune
161

complex with DCBLD1 suggest that ABL increases the levels of 14-3-3 proteins bound
to DCBLD1. Two DCBLD2 serine residues in RXXS motifs (S599 and S724) were
also found phosphorylated, although they were not strongly ABL-induced (Figure 17).
It remains possible that the DCBLD2/14-3-3 interaction could be mediated by
phosphorylation outside the canonical motifs. It is still likely a phosphorylationdependent interaction, given the strong evidence of a direct interaction between 14-3-3
proteins and DCBLD2 in the presence of ABL (Figure 20). These questions could be
addressed with mutagenesis in future studies.
This observed ABL-induced DCBLD2/14-3-3 interaction is likely mediated by
ABL-regulated activity or localization of a serine/threonine kinase or phosphatase
(Figure 22). The SILAC screen for human DCBLD interactors identified members of
the CaMKII holoenzyme, namely, the β and δ subunits (Figure 20). An additional
CaMKII subunit, γ, was identified alongside the δ subunit in zebrafish extracts (Figure
44). Interestingly, CaMKII preferentially phosphorylates serine and threonine residues
in RXXS/T motifs (Figure 47) (Obenauer, Cantley et al. 2003), the minimal canonical
binding motif of 14-3-3 family members. CaMKII could phosphorylate DCBLD1 or
DCBLD2, potentially through CaMKII activation downstream of ABL, in effect
recruiting 14-3-3 family members to the DCBLD scaffold.
This work employed overexpression systems to elucidate phosphorylation sites
and interactors of DCBLD family members, however, future work will aim to identify
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and characterize these interactions with endogenous proteins. Overexpression can drive
interactions and phosphorylation that would not occur under normal conditions,
however, it can also serve as a model for systems with elevated expression, such as at
certain time points in development or in cancer biology. Future work will determine
whether the phosphorylation sites and interactions identified in this screen are
biologically relevant. It should be noted that the majority of FYN- and ABL-regulated
phosphorylation sites identified in these studies have been previously reported on
PhosphoSitePlus (Figure 17). Our original identification of the DCBLD2/CRKL
interaction identified endogenous DCBLD2 bound to the GST-CRKL-SH2 construct in
cells with activated endogenous SFKs (Aten, Redmond et al. 2013). With our later
studies using endogenous kinases and SFK/ABL inhibitors, we were able to
characterize phosphorylation at specific sites on DCBLD1 and 2, granted, under the
overexpression of DCBLD proteins (Schmoker, Weinert et al. 2017). We have yet to be
able to purify sufficient levels of DCBLD proteins to conduct these same experiments
at the endogenous level, although we hope to achieve this in the future. Even so, the
data we have presented here represent the first step in identifying FYN- and ABLregulated phosphorylation sites and interactors of DCBLD proteins, and future work
will necessarily characterize biological systems in which these signaling events are
relevant.
In summary, this work quantitatively characterizes the FYN- and ABLregulated interacting proteins and maps regulated post-translational modifications of the
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scaffolding receptors DCBLD1 and DCBLD2. Insight provided by these studies will
inform future work toward understanding the fundamental signaling mechanisms of
DCBLD proteins, whose important roles are emerging in developmental processes,
vascular repair, glucose homeostasis, oncogenesis and cancer progression.
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CHAPTER 4: ELEVATED EXPRESSION OF DCBLD2 ALTERS PDGFRβ AND
INSULIN RECEPTOR SIGNALING, ATTENUATING PROLIFERATION
THROUGH AN ERK-INDEPENDENT MECHANISM
4.1. Abstract
The Discoidin, CUB, and LCCL domain-containing protein DCBLD2 is known to
modulate the signaling of certain receptor tyrosine kinases in development, homeostasis
and cancer. However, the molecular mechanisms of DCBLD2 action in these signaling
pathways are not well understood. Here, we investigate signaling downstream of
PDGF-BB and insulin in a cellular environment with elevated PDGFRβ and insulin
receptor (INSR) expression in the presence of high or low expression of DCBLD2,
simulating certain cancer systems and possible variability in normal biological
processes. High levels of DCBLD2 promoted ERK1/2 activation downstream of both
PDGF-BB and insulin. Interestingly, proliferation was attenuated under these same
conditions, suggesting an ERK1/2-independent mechanism of proliferation is affected
by elevated levels of DCBLD2. In addition, PDGFRβ and the cytoplasmic tyrosine
kinase ABL, which can be activated downstream of PDGFRβ, were found to directly
phosphorylate DCBLD2 tyrosine residues.
4.2. Abbreviations
ABL, Abelson tyrosine protein kinase 1; AKT, RACα serine/threonine-protein
kinase; CRK(L), CT10 regulator of kinase (like); DCBLD, Discoidin, CUB, and LCCL
domain-containing protein 2; EC, endothelial cell; EGFR, epidermal growth factor
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receptor; ERK1/2, extracellular signaling-related kinase 1/2; FYN, tyrosine protein
kinase Fyn; INSR, insulin receptor; IP, immunoprecipitation; PDGF, platelet derived
growth factor; PDGFRβ, platelet derived growth factor receptor β; RTK, receptor
tyrosine kinase; SFK, Src family kinase; SMC, smooth muscle cell; TRAF6, tumor
necrosis factor receptor (TNFR)-associated factor 6; VEGF, vascular endothelial
growth factor; VEGFR2, vascular endothelial growth factor receptor 2; WCE, whole
cell extract.
4.3. Introduction
Discoidin, CUB, and LCCL domain-containing protein 2 (DCBLD2, also ESDN
and CLCP-1) is a plasma membrane orphan receptor that plays important roles in
development, homeostasis and disease (Kobuke, Furukawa et al. 2001, Koshikawa,
Osada et al. 2002, Chen, Low et al. 2007, Nagai, Sugito et al. 2007, Sadeghi,
Esmailzadeh et al. 2007, Hofsli, Wheeler et al. 2008, Kim, Lee et al. 2008, Guo, Nie et
al. 2009, Osella-Abate, Novelli et al. 2012, Nie, Guo et al. 2013, Feng, Lopez et al.
2014, Topkas, Cai et al. 2014, Li, Jung et al. 2016, Kikuta, Kubota et al. 2017,
Schmoker, Ebert et al. 2019). DCBLD2 is known to modulate signaling of certain
receptor tyrosine kinases (RTKs), namely, VEGFR2 and PDGFRβ in blood vessel
development and repair (Kobuke, Furukawa et al. 2001, Guo, Nie et al. 2009, Nie, Guo
et al. 2013), insulin receptor (INSR) in glucose homeostasis (Li, Jung et al. 2016), and
EGFR in certain cancers (Feng, Lopez et al. 2014). Interestingly, the effect of knocking
out DCBLD2 expression in different RTK/ligand systems has distinct effects on
169

signaling downstream of these RTKs (Schmoker, Ebert et al. 2019). In smooth muscle
cells (SMCs), DCBLD2 attenuates ERK1/2 and AKT phosphorylation downstream of
PDGF-BB and insulin (Guo, Nie et al. 2009, Li, Jung et al. 2016). In endothelial cells
(ECs), DCBLD2 strongly promotes VEGF-driven AKT and ERK1/2 activation through
VEGFR2 (Nie, Guo et al. 2013). However, the molecular mechanism of DCBLD2
function in these systems is not well understood.
Increased levels of DCBLD2 are associated with oncogenesis, survival and
metastasis of certain cancers (Koshikawa, Osada et al. 2002, Chen, Low et al. 2007,
Nagai, Sugito et al. 2007, Hofsli, Wheeler et al. 2008, Feng, Lopez et al. 2014, Kikuta,
Kubota et al. 2017, Raman, Maddipati et al. 2018). Co-expression of high levels of
DCBLD2 and EGFR drives glioblastoma and head-and-neck cancer and is associated
with increased mortality. In aberrant EGFR signaling in glioblastoma, EGFR
phosphorylation of DCBLD2 Y750 is required for recruitment of the E3 ubiquitin
ligase TRAF6 to EGFR for activation (Feng, Lopez et al. 2014). Active TRAF6 then
ubiquitylates AKT, promoting its translocation to the membrane, ultimately driving
proliferation (Feng, Lopez et al. 2014). Similarly, DCBLD2 phosphorylation of the
long intracellular scaffolding region likely plays a role in the modulation of general
RTK signaling observed in SMCs and ECs, recruiting positive or negative regulators of
various RTKs depending on the cellular environment and modified sites.

170

Previously, we characterized phosphorylation of SH2 binding sites of the CRK
(CT10 regulator of kinase) family of signaling adaptors, driven by the cytoplasmic
tyrosine kinases FYN and ABL (Aten, Redmond et al. 2013, Schmoker, Weinert et al.
2017). CRK family members, first discovered from the related viral gag-CRK
oncogene, are also important regulators of fundamental developmental processes,
including cell proliferation, migration, and survival (Klemke, Leng et al. 1998,
Cheresh, Leng et al. 1999, Cho and Klemke 2000, Feller 2001, Nakamura, Komiya et
al. 2002, Ballif, Arnaud et al. 2004, Chodniewicz and Klemke 2004, Brábek,
Constancio et al. 2005, Park and Curran 2014). As both SRC family kinases (SFKs) and
ABL can become activated downstream of RTKs (Plattner, Kadlec et al. 1999, Lu, Zhu
et al. 2009, Zhang, Fan et al. 2017), the observed modification of DCBLD proteins
could represent a mode of action downstream of RTK signaling. Here, we investigate
the effect of elevated co-expression of DCBLD2 with PDGFRβ and INSR on
downstream signaling through ERK1/2 and cell proliferation, as a model for certain
normal biological systems and cancers in which these proteins are highly expressed.
4.4. Experimental Procedures
4.4.1. Materials
Penicillin/Streptomycin 100X solution and Dulbecco’s Modified Eagle Medium
(DMEM) were obtained from Mediatech (Manassas, VA, USA). Fetal bovine serum
(FBS) and cosmic calf serum (CCS) were purchased from Hyclone (Logan, Utah,
USA). The sequencing-grade trypsin used in enzymatic digests prior to LC-MS/MS
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analysis were from Promega (Madison, WI, USA). The BSA standard for Bradford
assays and the Bradford Reagent were obtained from Amresco Life Sciences, LLC.
(Cleveland, OH, USA). Protein G resin was obtained from G-Biosciences (St. Louis,
MO, USA). Protein A resin and enhanced chemiluminescence (ECL) reagents were
purchased from Pierce (Rockford, IL, USA), and film was from Denville scientific
(Metuchen, NJ, USA). Packing material used for HPLC was purchased from Michrom
Bioresources nc. (Auburn, CA, USA). Nitrocellulose membranes were from GVS Life
Sciences (Sanford, ME, USA). All additional reagents were purchased from Sigma (St.
Louis, MO, USA) unless otherwise noted. Recombinant PDGF-BB was obtained from
Invitrogen (Waltham, MA, USA). Recombinant PDGFRβ C-terminal fragment (amino
acids R561-L1106 with GST-His6 N-terminal tags) and Abl1 internal fragment (amino
acids P118-S535 with GST-His6 N-terminal tags) were obtained from ProQinase
GmbH (Freiburg, Germany).
4.4.2. Plasmids
The mammalian expression construct for full-length human DCBLD2
(RC224483) in pCMV6-Entry, tagged with FLAG and MYC sequences at C-termini,
were obtained from OriGene (Rockville, MD, USA). The C-terminal MYC- and
FLAG-tagged DCBLD1 construct in pCMV6 vectors was synthesized by Bio Basic
Inc. (Markham, ON). The bacterial expression plasmids encoding the fusion of
glutathione S-transfeRase with the SH2 domain of CRKL was a kind gift from A.
Imamoto (U. of Chicago). Human wild-type insulin receptor (INSR) was a gift from
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Frederick Stanley (Addgene plasmid # 24049; http://n2t.net/addgene:24049;
RRID:Addgene_24049).
4.4.3. Antibodies
The mouse α-Flag (M2) antibody (Ab) and Affinity Gel were from Sigma and
the free Ab was used for Western blotting at a concentration of 0.5 µg/mL. Cell
Signaling Technologies Inc. (Danvers, MA, USA) was the source of the following
antibodies, used at 1:1000 dilutions: α-FLAG (M2, rabbit mAb), α-MYC (71D10,
rabbit mAb), α-PDGFRβ (28E1, rabbit mAb), α-INSRβ (4B8, rabbit mAb). The α-pY
(4G10, mouse mAb) was from EMD Millipore (Billerica, MA, USA). All primary
antibodies were diluted in 1.5% BSA in Tris-Buffered Saline (0.9% NaCl, 0.4% TrisHCl, and 0.1% Tris-base) with 0.05% Tween 20 (TBS-T) and containing 0.005%
sodium azide. Horseradish peroxidase (HRP)-conjugated secondary antibodies were
obtained from EMD Millipore and used at the following concentrations: goat α-mouse
IgG-HRP (1:5,000), light-chain-specific goat α-mouse and α-rabbit IgG-HRP
(1:10,000), and goat α-rabbit IgG-HRP (1:15,000). The Veriblot reagent (HRP) for
native antibody detection was purchased from Abcam (Cambridge, UK). All secondary
antibodies were diluted in TBS-T.
4.4.4. Cell culture, transfection, and lysis for Western blotting
Adenovirus early region transformed HEK 293 cells were cultured in DMEM
supplemented with 5% each of FBS and CCS, 50 U/mL penicillin, and 50 μg/mL
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streptomycin at 37 ˚C in 5% atmospheric CO2. HEK 293 cells were grown to 60% of
confluence prior to transfection via calcium phosphate precipitation. The following
amount of plasmid was transfected per 10-cm dish: wild type and mutant DCBLD2 (6
µg), PDGFRβ (5 µg), INSRβ (5 µg). Six hours post-transfection, cells were washed
with warm phosphate-buffered saline (PBS) and returned to full medium overnight. In
experiments involving treatment with PDGF-BB or insulin, cells were washed in warm
PBS the following day and incubated in DMEM lacking FBS and CCS for 24 hours.
Cells were treated with RTK ligands (20 ng/mL PDGF-BB, 100 nM insulin) for various
time periods prior to lysis. Cells were placed on ice and immediately washed with PBS
(4 ˚C) prior to lysis in Brain Complex Lysis Buffer (BCLB: 25 mM Tris pH 7.2, 137
mM NaCl, 10% glycerol, 1% igepal, 25 mM NaF, 10 mM Na2H2P2O7, 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/mL each leupeptin and pepstatinA). Lysates were centrifuged and the supernatant was reserved for
immunoprecipitation.
4.4.5. Immunoprecipitation, pulldown assays and SDS-PAGE for immunoblotting
Protein concentration was determined as described above. For
immunoprecipitations, normalized lysates (1 µg/µL) were incubated separately with αFLAG Affinity Gel (10 µL of a 50 % slurry) or the -MYC antibody with a 50/50
mixture of protein A and G resin (20 µL of a 50 % slurry) overnight, rocking at 4˚C.
For pulldown assays, GST-CRKL-SH2 fusion proteins were generated and assays were
conducted as previously described (Schmoker, Weinert et al. 2017). Beads were
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washed three times with BCLB, after which bound proteins were eluted and denatured
in 25 µL sample buffer at 95˚C for 5 min. For whole cell extracts (WCEs), normalized
lysates were denatured in sample buffer (final concentration of 0.75 µg/µL) at 95˚C for
5 min. Immunoprecipitations and WCEs (15 µg per well) were separated on 10%
acrylamide gels with 4.2% acrylamide stacking gels, as described above. Following
separation, proteins were transferred onto nitrocellulose membranes in a submersible
transfer unit at 4˚C in 1.13% glycine, 0.25% Tris-base and 20% methanol. Membranes
were stained with a reversible Ponceau stain to assess total protein levels. Membranes
were blocked with 5% non-fat dry milk in TBS-T and incubated in primary antibody
solutions overnight at 4˚C. Membranes were then washed and incubated with HRPconjugated secondary antibody solution for three hours at 25˚C. Membranes were
briefly incubated in ECL reagents and exposed to x-ray film.
4.4.6. Proliferation assays
Cells were grown to 50% confluence in serum-containing DMEM and
transfected with DCBLD2 WT, DCBLD2 Y7F, INSRβ, and PDGFRβ DNA plasmids in
various combinations by calcium phosphate precipitation. After a 24-hr incubation
period, cells were diluted 1:4 in serum-containing DMEM and permitted 8 hours to
adhere to culture dishes. Cells were then starved overnight prior to a 48-hr incubation
with insulin or PDGF-BB. Hemocytometers were used to count cells following growth
factor treatment. Cells were lifted from culture dished with trypsin-EDTA (0.25%) and
diluted in 3 mL DPBS. Aliquots (10 µL) were pipetted into the chamber and visualized
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by phase-contract microscopy. Cells in seven of 25 grid squares were counted with a
hand tally counter. Three individual aliquots were assessed for each experimental
condition in a given biological replicate and averaged.
4.4.7. Kinase assays
Transiently expressed DCBLD2-FLAG was immunoprecipitated (α-FLAG)
from 293 cells lysates and eluted with FLAG peptide (100 μg/mL in) 30 μL of 25 mM
Tris (pH 7.5) for 5 min on ice. Supernatant was reserved and a second elution was
carried out with another 20 μL of 25 mM Tris. Fractions were combined and dialyzed
against 25 mM Tris in 50% glycerol across a Tube-O-Dialyzer membrane with a 4-kDa
pore size (G-Biosciences, St. Louis, MO, USA), overnight at 4°C. Eluted proteins were
stored at 20°C.
Kinase assays were conducted for 30 min at 30°C in 60 mM HEPES with 3 mM
MgCl2, 3 mM MnCl2, 3 μM Na3VO4, 50 μM PEG20,000, 1.2 mM DTT. ABL kinase
assays were conducted with 3 μM ATP, 1.5 ng/μL GST-His6-ABL, and 1/50th dilution
of DCBLD2 eluent (Figure 48). PDGFRβ kinase assays were conducted with 15 μM
ATP, 6 ng/μL GST-His6-PDGFRβ, and 1/25th dilution of DCBLD2 eluent (Figure 48).
The concentrations of kinase, substrate and ATP were informed by the manufacturer’s
guidelines for operation at Vmax for ATP (proqinase.com). Kinase assays were
terminated by denaturing in sample buffer for 5 min at 95°C and subjected to SDSPAGE and Western blotting for α-pY.
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4.5. Results
4.5.1. PDGFRβ co-expression and activation by PDGF-BB induces DCBLD2
phosphorylation and CRKL-SH2 interaction
To study DCBLD2 tyrosine phosphorylation in the presence of basally active
and PDGF-BB-activated PDGFRβ, we first established PDGFRβ signaling using
ERK1/2 phosphorylation as a readout through transient transfection in 293 cells, which
do not express endogenous PDGFRβ. PDGF-BB concentrations between 1–20 ng/mL
were chosen because these concentrations are within ranges that other investigators
have used to induce proliferation (De Donatis, Comito et al. 2008).

177

C
A

B

E

D

Figure 23. PDGF-BB drives phosphorylation of DCBLD2 tyrosines through direct phosphorylation
by the PDGFRβ and ABL, promoting CRKL-SH2 binding.
A) PDGF-BB signaling through PDGFRβ established in 293 cells. HEK 293 cells transiently
expressing PDGFRβ were treated with 1 ng/mL (41 pM), 5 ng/mL (205 pM), or 20 ng/mL (820 pM)
PDGF-BB for 5 or 15 min prior to lysis. Whole cell extracts (WCEs) were analyzed by SDS-PAGE
and Western blotting for phosphorylated ERK1/2 (pERK1/2) as a read-out of PDGFRβ activity
and total ERK1/2 and PDGFRβ as loading controls. B) ERK phosphorylation across three
biological replicates of (A) is quantified via densitometry as the Log2-transformed fold change
(FC) in pERK1/2 signal (normalized to total ERK1/2) in each experimental condition relative to
untreated cells. Additional biological replicates used for quantification are included in Figure S1.
ANOVA and Tukey-HSD tests did not produce low (90% CL) p-values. C) PDGF-BB drives
phosphorylation of YXXP and non-YXXP DCBLD2 tyrosine residues and CRKL-SH2 interaction.
Wild type (WT) and mutant (seven Y-to-F mutations, Y7F) DCBLD2-FLAG were transiently
expressed alone or with the PDGFRβ and 293 cells were treated with H 2O2 (8.8 mM for 15 min) or
PDGF-BB (20 ng/mL for 30 min) prior to lysis. Immunoprecipitations (IPs, α-FLAG), pulldowns
(GST-CRKL-SH2), and WCEs were analyzed by SDS-PAGE and probed with antibodies for the
FLAG epitope, phosphotyrosine (pY), PDGFRβ, pERK1/2 and ERK1/2. D) in vitro kinase assay
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demonstrates direct phosphorylation of DCBLD2 by both ABL and PDGFRβ. Recombinant ABL
(1.5 ng/μL) and PDGFRβ (6 ng/μL) were incubated with DCBLD2 for 30 min at 30°C. Proteins
were denatured and analyzed by SDS-PAGE and Western blotting for α-pY. Western blots of
DCBLD2 and kinase stocks used in the assay are included in Figure 48. E) Densitometric analysis
of DCBLD2 tyrosine phosphorylation signal (α-pY) resulting from various in vitro kinase assay
reaction conditions. Fold change in DCBLD2 α-pY signal with the addition of ATP is shown for
reaction conditions in Figure 48 (4 ng/μL ABL) and Figure 23D (1.5 ng/μL ABL and 6 ng/μL
PDGFRβ). Numeric fold change values are indicated above each condition where ATP was added.

In three biological replicates, 293 cells transiently expressing PDGFRβ were
treated with 1, 5, or 20 ng/mL recombinant PDGF-BB for 5 or 15 min prior to lysis.
Whole cell extracts (WCEs) were subjected to SDS-PAGE and Western blotting for
phosphorylated ERK1/2 (pERK1/2), total ERK1/2, and PDGFRβ (Figure 23A, Figure
48A-B). Densitometric analysis of pERK1/2 signal across replicates, normalized to
total ERK1/2, is quantified in Figure 23B as the ratio of pERK1/2 signal in each
condition relative to untreated PDGFRβ-expressing cells. Although ANOVA and
Tukey-HSD tests for each time point did not produce low (90% CL) p-values, the
pERK1/2 signal was observed to increase when cells were treated with 20 ng/mL
PDGF-BB across all replicates (Figure 23A, Figure 48A-B). Therefore, remaining
investigations into the interface between DCBLD2 and PDGFRβ employed PDGF-BB
treatments at 20 ng/mL.
To determine whether PDGFRβ co-expression and/or PDGF-BB driven
activation lead to DCBLD2 phosphorylation, DCBLD2 was co-expressed with
PDGFRβ. DCBLD2 tyrosine phosphorylation and CRKL-SH2 binding was assessed in
the presence and absence of PDGF-BB treatment. Cell lysate aliquots were subjected to
immunoprecipitation (α-FLAG) or a GST-CRKL-SH2 pulldown assay prior to analysis
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by SDS-PAGE and Western blotting. Immunoprecipitations (IPs) were blotted for
DCBLD2 levels (α-FLAG) and DCBLD2 tyrosine phosphorylation (α-pY), while
pulldowns were blotted for DCBLD2 (α-FLAG), only. WCEs were probed for
PDGFRβ expression levels, pERK1/2, and total ERK1/2. As a positive control for
tyrosine phosphorylation and CRKL-SH2 binding, DCBLD2 was expressed alone and
treated with H2O2, which reversibly inhibits tyrosine phosphatases by oxidation of the
catalytic cysteine (Denu and Tanner 1998). A strong induction of both DCBLD2
tyrosine phosphorylation and CRKL-SH2 binding is observed in the presence of H2O2
(Figure 23C). Co-expression of PDGFRβ alone increased DCBLD2 tyrosine
phosphorylation. However, phosphorylation either occurred at non-YXXP tyrosine
residues or was not sufficiently abundant to detect DCBLD2 in complex with CRKLSH2 (Figure 23C). However, the addition of 20 ng/mL PDGF-BB for 30 min prior to
lysis increased DCBLD2 phosphotyrosine signal in the immune complex and was
sufficient to detect DCBLD2 in complex with GST-CRKL-SH2 (Figure 23C). When a
mutant DCBLD2 construct with all seven YXXP tyrosine residues mutated to
phenylalanine (Y7F) was subjected to the same experimental conditions, the CRKLSH2 interaction was abolished (Figure 23C). Interestingly, Y7F tyrosine
phosphorylation remained increased over basal WT DCBLD2 phosphorylation (Figure
23C), indicating that both YXXP and non-YXXP tyrosine residues are phosphorylated
downstream of the PDGF-BB/PGDFRβ.
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SRC family kinase (SFKs) and ABL are known to drive DCBLD2 tyrosine
phosphorylation (Aten, Redmond et al. 2013, Schmoker, Weinert et al. 2017), and these
cytoplasmic kinases can be activated downstream of PDGFRβ signaling (Plattner,
Kadlec et al. 1999, Takikita-Suzuki, Haneda et al. 2003, Srinivasan, Kaetzel et al. 2009,
Wagner and Gorin 2014). To determine whether PDGFRβ driven DCBLD2 tyrosine
phosphorylation was the result of SFK or ABL activation downstream of the PDGFBB/PDGFRβ interaction, we treated 293 cells transiently expressing DCBLD2 and
PDGFRβ with SRC-1, a SFK inhibitor, or STI571, which inhibits both ABL and
PDGFRβ (Figure 48C). The addition of SRC-1 to cells co-expressing DCBLD2 and
PDGFRβ reduced DCBLD2 tyrosine phosphorylation relative to the untreated
condition (α-pY blot of the α-FLAG IP, Figure 48C). STI571 abolished DCBLD2
tyrosine phosphorylation (Figure 48C), however, this inhibitor does not distinguish
between PDGFRβ and ABL. Even so, these observations suggest that the increase in
DCBLD2 tyrosine phosphorylation is likely the result of PDGFRβ activity, rather than
increased levels of PDGFRβ scaffolding sites afforded by high expression levels. It will
be important to repeat this experiment with the addition of PDGF-BB.
To determine whether ABL and/or PDGFRβ directly phosphorylate DCBLD2,
in vitro kinase assays were conducted with recombinant kinases. First, DCBLD2-FLAG
was immunoprecipitated (α-FLAG) from 293 cells, eluted with 100 μg/mL FLAG
peptide, and dialyzed against 25 mM Tris in 50% glycerol (Figure 48D). DCBLD2FLAG and GST-His6-AblP118-S535 and GST-His6-PDGFRβR561-L1106 were diluted from
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the stocks shown in Figure 48D-E for kinase assays. GST-His6-AblP118-S535 and GSTHis6-PDGFRβR561-L1106 were incubated for 30 min at 30°C with and without DCBLD2FLAG and ATP. ATP concentrations were used at manufacturer recommendations for
operation at Vmax for each kinase. Quenched assays were analyzed by SDS-PAGE and
Western blotting for α-pY (Figure 23D). A strong induction of DCBLD2 tyrosine
phosphorylation was observed in both ABL and PDGFRβ kinase assays (Figure 23D).
Figure 48F demonstrates that the α-pY signal in lane 3 of Figure 23D is ABL
autophosphorylation. Although there is not a similar control for PDGFRβ, the band
labelled as the DCBLD2 α-pY signal migrates with the same signal in the ABL kinase
assay (Figure 23D), and likely originates from DCBLD2 tyrosine phosphorylation sites.
The fold change (over no ATP) of DCBLD2 α-pY signal in the presence vs. absence of
ATP was quantified from the Western blots of kinase assays in Figure 23D and Figure
48F (Figure 23E). The ABL kinase assays carried out at 1.5 and 4 ng/μL (Figure 23D
and Figure 48F, respectively) did not show a substantial difference in DCBLD2
tyrosine phosphorylation (2.20-fold vs. 2.49-fold increase over no ATP, Figure 23E).
The approximately equal fold changes of DCBLD2 α-pY signal by 1.5 ng/μL ABL and
6 ng/μL PDGFRβ (Figure 23D,E) suggests that the GST-His6-AblP118-S535 construct is
~3.5x more efficient at phosphorylating DCBLD2 than the GST-His6-PDGFRβR561-L1106
construct, given their theoretical molecular weights of ~76 and 88 kDa, respectively
(proqinase.com). These data suggest that both ABL and PDGFRβ are capable of
directly phosphorylating DCBLD2 tyrosine residues, although ABL is more efficient.
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4.5.2. DCBLD2 inhibits PDGF-BB driven proliferation in an ERK-independent
manner
DCBLD2 attenuates PDGFRβ signaling through ERK1/2, as well as
downstream proliferation, at normal expression levels (Kobuke, Furukawa et al. 2001,
Guo, Nie et al. 2009). Given the links between DCBLD2 and certain cancers, the effect
of high levels of DCBLD2 on PDGFRβ signaling, including PDGFRβ phosphorylation
and downstream ERK1/2 activation, was explored.
PDGFRβ tyrosine phosphorylation and downstream ERK1/2 activation were
monitored over time (0-30 min) following PDGF-BB treatment in 293 cells transiently
expressing PDGFRβ alone or with DCBLD2. PDGFRβ tyrosine phosphorylation was
quantified from phosphotyrosine immunoblots of α-PDGFRβ immunoprecipitations
(Figure 24A, Figure 49B-C), and active ERK1/2 was quantified from α-pERK1/2
immunoblots of the WCE (Figure 24A, Figure 49B-C). Three biological replicates were
completed (Figure 24A, Figure 49B-C) for quantification by densitometry (Figure 24CD). PDGFRβ tyrosine phosphorylation was, on average, increased in the presence of
DCBLD2 at 5 and 10 min after PDGF-BB treatment (Figure 24C). ERK1/2 activation
was also increased both basally and at early time points following PDGF-BB treatment
(Figure 24D). In addition, DCBLD2 tyrosine phosphorylation downstream of PDGFBB treatment was monitored over time and the α-pY signal of a DCBLD2
immunoprecipitation (α-FLAG, Figure 24A & Figure 49A-C) was quantified by
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densitometry (Figure 24B). DCBLD2 tyrosine phosphorylation exhibited a steady
increase from 0-30 min following PDGF-BB treatment (Figure 24B).
Given the observed increase in PDGFRβ tyrosine phosphorylation and ERK1/2
activation in the presence of high levels of DCBLD2, we hypothesized that ERK-driven
proliferation would be increased in this system. In addition, we hypothesized that the
DCBLD2/CRKL-SH2 interaction would be involved in driving proliferation. PDGFRβ
was expressed alone or with wild-type or Y7F DCBLD2 in 293 cells and treated with 0,
1, 5, or 20 ng/mL PDGF-BB in serum-free medium for 48 hr. Cells counts were
compared across three replicate experiments. Interestingly, high levels of DCBLD2
attenuated proliferation markedly at 5 and 20 ng/mL PDGF-BB in a YXXPindependent manner (Figure 24E). This observed decrease in proliferation downstream
of PDGF-BB suggests that ERK-independent signaling is driving proliferation in this
system.
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Figure 24. High expression of DCBLD2 promotes PDGF-BB-driven ERK phosphorylation but
attenuates proliferation.
A-D) High DCBLD2 promotes ERK and PDGFRβ phosphorylation at early time points following
PDGF-BB treatment. A) 293 cells transiently expressing PDGFRβ with or without DCBLD2 were
treated with 20 ng/mL PDGF-BB for 0, 5, 10, or 30 min prior to lysis. Immunoprecipitations (αFLAG and α-PDGFRβ) and WCEs were analyzed by SDS-PAGE and probed with antibodies to
phosphotyrosine (pY) and pERK1/2 as well as loading controls. B) DCBLD2 tyrosine
phosphorylation from four biological replicates of the α-FLAG IP shown in (A) (also Figure 49A-C)
was quantified by densitometry and plotted as the Log2-transformed ratio of α-pY signal
(normalized to α-FLAG) in each experimental condition relative to the untreated condition. C)
PDGFRβ tyrosine phosphorylation from three biological replicates of the α-PDGFRβ IP shown in (A)
(also Figure 49B-C) was quantified by densitometry and plotted as the Log2-transformed ratio of αpY signal (normalized to α-PDGFRβ) in each experimental condition with DCBLD2 co-expression to
PDGFRβ alone. D) ERK1/2 phosphorylation in the WCE of three biological replicates of the
experiment shown in (A) (also Figure 49B-C) was quantified by densitometry and plotted as the
Log2-transformed ratio of α-pERK1/2 signal (normalized to total ERK1/2 signal) in each
experimental condition with DCBLD2 co-expression to PDGFRβ alone. E) DCBLD2 attenuates
PDGF-BB-driven proliferation independent of YXXP tyrosines. 293 cells transiently expressing the
PDGFRβ alone or with DCBLD2 (WT or Y7F) were treated with 0, 1, 5, or 20 ng/mL PDGF-BB and
incubated for 48 hr. Cell number was determined with a hemocytometer. Cell counts following 48 hr
treatment with PDGF-BB relative to untreated cells are plotted for three biological replicates at each
concentration. Significant (95% CL) ANOVA and Tukey-HSD p-values are indicated.
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4.5.3. Insulin-mediated activation of the insulin receptor (INSR) induces
phosphorylation of DCBLD2 YXXP tyrosine residues
Given the observed differential effect of co-expression of DCBLD2 and
PDGFRβ at high levels on ERK1/2 phosphorylation and downstream proliferation, we
investigated whether the same was true in another system that normal DCBLD2
expression attenuates, namely, insulin signaling (Li, Jung et al. 2016). Although the
insulin receptor (INSR) is expressed in 293 cells, we transiently expressed the human
INSR at higher levels in order to simulate cancer or developmental environments. To
determine the concentration of insulin necessary to activate ERK1/2 in this system, 293
cells transiently expressing INSR were treated with 100, 200, or 400 nM insulin for 5
and 15 min prior to lysis. WCEs were subjected to SDS-PAGE and Western blotting,
and normalized pERK1/2 was quantified across conditions using densitometry in three
replicate experiments (Figure 25A-B & Figure 50A-B). ERK1/2 phosphorylation was
increased, on average, over untreated cells at every concentration of insulin (Figure
25A-B & Figure 50A-B). The minimum concentration necessary to elicit ERK1/2
activation, 100 nM, was used in further experiments.
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Figure 25. Insulin drives phosphorylation of DCBLD2 tyrosines and promotes CRKL-SH2 binding.
A) Insulin signaling through highly expressed INSRβ established in 293 cells. HEK 293 cells
transiently expressing INSRβ were treated with 100 nM, 200 nM, or 400 nM insulin for 5 or 15 min
prior to lysis. Whole cell extracts (WCEs) were analyzed by SDS-PAGE and Western blotting for
phosphorylated ERK1/2 (pERK1/2) as a read-out of INSRβ activity and total ERK1/2 and INSRβ as
loading controls. B) ERK phosphorylation across three biological replicates of (A) is quantified via
densitometry as the Log2-transformed fold change (FC) in pERK1/2 signal (normalized to total
ERK1/2) in each experimental condition relative to untreated cells. Additional biological replicates
used for quantification are included in Figure 50. Low (90% CL) p-values resulting from ANOVA
and Tukey-HSD tests are indicated. C) Insulin drives phosphorylation of YXXP and non-YXXP
DCBLD2 tyrosine residues and CRKL-SH2 interaction. Wild type (WT) and mutant (seven Y-to-F
mutations, Y7F) DCBLD2-FLAG were transiently expressed alone or with the INSRβ and 293 cells
were treated with H2O2 (8.8 mM for 15 min) or insulin (100 nM for 30 min) prior to lysis.
Immunoprecipitations (IPs, α-FLAG), pulldowns (GST-CRKL-SH2), and WCEs were analyzed by
SDS-PAGE and probed with antibodies for the FLAG epitope, phosphotyrosine (pY), INSRβ,
pERK1/2 and ERK1/2. The α-pY blot of the α-FLAG IP is composed of a short exposure of WT
DCBLD2 treated with H2O2 and a long exposure of the remaining experimental conditions, separated
with a black line.

To determine whether insulin promotes DCBLD2 tyrosine phosphorylation and
CRKL-SH2 binding, DCBLD2 was expressed alone and with INSR in 293 cells and
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lysates were subjected to DCBLD2 immunoprecipitation (α-FLAG) and a GST-CRKLSH2 pulldown assay. Co-expression of DCBLD2 and INSR alone did not increase
DCBLD2 tyrosine phosphorylation above basal levels, however, DCBLD2
phosphorylation was induced following insulin treatment (Figure 25C). Interestingly,
no phosphotyrosine signal was observed when cells co-expressing INSR with the Y7F
DCBLD2 mutant were treated with insulin (Figure 25C), suggesting that all
phosphorylation induced during insulin signaling occurs at YXXP tyrosines, despite the
absence of an α-FLAG signal in the GST-CRKL-SH2 pulldown (Figure 25C). Given
the relatively low tyrosine phosphorylation induced by insulin (Figure 25C), relative to
PDGF-BB (Figure 23C), it is not surprising that no DCBLD2 was detected in complex
with CRKL-SH2 in this assay. Even so, the observed phosphorylation of DCBLD2
YXXP tyrosines, although at low levels, could lead to an interaction with CRK adaptors
downstream of insulin binding INSR.
Similar to PDGF-BB signaling, SFKs and ABL can be activated as a result of
insulin signaling (Rosenzweig, Aga-Mizrachi et al. 2004, Frasca, Pandini et al. 2007,
Genua, Pandini et al. 2009). To determine whether DCBLD2 phosphorylation
downstream of insulin binding to INSR was the result of the activation of cytoplasmic
kinases downstream of insulin, SRC-1 and STI571 were added to cells co-expressing
INSR and DCBLD2 prior to insulin treatment (Figure 50C). A subtle decreased in
DCBLD2 tyrosine phosphorylation was observed when SFK activity was inhibited
(SRC-1), however, the addition of STI571 resulted in the increased α-pY signal from a
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higher molecular weight species in the α-FLAG immune complex (Figure 50C). ABL
was shown to directly phosphorylate DCBLD2 in Figure 23D, however, these results
indicate that ABL may not play a role in DCBLD2 phosphorylation downstream of
insulin. This experiment should be repeated to determine whether these results are
reproducible. In addition, in vitro kinase assays with INSR and a SFK could
definitively inform whether either of these kinases are capable of directly
phosphorylating DCBLD2.
4.5.4. DCBLD2 inhibits insulin driven proliferation in an ERK-independent
manner
We then asked whether DCBLD2 would modulate insulin signaling in this
system. INSR phosphorylation and activation of ERK1/2 was monitored from 0-30 min
following insulin treatment in the presence and absence of DCBLD2 co-expression.
DCBLD2-MYC-FLAG immunoprecipitations (α-FLAG) were divided across three
SDS-PAGE analyses that were immunoblotted for α-MYC (DCBLD2), α-pY, and the β
subunit of INSR (α-INSRβ; Figure 26A, Figure 51A-C). The α-pY signal, quantified
across four replicate experiments by densitometry (Figure 26A & Figure 51A-C), was
subtly increased at early time points following insulin treatment (Figure 26B). INSR
was identified in complex with DCBLD2 in an insulin-independent manner (Figure
26A), as has been previously described (Li, Jung et al. 2016). INSR tyrosine
phosphorylation, observed in the α-pY blot of the α-INSRβ IP (Figure 26A & Figure
51B-C), was not markedly affected by DCBLD2 co-expression across three replicate
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experiments, although INSR tyrosine phosphorylation was, on average, increased in the
presence of DCBLD2 at 30 min following insulin treatment (Figure 26C). It could be
more informative to employ an INSR active site-specific antibody to monitor the effect
of DCBLD2 on INSR activation in this system. Downstream signaling in the MAPK
cascade, however, was increased in the presence of DCBLD2 at later timepoints
following insulin treatment (Figure 26D).
Given the observed increase in ERK1/2 activation downstream of insulin in
cells expressing high levels of INSR and DCBLD2, we looked at the resulting effect on
cell proliferation. Cells expressing INSR alone or with WT or Y7F DCBLD2 were
treated with 100, 200, and 400 nM insulin and compared to untreated cells expressing
the same constructs (Figure 26E). As was observed with the high DCBLD2/PDGFRβ
system, on average, DCBLD2 attenuated insulin signaling in a YXXP-independent
manner (Figure 26E).
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Figure 26. High expression of DCBLD2 promotes insulin driven ERK phosphorylation but
attenuates proliferation.
A-D) High DCBLD2 promotes ERK and INSRβ phosphorylation at early time points following
insulin treatment. A) 293 cells transiently expressing INSRβ with or without DCBLD2 were treated
with 100 nM insulin for 0, 5, 10, or 30 min prior to lysis. Immunoprecipitations (α-FLAG and αINSRβ) and WCEs were analyzed by SDS-PAGE and probed with antibodies to phosphotyrosine
(pY) and pERK1/2 as well as loading controls. α-FLAG IPs were also probed with α-INSRβ,
demonstrating that DCBLD2 and INSRβ co-immunoprecipitate. B) DCBLD2 tyrosine
phosphorylation from four biological replicates of the α-FLAG IP shown in (A) (also Figure 51AC) was quantified by densitometry and plotted as the Log2-transformed ratio of α-pY signal
(normalized to α-FLAG) in each experimental condition relative to the untreated condition. C)
INSRβ tyrosine phosphorylation from three biological replicates of the α- INSRβ IP shown in (A)
(also Figure 51B-C) was quantified by densitometry and plotted as the Log2-transformed ratio of
α-pY signal (normalized to α- INSRβ) in each experimental condition with DCBLD2 co-expression
to INSRβ alone. D) ERK1/2 phosphorylation in the WCE of three biological replicates of the
experiment shown in (A) (also Figure 51B-C) was quantified by densitometry and plotted as the
Log2-transformed ratio of α-pERK1/2 signal (normalized to total ERK1/2 signal) in each
experimental condition with DCBLD2 co-expression to INSRβ alone. E) DCBLD2 attenuates
insulin-driven proliferation independent of YXXP tyrosines. 293 cells transiently expressing the
INSRβ alone or with DCBLD2 (WT or Y7F) were treated with 0, 100, 200, or 400 nM insulin and
incubated for 48 hr. Cell number was determined with a hemocytometer. Cell counts following 48
hr treatment with insulin relative to untreated cells are plotted for three biological replicates at
each concentration. Low (90% CL) ANOVA and Tukey-HSD p-values are indicated.
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4.6. Discussion
The plasma membrane receptor DCBLD2 modulates basic cellular processes
that are fundamental to vertebrate development, glucose homeostasis, and the
progression of certain cancers (Kobuke, Furukawa et al. 2001, Koshikawa, Osada et al.
2002, Chen, Low et al. 2007, Nagai, Sugito et al. 2007, Sadeghi, Esmailzadeh et al.
2007, Hofsli, Wheeler et al. 2008, Kim, Lee et al. 2008, Guo, Nie et al. 2009, OsellaAbate, Novelli et al. 2012, Nie, Guo et al. 2013, Feng, Lopez et al. 2014, Topkas, Cai et
al. 2014, Li, Jung et al. 2016, Kikuta, Kubota et al. 2017, Schmoker, Ebert et al. 2019).
In many of these systems, DCBLD2 has been found to either promote or attenuate RTK
signaling. Previous investigations have focused on the effect of DCBLD2 knock-down
or knock-out on RTK activation, interactors, and phenotypic outcomes. Here, we
explore PDGFRβ and INSR signaling in a DCBLD2 centered context, in preliminary
investigations into the mechanism of DCBLD2 action on RTK signaling.
Loss of DCBLD2 expression is known to increase signaling events downstream
of PDGFRβ and INSR, including receptor phosphorylation, MAPK and AKT
activation, and downstream phenotypes, such as cell proliferation or glucose uptake in
the context of PDGFRβ and INSR signaling, respectively (Kobuke, Furukawa et al.
2001, Guo, Nie et al. 2009, Li, Jung et al. 2016) (Figure 7). Although the molecular
roles of DCBLD2 in these systems is unknown, it has been hypothesized that DCBLD2
recruits positive or negative regulators of these RTKs to the membrane (Schmoker,
Ebert et al. 2019). In PDGFRβ signaling, loss of DCBLD2 decreases the amount of c192

CBL bound to PDGFRβ and receptor ubiquitylation, which negatively regulates
downstream signaling (Guo, Nie et al. 2009). Interestingly, the absence of DCBLD2
increased INSR-bound APS/c-CBL complexes, which are considered positive
regulators of INSR signaling (Li, Jung et al. 2016). A reciprocal decrease in bound
GRB10/NEDD4 complexes were observed, which are thought to negatively regulate
INSR signaling (Li, Jung et al. 2016). Most likely, DCBLD2 post-translational
modification, i.e. phosphorylation, downstream of RTK activation, is involved in
recruiting various RTK regulating proteins.
To study DCBLD2 tyrosine phosphorylation is these systems, we modeled
PDGF-BB and insulin signaling in 293 cells in the presence of high levels of DCBLD2.
Not only did this allow us to robustly monitor DCBLD2 phosphorylation, but we
hypothesized that high levels may have different effects on downstream signaling than
observed in DCBLD2-/- systems (Kobuke, Furukawa et al. 2001, Guo, Nie et al. 2009,
Li, Jung et al. 2016). In addition, this could potentially model normal biological
systems in which DCBLD2 and PDGFRβ or INSR expression is elevated, and would
also model certain cellular environments in cancer. In addition to assessing whether
DCBLD2 tyrosine phosphorylation increased downstream of the PDGF-BB/PDGFRβ
or insulin/INSR interactions, we investigated the effect of elevated DCBLD2
expression on RTK phosphorylation, ERK1/2 activation, and cell proliferation.
Although the role of DCBLD2 on insulin-induced proliferation has not yet been
investigated, insulin-induced proliferation has been implicated in certain cancers,
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including breast and colorectal cancer (Rose and Vona-Davis 2012, Djiogue, Nwabo
Kamdje et al. 2013, Lu, Chu et al. 2017). Given the known role of DCBLD2 in
modulating general insulin-related signaling events (Li, Jung et al. 2016), we
hypothesized that DCBLD2 could also alter insulin-driven proliferation.
PDGFRβ and INSR signaling models in systems with no DCBLD2, as well as
DCBLD2 expression at low and elevated levels, is shown in Figure 27. We found that
high DCBLD2 expression attenuated PDGF-BB driven proliferation (Figure 24E),
which agreed with previous studies conducted under normal PDGFRβ and DCBLD2
expression levels (Kobuke, Furukawa et al. 2001, Guo, Nie et al. 2009). Similarly,
insulin driven proliferation was decreased in the presence of high DCBLD2 (Figure
26E). However, the effect of high DCBLD2 expression had different effects on ERK1/2
signaling downstream of PDGFRβ and INSR than that observed previously. In SMCs,
other investigators have reported ERK1/2 activation to increase with loss of DCBLD2
expression (Kobuke, Furukawa et al. 2001, Guo, Nie et al. 2009, Li, Jung et al. 2016).
Here, we found that high levels of DCBLD2 subtly promoted ERK1/2 activation
downstream of PDGF-BB and insulin (Figure 24 and Figure 26). These observations
suggest that there exists a) an ERK1/2-driven cellular phenotype not assessed in this
study that is likely altered by high levels of DCBLD2, and b) an ERK1/2-independent
mechanism of proliferation that is attenuated by DCBLD2 (Figure 27).
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ERK1/2 activation leads not only to proliferation, but also to cell growth,
survival, inflammation, and differentiation. Once phosphorylated, ERK is transported
into the nucleus where it regulates transcriptional machinery related to proliferation and
survival, but it also has cytosolic target proteins, including ribosomal S6 kinase (RSK).
Active RSK promotes cell growth and proliferation in parallel with ERK, but can also
provide negative feedback to the MAPK cascade. Active RSK phosphorylates SOS,
leading to dissociation of the GRB2/SOS complex and SOS/14-3-3 complex formation
(Saha, Carriere et al. 2012). The presence of high DCBLD2 could promote SOS
membrane recruitment and downstream ERK activation, either through the recruitment
of GRB2/SOS or other adaptor/SOS complexes (Birge, Kalodimos et al. 2009) or
through another mechanism of inhibition, potentially at the level of RSK in the MAPK
cascade (Figure 27).
DCBLD2 could also inhibit proliferation through other mechanisms. One
pathway that was not explored in this work was PI3K/AKT driven proliferation. We
attempted to monitor AKT activity in this system, however, we observed high basal
AKT activity and could not detect any substantial change in AKT activation upon
PDGF-BB or insulin treatment. It would be necessary to compare the proliferative
effects observed here to the same systems in which PI3K or MAPK inhibitors have
been added in future studies. Interplay between the MAPK cascade and PI3K/AKT
could be involved in the observed increased pERK and decreased proliferation. AKT
promotes phosphorylation of Raf S259, which inhibits downstream signaling in the
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MAPK cascade (Zhou, Du et al. 2015). In addition, ERK phosphorylation has been
shown to inhibit regeneration of neural progenitor cells through AKT and instead
promotes their differentiation (heon Rhim, Luo et al. 2016). If DCBLD2 attenuates
proliferation through inhibiting signaling upstream of or at the level of AKT activation,
this could also contribute to increased pERK and the promotion of non-proliferative
downstream phenotypes.
SFKs are also known to regulate MAPK signaling (Stokoe and McCormick
1997). SRC can activate Ras GTPase activity, but also phosphorylates and activates
Raf, promoting downstream signaling through the MAPK cascade (Bunda, Heir et al.
2014). Previously, we demonstrated that the SFK FYN interacts with DCBLD2 through
the FYN-SH2 domain (Aten, Redmond et al. 2013), which could stabilize the active
conformation of FYN. High levels of the phosphorylated DCBLD2 scaffold
downstream of RTK activation could substantially increase the pool of active FYN, and
potentially other SFKs and ABL. This could increase phosphorylation of scaffolding
sites for adaptors such as GRB2 on not only DCBLD2, but also PDGFRβ or INSR
without promoting RTK activity (Figure 27). This could represent a mechanism by
which high levels of DCBLD2 promote ERK phosphorylation downstream of PDGFRβ
and INSR. It would be interesting to assess relative SFK and ABL activity in systems
with low and high DCBLD2 to determine whether it parallels ERK activation.

196

Figure 27. Signaling model for PDGFRβ and INSR signaling in the presence and absence of
DCBLD2.
In models with “No”, “Low” and “Elevated” levels of DCBLD2, a simplified summary is given to the
left, with a more in-depth signaling model to the right. In the absence of DCBLD2 (“No DCBLD2”),
such as in knock-down or knock-out systems (Guo, Nie et al. 2009, Li, Jung et al. 2016), MAPK and
PI3K/AKT signaling is elevated, given the absence of negative regulatory mechanisms imposed by
DCBLD2. Active RTK can also activate SFKs/ABL, which contribute to cell proliferation, growth,
migration, etc., either through phosphorylation of RTK scaffolding sites or through other
mechanisms.
In systems with low levels of DCBLD2 (“Low DCBLD2”), phosphorylation of DCBLD2 non-YXXP
tyrosines, either by the RTK or an SFK or ABL, leads to the recruitment of negative regulatory
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molecules, such as phosphatases or ubiquitin ligases, that either dephosphorylate the receptor or
promote receptor endocytosis and degradation. Inhibition could act solely on RTK activation, but it
could also act further downstream to attenuate MAPK or AKT signaling. At the same time,
phosphorylation of DCLBD2 YXXP tyrosines would recruit CRK adaptors, promoting downstream
signaling of the associated CRK/CRKL-SH3 cargo. Conceivably, SH3 interactors associated with
actin dynamics or adhesions would be the most prominent cargo proteins in these systems.
In systems with “Elevated DCBLD2”, the concentrated DCBLD2 scaffold could recruit positive
regulators of ERK activation to non-YXXP tyrosines. Despite the inhibitory effect on MAPK and
PI3K/AKT signaling leading to proliferation via the RTK itself, the abundance of scaffolding
DCBLD2 sites for adaptors such as GRB2 could recruit SOS or other positive regulators of ERK
signaling to the membrane. High abundance of DCBLD2 scaffolds could also promote activation of
SFKs or ABL. This could promote not only DCBLD2 phosphorylation, but also phosphorylation of
scaffolding sites on RTKs, leading to membrane recruitment of various signaling molecules.

We originally hypothesized that high levels of DCBLD2 could concentrate
CRK and CRKL complexes at the membrane, similarly to the related viral oncogene
gag-CRK (Klemke, Leng et al. 1998, Cheresh, Leng et al. 1999, Cho and Klemke 2000,
Feller 2001, Nakamura, Komiya et al. 2002, Ballif, Arnaud et al. 2004, Chodniewicz
and Klemke 2004, Brábek, Constancio et al. 2005, Park and Curran 2014), and that this
could be a mechanism by which DCBLD2 drives cancer. We found that signaling
downstream of PDGFRβ and INSR could both drive phosphorylation of CRK/CRKLSH2 docking sites on DCBLD2. In addition, PDGF-BB could drive the formation of a
detectable DCBLD2/CRKL-SH2 complex in a pulldown assay (Figure 23). This
interaction did not promote 293 proliferation, although DCBLD2/CRK(L) complexes
could still drive other cellular phenotypes, such as migration or adhesion, in this
system. It would be interesting to immunoprecipitate DCBLD2 and immunoblot for
known CRK/CRKL-SH3 interactors in the immune complex, such as C3G, DOCK1, or
SOS, which may indicate the appropriate cellular phenotype to monitor.
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Although insulin did promote phosphorylation of DCBLD2 YXXP tyrosine
residues, the DCBLD2/CRKL-SH2 complex was not detected in the pulldown assay
(Figure 25). It remains possible that the specific insulin driven pYXXP motifs are not
CRK adaptor binding sites. However, the effect of higher doses of insulin on both
DCBLD2 tyrosine phosphorylation sites and the potential for DCBLD2/CRKL-SH2
complexation should be assessed. In addition, it will be necessary to determine whether
DCBLD2 tyrosine phosphorylation occurs directly by INSR, or whether SFKs activated
downstream of INSR phosphorylate DCBLD2. ABL was found to directly
phosphorylate DCBLD2 in an in vitro kinase assay, and ABL can be activated
downstream of insulin in some systems (Rosenzweig, Aga-Mizrachi et al. 2004, Frasca,
Pandini et al. 2007, Genua, Pandini et al. 2009). However, the addition of an ABL
inhibitor prior to insulin treatment did not have a marked effect on DCBLD2
phosphorylation (Figure 50). We can induce ERK activation downstream of insulin in
murine embryonic fibroblasts (MEFs) derived from mice lacking the SFKs SRC, Yes,
and FYN (SYF-/-) as well as control MEFs that retain SRC expression (SRC+) (Figure
52) (Klinghoffer, Sachsenmaier et al. 1999). This may be a helpful tool to study the
effect of DCBLD2 on insulin signaling in the presence and absence of SFKs.
Both PDGFRβ and ABL were capable of phosphorylating DCBLD2 in an in
vitro kinase assay (Figure 23D). As ABL is activated downstream of PDGFRβ,
PDGFRβ could be responsible for DCBLD2 tyrosine phosphorylation at early time
points following PDGF-BB binding, and ABL phosphorylation could occur at later
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time points. Given the similar preferences of PDGFRβ and ABL kinase substrates
(Schmoker, Driscoll et al. 2018), DCBLD2 is likely phosphorylated on the same sites
by these kinases, which could serve to amplify downstream effects. CRK adaptor
binding sites are likely substrates of both ABL and PDGFRβ, given the observed
increase in phosphorylation of YXXP tyrosines and the known preference of both
kinases for tyrosine substrates within these motifs (Schmoker, Driscoll et al. 2018).
Non-YXXP tyrosine phosphorylation also increased following PDGF-BB treatment,
although it remains to be determined whether these are direct PDGFRβ or ABL sites, or
whether another downstream kinase is responsible.
Given the decrease in proliferation observed with both wild-type and Y7F
DCBLD2, YXXP sites are likely not the primary drivers of inhibitory effects on
proliferation downstream of PDGFRβ and INSR. In addition to CRK adaptors, other
proteins could be induced to interact with DCBLD2, particularly at these non-YXXP
tyrosines. Previously, we reported that FYN and ABL can alter phosphorylation of
serine and threonine residues on DCBLD2 (Chapter 4), and it remains possible that
these sites could be involved in recruiting negative regulators of PDGFRβ and INSR
signaling, particularly in the case of INSR, as phosphorylation of non-YXXP sites was
observed. Although no systematic studies were carried out to determine whether the
observed increase in ERK activation in the presence of elevated DCBLD2 levels was
dependent upon DCBLD2 YXXP tyrosines, we have not observed any striking changes
in ERK activation in the presence of wild-type versus Y7F DCBLD2 (Figure 23C).
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Therefore, the increased ERK activation is likely CRK-independent, and the
recruitment of ERK positive regulators occurs through non-YXXP tyrosines (Figure
27).
While the work presented in this chapter provokes more questions than it
answers, it sets the groundwork for studying PDGFRβ and INSR signaling in the
context of elevated DCBLD2 expression and provides a model by which the effect of
high DCBLD2 on other RTK signaling pathways may be assessed. Importantly, we
identified differences in systems with high versus low levels of DCBLD2, which were
not assessed in previous studies that focused on the effects of knocking-out or
knocking-down DCBLD2 expression (Figure 27). The conditions employed in this
study model certain developmental and cancer cellular environments and can be used to
inform signaling in similar systems represented in vivo.
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CHAPTER 5: AN IN SILICO PROTEOMICS SCREEN TO PREDICT AND
PRIORITIZE PROTEIN-PROTEIN INTERACTIONS DEPENDENT ON POSTTRANSLATIONALLY MODIFIED MOTIFS
5.1. Abstract
5.1.1. Motivation
The development of proteomic methods for the characterization of
domain/motif interactions has greatly expanded our understanding of signal
transduction. However, proteomics-based binding screens have limitations including
that the queried tissue or cell type may not harbor all potential interacting partners or
post-translational modifications (PTMs) required for the interaction. Therefore, we
sought a generalizable, complementary in silico approach to identify potentially novel
motif and PTM-dependent binding partners of high priority.
5.1.2. Results
We used as an initial example the interaction between the SH2 domains of the
adaptor proteins CRK and CRKL and phosphorylated-YXXP motifs. Employing wellcurated, publicly available resources, we scored and prioritized potential CRK/CRKLSH2 interactors possessing signature characteristics of known interacting partners. Our
approach gave high priority scores to 102 of the more than 9,000 YXXP motifcontaining proteins. Within this 102 were 21 of the 25 curated CRK/CRKL-SH2
binding partners showing a more than 80-fold enrichment. Several predicted interactors
were validated biochemically. To demonstrate generalized applicability, we used our
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workflow to predict protein-protein interactions dependent upon motif-specific arginine
methylation. Our data demonstrate the applicability of our approach to, conceivably,
any modular binding domain that recognizes a specific post-translationally modified
motif.
5.1.3. Supporting Information
Supplementary data are available at Bioinformatics online (doi:
10.1093/bioinformatics/bty434).
5.2. Abbreviations
ABL, Abelson tyrosine protein kinase; BCAR1, breast cancer anti-estrogen
resistance protein 1; CAS, Crk-associated substrate of Src; CAV1, caveolin 1; CRK(L),
CT10 regulator of kinase (like); DAB1, disabled 1; DAZ2, deleted In azoospermia 2;
DCBLD, discoidin, CUB, and LCCL domain-containing protein; EGFR, epidermal
growth factor receptor; EMD, emerin; EPHA2, ephrin A2; FAK, focal adhesion kinase;
FLI1, friend leukemia integration 1 transcription factor; GST, glutathione S-transferase;
KIAA1143, uncharacterized protein; SH2, SRC homology 2; SH3, SRC homology 3;
SFK, SRC family kianse; SYK, spleen tyrosine kinase; PDGFR, platelet derived
growth factor receptor; PDLIM5, PDZ And LIM Domain 5; PPI, protein-protein
interaction; PRMT, protein arginine methyl transferase; PTM, post-translational
modification; TMEM192, transmembrane protein 192; WBP2, WW domain binding
protein 2.
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5.3. Introduction
The first description of the SRC homology 2 (SH2) domain (Sadowski, Stone et
al. 1986) and the subsequent discovery that SH2 domains bind phosphorylated tyrosine
(pTyr) residues (Moran, Koch et al. 1990, Matsuda, Mayer et al. 1991, Mayer, Jackson
et al. 1991) enlightened our previous understanding of signal transduction, taking pTyr
past simple allosteric regulation to a world of multiprotein complexes. Our emerging
understanding involved enzyme-induced protein/lipid modifications that could
modulate the formation/dissociation of signaling hubs, affecting affinities of molecular
interactions and subcellular localization (Mayer 2015). The characterization of the SH2
domain spurred the identification of additional post-translational modification (PTM)
recognition domains (Seet, Dikic et al. 2006), most of which possess a unique affinity
for amino acids (AAs) surrounding the modified site.
The SH2 domain is comprised of a highly conserved sequence of ~100 AAs
found in many adaptors, scaffolding proteins, transcription factors, and non-receptor
tyrosine kinases (Sadowski, Stone et al. 1986). SH2 domains bind pTyr residues within
motifs specific to each SH2 domain, linking tyrosine kinases and their substrates with
downstream effectors. CT10 regulator of kinase (CRK) and CRK-like (CRKL) are
broadly expressed adaptors that execute central roles in complex formation during
fundamental cellular processes including differentiation, proliferation, and migration
(Klemke, Leng et al. 1998, Brábek, Constancio et al. 2005, Park and Curran 2014).
Each family member possesses a single SH2 domain that binds phosphorylated YXXP
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(pYXXP) motifs and two SH3 domains, although the C-terminal CRK-SH3 can be
deleted through alternative splicing. The N-terminal CRK/CRKL-SH3 domain is
responsible for most intermolecular interactions and binds PXXPXK sequences (Wu,
Knudsen et al. 1995). While these adaptors facilitate complex assembly required for
many well-studied metazoan signaling mechanisms, CRK family members are
hypothesized to serve additional undiscovered roles.
The CRK/CRKL-SH2 domain binds with high specificity to pYXXP, generated
by the activity of kinases including SRC family kinases (SFKs), ABL/ARG, FAK,
SYK, PDGFR and EGFR (Figure 53, Table 19). SFKs/ABL are responsible for
phosphorylation events critical to CRK/CRKL binding in several important systems,
including Reelin signaling (Ballif, Arnaud et al. 2004), and focal adhesion dynamics
(Chodniewicz and Klemke 2004, Park and Curran 2008). Previously, we conducted a
proteomics screen that aimed to identify SFK substrates whose pYXXP motifs would
bind CRKL-SH2 in HEK293 cells (Aten, Redmond et al. 2013). We identified the
novel CRKL-SH2 interactor DCBLD2 (also ESDN, CLCP1), a scaffolding receptor
with seven intracellular YXXP motifs. We recently characterized DCBLD2 alongside
its family member DCBLD1, and found them to be SFK- /ABL-mediated pYXXPdependent CRKL-SH2 interactors (Schmoker, Weinert et al. 2017).
While proteomic methods that facilitate characterization of domain/motif
interactions have accelerated explorations into mechanistic signaling, proteomics-based
binding screens are accompanied by certain limitations. The organism/tissue/cell type
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employed may not express all potential interactors. Further, PTM-dependent screens
may fail to identify important interactions if certain modifying enzymes
(kinases/ligases/transferases) are not sufficiently activated, particularly if only a subset
of cells within a given tissue have the relevant signaling pathway engaged. Therefore,
we sought a complementary approach to identify novel interactors of modular domains
that might circumvents these limitations.
Here we describe an in silico screen that uses signature characteristics of known
domain/motif interactions and empirical data from mass spectrometric screens to
predict PTM-dependent motif-specific interactions. By approaching this question from
a bioinformatics perspective, the query is not limited to the proteome of a particular cell
type, but is expanded to encompass that of an entire organism. As an initial example,
we explored the CRK/CRKL-SH2-pYXXP interaction. Using well-curated databases
and predictive tools, we compiled lists of proteins possessing defined characteristics of
CRK/CRKL-SH2 domain interactors and then weighted and prioritized candidates by
list membership. Our application of this bioinformatics pipeline to the CRK/CRKLSH2-pYXXP interaction was successful in identifying both known and novel
CRK/CRKL-SH2 candidate interactors, and several novel candidates were validated
biochemically. We then tested our generalized workflow on the prediction of proteinprotein interactions (PPIs) requiring motif-specific arginine methylation. Together our
data show the applicability of this approach to, conceivably, any modular domain that
recognizes a specific modified motif.
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5.4. Methods
5.4.1. Generation of protein lists guided by signature characteristics of known
interactors.
Lists of potentially interesting proteins were compiled by considering signature
characteristics of known CRKL-SH2 interactors.
Scansite 3.0 (Yaffe, Leparc et al. 2001) was used to identify all proteins
containing the CRKL-SH2 preferred binding motif (YXXP). A list of all human
proteins containing at least one YXXP motif in the SwissProt database was generated
using the Scansite 3.0 Sequence Pattern tool assigning tyrosine as the central residue
and requiring a proline in the +3 position (Supplementary File 1, PMCID:
PMC6223376, DOI: 10.1093/bioinformatics/bty434). The output of the Sequence
Pattern search included the frequency of the motif per protein, listed in UniProtKB
entry format. It is noted that when motifs overlap they may not be appropriately
counted by the Scansite Sequence Pattern search. We noticed this with the protein
WBP2 which contains 11 YXXP motifs, two of which are overlapping (Supplementary
File 1, PMCID: PMC6223376, DOI: 10.1093/bioinformatics/bty434). The Sequence
Pattern search reported back nine YXXP motifs. To obtain the number of amino acids
per protein, UniProtKB entries were input into the UniProtKB (Consortium 2017)
Retrieve/ID Mapping tool, using “UniProtKB AC/ID” as the input and “UniProtKB” as
the output. A simplified proxy for this is the theoretical molecular weight which is
provided by Scansite. A similar approach was taken to obtain mouse and zebrafish
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proteins containing YXXP motifs. Mouse and zebrafish IDs were mapped to human
IDs using Metascape (Supplementary File 1, PMCID: PMC6223376, DOI:
10.1093/bioinformatics/bty434).
Additionally, the Scansite 3.0 Databases and Motifs tool was used to predict
tyrosine residues in YXXP motifs that were likely substrates of SRC and ABL. To
generate lists of predicted ABL or SRC kinase human substrates in the SwissProt
database, either “ABL kinase” or “SRC kinase” was selected from the drop-down menu
on the Scansite search page. Included in the output was a Scansite score for each YXXP
motif-centric predicted substrate site, which is based on the preference of each kinase
for the surrounding amino acid composition ±7 amino acids from the central pTyr
residue. The resulting output was 12,121 predicted ABL kinase substrate sites [mean
score=0.562 (±0.034)] and 11,367 predicted SRC kinase substrate sites [mean
score=0.569 (±0.031)]. Toward generating high priority lists, only predicted sites that
fell two standard deviations below the mean score were taken, resulting in the ABL
(457 proteins) and SRC (17 proteins) predicted substrate lists.
The PhosphoSitePlus (Hornbeck, Zhang et al. 2014) Site Search tool was used
to construct a list of proteins with pYXXP motifs that were experimentally identified
predominantly using tandem mass spectrometry. The motif of interest was entered in
the “Sequence or Motif” box and searched with the remaining parameters left
unspecified. Included in the output for this search was the number of experimental
identifications of pYXXP sites using both low- (protein-specific molecular/biochemical
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targeting) and high-throughput (tandem mass spectrometry) methods reported in the
literature or observed in-house by Cell Signaling Technology (CST; Danvers, MA). All
identifications per site and within a single protein were summed to obtain the total
number of pYXXP identifications per protein. The pYXXP list found 8 entries which
were not found via Scansite and we added these to our list of YXXP-containing
proteins (Supplementary File 1, PMCID: PMC6223376, DOI:
10.1093/bioinformatics/bty434).
Additional lists generated through PhosphoSitePlus included known substrates
of ABL, FYN, and SRC. Each kinase was individually searched using the Protein or
Substrate search tool under the “Substrates of:” database. The output list of proteins
included a column of peptides with ±7 amino acids from the central pTyr residue. For
these substrate lists, peptides were sorted to include only those with a proline in the +3
position, which reduced ABL substrates from 103 to 52, FYN substrates from 86 to 17,
and SRC substrates from 279 to 57.
Finally, a list of known CRK and CRKL interactors was generated by searching
the gene names in the IntAct (Orchard, Ammari et al. 2013) database. The “Interactors”
list was exported and lists of CRK/CRKL interactors were merged, removing duplicate
entries.
5.4.2. Reactome enrichment analysis, Metascape annotation, and amino acid
conservation.
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Reactome (Fabregat, Sidiropoulos et al. 2015), an open-source, manuallycurated database of biological pathways, was used to perform a pathway enrichment
analysis using protein accessions of interest, and to parse entries from the lists
described above. Statistically significant overrepresented Reactome pathways were
defined based on a false discovery rate multiple test correction of < 0.05. Metascape's
meta-analysis workflow (Tripathi, Pohl et al. 2015) was used to annotate UniProtKB
accessions from the eleven significantly overrepresented parent pathways from the
Reactome analysis (Supplementary File 2, PMCID: PMC6223376, DOI:
10.1093/bioinformatics/bty434). Ten of these eleven were pursued as relevant to our
interests (see Results section) and proteins within these groups which contained YXXP
motifs were extracted. Metascape produced one matrix annotated with unique
identifiers (NCBI Gene IDs, UniProt Accessions, UniProt IDs) and binary group
membership (1/0) for all 18 groups, which were then manually converted to point
values (Supplementary File 3, PMCID: PMC6223376, DOI:
10.1093/bioinformatics/bty434). Primary characteristics were given 3 points, while
secondary features were given 1 or 0.5 for empirical or predicted features, respectively,
the sum of which amounted to a given protein’s priority score. Identifiers from multiple
species from the input protein lists were converted to H. sapiens orthologs for both the
Reactome analysis and Metascape annotation. By default, Metascape converted input
identifiers to the specified organism (human) NCBI Gene IDs. Metascape also aided in
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the identification and elimination of duplicate/obsolete entries (Supplementary File 3A,
PMCID: PMC6223376, DOI: 10.1093/bioinformatics/bty434).
To assess conservation of motif-specific amino acid residues, protein sequences
of five representative vertebrates (H. sapiens, M. musculus, G. gallus, D. rerio, X.
tropicalis) were downloaded from UniprotKB and aligned using ClustalOmega
(Sievers, Wilm et al. 2011). Percent conservation was assessed for individual motifs
within a given sequence by the number of sequences with an aligned motif per total
sequence number. Total sequence number was five unless the protein was not
conserved in one of the above species. Conservation was calculated for each individual
motif within the human sequence. Additionally, the MGI database (Blake, Eppig et al.
2017) was queried for expression of high priority proteins in the developing murine
nervous system.
5.4.3. Materials
Penicillin/Streptomycin 100X solution and Dulbecco’s Modified Eagle Medium
(DMEM) were obtained from Mediatech (Manassas, VA, USA). Fetal bovine serum
(FBS) and cosmic calf serum (CCS) were purchased from Hyclone (Logan, Utah,
USA). The BSA standard for Bradford assays and the Bradford Reagent were obtained
from Amresco Life Sciences, LLC. (Cleveland, OH, USA). For the development of
Western blots, enhanced chemiluminescence (ECL) reagents were purchased from
Pierce (Rockford, IL, USA), and x-ray film was from Denville scientific (Metuchen,
NJ, USA). Nitrocellulose membranes were from GVS Life Sciences (Sanford, ME,
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USA). All additional reagents were purchased from Sigma (St. Louis, MO, USA)
unless otherwise noted.
5.4.4. Plasmids
The following mammalian expression constructs were used for transfection in
HEK 293 cells. The pFlag-CMV2-WBP2 was a gift from M. Sudol (Addgene #27478;
Cambridge, MA) (Chen, Einbond et al. 1997). C-terminal Flag- and Myc-tagged mouse
EPHA2, and human PDLIM5 and KIAA1143 constructs were obtained from Origene
(Cat. # MR226151, RC200592, and RC203327). C-terminal V5-tagged human TM192,
EMD, DAZ2, FLI1, and CAV1 in pLX304 vectors (HsCD00443748, HsCD442327,
HsCD00446629, HsCD00438298, and HsCD00434417) were obtained from the
DNASU Plasmid Repository (Tempe, AZ) (Cormier, Mohr et al. 2009, Yang, Boehm et
al. 2011, Cormier, Park et al. 2012, Seiler, Park et al. 2013). The human c-ABL
construct with a c-terminal Flag tag was kindly gifted by A. Howe (U. of Vermont),
originally constructed in the lab of D. Kufe. The bacterial expression plasmid encoding
the fusion of glutathione-S-transferase (GST) with the CRKL SH2 domain (GSTCRKL-SH2) was kindly gifted by A. Imamoto (U. of Chicago), as was the GFP- and
Flag-tagged CRKL (Li, Guris et al. 2003).
5.4.5. Antibodies
The mouse α-Flag (M2) antibody was acquired from Sigma and used at 0.5
µg/mL for Western blotting. The rabbit α-ABL Ab (K-12, 0.2 µg/mL) was from Santa
Cruz Biotechnology (Dallas, TX, USA). The α-Myc Ab (9E10; 1:1000) was from
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American Type Tissue Collection (Manassas, VA, USA). The α-V5 Ab (0.1 µg/mL)
was purchased from Rockland Immunochemicals, Inc (Limerick, PA). All primary
antibodies were diluted in 1.5% BSA in Tris-Buffered Saline (0.9% NaCl, 0.4% TrisHCl, 0.1% Tris-base) with 0.05% Tween 20 (TBS-T) and containing 0.005% sodium
azide. Horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained
from EMD Millipore and used at the following concentrations: goat α-mouse IgG-HRP
(200 ng/mL) and goat α-rabbit IgG-HRP (67 ng/mL). All secondary antibodies were
diluted in TBS-T.
5.4.6. Cell culture, transfection, inhibitors, stimulation, and cell lysis
E1A-transformed human embryonic kidney (HEK) 293 cells were cultured in
DMEM supplemented with 5% each of FBS and CCS, 50 U/mL penicillin, and 50
μg/mL streptomycin at 37 ˚C in 5% atmospheric CO2. HEK 293 cells were grown to
60% of confluence prior to transfection via calcium phosphate precipitation. All
plasmids were transfected at 5 µg per 10 cm dish, with the exception of c-ABL (2
µg/dish), DAZ2 (8 µg/dish) and FLI1 (2.5 µg/dish). Six hours post-transfection, cells
were washed with phosphate-buffered saline (PBS) and returned to full medium
overnight before lysis. Cells were placed on ice immediately following H2O2
stimulation and washed with PBS (4 ˚C) prior to lysis in Brain Complex Lysis Buffer
(BCLB: 25 mM Tris pH 7.2, 137 mM NaCl, 10% glycerol, 1% igepal, 25 mM NaF, 10
mM Na2H2P2O7, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10
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µg/mL each leupeptin and pepstatin-A). Lysates were centrifuged and the supernatant
was reserved and stored at -20 ˚C.
HEK 293 cells were grown to 60% of confluence prior to transfection via
calcium phosphate precipitation. The following amount of plasmid was transfected per
10 cm dish: wild type and mutant DCBLD1 and DCBLD2 (6 µg), wild type FYN (1.5
µg), kinase-dead FYN (2.5 µg), and wild type c-ABL (2 µg). Six hours posttransfection, cells were washed with phosphate-buffered saline (PBS) and returned to
full medium overnight before lysis.
5.4.7 GST-CRKL-SH2 pull-down assay, SDS-PAGE, and Western blotting
Glutathione S-transferase (GST)-CRKL-SH2-conjugated glutathione beads as
described previously (Schmoker, Weinert et al. 2017). Pull-downs and whole cell
lysates were separated on 10% acrylamide gels (30% w/v and 37.5:1 acrylamide:bisacrylamide) with 4.2% acrylamide stacking gels. Current was maintained at 20 mA and
30 mA per gel through the stacking and separating layers, respectively. Following
separation, proteins were either transferred to a nitrocellulose membrane for Western
blotting or stained with Coomassie for mass spectrometric analysis. Transfers to
nitrocellulose membranes were in a submersible transfer unit at 4 ˚C (400 mA for 2
hours) in 1.13% glycine, 0.25% Tris-base and 20% methanol. Membranes were stained
with a reversible Ponceau stain (0.5% Ponceau and 1% acetic acid in H2O) to assess
total protein levels and were then blocked with 0.5% non-fat dry milk in TBS-T.
Primary antibody solutions were incubated overnight at 4 ˚C. Membranes were then
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washed three times with TBS-T and incubated with HRP-conjugated secondary
antibody solution for three hours at 25 ˚C. After three final washes in TBS-T,
membranes were briefly incubated in ECL reagents and exposed to x-ray film.
5.5. Results
5.5.1. In silico motif-based proteomics screen
To formulate a generalizable workflow for prioritizing PTM-dependent
domain/motif interactions, we considered important characteristics of known domain
interactors. We extracted all motif-containing proteins from the proteome-of-interest
and then further focused the screen into a central bullseye defined by primary
characteristics (Figure 28).
First, we hypothesized that a sequence enriched in a particular domain-docking
motif would, if properly modified, have a higher probability of interacting with that
domain. This could facilitate multiple interactions simultaneously, allowing rapid signal
propagation and increasing overall avidity. We conducted a motif enrichment analysis
of the human proteome for the CRK/CRKL-SH2 binding motif. A Scansite query
against the SwissProt database for all human proteins containing at least one YXXP
yielded 9,297 sequences (9,153 unique proteins) (Supplementary File 1, PMCID:
PMC6223376, DOI: 10.1093/bioinformatics/bty434). Figure 29A shows the binary
logarithmic distribution of YXXP count per AA number for all human sequences
(Supplementary File 1, PMCID: PMC6223376, DOI: 10.1093/bioinformatics/bty434).

219

A total of 225 unique proteins fell two standard deviations above the mean and were
extracted as the “Enriched” list.

Figure 28. A tripartite bullseye defines high priority targets.
From the entire proteome of the organism of interest, all motif-containing proteins are extracted.
Candidate interactors are focused by the following characteristics: (A) proteins enriched in the
motif-of-interest (Scansite), (B) proteins with confirmed experimental identifications of the PTMmotif (PhosphoSitePlus), and (C) motif-containing proteins that participate in enriched pathways
of A and B (Reactome).

We next reasoned that proteins empirically shown to be highly phosphorylated
in pYXXP motifs would be strong candidate CRK/CRKL-SH2 interactors, and that
such proteins would not necessarily be YXXP-enriched and, therefore, would only
partially overlap with our “Enriched” list. We extracted all proteins with experimentally
identified pYXXP using PhosphoSitePlus and constructed a distribution of the total
number of pYXXP identifications per protein (Figure 29B). Only the top ranking 700
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of the 2086 total pYXXP proteins are shown. Of these, 289 proteins fell above the
mean and were extracted as the “pYXXP” list.
The most evident requirement for CRK/CRKL-SH2 interactors is the possession
of pYXXP motifs; indeed, known interactors often harbor multiple phosphorylated
motif occurrences. CAS1 (also BCAR1; Figure 29A,B), a prominent scaffolding
protein in focal adhesions, harbors 16 YXXP motifs within 870 AAs. PhosphoSitePlus
has curated phospho-identifications of 15 CAS1 YXXP sites through high-throughput
methods, as well as CAS1 site-specific evaluations of 13 of these. Signaling
mechanisms, including adhesion-regulated SFK-induced YXXP phosphorylation of
CAS1 (Hamasaki, Mimura et al. 1996, Sakai, Nakamoto et al. 1997, Sharma and Mayer
2008), induce binding of the CRK/CRKL-SH2 domain, bringing CRK/CRKL-SH3bound cargo (e.g. C3G or DOCK180) to the CAS1-associated complex to alter cell
adhesion/migration.
However, only one pYXXP motif is required for a CRK/CRKL-SH2
interaction, and an enrichment assumption would fail to identify proteins such as DAB1
(two YXXP per 588 AAs). Expressed primarily in the embryonic brain, DAB1 is a
SFK-mediated CRK/CRKL-SH2 interactor downstream of Reelin (Arnaud, Ballif et al.
2003, Bock and Herz 2003, Ballif, Arnaud et al. 2004). While DAB1 tyrosine
phosphorylation is essential for proper neuronal positioning (Howell, Herrick et al.
2000), DAB1 is poorly represented in high-throughput proteomic studies, as the
majority of studies are not conducted with embryonic brain tissue. PhosphoSitePlus
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cites 3,929 total pYXXP identifications of the ubiquitously-expressed BCAR1, while
DAB1 has only 18 identifications. Thus, poor discovery-based identifications of
YXXP-containing DAB1-like molecules might lead us to disregard them as high
priority potential CRK/CRKL-SH2 interactors.

Figure 29. Formation of the tripartite bullseye of YXXP-containing proteins.
A) Binary logarithmic distribution of the number of YXXP sites per AA. Proteins that fell two
standard deviations above the mean were taken as the “Enriched” group. B) Number of pYXXP
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experimental confirmations (sum low- and high-throughput) per protein (PhosphoSitePlus). All
proteins above the mean were taken as the “pYXXP” group. C) “Enriched” and “pYXXP”
proteins (493 Uniprot Accessions mapped to 475 NCBI Gene IDs) were subjected to a Reactome
pathway analysis to extract enriched pathways. All YXXP-containing proteins in significantly
enriched pathways (FDR <0.05) were extracted as the “Enriched Pathways” list. Venn diagrams
show overlap of proteins in the Reactome input and enriched parent pathways with all human
YXXP-containing proteins. Populations of overlapping sections are given in the subplots.
Populations of the tripartite bullseye overlap (center) reflect identifiers post-Metascape conversion.

In consideration of ways that DAB1-like proteins might emerge as high priority
candidates, we hypothesized that proteins in PPI networks with known pYXXP
substrates might have a higher probability of getting phosphorylated by an active
YXXP-directed kinase. This would therefore increase their likelihood of becoming
CRK/CRKL-SH2 binding partners. Corwin et al. demonstrated clustering of tyrosine
kinase substrates within PPI networks when expressing human non-receptor tyrosine
kinases in yeast (Corwin, Woodsmith et al. 2017), and similar results have been
demonstrated in human PPI networks (Beltrao, Albanèse et al. 2012, Woodsmith,
Kamburov et al. 2013, Duan and Walther 2015). These studies suggest that members of
protein complexes within close proximity to a kinase have a high probability of getting
phosphorylated simultaneously, and that proteins generally co-participating in signaling
networks are more likely to be substrates of the same kinase. Therefore, we also
considered proteins within PPI networks of the enriched YXXP-containing protein list
as well as the PPI networks of the list of proteins with greater than average pYXXP
identifications as a primary feature.
To incorporate the PPI network aspect of the tripartite bullseye, “Enriched” and
“pYXXP” proteins were combined to a single list that was input to Reactome.org. Of
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these 475 proteins, 288 mapped to the Reactome database and were used for a pathway
enrichment analysis. Pathway enrichment results recovered 25 significantly overrepresented pathways (FDR <0.05) (Supplementary File 2, PMCID: PMC6223376,
DOI: 10.1093/bioinformatics/bty434). Eleven overrepresented pathways were parent or
higher-level pathways. Parental pathways were assessed for overlap with the list of all
YXXP-containing proteins in the human proteome (Figure 29C). The higher-level
“Developmental Biology” pathway (1,080 proteins) was deemed too broad for practical
analysis. Extracted proteins from the remaining ten pathways were combined to form
the “Enriched Pathways” list (492 proteins). Notably, the “Axon Guidance” pathway
extracted DAB1 as a member of this group, as well as 292 other YXXP-containing
proteins that were neither found to be enriched in YXXP motifs nor identified as highly
phosphorylated (Figure 29C). The intersection of the resulting tripartite bullseye
included four central proteins (CRKL, DOK1, DOK2, SHB) and 97 possessing at least
two primary characteristics. To further prioritize, we considered a series of secondary
characteristics. Secondary characteristics will be based strongly on the unique goals of
investigative teams, however, our approach exemplifies the process.
Given our priorities in developmental cell motility-related signaling and the
importance of SFKs/ABL in these processes, all known pYXXP substrates of
Abl/SRC/FYN were obtained from PhosphoSitePlus using the “Substrates of:” search
tool (Supplementary Methods). Scansite-predicted pYXXP substrates of SRC/ABL
were extracted and narrowed to top-scoring proteins, and known CRK/CRKL
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interactors were extracted from the IntAct database (Supplementary Methods). The
total number of proteins in each group was calculated for the 8,887 YXXP-containing
proteins previously defined in the Metascape-annotated matrix. Non-unique identifiers
were removed and proteins were scored by the sum of weights (Table 8) applied via
each primary or secondary feature (Supplementary File 3, PMCID: PMC6223376, DOI:
10.1093/bioinformatics/bty434).
Table 8. Scoring system for primary and secondary characteristics.
Webtools and databases used to annotate YXXP-containing proteins for each characteristic are
listed, along with stringencies and assigned weights. All primary characteristics were weighted
equally. Secondary characteristics were given 1-pt if experimentally determined, while predictive
features were awarded 0.5-pt. The star (*) indicates features for which weights were potentially
awarded multiple times for a given protein, as these were summed for each kinase separately.
Weights summed across all primary/secondary characteristics for a given protein to obtain its
Priority Score (Figure 30B).

To determine the relative importance of primary and secondary characteristics
in their predictive power, the distribution of priority scores of 25 known CRK/CRKLSH2 interacting proteins were considered when various combinations of these
predictive features were considered (Figure 30A; Supplementary File 3, PMCID:
PMC6223376, DOI: 10.1093/bioinformatics/bty434), demonstrating the effective
clustering of positive controls in high-scoring regions. In addition, we assessed the
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enrichment of these known interactors within each category of interest in comparison to
the total number of proteins in a given category (Figure 30B). We then compared these
enrichment indexes to those achieved in high-scoring regions when considering the
prioritization scheme (“All, score ≥6/8” in Figure 30B). Proteins scoring ≥8 were
primarily positive controls (~80% of the total) and, therefore, novel interactors within
that scoring region would be highest-priority candidates for biochemical validation.
However, we expanded our region of interest to encompass scores ≥6 to capture the top
~1% of all YXXP-containing proteins (Figure 30C) in order to, reasonably, capture
less-studied proteins. Notably, both scoring regions effectively enriched positive
controls more so than each characteristic alone or primary characteristics in
combination (Figure 30B). Surprisingly, consideration of known SRC/FYN/ABL
substrates alone enriched positive controls more effectively than any other
characteristic alone. However, we maintained this feature as a secondary characteristic
as it could present considerable bias in favor of identifying well-characterized proteins
if weighted as a primary feature.
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Figure 30. Validation of primary and secondary characteristics and prioritization of potential
CRK/CRKL-SH2 interactors.
A) Chosen primary (“Enriched YXXP”, “Phospho-YXXP”, “Enriched Pathways”) and secondary
(“CRK/CRKL interactors”, “Predicted Kinase Substrates”, “Known Kinase Substrates”)
characteristics were compared for their ability to prioritize known CRK/CRKL-SH2 interactors
using the scoring system summarized in Table 8. The percent of positive controls scoring ≥6 and 8
are shown to the right of each histogram. Four known interactors (INPP5D (SHIP-1), DCBLD1,
FLT4 (VEGFR-3), and ZAP70) remained with priority scores below 6. B) Each primary and
secondary characteristic is considered for its ability to enrich for CRK/CRKL-SH2 interactors.
The “Enrichment Index”, defined as the percentage of positive controls relative to all YXXPcontaining proteins, is plotted for each characteristic separately, as well as for combined primary
characteristics. These enrichment indexes are compared to scoring regions of interest (in bold)
when all characteristics are considered as outlined in Table 8. C) All YXXP-containing proteins
were scored by weighted primary and secondary features, as described in the Methods. The y-axis
for priority scores 3.5–11.5 is magnified in the inset. Proteins validated biochemically (Figure 31)
are indicated by gene symbol and are either black (induced to bind) or red (no interaction). (A, C)
Percentage of positive controls scoring ≥6 and 8 are compared to all YXXP-containing proteins,
highlighting the concentration of known CRK/CRKL-SH2 interactors in high-scoring bins

227

(binwidth = 0.5). (D) All proteins that emerged with a priority score >6.5 are tabulated. Known
CRK/CRKL-SH2 interactors are shown in bold.

The distribution of priority scores for all YXXP-containing proteins is shown in
Figure 30C. Proteins chosen for biochemical validation in a pulldown assay are
indicated in either black (confirmed CRKL-SH2 interactors) or red (no interaction).
Top-scoring proteins (>6.5) are displayed in Figure 30D, with known CRK/CRKL-SH2
interactors highlighted in bold font.
5.5.2. Biochemical validation: identification of novel CRKL-SH2 interactors.
For biochemical validation, we chose ten proteins (Figure 30C) to test in a
CRKL-SH2 pulldown assay following co-expression with c-ABL. In addition to
choosing several high-scoring proteins, we chose one protein with a low priority score
(FLI1) and one highly enriched in YXXP sites but with few pYXXP identifications
(DAZ2). In candidate selection, we also considered proteins with strong YXXP
conservation across vertebrates and those expressed in the developing nervous system
(MGI). cDNA constructs of selected candidates were expressed in HEK293 cells with
or without c-ABL. While not a suitable kinase for all YXXP tyrosines, c-ABL was
selected for its robustness and high selectivity for YXXP substrates (Ballif, Carey et al.
2007, Colicelli 2010). Cell lysates were incubated with GST-CRKL-SH2 resin and
following washing, bound protiens were subjected to SDS-PAGE and immunoblotting.
Figure 31 shows immunoblots of pulldown assays alongside schematics of each protein
tested, which display domain structure, YXXP location, experimental pYXXP
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identifications, and percent motif conservation. For reference, similar schematics for
select positive controls are summarized in Figure 54.
To demonstrate the potential limitations of solely considering YXXP-enriched
proteins, we compared the CRKL-SH2 binding ability of DAZ2 (15 YXXP, 558 AAs),
a spermatogenesis-related protein (Reijo, Lee et al. 1996), to that of FLI1 (3 YXXP,
452 AAs) which is implicated in cell growth and malignancy (Truong and Ben-David
2000). While highly YXXP-enriched, DAZ2 was not an obvious CRK/CRKL-SH2
interactor for several reasons. The Y-chromosomal DAZ genes (DAZ1–4), common
only to higher primates, possess 1–15 repeats of a 24-AA polymorphic sequence.
Conservation of these repeats implies important functionality, however, only six
possess a YXXP motif (Fu, Cheng et al. 2015), suggesting that this motif is not
essential to the conserved repeat function. Furthermore, DAZ2 had no other primary or
secondary features to suggest it might interact with the CRK/CRKL-SH2 domain. Our
biochemical analysis found that c-ABL co-expression did not induce DAZ2 to bind the
CRKL-SH2 domain (Figure 31A). While it is formally possible that another tyrosine
kinase with a YXXP target preference (Figure 53, Table 19) can phosphorylate DAZ2,
it is important to note that a protein with 15 target motifs cannot be induced spuriously
to bind the CRKL-SH2 domain by co-expressing a kinase with a strong YXXP-target
preference.
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Figure 31. Domain structure, YXXP conservation, and GST-CRKL-SH2 pulldowns of tested
candidates.
Mammalian expression vectors were introduced to HEK293 cells with/without c-ABL-Flag. GSTCRKL-SH2 pulldown assays were performed on cell extracts. Ponceau staining indicates relative
GST-CRKL-SH2 levels. Immunoblotting was conducted with the indicated antibodies. Candidate
domain structure and YXXP sites are shown with their corresponding blots. Percentages denote
conservation of YXXP across five representative vertebrates, with two exceptions. DAZ2 is specific
to higher primates; therefore, conservation could not be assessed across multiple vertebrate taxa.
EMD was not found in G. gallus; therefore, percentage values reflect conservation across only four
vertebrates. The number of experimental pYXXP identifications (if >5) are given at the indicated
tyrosine residue (PhosphoSitePlus).
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Although FLI1 is not YXXP-enriched, it does possess one YXXP site with 26
pTyr identifications. Still, this fell below the average pYXXP number per protein and,
with no score from any primary or secondary feature, FLI1 received a priority score of
zero (Figure 30C). Mechanistically, FLI1 has been shown to block erythropoietininduced differentiation and promote erythroblast proliferation, however, the signaling
mechanisms involved remain unknown (Pereira, Quang et al. 1999, Tamir, Howard et
al. 1999). FLI1’s involvement in CRK/CRKL-related processes and expression in the
developing nervous system (MGI) led us to investigate its CRKL-SH2-binding ability.
Surprisingly, FLI1 was induced to bind the CRKL-SH2 domain when co-expressed
with c-ABL (Figure 31A), suggesting this interaction may be important in FLI1
signaling to modulate its roles in cell proliferation, differentiation or transformation.
We next chose to test two high-scoring proteins that are expressed in the
developing nervous system, WBP2 and CRKL itself. WBP2 was the most YXXPenriched protein identified, possessing 11 YXXP motifs within 261 AAs, but with
motifs showing variable conservation across vertebrates (20-100%). WBP2 is a
coactivator of the estrogen receptor (ER) (Dhananjayan, Ramamoorthy et al. 2006) and
mediates cell proliferation/differentiation associated with breast cancer by regulating
ER target gene expression (Buffa, Saeed et al. 2013). WBP2 is phosphorylated on
YXXP Tyr192 and Tyr231 by SRC and Yes downstream of EGF, and overexpression
in mice induces ER-dependent and independent loss of cell adhesion and increased
tumor proliferation/invasion (Lim, Orhant-Prioux et al. 2011). Figure 31B displays the
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GST-CRKL-SH2 pulldown, demonstrating ABL-induced binding of WBP2. Currently,
we are working to determine signaling pathways in which a WBP2/CRKL interplay
makes a contribution.
Intriguingly, CRKL is highly enriched with five strongly conserved YXXP
motifs (within 303 AAs). Three sites have been found phosphorylated >100 times, with
pTyr207 possessing 1,212 identifications (Figure 31B), however, the functional
significance has not been fully analyzed. The analogous CRK Tyr221 has been
characterized to be part of a negative-regulatory intramolecular pTyr221/CRK-SH2
interaction, which prevents intermolecular CRK-SH2/pTyr and CRK-SH3/PXXPXK
interactions (Chodniewicz and Klemke 2004). While a similar mechanism is presumed
for CRKL Tyr207, this remains to be demonstrated. Additionally, CRKL pTyr207 or
other sites might facilitate intermolecular dimerization, as has been demonstrated for
CRK (Feller, Knudsen et al. 1994). To test this, we conducted our pulldown on extracts
from cells co-expressing c-ABL and CRKL, and found that ABL induced a
CRKL/CRKL-SH2 interaction (Figure 31B).
Additional proteins tested are shown in Figure 31C–E. We observed ABLinduced CRKL-SH2 binding of TMEM192, EMD, PDLIM5, KIAA1143, and CAV1.
However, neuronally-expressed EPHA2 (MGI), with a high pYXXP count on
conserved motifs, did not interact with CRKL-SH2 when co-expressed with c-ABL
(Figure 31D). EPHA2 regulates cell migration, adhesion, and differentiation (Miao, Li
et al. 2009, Lin, Gordon et al. 2010) and is required for proper lens organization in mice
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(Cheng, Ansari et al. 2013). Despite these signature CRKL-SH2-interactor
characteristics, EPHA2 was not induced to bind, although it is possible that
pTyr588/pTyr594 are not ABL-induced. Together these data validate an ABL-mediated
interaction between the CRKL-SH2 domain and several proteins identified from our
screen.
5.5.3. Application to the methylated RG motif: a proof-of-principle
Figure 55 summarizes the in silico screen in a stepwise workflow that includes a
generalized approach alongside examples from our CRKL-SH2 screen. As a proof-ofprinciple, we applied this screen to a different modification-dependent interaction,
namely, those facilitated by arginine methylation in RG motifs (MeRG). RGG/GRG
motifs are the preferred targets of many PRMTs, inducing protein-protein/nucleic acid
interactions (Thandapani, O’Connor et al. 2013, Blanc and Richard 2017). To date, the
Tudor domain is the only known MeArg-binding domain, however, many PPIs are
mediated through MeRG motifs, suggesting that additional MeArg-binding domains
remain undiscovered. Figure 56 shows the formation of the tripartite bullseye from all
human RG-containing proteins, using the same databases and approach outlined in
Figure 55. The results had a generally similar profile to our YXXP analysis (Figure 56;
Supplementary File 4, PMCID: PMC6223376, DOI: 10.1093/bioinformatics/bty434).
These primary characteristics successfully focused known Tudor interactors and PRMT
substrates into the central bullseye (Supplementary File 4C, PMCID: PMC6223376,
DOI: 10.1093/bioinformatics/bty434). Among these were SMD3, which, along with its
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homolog SMD1 (“Enriched”/“MeRG” overlap), binds the Tudor domain of SMN
(Friesen, Massenet et al. 2001), and Sam68, a MeRG-dependent SND1-Tudor
interactor (Cappellari, Bielli et al. 2014). Another important SMN-Tudor interactor,
GAR1 (Whitehead, Jones et al. 2002), emerged in the overlap of the enriched RG and
enriched pathways groups. This provides a strong foundation for the application of
appropriate secondary characteristics, prioritization, and biochemical validation.
5.5. Discussion and Conclusions
Here, we present a generalized in silico proteomics screen that utilizes publiclyavailable databases/tools to predict and prioritize domain-motif interactions. Using the
CRK/CRKL-SH2-pYXXP interaction as an example, we successfully identified
potential interactors with a priority-scoring system using signature CRKL-SH2interactor characteristics, employing curated PTM data, PPI networks, and the
molecular/cellular roles of CRK/CRKL in the developing nervous system. Alongside
other known CRK/CRKL-SH2 interactors, our positive controls emerged with high
priority scores (Figure 30A–C; Supplementary File 3, PMCID: PMC6223376, DOI:
10.1093/bioinformatics/bty434).
In spite of the demonstrated success of our approach, it presents certain
limitations. Although we successfully identified the critical CRK/CRKL interactor
DAB1 using the pathway enrichment data, and possibly other DAB1-like molecules not
enriched in YXXP motifs or with few pYXXP identifications, not all such proteins
would be readily detected. Proteins that are not characterized in PPI networks at the
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gene ontology level could continue to receive low priority scores. However, as new
information populates the databases/tools employed here, relevant but obscured
proteins will increase their priority scores. If identified as direct CRK/CRKL-SH2
interactors in proteomics screens, the in silico screen would be less important.
However, if proteins emerge as general CRK/CRKL interactors, are placed in
CRK/CRKL-related networks, or are identified experimentally with high pYXXP
counts in a new tissue-type, then their priority scores will increase in a future repetition
of the screen. This could be the fate of proteins such as FLI1, which received no points
and bound the CRKL-SH2 domain in ABL-active conditions. These points represent a
bias toward well-characterized proteins and those upregulated in cancer cells, from
which the bulk of available proteomics data is composed. However, it is argued that our
in silico approach provides a strong user-friendly companion to directed proteomics
screens.
While we chose to include all YXXP-containing proteins within enriched
Reactome pathways as a primary characteristic, researchers could further narrow their
screen by choosing enriched pathways that are of relevance to their area of study. Such
an approach would allow focus on a biological pathway of interest, rather than all
enriched pathways.
Motif conservation and tissue-specific expression were taken into account postscoring, however, these could be included as weighted secondary characteristics in a
future iteration. We attempted to integrate AL2CO conservation analysis (Pei and
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Grishin 2001), but found it was not easily amenable to bulk analysis of motif
conservation across our chosen taxa. Motif count per protein would be an acceptable
proxy for evolutionary conservation, and we conducted this for YXXP motifs within
mouse and zebrafish using a Scansite query (Supplementary File 3, PMCID:
PMC6223376, DOI: 10.1093/bioinformatics/bty434). While certain challenges were
encountered in mapping non-human protein identifiers to human (Supplementary File
3, PMCID: PMC6223376, DOI: 10.1093/bioinformatics/bty434), these will be less of
an issue as proteomes of other organisms become more comprehensive.
Binding motif surface accessibility is another attractive secondary feature to
consider, as it would theoretically weight likely PPI surfaces. We sought to include this
as a weighted characteristic, however, upon reviewing the currently available surface
accessibility prediction software in their ability to predict exposure of well
characterized phosphorylated-YXXP motifs within known CRKL-SH2 interactors, we
found that many of these tyrosine residues were predicted to be buried. Further, we did
not find programs that would accommodate batch searches of ~9,000 sequences. For
these reasons, we concluded that our phospho-YXXP dataset was sufficient to represent
this aspect in our screen. However, this has limitations including when motifs remain
hidden due to partial protein coverage when using bottom-up proteomics with common
proteolytic enzymes such as trypsin. Additionally, protein expression/motif
modification in specific tissues/environments that are under-sampled will leave some
modifications hidden.
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We employed expression databases to determine whether high-scoring proteins
were expressed in our tissues of interest. We used the MGI database to query
expression levels in mice, which is easily focused to a tissue/developmental stage of
choice. Attempting to include tissue-of-interest expression as a secondary feature, we
mapped mRNA expression in the embryonic nervous system to our protein list using
the MGI mouse-to-human identifier conversion tool. However, we encountered issues
in the conversion of unconserved genes, such as dazl, which mapped to DAZ2 in our
data set. DAZ2, specific to higher primates, is only expressed in the male germline;
therefore, we restricted prioritization based on expression data to a case-by-case search
applied to high-scoring candidates from the initial screen.
The databases used here are generally applicable to domain/motif interactions
with post-translationally modified proteins, including PTMs beyond phosphorylation.
With our approach, and potentially the inclusion of additional generalized and specific
PTM databases/predictive tools for primary/secondary characteristics (Chen, Huang et
al. 2017), we anticipate that non-specialists can easily employ this strategy, using in
silico proteomics to unveil the identities of novel proteins relevant to specific biological
mechanisms of signal transduction. We anticipate this screen will be an important,
rapid first step to assist investigators in identifying top candidates warranting
biochemical and genetic examination in the signaling systems they are studying.
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CHAPTER 6: PERSECTIVES AND FUTURE DIRECTIONS
DCBLD proteins are type-I transmembrane scaffolding receptors with known
roles in cellular processes governing development and disease, including cell
proliferation, migration, and growth (Schmoker, Ebert et al. 2019). Although their
expression levels affect these cellular phenotypes in ways that are strongly dependent
upon the cellular environment, the molecular mechanisms by which DCBLD proteins
modulate these processes are not well understood.
The work presented in this dissertation focuses mainly on delineating how
DCBLD family members function as scaffolds in CRK-related signaling and deepens
our molecular understanding of DCBLD2 involvement in receptor tyrosine kinase
signaling. Further, it presents a bioinformatics-based screening system that predicts
protein-protein interactions that are important to signaling complex formation, which
may be easily applied by the signaling community to any biological system of interest.
A discussion of this work follows.
6.1. Insights into DCBLD protein phosphorylation and interacting partners
The majority of work presented in this dissertation focuses on elucidating
intracellular signaling events involving DCBLD proteins in the presence of elevated coexpression levels and/or activation of tyrosine kinases, including the cytoplasmic
kinases ABL and FYN, as a representative SFK, and later the receptor tyrosine kinases
PDGFRβ and INSR. Signaling events downstream of RTK activation are initiated by
the RTK ligands, the main ligands investigated in this work being PDGF-BB and
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insulin. However, studies involving FYN and ABL, directly, were carried out in the
absence of an extracellular instigator. FYN and ABL are known to be activated
downstream of PDGFRβ and INSR (Plattner, Kadlec et al. 1999, Lu, Zhu et al. 2009,
Zhang, Fan et al. 2017), as well as other RTKs, and therefore it is conceivable that
these signaling events could be activated following RTK/ligand interactions. It also is
possible that overexpression alone, either of DCBLD proteins or either FYN or ABL,
such as in cancer or in certain cellular environments in development, could lead to
kinase activation and induction of the signaling events discussed in the following
sections.
There is also evidence to suggest that DCBLD2 can function as an autonomous
receptor for an as-of-yet unknown extracellular ligand. We have previously shown that
treating cells expressing DCBLD2 with an antibody to the DCBLD2 ectodomain, in
effect clustering multiple DCBLD2 molecules, induces DCBLD2 tyrosine
phosphorylation (Aten, Redmond et al. 2013). This could occur, for example, by a
constitutive interaction between DCBLD2 and a SFK inside the cell. Receptor/ligand
binding could cluster multiple SFKs, allowing trans-activation and phosphorylation of
DCBLD2 and other downstream targets, such as ABL.
The following sections review and discuss DCBLD receptor-proximal
intracellular signaling events.
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6.1.1. The DCBLD/CRKL-SH2 interaction
DCBLD2 was first identified as a SFK-regulated interactor of the CRKL-SH2
domain in a proteomics screen conducted in our laboratory in 293 cells (Aten,
Redmond et al. 2013). This work characterized the DCBLD2/CRKL-SH2 interaction as
SFK- and, more specifically, FYN-dependent and demonstrated that the FYN-SH2
domain could interact with DCBLD2 phosphotyrosine residues (Aten, Redmond et al.
2013). Further, this work demonstrated that DCBLD2 tyrosine residues within the
CRKL-SH2 binding motif, pYXXP, were critical to this interaction, and suggested that
the DCBLD2/CRKL-SH2 interaction is direct and occurs through multiple pYXXP
interfaces (Aten, Redmond et al. 2013).
From this original characterization of the DCBLD2/CRKL-SH2 interaction, it
was apparent that another tyrosine kinase expressed in 293 cells was likely involved in
regulating the DCBLD2/CRKL-SH2 interaction. The cytoplasmic tyrosine kinase ABL
is a known CRK and CRKL collaborator in multiple signaling pathways (Birge,
Kalodimos et al. 2009) and is strongly directed to substrate tyrosines in YXXP motifs.
In Chapter 2, we demonstrate that ABL is capable of inducing the DCBLD2/CRKLSH2 interaction, as is FYN (Schmoker, Weinert et al. 2017).
In addition, we investigated the ability of DCBLD1 to interact with the CRKLSH2 domain, given that the DCBLD1 intracellular sequence houses eight potential
CRKL-SH2 docking sites. Although FYN strongly induced the CRKL-SH2 domain to
interact with DCBLD2, it did not induce an interaction with DCBLD1. Interestingly,
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ABL was a strong driver of the DCBLD1/CRKL-SH2 interaction (Schmoker, Weinert
et al. 2017).
These findings have interesting implications for signaling involving these
interactions. FYN and ABL are both expressed in most cell types, but each exhibit
higher expression levels in different tissues. FYN is highly expressed in the brain, while
ABL is highly expressed in muscle tissues. Interestingly, DCBLD1 is more
ubiquitously expressed than DCBLD2 at low levels, but is enriched in muscle tissues,
while DCBLD2 is enriched in the brain (www.proteinatlas.org, (Uhlén, Fagerberg et al.
2015)). Differential expression of these kinases alongside DCBLD proteins could affect
interactions modulated by FYN/ABL (more below).
Treatment of cells expressing DCBLD2 and PDGFRβ with PDGF-BB also
induced a YXXP-dependent interaction between DCBLD2 and the CRKL-SH2 domain
(Chapter 4). Although insulin-mediated INSR activation did not induce CRKL-SH2
binding, it did induce subtle phosphorylation of CRKL-SH2 docking sites, suggesting
that a DCBLD2/CRKL-SH2 could occur, even if not detectable by Western blotting
(Chapter 4). Further investigation into the function of this interaction downstream of
PDGFRβ/INSR activation are required. Conceivably, the biological outcomes of CRK
adaptor membrane recruitment would differ depending on the cellular environment, as
the CRK/CRKL-SH3 interactions are constitutive and therefore depend largely on
expression levels of various SH3 interactors.
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Notably, the DCBLD/CRKL-SH2 interactions have been identified using
multiple experimental approaches. In addition to pulldown assays in overexpression
systems, three separate immunoprecipitations of DCBLD1 and DCBLD2 identified
endogenous CRK and CRKL bound to both family members in a SILAC proteomics
screen (Chapter 3). Endogenous DCBLD2 was also identified in a functional
proteomics screen of CRK-SH2 and CRKL-SH2 interactors in a mouse neuronal cell
line (Neuro2A, or N2A), described in Appendix A, simulating the initial CRKL-SH2
interactor screen in 293 cells (Aten, Redmond et al. 2013). The DCBLD/CRK(L)
interaction is can be detected in multiple cellular environments using both DCBLD
proteins and CRK adaptors as bait. This interaction can be induced by activation of
multiple kinases and occurs at high abundance, given its identification using multiple
LC-MS/MS approaches, suggesting that it is a common occurrence in tyrosine kinase
signaling involving DCBLD proteins.
6.1.2. Control of DCBLD1 and DCBLD2 phosphorylation
In Chapter 2, we use multiple quantitative approaches of targeted mass
spectrometry to identify and quantify phosphorylation of DCBLD proteins when coexpressed with FYN or ABL, and when endogenous kinases were activated after
treating cells expressing DCBLD proteins with SFK or ABL inhibitors. This first study
was specifically focusing on phosphorylation within CRK(L)-SH2 binding motifs,
pYXXP. We were able to quantify phosphorylation of three YXXP tyrosines on both
DCBLD proteins (DCBLD1 Y589, Y600 and Y621and DCBLD2 Y565, Y621, and
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Y750), as well as the non-YXXP DCBLD2 Y715, which we found highly
phosphorylated. As we observed with the CRKL-SH2 interactions, ABL was the
primary driver of DCBLD1 tyrosine phosphorylation. While both FYN and ABL could
induce phosphorylation of DCBLD2 tyrosines, they interestingly exhibited both
overlapping and distinct preferences for DCBLD2 tyrosines (Schmoker, Weinert et al.
2017). It would be interesting to determine whether cellular phenotypes resulting from
DCBLD2 phosphorylation at FYN- versus ABL-directed sites differ. A comparison of
cell migration, proliferation, and growth resulting from expression of DCBLD2
constructs possessing tyrosine-to-phenylalanine mutations at FYN- versus ABLdirected sites could be carried out in future studies.
In Chapter 3, we took a more comprehensive approach using a double enzyme
digest that allowed us to identify and quantify the majority of YXXP tyrosine
phosphorylation sites that remained hidden in the Chapter 2 analysis, due to their
presence in tryptic peptides that were not easily observed from a tryptic digest, alone.
Using this approach, we were able to quantify all eight DCBLD1 YXXP tyrosines, and
six out of seven DCBLD2 YXXP tyrosines (pY732 was not identified). Interestingly,
no DCBLD1 non-YXXP tyrosines were identified phosphorylated in the presence of
ABL, although ABL is known to be strongly directed toward YXXP tyrosine
substrates. As in our previous analysis, DCBLD2 Y565 was strongly FYN-directed, as
was Y569. Phosphorylation at either Y663 or Y666 was also induced when FYN was
co-expressed, however, no distinct fragment ions were observed that could distinguish
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between phosphorylation at either site. DCBLD2 Y649, Y677, and Y750 were more
strongly ABL-directed. From the results of the CRKL-SH2 binding assays and
phosphorylation data reported in Chapter 2, FYN was not considered as a potential
driver of DCBLD1 phosphorylation, and phosphopeptides containing all eight YXXP
sites were identified when ABL was co-expressed.
We were surprised to find not only tyrosine phosphorylation sites changing
upon FYN or ABL co-expression, but also serine and threonine phosphorylation sites
(Chapter 3). Activation and/or co-expression of these cytoplasmic kinases either
directly or indirectly affect DCBLD phosphorylation and protein interactions (discussed
below), and therefore are important regulators of signaling involving DCBLD proteins,
as they affect protein complex formation at DCBLD scaffolds.
In Chapter 4, we demonstrate that ABL directly phosphorylates DCBLD2
tyrosine residues, although further investigations are required to determine whether
these are strictly YXXP tyrosine residues, or whether ABL can phosphorylate the nonYXXP tyrosines identified in our LC-MS/MS studies. We also demonstrated direct
phosphorylation of DCBLD2 by PDGFRβ. Given the preferences of both kinases for
tyrosines in YXXP motifs (Figure 53), it is likely that CRKL-SH2 binding sites are
phosphorylated directly by these kinases. Feng, et. al. have demonstrated that DCBLD2
Y750 is directly phosphorylated by the EGFR, a site that is responsible for recruiting
TRAF6, resulting in AKT-driven proliferation in glioblastoma (Feng, Lopez et al.
2014). Further investigation is required to determine whether INSR or FYN directly
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phosphorylate DCBLD2. This analysis should be further extended to VEGFR2, as
downstream signaling is positively regulated by DCBLD2 (Nie, Guo et al. 2013).
Although there is not yet any evidence to suggest that DCBLD1 alters RTK
signaling, ABL co-expression and/or activation does, and ABL can be activated
downstream of RTKs. Despite the associations with cancers (Lan, Hsiung et al. 2012,
Seow, Matsuo et al. 2017, Yang, Stueve et al. 2018, Wang, Ma et al. 2020), DCBLD1
remains the more understudied of the DCBLD family members, and thus, effort should
be directed toward determining its role in signaling, starting with environmental cues
leading to its post-translational modification.
6.1.3. Novel interactors of DCBLD family members
In Chapter 3, we also describe a SILAC proteomics screen that identified
several known and novel FYN- and ABL-induced interactors of DCBLD2 as well as
ABL-induced interactors of DCBLD1. These included the CRK adaptor family as
positive controls, as well as several members of the 14-3-3 adaptor family that play
important roles in the regulation of protein interactions and enzyme activity (Fu,
Subramanian et al. 2000). There likely exists either a serine/threonine kinase or
phosphatase that is regulated by ABL expression or activation, which is then regulating
phosphoserine/threonine sites on DCBLD proteins and the resulting interaction with
various 14-3-3 family members (Figure 22).
Interestingly, 14-3-3 adaptors form dimeric complexes that canonically bind
phosphoserine and sometimes phosphothreonine residues in RXXpS/pT motifs (Yaffe,
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Rittinger et al. 1997, Ottmann C 2007). We were intrigued to see these
phosphoserine/threonine binding proteins demonstrating differential binding to DCBLD
proteins in the presence and absence of the tyrosine kinase ABL. In our comprehensive
analysis of DCBLD phosphorylation sites, we identified several ABL-regulated serine
and threonine sites, many of which resided within potential 14-3-3 binding motifs
(Figure 17). Phosphorylation of DCBLD1 RXXS serine residues S513, S556, and S657
all increased in the presence of ABL, although S513 and S556 were also highly
phosphorylated when DCBLD1 was expressed alone (Figure 17). Although the
DCBLD1/14-3-3 interaction was not investigated further biochemically in Chapter 3,
due to the loss of protein levels in the presence of ABL, it was apparent from the
SILAC data that DCBLD1 can interact with 14-3-3 proteins in the absence of ABL
(Figure 19). We have further investigated this interaction using far-Western blotting,
demonstrating that 14-3-3 proteins bind directly to DCBLD1 in the absence of ABL
(Figure 32A). This likely occurs through DCBLD1 RXXpS motifs that are highly
phosphorylated basally on DCBLD1, identified both using mass spectrometry (likely
S513 and S556 in Figure 17) and Western blotting (α-RXXpS, Figure 32B). Although
several potential 14-3-3 binding sites on DCBLD1 increased in phosphorylation with
ABL co-expression, the loss of DCBLD1 protein makes it difficult to determine
whether ABL regulates the DCBLD1/14-3-3 interaction. Most likely, the observed
ABL-promoted increase of RXXpS sites (Figure 17) increases DCBLD1/14-3-3
binding. Once a system in which DCBLD1 and ABL co-expression can be modulated
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without losing substantial levels of DCBLD1 protein is established, it will be important
to determine whether ABL co-expression and/or activation promotes the DCBLD1/143-3 interaction.
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Figure 32. 14-3-3 proteins bind directly to DCBLD1, likely through DCBLD1 RXXpS sites.
A) 14-3-3 proteins bind directly to DCBLD1. DCBLD1-FLAG-MYC was transiently expressed in 293
cells. Immunoprecipitations (α-FLAG) from 293 cell lysates were subject to SDS-PAGE and farWestern blotting with eluted GST-14-3-3 fusions proteins, followed by α-GST primary antibodies.
Signals in α-GST blots show relative levels of GST-fusions interacting with DCBLD1. B) DCBLD1 is
phosphorylated within the minimal canonical 14-3-3 binding motif, RXXpS. DCBLD1 was
immunoprecipitated by its MYC tag and subjected to Western blotting with α-RXXpS and α-MYC.

DCBLD2 RXXS serine residues S599 and S724 were also found in our
comprehensive phosphorylation site analysis, although they were not strongly induced
by ABL (Figure 17). It remains possible that the DCBLD2/14-3-3 interaction could be
mediated by phosphorylation outside the canonical motifs. Given the strong ABLinduced interaction between 14-3-3 proteins and DCBLD2 (Figure 21), the interaction
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is still likely mediated by phosphorylation events regulated by ABL co-expression or
activity. This could either be through ABL-regulated activation or membrane
recruitment of a serine/threonine kinase or phosphatase (Figure 22).
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Figure 33. PhosphoSitePlus curations of serine/threonine phosphorylation sites and conservation of
potential 14-3-3 binding sites on DCBLD1 and DCBLD2.
Human (Hs), macaque (Mac), mouse (Mm), rat (Rn), zebrafish (Dr), frog (Xt), and chicken (Gg)
DCBLD1 and DCBLD2 amino acid sequences were aligned using the ClustalOmega webtool and
sequences surrounding 14-3-3 binding motifs were extracted and plotted along the intracellular
domains of DCBLD1 and DCBLD2. Intracellular serine and threonine residues identified
phosphorylated in our comprehensive phosphorylation site analysis (Figure 17) are also mapped onto
DCBLD intracellular domains. PhosphoSitePlus (PhosphoSitePlus.org) curations of phosphorylation
identifications in large-scale proteomics screens are included for each site (yellow sites).
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The SILAC screen for human DCBLD1 and DCBLD2 interactors identified
ABL-induced CaMKII holoenzyme subunits β and δ (Figure 20), which could promote
phosphorylation within the 14-3-3 binding motif, as CaMKII holoenzyme substrates
reside within RXXS/T motifs (Figure 47) (Obenauer, Cantley et al. 2003). CaMKII
subunits γ and δ were also found in complex with DCBLD2 in zebrafish extracts,
suggesting that this may also represent a conserved interaction (Figure 44). CaMKII
could phosphorylate DCBLD1 or DCBLD2, potentially through CaMKII activation
downstream of ABL, in effect recruiting 14-3-3 family members to DCBLD proteins.
Potential phosphorylation-mediated 14-3-3 docking sites on DCBLD proteins
identified in the comprehensive phosphorylation site analysis and SILAC screen are
summarized in Figure 33. PhosphoSitePlus (phosphositeplus.org) curations of
phosphorylation at each serine and threonine site are indicated. Sites that reside within
the minimal mode-1 14-3-3 binding motif have been aligned across representative
vertebrate species. DCBLD1 S513 and S556, which were identified highly
phosphorylated in the presence and absence of ABL, are highly conserved across these
representative vertebrate species, suggesting that they are likely important to DCBLD1
function (Figure 32). Further, S513 has been identified in several large-scale
proteomics screens (Figure 33). These sites could represent DCBLD1/14-3-3
interaction interfaces. DCBLD2 14-3-3 binding motifs are somewhat less conserved,
with the only motif present in zebrafish being that containing S599 of the human
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sequence. Even so, the fairly high conservation suggests that these sites may be
important to DCBLD protein interactions, such as with 14-3-3 adaptors.
While the implications of the DCBLD/14-3-3 interaction are not yet elucidated,
they likely function to modulate other DCBLD protein interactors. We know that the
DCBLD2/14-3-3 requires ABL, and the 14-3-3 proteins bind directly to DCBLD2
(Figure 21). Although we have not systematically tested whether the induction of this
interaction requires ABL expression alone, as it possesses modular binding domains, or
whether ABL activation is a requirement, it is clear that ABL modulates the activity or
localization of a serine/threonine kinase or phosphatase. From the phosphorylation
analyses, we know that phosphorylation within DCBLD1 14-3-3 binding motifs
increases when ABL is co-expressed. This likely means that, although we were unable
to robustly study the effect of DCBLD1/ABL co-expression on the DCBLD1/14-3-3
interaction, ABL co-expression would conceivably promote the DCBLD1/14-3-3
interaction.
The fact that 14-3-3 proteins constitute approximately 1% of soluble brain
protein is particularly intriguing (Cornell and Toyo-Oka 2017), as we are interested in
DCBLD proteins in the context of neuronal development. The DCBLD/14-3-3
interaction could either function to either prevent or promote protein interactions. In the
former, binding of the 14-3-3 dimer to multiple RXXpS/pT motifs could mask binding
sites of certain interactors, for example, they could block CRK adaptors from binding to
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pYXXP motifs. In the latter, 14-3-3 proteins could form a bridge between DCBLD1 or
DCBLD2 and other proteins. Although we do not yet know the implications of these
interactions, they would be best tested with mutant DCBLD1 and DCBLD2 proteins
with serine-to-alanine mutations at 14-3-3 binding sites. These mutants could be tested
alongside the wild-type counterparts in their ability to modulate cellular phenotypes
known to involved DCBLD proteins, such as proliferation, migration, or growth.
6.2. DCBLD degradation
One major challenge we have encountered in attempting to study DCBLD1
phosphorylation and protein interactions mediated by ABL co-expression is the loss of
DCBLD1 protein in these conditions. We observed DCBLD1 protein levels to decrease
considerably when wild-type ABL was co-transfected in the SILAC screen in Chapter 3
(Figure 19). For this reason, further attempts to characterize some of the interactions
identified in this screen proved futile. Interestingly, we did not observe this in our
original publication characterizing the DCBLD1/CRKL-SH2 interaction (Schmoker,
Weinert et al. 2017), although this work used the mouse construct of DCBLD1 in coexpression studies involving ABL. There exist some differences between mouse and
human DCBLD1 sequences, the most striking being the absence of the Discoidin, or
FV/FVIII, domain in mouse DCBLD1 (Figure 3) (Schmoker, Ebert et al. 2019).
Anecdotally, the human construct has generally been more challenging to express than
the mouse construct in 293 cells, and therefore its stability may be tightly regulated. We
hypothesize that this stems from a difference in human and mouse sequences. Future
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work directly comparing expression, signaling, and regulation of human and mouse
DCBLD1 proteins will help distinguish these differences.
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Figure 34. Loss of DCBLD1 and DCBLD2 protein levels is dependent upon tyrosine kinase activity.
A) DCBLD1 levels are regulated by ABL activity. DCBLD1-FLAG-MYC was transiently expressed
in 293 cells in the presence of absence of a fusion of the ABL SH2 and kinase domains with hormone
binding domain (HBD) of estrogen receptor (ABL:ER-ΔSH3). Cells were treated with 1µM 4hydroxytamoxifen (4-HT), an estrogen analog, for 10 min, 30 min, or 4 hr prior to lysis. Cell extracts
were subjected to an α-FLAG immunoprecipitation (IP) prior to SDS-PAGE and Western blotting
for DCBLD1 (α-MYC). DCBLD1 levels decreased when ABL:ER-ΔSH3 was co-expressed and left
untreated, although the ABL:ER-ΔSH3 construct has some activity in the absence of 4-HT (αpY412ABL in the WCE). The addition of 4-HT rapidly increased ABL activity (α-pY412ABL in the
WCE) and reduced DCBLD1 levels below the limit of detection ((α-MYC in α-FLAG IP) after only
10 min of 4-HT stimulation. ABL:ER-ΔSH3 are shown in the WCE (α-ABL). The tubulin blot of the
WCE served as a loading control. B) DCBLD2 protein levels decrease with 15 min of H2O2
treatment. 293 cells transiently expressing DCBLD2-FLAG were treated with 8.8 mM H2O2 before
lysis. Whole cell extracts were analyzed by SDS-PAGE and Western blotting for DCBLD2 levels (αFLAG). Background bands serve as a loading control. C) Endogenous DCBLD2 was
immunoprecipitated (α-DCBLD2) from 293 cells in which wild-type (WT) or kinase-dead (KD) FYN
were co-expressed. Although there is not loading control in this experiment, protein levels were
normalized prior to immunoprecipitation.

From the studies presented in Chapters 2 and 3 of this dissertation, we were
unable to determine whether the loss of DCBLD1 protein occurred on the
transcriptional, translational, or protein level. Because the human DCBLD1-MYC257

FLAG sequence was housed in the same vector as human DCBLD2-MYC-FLAG,
mouse Dcbld1-MYC-FLAG, and several other protein construct employed in Chapter 5
(Schmoker, Driscoll et al. 2018), and because these constructs largely did not exhibit a
decrease in protein levels when co-transfected with ABL, we hypothesized that the loss
of DCBLD1 was occurring at the protein level.
To determine whether ABL activation plays a role in DCBLD2 degradation, we
obtained an inducible ABL construct to co-express with DCBLD1 so that acute
activation of ABL could be induced and thereby mitigate the long-term effects of
expressing DCBLD1 with ABL. The fusion of the kinase and SH2 domains of ABL
with the hormone binding domain of the estrogen receptor (ABL:ER-ΔSH3) activated
more quickly than the SH3-containing WT ABL:ER fusion (previously described by
Jackson, et al. (Jackson, Baltimore et al. 1993)), and therefore was chosen for coexpression with DCBLD1. To first determine whether ABL activation leads to
DCBLD1 degradation, DCBLD1 and ABL:ER-ΔSH3 were co-expressed in 293 cells,
treated with 4-hydroxytamoxifen (4HT) to induce ABL activation, and lysed at various
time points following 4HT treatment (Figure 34A). Co-expression alone was sufficient
to reduce DCBLD1 levels by more than half (α-MYC, Figure 34A), although the
ABL:ER-ΔSH3 protein exhibited some activity in the absence of 4HT treatment (αpY412ABL, Figure 34A). However, the addition of 4HT rapidly increased ABL activity
and markedly reduced DCBLD1 levels after only 10 minutes of stimulation (Figure
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34A). Phosphorylation by or downstream of activation of ABL appears to strongly
regulate DCBLD1 degradation and/or solubility.
The SILAC screen described in Chapter 3 identified ABL-induced DCBLD1
interactors involved in ubiquitylation dynamics, including c-CBL (Figure 20). Although
no ubiquitin linker sequences were identified in the label free or SILAC analyses of
DCBLD1 PTMs, ubiquitin-containing peptides were not targeted in the analyses and
would be relatively rare. DCBLD1 ubiquitylation could lead either to its proteasomemediated degradation or endocytosis and subsequent degradation in lysosomes.
Although these degradation-related proteins were found in complex with
DCBLD1, only, we have observed tyrosine kinase-regulated reduction in DCBLD2
protein levels. We regularly observe loss of DCBLD2 protein levels when cells are
treated with H2O2 prior to lysis (Figure 34B), suggesting that the loss of DCBLD2 is
related to DCBLD2 tyrosine phosphorylation. Previously, we found that the seven
tyrosine residues in the intracellular YXXP motifs of DCBLD2 were not required for
DCBLD2 degradation in the presence of FYN (Schmoker, Weinert et al. 2017) (Figure
15) and we show here that the loss of endogenous DCBLD2 is dependent upon FYN
kinase activity (Figure 34C). However, there remain several additional intracellular
tyrosines that reside outside of YXXP motifs (Figure 17), which may be required for
the degradation and/or loss in solubility of DCBLD2. Investigations into the
implications of DCBLD degradation will be important avenues of research, given the
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necessary insight into these processes in order to understand and control their complex
roles in cancer biology. Because ubiquitylation is a dynamic and transient process, the
use of inducible kinases, such as the ABL:ER-ΔSH3 construct, could be helpful in
studying the processes of degradation downstream of kinase activation in a timedependent manner.
6.3. DCBLD2 autonomous signaling through class IV semaphorins
DCBLD2 is known interactor of SEMA4B in non-small cell lung cancer (Nagai,
Sugito et al. 2007), but how that interaction occurs and the biological consequences are
unknown. DCBLD2 extracellular domains are similar to those of neuropilins (NRPs),
which act as critical co-receptors alongside VEGFR2 and plexins for VEGF165 and
class III semaphorins in migrating cells in blood vessel and immune system
development, as well as in certain cancers (Anil Karihaloo 2005, Jia, Cheng et al. 2010,
Schwarz and Ruhrberg 2010, Li, Parker et al. 2014, Mendes-da-Cruz, Brignier et al.
2014). NRP1 acts as a co-receptor for VEGFR2 and enhances the VEGF165/VEGFR2
interaction (Gu, Limberg et al. 2002, Soker, Miao et al. 2002), while the
SEMA3A/NRP1 interaction prevents VEGF165 form binding the NRP1/VEGFR2
complex. DCBLD2 could similarly act both autonomously and as a co-receptor with
RTKs or other transmembrane proteins in ligand binding.
Nagai, et. al. demonstrated that full length SEMA4B and SEMA4B-Fc interact
with DCBLD2 and increase DCBLD2 ubiquitylation (Nagai, Sugito et al. 2007). We
have observed an interaction between a secreted form of SEMA4B, as well as other
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class IV semaphorins, with DCBLD2 (Figure 33), indicating that SEMA4A, B, and C
may serve as extracellular ligands for DCBLD2.
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Figure 35. DCBLD2 interacts with multiple secreted class IV semaphorins.
DCBLD2-FLAG was expressed with SEMA4A, B, or C constructs possessing Fc and His tags.
Protein A (Fc-binding) pulldowns were divided in two and subjected to SDS-PAGE and Western
blotting for DCBLD2 (α-FLAG) and SEMAs (α-His). DCBLD2 was identified in complex with all
three SEMAs tested. The α-FLAG blot of the α-FLAG IP acts as a loading control for DCBLD2.

Class IV semaphorins have not been extensively studied, although SEMA4D
has been characterized in the immune system, where it interacts primarily with CD72, a
C-type lectin (Kumanogoh, Watanabe et al. 2000). In invasive growth of epithelial
cancers, SEMA4D recruits the RTK MET to the SEMA4D/PlexinB1 complex
(Giordano, Corso et al. 2002). SEMA4A is also known to interact with PlexinB1 in
neural synapse development in the hippocampus (McDermott, Goldblatt et al. 2018).
Although no receptor has been identified for SEMA4B, it is known to potently inhibit
metastasis of non-small cell lung cancers (Jian, Zhao et al. 2015), indicating a potential
phenotypic result of the DCBLD2/SEMA4B interaction in lung cancers.
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Because SEMA4B-Fc can induce ubiquitin-mediated degradation of DCBLD2,
the interaction between DCBLD2 and SEMA4B likely induces an intracellular
response, such as activation of a membrane-localized kinase (e.g., a SFK) via DCBLD2
clustering. A constitutive DCBLD2/SFK-SH3 interaction could lead to SFK
autophosphorylation upon ligand-induced clustering of DCBLD2 molecules, which
could recruit a ubiquitin ligase possessing a phosphotyrosine binding (PTB) or SH2
domain to DCBLD2 phosphorylation sites, ultimately leading to DCBLD2
ubiquitylation and degradation. As such, SEMA4B, and possibly other class IV
SEMAs, could serve as extracellular ligands for DCBLD2 in a signaling mechanism
where DCBLD2 can activate intracellular signaling autonomously from RTKs.
DCBLD1 and 2 each possess extracellular CUB, LCCL, and FV/FVIII domains,
following by a transmembrane (TM) domain and a scaffolding domain. The NRP1
CUB and FV/FVIII domains are required for ligand binding; namely, the two CUB
domains of NRP1 complex the Sema domain of Class III Semaphorins while the Cterminal basic region interacts with the FV/FVIII domains, and VEGF165 interacts with
the two NRP1 FV/FVIII domains. The DCBLD2/SEMA4(A,B,C) interaction could
occur through similar binding interfaces.
Future work should focus on determining whether these secreted SEMAs bind
to DCBLD2 extracellularly, and whether this interaction induces an intracellular
response. The SEMAs employed in Figure 35 are easily extracted with metal ion
affinity chromatography via the His tags. Extracted SEMAs could then be used to treat
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cells expressing DCBLD2 alone, and resulting phosphorylation and ubiquitylation of
DCBLD2 could be assessed. This work will be important in elucidating the interactions
between these proteins in metastasis of non-small cell lung cancers, as well as other
biological systems in which these interactions may function.
6.4. DCBLD RTK-dependent and autonomous signaling
The work outlined throughout this dissertation has contributed to our working
signaling model (Figure 7, Figure 16, Figure 22 and Figure 27). Intracellular signaling
events are instigated by an extracellular cue, either ligand-mediated clustering of
DCBLD proteins in an autonomous signaling pathway, or by a proximal RTK
becoming activated by its ligand, such as PDGFRβ or INSR. In the case of PDGFBB/PDGFRβ, active PDGFRβ directly phosphorylates proximal DCBLD2 molecules,
which could immediately affect bound DCBLD2 interactors. PDGFRβ activation also
results in the activation of the cytoplasmic kinase ABL, either through ABL-SH2
recruitment to PDGFRβ or DCBLD2 scaffolding sites, or by the activation of
membrane localized SFKs, which then activate ABL. Active ABL then directly
phosphorylates DCBLD2, likely on the same substrate sites as PDGFRβ, amplifying
the signal. Proteins recruited to the DCBLD2 scaffold include CRK adaptors along with
bound regulators of small G-proteins, resulting in the activation of signaling
downstream of their associated GTPase, which, depending on the GEFs recruited to the
membrane, could result in cell migration, proliferation, or growth.
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There are likely other DCBLD2 interactors recruited by these signaling events
that regulate signaling downstream of RTKs, such as AKT and ERK activation. We and
others have observed that DCBLD2 reduces proliferation downstream of PDGFRβ and
INSR (Chapter 4) (Guo, Nie et al. 2009, Li, Jung et al. 2016), but the molecular
mechanisms leading to these phenotypes are not understood. Others have observed
attenuated ERK and AKT activation when DCBLD2 is expressed at normal levels,
however, we have observed increased ERK activation when DCBLD2 is expressed at
high levels. It is possible that the observed proliferative affect is not through ERK
signaling, and that ERK signaling in the system studied in Chapter 4 leads to another
phenotype. Possibly, DCBLD2 attenuates both ERK- and AKT-driven proliferation in
this system by inhibition at the level of RTK activation. DCBLD2 expression could
also inhibit ERK- and AKT-driven proliferation at downstream checkpoints (Figure
27).
Whether DCBLD1 can similarly function in RTK signaling remains unknown,
however, in any system in which ABL is activated, DCBLD1 CRK(L)-SH2 binding
sites will likely become phosphorylated. However, DCBLD1 is also rapidly degraded
following ABL activation. CRK adaptors may be quickly recruited following ABLinduced DCBLD1 phosphorylation, however, so are negative regulators of DCBLD1
signaling, potentially c-CBL, which could result in rapid ubiquitylation and endocytosis
of DCBLD1.
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DCBLD1 and DCBLD2 serine/threonine residues would also be differentially
phosphorylated, likely by the modulation of serine/threonine kinase or phosphatase
activity or membrane localization via ABL. This would affect interactors at later
timepoints following induction of signaling by an extracellular cue. The interaction of
DCBLD2 with various 14-3-3 family members could represent such an interaction. We
hypothesize that signaling events occurring at later timepoints likely represent negative
regulatory mechanisms, although further investigations into the functional implications
of specific serine/threonine phosphorylation sites and the resulting DCBLD/14-3-3
interaction will need to be an area of future study.
In the hypothesized autonomous signaling mechanism, DCBLD1 or DCBLD2
clustering could lead to the activation of bound kinases, resulting in DCBLD tyrosine
phosphorylation and recruitment of CRK adaptors and other interactors. As discussed
in the previous section, class IV semaphorins could represent a mode by which
DCBLD2 signals autonomously from RTKs, although further studies in that line of
signaling are required. Many of the same signaling events discussed above could be set
in motion following clustering.
The work presented here contributes to our understanding of cell signaling
involving DCBLD family members, however, there remains considerable ground to be
covered in future investigations before we can fully understand the biological roles of
DCBLD proteins as well as their role in modulating RTK signaling.
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6.5. Bioinformatics screening as a complement to proteomics datasets
In the final research chapter, Chapter 5, we returned to our original proteomics
screen in which we identified DCBLD2 as an SFK-dependent interactor of the CRKLSH2 domain in 293 cells (Aten, Redmond et al. 2013). Although we identified the
known CRKL interactor BCAR1, we did not identify other positive controls, such as
DAB1. DAB1 is critical to neuronal development, however, it is expressed for a short
period of time, and only in the embryonic brain. For this reason, we did not expect to
find DAB1 in the screen of CRKL-SH2 interactors in 293 cells. Even so, this brought
the fact that we may be missing a large pool of unknown interactors to our attention.
Functional proteomics screens require that interacting partners are expressed in
the tissue or cell type of study at the time of sample acquisition. Further, if the assayed
interactions are dependent upon post-translational modifications, the modifying
enzymes also need to be expressed and activated, and the percent of a given interactor
that becomes modified at the required site needs to be relatively high for identification
using proteomics. Proteomics is an essential tool in identifying protein-protein
interactions, however, we wanted to develop a complement to these screens, using
bioinformatics, that would not only overcome some of these caveats, but also help
focus investigators in interpreting large proteomics datasets.
Using publicly available bioinformatics web-based tools and repositories, we
compiled empirical data and predictions pertaining known characteristics of
domain/motif interactions, using the CRKL-SH2/pYXXP interaction as a model in the
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first iteration of the screen. By scoring various characteristics of all YXXP-containing
proteins in the human proteome, we were able to prioritize potential CRKL-SH2
interactors by applying a scoring and prioritization system. Ultimately, we tested 11
proteins that scored highly in pulldown assays, and 10 of the 11 were induced to
interact with the CRKL-SH2 domain by co-expression with ABL (Schmoker, Driscoll
et al. 2018).
We then compared CRK- and CRKL-SH2 interactors identified in a functional
proteomics screen in a neuronal cell line (N2A) to the results of our bioinformatics
screen. Several proteins identified as CRK- or CRKL-SH2 interactors in N2A cells
mapped to potential interactors that scored highly in the bioinformatics-based approach
(Appendix A, Table 10). Out of the 79 YXXP-containing proteins identified as a CRK
and/or CRKL interactor, 15 of these proteins scored higher than a 6 in our
bioinformatics screen (top 1% of all YXXP-containing proteins) and 5 proteins scored
higher than 8 (top 0.2%) (Schmoker, Driscoll et al. 2018). By mapping the results of
our bioinformatics screen to this proteomics dataset, we were able to narrow down
interactors that were likely relevant to our biological system of interest, neuronal
migration during vertebrate brain development, for biochemical validation.
This tool is easily tailorable to other protein interaction systems. In Chapter 5,
we also apply these principles to the interaction between the Tudor domain and
methylated arginine-glycine (MeRG) motifs. Using the same approach, we successfully
identified known interactions from the pool of all RG-containing human proteins. This
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approach is a valuable tool that can be employed by the signaling community to
identify interactions that are relevant to any biological system of interest. This approach
could serve as a stand-alone bioinformatics screen used for quick assessments or be
employed alongside large proteomics datasets as a way for investigators to prioritize
interactions for further study.
6.6. Conclusions and outlook
The structure and function of the SH2 domain of CRK adaptor proteins is
conserved in an ancestral crk/crkl gene found in the premetazoan choanoflagellate
Monosiga brevicollis (Shigeno-Nakazawa, Kasai et al. 2016), as are ancestors to
tyrosine kinases that possess SRC Homology (SH) domains, such as SFKs and ABL
(Manning, Young et al. 2008). The co-evolution of this class of tyrosine kinases
alongside phosphotyrosine-dependent adaptor proteins has shaped outside-in signaling
networks established in pre-metazoans through vertebrates that govern fundamental
cellular processes leading to cell proliferation, growth, migration and survival.
The conservation of the DCBLD receptor family across vertebrate species is
defined primarily by their extracellular domains (Figure 3 and Figure 4), the functions
of which are not yet delineated (Schmoker, Ebert et al. 2019). The long intracellular
scaffolding regions are less conserved in amino acid sequence, however, one striking
exception is the concentration of conserved CRK/CRKL-SH2 binding motifs. The
conservation of these YXXP motifs suggests that DCBLD proteins and CRK adaptors
have likely co-evolved in signaling mechanisms that are important to vertebrate
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development and function, and therefore are also likely involved in cancer systems with
upregulated DCBLD1 or DCBLD2. Although the full functional implications of these
interactions are not yet fully understood, the DCBLD/CRK interaction will likely
emerge as an important target of therapeutic agents to combat cancer progression
(Schmoker, Ebert et al. 2019). Overexpression of DCBLD proteins could represent a
mechanism of concentrating membrane localized CRK adaptors, similar to the gagCRK oncogene. Future studies are warranted to determine whether and how these
interactions may have contributed to the evolution of vertebrate development and
homeostasis, and how to target these transmembrane scaffolding receptors in cancer.
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APPENDIX A: NOVEL INTERACTORS OF THE SH2 DOMAIN OF THE
SIGNALING ADAPTORS CRK AND CRKL IDENTIFIED IN NEURO2A CELLS
A.1. Abstract
CRK and CRK-like (CRKL) form a family of signaling adaptors that serve
important roles in the regulation of fundamental cellular processes, including cell
motility and proliferation, in a variety of cell types. The SRC Homology 2 (SH2)
domain of CRK and CRKL interacts with proteins containing phosphorylated tyrosineX-X-proline (pYXXP) motifs, facilitating complex formation during signaling events.
A handful of CRK/CRKL-SH2-specific interactors have been identified to date,
although in silico analyses suggest that many additional interactors remain to be found.
To identify CRK/CRKL-SH2 interactors with potential involvement in neuronal
development, we conducted a mass spectrometry-based proteomics screen using a
neuronal cell line (Neuro2A, or N2A). This resulted in the identification of 132 (6
known and 126 novel) YXXP-containing CRK/CRKL-SH2 interactors, of which 77
were stimulated to bind to the CRK/CRKL-SH2 domain following tyrosine
phosphatase inhibition. Approximately half of the proteins identified were common
interactors of both the CRK- and CRKL-SH2 domains. However, both CRK family
member SH2 domains exhibited unique binding partners across experimental replicates.
These findings reveal an abundance of novel neuronal CRK/CRKL-SH2 domain
binding partners and suggest that CRK family SH2 domains possess undescribed
docking preferences beyond the canonical pYXXP motif.
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A.2. Introduction
CT10 regulator of kinase (CRK) and CRK-Like (CRKL) form a family of
signaling adaptors that are conserved throughout metazoans and pre-metazoans, playing
essential roles in fundamental cellular processes such as proliferation and motility.
CRK family members possess a SRC homology 2 (SH2) domain, which binds
phosphorylated tyrosine residues in YXXP motifs (Y=tyrosine, P=proline, X=any
amino acid), and two SH3 domains, which bind proline-rich sequences. Through these
modular binding domains, CRK and CRKL facilitate the formation of cellular signaling
complexes required for numerous signal transduction pathways (Feller 2001, Ballif,
Arnaud et al. 2003, Ballif, Arnaud et al. 2004, Park and Curran 2008, Kobashigawa and
Inagaki 2012).
CRK and CRKL are particularly important for the proper positioning of cortical
neurons during embryonic brain development via Reelin signaling (Ballif, Arnaud et al.
2004). SRC family kinases (SFKs) are activated within a migrating neuron following
the binding of Reelin to the Reelin receptors VLDLR and ApoER2. Activated SFKs
then phosphorylate tyrosine residues of receptor-bound Disabled-1 (DAB1) in YXXP
motifs, which leads to the translocation of CRK/CRKL and their SH3-bound guanine
nucleotide exchange factors (GEFs) complexes to membrane-localized small GTPases,
which regulate cytoskeletal dynamics (Park and Curran 2008) (Ballif, Arnaud et al.
2003, Ballif, Arnaud et al. 2004).
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In addition to DAB1, several known CRK/CRKL-SH2 interactors have been
characterized, including members of the CRK-associated substrate (CAS) and
discoidin, CUB, and LCCL domain-containing protein (DCBLD) families (Table 9)
(Aten, Redmond et al. 2013, Schmoker, Weinert et al. 2017, Schmoker, Driscoll et al.
2018). Further, in a recent in silico proteomics screen we predicted several CRK- and
CRKL-SH2 binding partners, although many of these have yet to be shown to interact
experimentally (Schmoker, Driscoll et al. 2018). To identify new neuronal
CRK/CRKL-SH2 interactors we made use of a murine neuroblastoma cell line,
Neuro2A (or N2A). N2A cells were treated with or without tyrosine phosphatase
inhibitors and extracts were incubated with either the CRK- or the CRKL SH2 domain.
Bound proteins were ultimately identified using liquid chromatography–tandem mass
spectrometry (LC-MS/MS).

297

Table 9. Known CRK-SH2 and/or CRKL-SH2 interactors.
NCBI
Gene
ID

Input ID

Gene
Symbol

Description

1796

Q99704;P97465

DOK1

docking protein 1

1399

P46109;P47941;Q5U2U2

CRKL

CRK like proto-oncogene, adaptor protein

5829

P49023;Q8VI36

PXN

paxillin

867

P22681;P22682

CBL

Cbl proto-oncogene

3927

Q14847

LASP1

LIM and SH3 protein 1

6461

Q15464

SHB

SH2 domain containing adaptor protein B

1398

Q64010;P46108;Q9XYM0;Q63768

CRK

CRK proto-oncogene, adaptor protein

2549

Q9QYY0;Q13480

GAB1

GRB2 associated binding protein 1

9564

Q61140;Q63767;P56945

BCAR1

BCAR1, Cas family scaffolding protein

6776

P42229

STAT5A

25

P00520;P00519

ABL1

1600

P97318;O75553

DAB1

DAB1, reelin adaptor protein

10278

O43281

EFS

embryonal FYN-associated substrate

4739

O35177;Q14511

NEDD9

neural precursor cell expressed, developmentally
down-regulated 9

131566

Q96PD2

DCBLD2

discoidin, CUB and LCCL domain containing 2

57091

Q9NQ75

CASS4

Cas scaffolding protein family member 4

3815

P10721

KIT

KIT proto-oncogene receptor tyrosine kinase

5156

P16234

PDGFRA

platelet derived growth factor receptor alpha

6777

P51692

STAT5B

signal transducer and activator of transcription
5B

2050

P54760

EPHB4

EPH receptor B4

1956

P00533

EGFR

epidermal growth factor receptor

7535

P43404;P43403

ZAP70

zeta chain of T-cell receptor associated protein
kinase 70

2324

P35916

FLT4

fms related tyrosine kinase 4

285761

Q8N8Z6

DCBLD1

discoidin, CUB and LCCL domain containing 1

3635

Q92835

INPP5D

inositol polyphosphate-5-phosphatase D
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signal transducer and activator of transcription
5A
ABL proto-oncogene 1, non-receptor tyrosine
kinase

A.3. Methods
A.3.1. Materials
Penicillin/Streptomycin (100X) and Dulbecco’s Modified Eagle Medium
(DMEM) were acquired from Mediatech (Manassas, VA, USA). Fetal bovine serum
(FBS) and cosmic calf serum (CCS) were obtained from Hyclone (Logan, Utah, USA).
The bovine serum albumin (BSA) standard for Bradford assays and the Bradford
Reagent were purchased from Amresco Life Sciences, LLC (Cleveland, OH, USA).
Enhanced chemiluminescence (ECL) reagents used for Western blot development were
purchased from Pierce (Rockford, IL, USA), and x-ray film was from Denville
scientific (Metuchen, NJ, USA). Nitrocellulose membranes were from GVS Life
Sciences (Sanford, ME, USA). All additional reagents were purchased from Sigma (St.
Louis, MO, USA) unless otherwise noted.
A.3.2. Plasmids and antibodies
The bacterial expression plasmid encoding the fusion of glutathione-Stransferase (GST) with the CRKL-SH2 domain (GST-CRKL-SH2) was a gift from A.
Imamoto (U. of Chicago). The bacterial expression plasmid encoding GST-CRK-SH2
was acquired from Addgene (Cambridge, MA; plasmid #46418), and was originally
constructed by Bruce Mayer (U. of Connecticut).
The α-tubulin (mouse) antibody (Cell Signaling Technology; Danvers, MA,
USA) and α-phosphotyrosine (pY; mouse) antibody (EMD Millipore; Burlington, MA,
USA) were diluted 1:1,000 in Tris-Buffered Saline (150 mM NaCl, 40 mM Tris, pH
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7.5) containing 0.05% Tween 20 (TBS-T) with 1.5% BSA and 0.005% sodium azide
for Western blotting. The secondary α-mouse-HRP antibody, diluted 1:10,000 in TBST for Western blotting, was obtained from Jackson Immunolabs (Westgrove, PA,
USA).
A.3.3. Cell culture, stimulation, and cell lysis.
N2A cells were grown at 37˚C in 5% atmospheric CO2 in DMEM with 5% FBS,
5% CCS, 50 U/mL penicillin, and 50 μg/mL streptomycin. Cells were either treated or
not treated with 8.8 mM H2O2 for 15 minutes prior to lysis. Cells were placed on ice,
washed with cold phosphate-buffered saline (PBS), then lysed in lysis buffer (25 mM
Tris pH 7.2, 137 mM NaCl, 10% glycerol, 1% Igepal, 25 mM NaF, 10 mM Na2H2P2O7,
1mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 mg/mL each
leupeptin and pepstatin-A). Lysates were centrifuged at 4˚C, and the supernatant was
reserved at -20˚C for pulldown assays. A Bradford assay was used to normalized
protein levels in the cell extract.
A.3.4. GST-CRKL-SH2 pull-down assay, Western blotting, and SDS-PAGE.
Purification of GST, and the GST-CRK-SH2 and GST-CRKL-SH2 fusion
proteins on glutathione resin was previously described (Aten, Redmond et al. 2013,
Schmoker, Weinert et al. 2017). N2A whole cell extracts (WCEs) used in pulldown
assays for LC-MS/MS analysis were pre-cleared on a column packed with GST-bound
glutathione resin. N2A extracts (1 mg total protein for Western blotting, 2-3 mg for LCMS/MS analysis) were incubated with GST-CRK-SH2 or GST-CRKL-SH2 resin for 1-
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2 days at 4 ˚C, rocking. The resin was then washed three times with lysis buffer. Bound
proteins were eluted and denatured in sample buffer (150 mm Tris pH 6.8, 2% SDS,
5% -mercaptoethanol, 7.8% glycerol, 0.01% bromophenol blue) at 95˚C for 5 min.
Denatured pulldowns and WCEs (15 µg per lane) were separated on a 10% acrylamide
gel (30% w/v and 37.5:1 acrylamide:bis-acrylamide) with 4.2% acrylamide stacking
gels. The current was kept at 20 mA per gel through the stacking layers and 30 mA
through the separating gels. Gels were either transferred to nitrocellulose membranes
for Western blot analysis or stained with Coomassie Brilliant Blue in preparation for
mass spectrometry.
For Western blotting, total protein levels on transfers were determined by
staining membranes with a reversible Ponceau stain (0.5% Ponceau and 1% acetic acid
in H2O). Membranes were then blocked with TBS-T containing 5% w/v non-fat dry
milk and incubated in primary antibodies overnight at 4 ˚C. Membranes were then
washed with TBS-T three times (ten minutes each wash) and incubated overnight with
the HRP-conjugated secondary antibody solution at 25˚C. After three final washes in
TBS-T, blots were developed with ECL reagents and x-ray film.
A.3.5. Peptide preparation and analysis by LC-MS/MS.
Pulldowns for LC-MS/MS analysis were conducted in triplicate (complete
biological replicates using separate cell cultures and conducted by separate personnel)
each with GST-CRK-SH2 and GST-CRKL-SH2. Each lane of a given Coomassiestained gel was divided into four regions by molecular weight (Figure 38A), and then
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cut into 1-mm cubes. Gel pieces were de-stained in 50 mM ammonium bicarbonate and
50% acetonitrile at 37oC, and dehydrated in 100% acetonitrile. Proteins were digested
with trypsin in-gel at 37 oC for 18 hours. Tryptic peptides were extracted with 2.5%
formic acid in 50% acetonitrile and further with 100% acetonitrile. Peptides were dried
under vacuum centrifugation and resuspended in 2.5% formic acid and 2.5%
acetonitrile.
Peptides were re-suspended in Solvent A (2.5% acetonitrile, 0.15% formic acid)
and separated via HPLC (300 nL/min) using the Easy n-LC 1200 prior to MS/MS
analysis on the Q Exactive Plus mass spectrometer fitted with a Nanospray Flex ion
source and supplied with Thermo Xcalibur 4.0 software (Thermo Fisher Scientific).
Chromatography columns (15 cm x 100 µm) were packed in-house with 2.7 µm C18
packing material (Bruker, Halo, pore size = 90 Å). Peptides were eluted using a 0-50%
gradient of Solvent B (80% acetonitrile, 0.15% formic acid) over 60 min and into the
mass spectrometer by electrospray ionization. This gradient was followed by 10 min at
100% Solvent B before a 15-min equilibration in 100% Solvent A. The precursor scan
(scan range = 360-1700 m/z, resolution = 7.0x104, AGC = 106, maximum IT = 100 ms,
lock mass=371.1012 m/z) was followed by ten collision-induced dissociation (CID)
tandem mass spectra of the top ten ions in the precursor scan (resolution = 3.5 x 104,
AGC = 5.0 x 104, maximum IT = 50 ms, isolation window = ±1.6 m/z, normalize
collision energy = 26%, dynamic exclusion=30 s). Raw spectra were searched for
matches within a forward and reverse mouse proteome (Uniprot, 2011) using
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SEQUEST (Eng, McCormack et al. 1994, Apweiler, Bairoch et al. 2004), requiring
tryptic peptides and permitting the following differential modifications:
phosphorylation of serine, threonine and tyrosine (+79.9663 Da), oxidation of
methionine (+15.9949 Da), and acrylamidation of cysteine (+71.0371 Da). Peptides
were filtered by mass accuracy (tolerance = ±4 ppm), cross correlation (XCorr) score
(for z=+1, XCorr  1.8; z=+2, XCorr  2.0; z=+3, XCorr  2.2; z=+4, XCorr  2.4;
z=+5, XCorr  2.6), and unique Corr ( 0.15). Proteins were considered identified if 8
or more total spectra were mapped to peptides within that protein across the three
replicates.
A.3.6. Bioinformatic analysis.
The number of YXXP motifs per protein in human and mouse sequences were
obtained from Scansite (scansite4.mit.edu) as previously described (Obenauer, Cantley
et al. 2003) (Schmoker, Driscoll et al. 2018). The number of phosphorylated YXXP
motifs in select proteins were obtained using a motif search in the Protein Search
section of PhosphoSitePlus (phosphosite.org) (Hornbeck, Zhang et al. 2015). Clustal
Omega was used to create multiple sequence alignments of select proteins across
representative vertebrates (Larkin, Blackshields et al. 2007, Sievers, Wilm et al. 2011).
A.4. Results and Discussion
CRK and CRKL are known to play important roles in several fundamental
developmental processes, however, it is hypothesized that they serve additional roles in
signaling pathways that have not yet been described. CRK and CRKL functional
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domains are highly conserved (Figure 36A, Figure 37), although it remains possible
that CRK and CRKL could possess distinct interacting partners, thereby carrying out
divergent functions. SH2-mediated interactions between CRK/CRKL and
phosphotyrosine residues are typically induced by specific signaling events involving
the activation of receptor or non-receptor tyrosine kinases. One way to stimulate
general tyrosine phosphorylation in cultured cells is the addition of hydrogen peroxide
(H2O2) to cell culture medium, simultaneously inhibiting tyrosine phosphatases and
activating tyrosine kinases through reactive oxygen species (Zick and Sagi-Eisenberg
1990). To identify neuronal SH2-specific binding partners of CRK and CRKL which
are regulated by endogenous kinases and phosphatases we either stimulated with H2O2
or left untreated N2A cells. Extracts from these cultures were used to conduct a
proteomics screen by incubating them with glutathione S-transferase (GST) fusions of
the CRK- or CRKL-SH2 domains. Proteins that bound to GST-CRK-SH2 or GSTCRKL-SH2 were separated by SDS-PAGE and subjected to in-gel tryptic digestion.
Peptides were subjected to LC-MS/MS leading to protein identification.
To generate resin coated with GST-CRK-SH2 and GST-CRKL-SH2, E. coli
harboring bacterial expression plasmids encoding each fusion protein were induced to
transcribe GST-CRKL-SH2 or GST-CRK-SH2 by the addition of IPTG (described in
(Schmoker, Weinert et al. 2017)). Cultures sampled before and after the induction were
lysed and denatured prior to SDS-PAGE and Coomassie staining. Figure 36B shows the
appearance of the fusion protein bands just above the 37 kDa marker in the induced (+
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IPTG) lanes. Fusion proteins were then concentrated on glutathione resin for use in
pulldown assays (Figure 36B).

Figure 36. Generation and validation of GST-CRK-SH2 and GST-CRKL-SH2 for pulldown assays
in N2A cells.
A) Domains structure and conservation of CRK family members. A full alignment of amino acid
sequences (ClustalOmega (Larkin, Blackshields et al. 2007, Sievers, Wilm et al. 2011)) can be
found in Figure 37B) Bacterial lysate prior to and following IPTG induction of GST-fusion protein
expression. Proteins were separated via SDS-PAGE and stained with Coomassie Brilliant Blue.
GST-CRK/CRKL-SH2 expression is visible in the induced lysate (+ IPTG) at 40-45 kDa (indicated
with arrows). After incubation with bacterial extracts, glutathione resin was subjected to SDSPAGE and Coomassie staining, showing successful concentration of the purified GST-fusion
protein on the resin. C) N2A cells were either left untreated or were treated with H2O2 (8.8 mM)
for 15 min prior to lysis. Protein extracts were separated by SDS-PAGE and transferred to a
nitrocellulose membrane for immunoblotting. The phosphotyrosine immunoblot (α-pY) shows an
induction of tyrosine phosphorylation following H2O2 treatment. The α-tubulin blot serves as a
loading control. D) Pulldown assays demonstrate functional SH2 domains. N2A extracts from (C)
were incubated with GST-alone, GST-CRK-SH2 or GST-CRKL-SH2 prior to SDS-PAGE and
Western blotting. The H2O2-treated extracts showed an increased phosphotyrosine signal relative
to untreated extracts in GST-CRK/CRKL-SH2 pulldowns, while no phosphotyrosine signal was
observed in the pulldowns with GST alone. The Ponceau stain shows GST-fusion protein levels
around 40 kDa (SH2 fusions are indicated with arrows and background binding of α-pY is
observed). GST alone runs at approximately 25 kDa.
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To verify that tyrosine phosphorylation could be induced in N2A cells by H2O2,
N2A cells were either left untreated or were treated with 8.8 mM H2O2 for 15 minutes
prior to lysis. N2A extracts were then subjected to SDS-PAGE and Western blotting
with a phosphotyrosine antibody (α-pY). Indeed, cells that were treated with H2O2
showed a stronger signal in the α-pY blot compared to the untreated controls (Figure
36C). Tubulin levels (α-tubulin) served as a loading control (Figure 36C). We then
tested whether the GST-SH2 fusion constructs could extract proteins containing
phosphotyrosine residues from N2A cells. Pulldown assays were conducted by
incubating stimulated and unstimulated N2A extracts with GST-CRK-SH2 or GSTCRKL-SH2 resin prior to SDS-PAGE and immunoblotting (α-pY). Resin coated with
GST alone was incubated with the same extracts as a control (Figure 36D). H2O2treated lanes demonstrate inducible binding of tyrosine phosphorylated proteins to
CRK- and CRKL-SH2 fusion proteins, but not to GST (Figure 36D). Notably, several
phosphotyrosine-containing proteins bound the CRK- and CRKL-SH2 domains in
untreated N2A cells (Figure 36D), suggesting that several YXXP-containing proteins
were phosphorylated in N2A cells prior to H2O2 treatment.
To identify the CRK-/CRKL-SH2-interacting phosphoproteins observed in
Figure 36D, GST-CRK-SH2 and GST-CRKL-SH2 pulldown assays were conducted to
analyze via LC-MS/MS. Pulldowns were conducted as described above, except that
N2A extracts were pre-cleared with GST alone prior to incubation with the GST-CRKSH2 or GST-CRKL-SH2 resin to substrate proteins that bound to GST or the resin.
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Pulldowns for analysis by mass spectrometry were carried out in triplicate for each SH2
domain. An example Coomassie-stained SDS-PAGE gel from one of the GST-CRKSH2 replicates is shown in Figure 38A. Coomassie-stained gels were then cut into four
regions by molecular weight (dashed lines in Figure 38A), subjected to an in-gel tryptic
digest, and extracted peptides were analyzed by LC-MS/MS.

Figure 37. Clustal Omega alignment of human CRK family amino acid sequences.
Overall conservation of CRK and CRKL were calculated to be 55.35%. Individual comparison of
SH2 and SH3 domains revealed the following percent identities: CRK(L)-SH2 is 68.22%
conserved, CRK(L)-SH3(N-term) is 65.57% conserved, CRK(L)-SH3(C-term) is 69.36%
conserved.

LC-MS/MS analysis of the GST-CRK-SH2 and GST-CRKL-SH2 pulldowns
from unstimulated and stimulated N2A cell extracts yielded a total of 135 and 234
binding partners of CRKL-SH2 and CRK-SH2, respectively. Of these, 121 proteins
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were common interactors of CRK and CRKL, while each SH2 domain exhibited certain
unique protein interactors in our study (Figure 38B). Spectral counts of proteins
induced to bind the CRK- or CRKL-SH2 domain following H2O2 treatment (123 in
total) are available upon request. To date, no distinct interactor preferences between
CRK family members have been described. However, further analysis will be required
to determine whether the unique binding partners observed here truly are due to
preferential differences between CRK family SH2 domains.

Figure 38. GST-CRK-/CRKL-SH2 pulldown assay for the identification of interactors via LCMS/MS.
A) The Coomassie-stained gel following a GST-CRK-SH2 pulldown from N2A extracts was divided
into 4 regions of molecular weight. Each individual sample was subjected to an in-gel tryptic digest
and analyzed via LC-MS/MS to identify bound proteins. N2A extracts were precleared with GST
alone. RAW files were searched for tryptic matches in a 2011 Uniprot mouse proteome via
SEQUEST. Proteins identified by eight or more peptides across three trials were considered SH2specific interactors. Venn diagrams of all (B) and only YXXP-containing (C) CRK- and/or CRKLSH2 interactors display the extent of overlapping binding partners identified in N2A cells. Full lists
of interactors are available upon request.

Of the 248 unique proteins identified to interact with the CRK- and/or CRKLSH2 domain, 132 contain at least one YXXP motif (Figure 38C), 77 of which were
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induced to bind CRK-SH2, CRKL-SH2, or both CRK family members following H2O2
treatment (Table 10). Ten of the inducible YXXP-containing interactors found in Table
10 are known to bind to CRK or CRKL (in bold, Table 10) (Schmoker, Driscoll et al.
2018), although only five of these have previously been shown to bind specifically to
the CRK/CRKL-SH2 domain: DOK1, CBL, LASP1, PXN, and DCBLD2 (Table 9).
Importantly, additional known and novel YXXP-containing proteins were found to bind
CRK- and/or CRKL-SH2, although they were not specific to the cells treated with H2O2
(data available upon request). For example, BCAR1 bound to the SH2 domains of both
family members regardless of stimulation (data available upon request), suggesting that
BCAR1 YXXP motifs may be highly phosphorylated in N2A cells.
Interactors in Table 10 were cross-referenced with predicted CRK/CRKL-SH2
interactors (Schmoker, Driscoll et al. 2018). Schmoker, et al. (2018) developed an in
silico screen to predict and prioritize domain/motif interactions, using the CRK/CRKLSH2/phospho-YXXP interaction as a model (Schmoker, Driscoll et al. 2018). In that
study, priority scores were calculated for each protein using signature characteristics of
known interactors, including phospho-motif enrichment parameters, known interacting
partners and participation in related signaling pathways (Schmoker, Driscoll et al.
2018). Priority scores calculated by Schmoker, et al. (2018) are included for interactors
in Table 10 (Schmoker, Driscoll et al. 2018). Several high-priority novel CRK/CRKLSH2 interactors were further investigated for their potential to interact with the CRK
family of signaling adaptors. Select high-priority interactors involved in developmental
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processes, particularly those related to neuronal development and cell motility
(underlined in Table 10), were assayed for conservation of their YXXP motifs across
representative vertebrates. Domain structures and multiple sequence alignments of
these novel CRK family SH2 interactors are available upon request.
Several peptides containing phosphorylated tyrosine residues in YXXP motifs
were identified in the pulldown assays. Fragmentation spectra of phosphopeptides were
manually validated to confirm localization of the phosphate group on the YXXP
tyrosine (available upon request). Several of the phosphorylated YXXP-containing
peptides were from the known CRK-/CRKL-SH2 interactors BCAR1, DOK1,
DCBLD2, and PXN (Table 11). Phospho-YXXP-containing peptides of eight of the 16
BCAR1 YXXP motifs were identified in both stimulated and unstimulated N2A
extracts (Table 11). It is likely that additional proteins that remain highly
phosphorylated in N2A cells, basally, could interact with CRK/CRKL-SH2 in this cell
type regardless of H2O2 stimulation. Therefore, the list of interactors included in Table
10 is likely not a complete list of potential phospho-YXXP-dependent CRK-/CRKLSH2 interactors identified in this study. In addition to these known binding partners,
CRMP1 was the only novel phospho-YXXP-containing protein found in complex with
CRK- or CRKL-SH2 (Table 11). Interestingly, CRMP1 bound to CRK-SH2 regardless
of stimulation (data available upon request). Even so, the identification of these
phospho-YXXP-containing peptides lends strong evidence toward the interaction of the
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proteins containing these peptides with CRK/CRKL-SH2 through the identified
phospho-YXXP sites (Table 11).
In this study, we aimed to identify novel CRK/CRKL-SH2 binding partners that
could play important roles in neurodevelopment. A proteomics screen produced 77
inducible CRK/CRKL-SH2 interactors in a neuronal cell line (N2A), with potential to
interact specifically via their YXXP motifs (Table 10). Given the high conservation of
the CRK family SH2 domains (Figure 36A, Figure 37), and the absence of any known
unique sequence preferences among these domains, we expected that many of the
CRK/CRKL-SH2 interactors identified would overlap. However, we found that
although approximately half of the interactors identified were common to CRK-SH2
and CRKL-SH2, each family member possessed a number of unique interactors in N2A
cells (Figure 38B,C). Although the list of unique CRKL-SH2 interactors was smaller
than that of CRK-SH2 (Figure 38B,C), this is likely a reflection of the fewer total
number of CRKL-SH2 interactors identified. Indeed, a weaker induction of GSTCRKL-SH2 expression prior to purification on glutathione resin (Figure 36B) resulted
in a lower concentration of fusion protein for use in pulldown assays, relative to GSTCRK-SH2. Despite this, five unique YXXP-containing proteins were identified as
unique interactors of CRKL-SH2 (Figure 38C), namely, DYNC1H1, PKP1, LMNA,
RPS3A, and RPS8. CRK and CRKL are known to play similar roles in developmental
processes, however, certain distinctions have been made between CRK family members
(Kobashigawa and Inagaki 2012). Although further studies will be necessary to
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determine whether the distinct CRK-SH2 and CRKL-SH2 interactors identified here
truly are unique to each family member, our findings suggest that certain sequence
preferences may exist for CRK family SH2 domains. In addition, several predicted
CRK/CRKL-SH2 interactors from our previous in silico screen were experimentally
validated in this study, providing novel avenues of research regarding CRK family
signaling in neuronal development.
Table 10. YXXP-containing proteins induced to bind CRK-/CRKL-SH2 in H2O2-stimulated N2A
cells.
The number of YXXP motifs (scansite4.mit.edu (Obenauer, Cantley et al. 2003)), the number of
experimental identifications of phosphorylated tyrosine residues in YXXP motifs (phosphosite.org
(Hornbeck, Zhang et al. 2015)) and priority scores from Schmoker, et al. (2018) are included for each
protein. Known general CRK/CRKL interactors (*) and SH2-specific interactors (**) are indicated.
Domain structures and multiple sequence alignments of select potentially novel SH2-specific
interactors (underlined gene symbols) are available upon request, as is a full list of CRK-/CRKL-SH2
interactors.
Gene
Symbol

Accession
H. sapiens

M.
musculus

Q99704

P97465

Dok1**

P49023

Q8VI36

P22681
Q14847

CRKSH2

CRKLSH2

# YXXP motifs

# pYXXP
IDs

Priority
Score
Schmoker,
et al.
(2018)

H.
sapiens

M.
musculus

x

6

6

2886

11.5

Pxn**

x

3

3

2656

10.5

P22682

Cbl**

x

3

3

761

10

Q61792

Lasp1**

x

3

3

517

9.5

Q05397

P34152

Ptk2*

x

5

5

172

8

Q96PD2

Q91ZV3

Dcbld2**

x

8

8

593

7.5

O15357

Q6P549

Inppl1*

x

2

2

351

7

P19174

Q62077

Plcg1

x

3

3

122

7

Q16555

O08553

Dpysl2

x

2

2

329

6.5

Q9UDY2

Q9Z0U1

Tjp2

x

2

3

943

6.5

Q07157

P39447

Tjp1

x

4

4

355

6.5

Q13813

P16546

Sptan1

x

5

5

35

6

O60716

P30999

Ctnnd1

x

3

2

1905

6

Q9UQC2

Q9Z1S8

Gab2

x

5

5

754

6

Q13835

P97350

Pkp1

3

3

456

6

Q13671

Q921Q7

Rin1

3

3

1074

4.5

x

x

x

x
x

312

P21333

Q8BTM8

Flna*

x

x

2

3

1

4

O75369

Q80X90

Flnb*

x

x

4

4

60

4

Q13191

Q3TTA7

Cblb*

x

Q14203

O08788

Dctn1

P49327

P19096

Fasn

Q00610

Q68FD5

Cltc

P61160

P61161

P61158
P52272

3

3

239

4

x

1

1

0

3.5

x

x

1

2

95

3.5

x

x

5

5

18

3.5

Actr2

x

1

1

0

3

Q99JY9

Actr3

x

1

1

15

3

Q9D0E1

Hnrnpm

x

1

1

264

3

O43707

P57780

Actn4

x

x

1

1

0

3

P78371

P80314

Cct2

x

x

1

1

25

3

P48643

P80316

Cct5

x

x

1

1

1

3

Q99832

P80313

Cct7

x

x

1

1

0

3

P50990

P42932

Cct8

x

x

1

1

0

3

Q14195

Q62188

Dpysl3

x

x

1

1

3

3

P15924

E9Q557

Dsp

x

x

1

1

0

3

P46940

Q9JKF1

Iqgap1

x

x

1

1

0

3

P55884

Q8JZQ9

Eif3b

x

x

2

2

64

3

P12814

Q7TPR4

Actn1

x

x

3

3

5

3

P13639

P58252

Eef2

x

x

4

4

148

3

P23588

Q8BGD9

Eif4b

x

1

1

63

3

Q8TEW0

Q99NH2

Pard3

x

2

1

9

3

Q9Y490

P26039

Tln1

x

1

1

6

3

P67809

P62960

Ybx1

x

1

1

168

3

Q9Y285

Q8C0C7

Farsa

x

2

2

105

3

P48147

Q9QUR6

Prep

x

2

2

131

3

Q16832

Q62371

Ddr2

x

3

3

92

3

P55196

Q9QZQ1

Mllt4

x

3

4

21

3

P02545

P48678

Lmna

x

1

1

1

3

P61247

P97351

Rps3a

x

1

1

418

3

Q14204

Q9JHU4

Dync1h1

x

7

7

4

3

Q04637

Q6NZJ6

Eif4g1

x

x

2

2

19

0.5

P55072

Q01853

Vcp

x

x

3

3

10

0.5

P26640

Q9Z1Q9

Vars

x

x

5

5

24

0.5

Q14444

Q60865

Caprin1

x

1

1

0

0

P08243

Q61024

Asns

x

x

1

1

0

0

O95817

Q9JLV1

Bag3

x

x

1

1

11

0

Q14008

A2AGT5

Ckap5

x

x

1

1

0

0

313

P06733

P17182

Eno1

x

x

1

1

4

0

Q92598

Q61699

Hsph1

x

x

1

1

1

0

P11940

P29341

Pabpc1

x

x

1

1

22

0

P62701

P62702

Rps4x

x

x

1

1

0

0

Q8N5H7

Q9QZS8

Sh2d3c

x

x

1

1

1

0

Q13428

O08784

Tcof1

x

x

1

1

1

0

Q8WWM7

Q7TQH0

Atxn2l

x

x

2

2

52

0

P60842

P60843

Eif4a1

x

x

2

2

0

0

Q14240

P10630

Eif4a2

x

x

2

2

0

0

P35637

P56959

Fus

x

x

2

2

0

0

P26599

P17225

Ptbp1

x

x

2

2

1

0

P53396

Q91V92

Acly

x

x

3

3

2

0

A5YKK6

Q6ZQ08

Cnot1

x

x

6

6

8

0

P14868

Q922B2

Dars

x

1

1

1

0

P41250

Q9CZD3

Gars

x

1

1

0

0

P14625

P08113

Hsp90b1

x

1

1

1

0

O95347

Q8CG48

Smc2

x

1

1

0

0

P40939

Q8BMS1

Hadha

x

2

2

2

0

P34932

Q61316

Hspa4

x

2

2

0

0

Q9Y2A7

P28660

Nckap1

x

2

2

0

0

P54577

Q91WQ3

Yars

x

2

2

0

0

Q96F07

Q5SQX6

Cyfip2

x

3

3

0

0

Q9P2J5

Q8BMJ2

Lars

x

5

5

7

0

P62241

P62242

Rps8

1

1

18

0

x
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Table 11. Phospho-YXXP-containing peptides found in complex with CRK- and/or CRKL-SH2.
Spectral counts were summed across CRK family members and experimental conditions.
Annotated fragmentation spectra of these phosphopeptides are available upon request.

Gene
Symbol

Uniprot
Accession

Peptide

Spectral
Count (per
site)

Q61140

K.GLLSSSHHSVY@DVPPSVSK.D

Q61140
Q61140

Site

H2O2

Untreated

19

x

x

K.TQQGLY@QAPGPNPQFQSPPAK.Q

10

x

x

R.DPLLDVY@DVPPSVEK.G

1

x

Q61140

R.GLLPNQYGQEVY@DTPPM*AVK.G

3

x

Q61140

R.HLLAPGPQDIY@DVPPVR.G

52

x

Q61140

R.RPGPGTLY@DVPR.E

7

x

Q61140

R.VGQGYVYEAAQTEQDEY@DTPR.H

2

x

Q61140

R.VLPPEVADGSVVDDGVY@AVPPPAER.E

26

x

P97427

R.GM*YDGPVY@EVPATPK.H

6

x

Q91ZV3

K.SAATPEELVY@QVPQSTQELSGAGR.D

5

x

Q91ZV3

K.TEGAY@DLPHWDR.A

1

x

P97465

R.GLY@DLPQEPR.D

2

x

P97465

R.IPPGPSQDSVY@SDPLGSTPAGAGEGVHSK.K

6

x

Q8VI36

R.AGEEEHVY@SFPNK.Q

2

x

Bcar1*

Crmp1

x

x

Dcbld2*

Dok1*

Pxn*
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APPENDIX B: SUPPLEMENTARY DATA TO CHAPTER 2
Table 12. Monoisotopic and average m/z values of a) DCBLD1 and b) DCBLD2
unphosphorylated and phosphorylated tryptic peptides harboring differentially regulated
tyrosine residues.
Table 13. Monoisotopic and average m/z values of a) DCBLD2 SL peptides, b) DCBLD1
heavy labeled peptides (SILAC), and c) DCBLD2 heavy labeled peptides harboring
targeted tyrosine residues.
Table 14. Monoisotopic and average m/z values of a) DCBLD1 and b) DCLBD2
reference peptides used in SILAC, SL and LF quantification.
Table 15. H:L ratios of unphosphorylated peptides harboring differentially regulated
tyrosine residues quantified in SILAC experiments.
Table 16. Statistical analysis of DCBLD2 Tyr phosphorylation.
Table 17. Statistical analysis of label free and internal standard quantification methods.
Table 18. Unquantified DCBLD2 tryptic peptides identified via LC-MS/MS.
Figure 39. SFK and ABL inhibition downstream of H2O2 and defining the
DCBLD2/ABL-SH2 interaction.
Figure 40. Workflow for LC-MS/MS quantification of regulated tyrosine phosphorylation
sites on DCBLD1 and DCBLD2.
Figure 41. Amino acid sequences, tryptic cleavage sites, and LC-MS/MS coverage maps
of (A) mouse DCBLD1 and (B) human DCBLD2.
Figure 42. Low energy CID fragmentation spectra of DCBLD1 and DCBLD2 tryptic
peptide ions harboring differentially regulated phosphorylated and unphosphorylated
tyrosine residues.

318

Table 12. Monoisotopic and average m/z values of a) DCBLD1 and b) DCBLD2 unphosphorylated
and phosphorylated tryptic peptides harboring differentially regulated tyrosine residues.
Amino acid sequences identified with LC-MS/MS are given alongside the charge state and
monoisotopic m/z values used to quantify peptide intensity, as well as the average m/z value, used
in targeted scans. Italicized peptides were not targeted but were identified in data dependent scans.
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Table 13. Monoisotopic and average m/z values of a) DCBLD2 SL peptides, b) DCBLD1 heavy
labeled peptides (SILAC), and c) DCBLD2 heavy labeled peptides harboring targeted tyrosine
residues.
The charge state of each ion and monoisotopic m/z values used in SL and SILAC quantification are
tabulated alongside the average m/z values. Underlined residues possess all 13C and 15N, resulting
in added masses of 7.0172 m/z for Leu and 6.0138 m/z for Val (a) or 10.0083 m/z for Arg and
8.0142 m/z for Lys (b,c).
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Table 14. Monoisotopic and average m/z values of a) DCBLD1 and b) DCLBD2 reference peptides
used in SILAC, SL and LF quantification.
Light and heavy masses are given with charge state and the quantification method that employed
each reference. The italicized peptide was targeted in SL quantification experiments. All remaining
peptides were identified in data dependent scans.
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Table 15. H:L ratios of unphosphorylated peptides harboring differentially regulated tyrosine
residues quantified in SILAC experiments.
Ratios of monoisotopic intensities for each peptide were Log2 transformed (in bold) for symmetry
around unity. Heavy conditions in which a kinase was overexpressed was paired with a light
unstimulated condition. Inhibitor treatments followed by H2O2 stimulation were given to light
cultures, which were paired with a heavy culture given H2O2 stimulation alone.
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Table 16. Statistical analysis of DCBLD2 Tyr phosphorylation.
DCBLD2 peptides harboring quantified Tyr phosphorylation (#) sites were subjected to a one-way
ANOVA and post-hoc Tukey HSD to identify statistical differences in phosphorylation of each
peptide across experimental conditions. Conditions with statistically significant differences (P =
0.05) are tabulated for (A) Tyr565 and (B) Tyr715 and Tyr750. K = kinase overexpressed group, I
= inhibitor treatment group. K/TEGTYDLPYWDR denotes summed intensities of
KTEGTYDLPYWDR and TEGTYDLPYWDR peptides.
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Table 17. Statistical analysis of label free and internal standard quantification methods.
Multiple quantification methods for individual peptides were compared with either (A) a one-way
ANOVA and Tukey HSD (> 2 methods; Tyr565) or (B) a t-test (2 methods; Tyr 715 and Tyr750).
Differences were tabulated if P ≤ 0.05 for set. K = kinase overexpressed group, I = inhibitor
treatment group.
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Table 18. Unquantified DCBLD2 tryptic peptides identified via LC-MS/MS.
Sites of Tyr phosphorylation (#) are highlighted in red. Annotated fragmentation spectra can be
found in Figure 42.
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Figure 39. SFK and ABL inhibition downstream of H2O2 and defining the DCBLD2/ABL-SH2
interaction.
(A) SRC-1 and STI571 titrations to determine concentrations of SFK and ABL inhibitors
necessary to disrupt the DCBLD2-CRKL-SH2 interaction. GST-CRKL-SH2 pulldown assays were
performed from DCBLD2-transfected HEK 293 lysates treated with 0.5, 1, or 2 µM SRC-1 or 5, 10,
or 20 µM STI571 for 15 min, followed by an additional 15 min in 8.8 mM H2O2 treatment prior to
lysis. Neither inhibitor was sufficient to abolish the interaction alone, however, 2 µM SRC-1 and 20
µM STI571 were deemed appropriate to prevent potential off-target effects at higher
concentrations. (B) Tyrosine residues in YxxP motifs are required for the increased ABL (and
SFK) activity observed in WT DCBLD2-transfected HEK 293 cells treated with H2O2. Compare
differences observed between pABL and pSRC blots in lanes 1-3 of panels A and B. In B, HEK 293
cells expressing DCBLD2-Y7F-Flag were treated with H2O2 alone or with inhibitors and H2O2
prior to lysis as described for A. Whole cell extracts were subjected to SDS-PAGE and proteins
were immunoblotted with the indicated antibodies. c) DCBLD2 Tyr phosphorylation in YxxP
motifs are required for the ABL-SH2 domain to bind. DCBLD2-WT-Flag and DCBLD2-Y7F-Flag
were immunoprecipitated from transfected HEK 293 cells treated with or without H2O2. Immune
complexes were then incubated with the GST-ABL-SH2 fusion protein. While some background
binding was observed in all lanes of the anti-GST blot, significantly higher levels of the GST-ABLSH2 protein bound to DCBLD2-WT when HEK 293 cells were treated with H2O2 prior to lysis,
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suggesting the Tyr residues in YxxP motifs are required to the DCBLD2-ABL-SH2 interaction.
The “*” on the panel showing Flag reactivity indicates the signal from a heavy-chain dimer of the
antibody in the IP.
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Figure 40. Workflow for LC-MS/MS quantification of regulated tyrosine phosphorylation sites on
DCBLD1 and DCBLD2.
Flag-tagged DCBLD proteins were expressed in HEK 293 cells under two general types of
conditions: (i) cells were left unstimulated, stimulated with H2O2, or pre-treated with SFK and/or
ABL inhibitors prior to H2O2 stimulation; and (ii) DCBLD proteins were co-expressed with FYN
and/or ABL. DCBLD proteins were immunoprecipitated from cell extracts and the immune
complexes were separated by SDS-PAGE. DCBLD proteins were subjected to in-gel tryptic
digestion and phosphorylation of intracellular YxxP sites were monitored with targeted LCMS/MS of tryptic phosphopeptides. The DCBLD2 peptide harboring the non-YxxP Tyr715 was
also targeted in our analysis. Quantification was achieved by three distinct methods for
comparison (SILAC, label-free, and the addition of stable isotope-labeled peptide standards).
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A
MGTGAGGPSVLALLFAVCAPLRLQAEELGDGCGHIVTSQDSGTMTSKNYPGTYPNYTVCEKIITVPKGKRLILRLGD
LNIESKTCASDYLLFSSATDQYGPYCGSWAVPKELRLNSNEVTVLFKSGSHISGRGFLLTYASSDHPDLITCLERGS
HYFEEKYSKFCPAGCRDIAGDISGNTKDGYRDTSLLCKAAIHAGIITDELGGHINLLQSKGISHYEGLLANGVLSRH
GSLSEKRFLFTTPGMNITTVAIPSVIFIALLLTGMGIFAICRKRKKKGNPYVSADAQKTGCWKQIKYPFARHQSTEF
TISYDNEKEMTQKLDLITSDMADYQQPLMIGTGTVARKGSTFRPMDTDTEEVRVNTEASGHYDCPHRPGRHEYALPL
THSEPEYATPIVERHLLRAHTFSTQSGYRVPGPRPTHKHSHSSGGFPPATGATQVESYQRPASPKPVGGGYDKPAAS
SFLDSRDPASQSQMTSGGDDGYSAPRNGLAPLNQTAMTALL

B
MASRAVVRARRCPQCPQVRAAAAAPAWAALPLSRSLPPCSNSSSFSMPLFLLLLLVLLLLLEDAGAQQGDGCGHTVL
GPESGTLTSINYPQTYPNSTVCEWEIRVKMGERVRIKFGDFDIEDSDSCHFNYLRIYNGIGVSRTEIGKYCGLGLQM
NHSIESKGNEITLLFMSGIHVSGRGFLASYSVIDKQDLITCLDTASNFLEPEFSKYCPAGCLLPFAEISGTIPHGYR
DSSPLCMAGVHAGVVSNTLGGQISVVISKGIPYYESSLANNVTSVVGHLSTSLFTFKTSGCYGTLGMESGVIADPQI
TASSVLEWTDHTGQENSWKPKKARLKKPGPPWAAFATDEYQWLQIDLNKEKKITGIITTGSTMVEHNYYVSAYRILY
SDDGQKWTVYREPGVEQDKIFQGNKDYHQDVRNNFLPPIIARFIRVNPTQWQQKIAMKMELLGCQFIPKGRPPKLTQ
PPPPRNSNDLKNTTAPPKIAKGRAPKFTQPLQPRSSNEFPAQTEQTTASPDIRNTTVTPNVTKDVALAAVLVPVLVM
VLTTLILILVCAWHWRNRKKKTEGTYDLPYWDRAGFYLMVSLACRHNEGWWKGMKQFLPAKAVDHEETPVRYSSSEV
NHLSPREVTTVLQADSAEYAQPLVGGIVGTLHQRSTFKPEEGKEAGYADLDPYNSPGQEVYHAYAEPLPITGPEYAT
PIIMDMSGHPTTSVGQPSTSTFKATGNQPPPLVGTYNTLLSRTDSCSSAQAQYDTPKAGKPGLPAPDELVYQVPQST
QEVSGAGRDGECDVFKEIL

Figure 41. Amino acid sequences, tryptic cleavage sites, and LC-MS/MS coverage maps of (A)
mouse DCBLD1 and (B) human DCBLD2.
Arg and Lys residues in red indicate anticipated cleavage sites within each protein during the
proteolytic digestion. Underlined portions of each sequence denote coverage observed via LCMS/MS.
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Figure 42. Low energy CID fragmentation spectra of DCBLD1 and DCBLD2 tryptic peptide ions
harboring differentially regulated phosphorylated and unphosphorylated tyrosine residues.
“Y#” denotes phosphorylated tyrosines. Spectra were acquired in a linear ion trap mass
spectrometer. Parent ion masses and charge states are tabulated in Table 12 & Table 13. Included
are MS/MS spectra of unphosphorylated, singly phosphorylated, and multiply phosphorylated
peptides harboring more than one tyrosine. MS/MS spectra of phosphorylated and
unphosphorylated tryptic peptide ions harboring (A-D) DCBLD1 Tyr589 and Tyr600 (E-J)
DCBLD2 Tyr565 and Tyr569, (K-Q) DCBLD2 Tyr649, Tyr655, Tyr663, Tyr666 and Tyr677.
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APPENDIX C: SUPPLEMENTARY DATA TO CHAPTER 3
Figure 43. Coomassie-stained gels from two experimental replicates of SILAC
immunoprecipitations for the identification of DCBLD1 and DCBLD2 interacting
proteins.
Figure 44. ABL-induced interactors of DCBLD proteins common among human and
zebrafish.
Figure 45. The GST-14-3-3 fusion constructs bind canonical (mode 1) 14-3-3 binding
motif.
Figure 46. 14-3-3 family members bind to the tyrosine kinase ABL.
Figure 47. The Calmodulin dependent kinase 2 (CaMKII) substrate motif.
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Figure 43. Coomassie-stained gels from two experimental replicates of SILAC immunoprecipitations
for the identification of DCBLD1 and DCBLD2 interacting proteins.
A,B) 293 cells grown in DMEM supplemented with arginine and lysine containing heavy (H, blue) or
light (L, red) stable isotopes of carbon and nitrogen were transiently transfected with plasmids
encoding DCBLD family members with or without the tyrosine kinases FYN and ABL.
Immunoprecipitations (α-FLAG) from heavy and light experimental pairs were denatured and
combined immediately prior to SDS-PAGE and Coomassie staining. Experimental heavy/light pairs
are indicated at the top of each gel lane. To ensure both maximum separation and identification of
both high and low molecular weight interactors, heavy/light pairs were split across 10% and 15%
gels. Each was analyzed separately via LC-MS/MS. A cut-map of each gel type and the Coomassiestained gel from the third experimental replicate are included in Figure 2.
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Figure 44. ABL-induced interactors of DCBLD proteins common among human and zebrafish.
A Venn diagram displays the overlap of ABL-induced interactors of DCBLD1 and DCBLD2 in
human cells (HEK 293) to ABL-induced DCBLD2 interactors in zebrafish lysates. Human DCBLD1
and DCBLD2 interactors were common to the three biological replicates used for the SILAC analysis
in Figure 20. Zebrafish DCBLD2 interactors were identified by incubating DCBLD2
immunoprecipitations from 293 cells expressing DCBLD2 alone or DCBLD2 and ABL with zebrafish
lysates. Only unique zebrafish peptides were used to identify zebrafish proteins in immune complex
with DCBLD2. Zebrafish proteins that were unique to the condition in which ABL was co-expressed
with DCBLD2 are represented in the Venn diagram. The full list of zebrafish DCBLD2 interactors
are available upon request.
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Figure 45. The GST-14-3-3 fusion constructs bind canonical (mode 1) 14-3-3 binding motif.
A,B) GST ad GST-14-3-3 fusion proteins were purified from bacterial extracts on glutathione resin
and incubated with 293 extracts from cells either left untreated or treated with calyculin A, a
serine/threonine phosphatase inhibitor, prior to lysis. Whole cell extracts (WCEs) show an induction
of serine/threonine phosphorylation in AKT substrate motifs (α-RXXpS/pT) following calyculin A
treatment. Pulldowns demonstrate increased binding of proteins containing the canonical (mode 1)
14-3-3 substrate motif (RXXpSXP) in 293 cells treated with calyculin A. Pulldowns with GST alone
and GST-14-3-3εK49E, which is unable to bind proteins in a phosphorylation-dependent manner,
served as controls. Ponceau staining shows levels of GST and GST-fusions.
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Figure 46. 14-3-3 family members bind to the tyrosine kinase ABL.
GST and GST-14-3-3 fusion proteins were purified from bacterial extracts on glutathione resin
and incubated with 293 cell extracts from cells transiently expressing ABL-FLAG in a pulldown
assay. All four GST fusion with 14-3-3 family members (β,σ,ε,ζ) bound specifically to ABL.
Ponceau staining shows levels of GST and GST fusions. Whole cell extracts (WCEs) show
expression of ABL-FLAG (α-ABL). The α-tubulin serves as a loading control.
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Figure 47. The Calmodulin dependent kinase 2 (CaMKII) substrate motif.
Motif logo was reproduced from Scansite 4.0 (scansite4.mit.edu) (Obenauer, Cantley et al. 2003).
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APPENDIX D: SUPPLEMENTARY DATA TO CHAPTER 4
Figure 48. Establishment of PDGF-BB signaling in 293 cells and investigation into
DCBLD2 phosphorylation downstream of PDGFRβ activation.
Figure 49. DCBLD2, PDGFRβ, and ERK1/2 phosphorylation over time following
PDGF-BB treatment.
Figure 50. Establishment of insulin induced ERK1/2 activation 293 cells and
investigation into DCBLD2 phosphorylation downstream of INSR activation.
Figure 51. DCBLD2, INSRβ, and ERK1/2 phosphorylation over time following insulin
treatment.
Figure 52. Activation of ERK1/2 following insulin treatment of SRC+ and SYF-/fibroblasts.
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A

C

B

D

E

F

Figure 48. Establishment of PDGF-BB signaling in 293 cells and investigation into DCBLD2
phosphorylation downstream of PDGFRβ activation.
A-B) Two additional biological replicates of Figure 23A, used in the quantification of pERK1/2
(Figure 23B). C) DCBLD2 tyrosine phosphorylation driven by PDGF-BB is regulated by SRC family
kinases (SFKs), ABL, and PDGFRβ. 293 cells transiently expressing DCBLD2 and PDGFRβ were
treated with a SFK inhibitor (SRC-1, 1 nM) or a dual ABL/PDGFRβ inhibitor (STI571, 20 nM) prior
to lysis. DCBLD2 tyrosine phosphorylation was reduced in the presence of SRC-1 and completely
abolished with STI571. D) Generation of DCBLD2-FLAG for in vitro kinase assay. DCBLD2 was
immunoprecipitated from 293 cells transiently expressing DCBLD2-FLAG and eluted with the
FLAG peptide (100 μg/mL) and dialyzed. Immunoprecipitations pre- and post-elution were analyzed
by SDS-PAGE alongside the dialyzed protein (1/50th of each yield) and immunoblotted for α-FLAG.
E) Recombinant GST-His6-ABLP118-S535 (40 ng) and GST-His6-PDGFRβR561-L1106 (80 ng) were
incubated for 30 min at 30°C with or without ATP and analyzed by SDS-PAGE and Western blotting
for α-GST. F) GST-His6-ABLP118-S535 (4 ng/μL) was incubated with DCBLD2 (1/100 th of yield) for 30
min at 30°C in the presence or absence of ATP. Kinase assays were subjected to SDS-PAGE and
Western blotting for α-pY, demonstrating that ABL directly phosphorylates DCBLD2.
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Figure 49. DCBLD2, PDGFRβ, and ERK1/2 phosphorylation over time following PDGF-BB
treatment.
A) PDGF-BB treatment of 293 cells in the presence and absence of PDGFRβ. 293 cells transiently
expressing DCBLD2 alone or alongside PDGFRβ were treated with PDGF-BB (20 ng/mL) for 0, 5,
10, or 30 min prior to lysis. Minimal ERK1/2 phosphorylation was observed in the absence of
PDGFRβ. DCBLD2 phosphorylation was quantified in Figure 2B. B-C) 293 cells transiently
expressing PDGFRβ alone or alongside DCBLD2 were treated with PDGF-BB (20 ng/mL) for 0, 5,
10, or 30 min prior to lysis. DCBLD2, PDGFRβ, and ERK1/2 phosphorylation are quantified in
Figure 2B-D.
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Figure 50. Establishment of insulin induced ERK1/2 activation 293 cells and investigation into
DCBLD2 phosphorylation downstream of INSR activation.
A-B) Two additional biological replicates of Figure 3A, used in the quantification of pERK1/2
(Figure 25). C) DCBLD2 tyrosine phosphorylation driven by insulin is subtly regulated by SRC
family kinases (SFKs). 293 cells transiently expressing DCBLD2 and INSRβ were treated with a SFK
inhibitor (SRC-1, 1 nM) or an ABL inhibitor (STI571, 20 nM) prior to insulin treatment. DCBLD2
tyrosine phosphorylation was subtly reduced in the presence of SRC-1.
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Figure 51. DCBLD2, INSRβ, and ERK1/2 phosphorylation over time following insulin treatment.
A) Insulin treatment of 293 cells in the presence and absence of INSRβ. 293 cells transiently
expressing DCBLD2 alone or alongside INSRβ were treated with insulin (100 nM) for 0, 5, 10, or 30
min prior to lysis. ERK1/2 phosphorylation in 293 cells expressing high levels of INSRβ was
markedly increased. DCBLD2 phosphorylation was quantified in Figure 4B. B-C) 293 cells
transiently expressing high INSRβ alone or alongside DCBLD2 were treated with insulin (100 nM)
for 0, 5, 10, or 30 min prior to lysis. DCBLD2, INSRβ, and ERK1/2 phosphorylation are quantified in
Figure 4B-D.
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Figure 52. Activation of ERK1/2 following insulin treatment of SRC+ and SYF-/- fibroblasts.
Murine embryonic fibroblasts (MEFs) lacking the SFKs SRC, Yes, and FYN (SYF-/-) and MEFs
retaining SRC expression (SRC+) were treated with 100 nM insulin for 15 min prior to lysis. Cell
extracts were subjected to SDS-PAGE and Western-blotting for active and total ERK1/2. Two
biological replicates for each condition are included.
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APPENDIX E: SUPPLEMENTARY DATA TO CHAPTER 5
Table 19. Preferences of A) receptor and B) non-receptor tyrosine kinases for proline
(Pro) three amino acids C-terminal to the phosphorylated tyrosine (Tyr) substrate.
Figure 53. Receptor (blue font) and non-receptor (red font) tyrosine kinase substrate
motif preferences.
Figure 54. Domain structure, YXXP Tyr positions, and statistics of four CRKL-SH2
interacting, positive controls.
Figure 55. Schematic of motif-based screening methodology.
Figure 56. Formation of the tripartite bullseye of high-priority RG-containing proteins.
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Table 19. Preferences of A) receptor and B) non-receptor tyrosine kinases for proline (Pro) three
amino acids C-terminal to the phosphorylated tyrosine (Tyr) substrate.
Estimates were obtained from PhosphoSitePlus substrate sequence logos (Figure 53). Scoring was
conducted as follows: “High” = Pro in top position +3 to Tyr, “Low” = Pro in a lesser position,
“None” = no preference, “Against” for selectivity against Pro +3 to Tyr. Kinases with little or no
data are shown in gray.

A
Family

Members

# input
sequences

Preference

Family

Members

# input
sequences

Preference

EGFR

EGFR
HER2
HER3
HER4

214
46
N/A
2

High
Low
No Data
None

EPH

RYK/MET

Met
RON
RYK

64
14
N/A

Low
None
No Data

InsR

IGF1R
INSR
IRR

52
164
N/A

Against
Low
No Data

FGFR/RET

RET
FGFR1
FGFR2
FGFR3
FGFR4

74
70
8
16
2

Against
Low
None
None
None

EPHA1
EPHA2
EPHA3
EPHA4
EPHA5
EPHA6
EPHA7
EPHA8
EPHA10
EPHB1
EPHB2
EPHB3
EPHB4
EPHB6

N/A
20
6
N/A
N/A
N/A
N/A
4
N/A
N/A
10
2
N/A
12

No Data
High
High
No Data
No Data
No Data
No Data
Low
No Data
No Data
High
High
No Data
High

ALK/SEV

ALK
LTK
ROS

18
N/A
N/A

High
No Data
No Data

PDGFRB
PDGFRA
KIT
CSF1R
FLT3

62
10
20
N/A
20

High
High
High
No Data
None

AXL

AXL
TYRO3

28
6

Low
None

VEGFR

VEGFR1
VEGFR2
VEGFR3

12
20
N/A

None
Low
No Data

TrkA
TrkB
TrkC

36
44
N/A

Low
Low
No Data

TIE

TIE1
TIE2

2
6

None
None

DDR

DDR1
DDR2

N/A
N/A

No Data
No Data

CCK4

CCK4

N/A

No Data

LMR/STYK
MUSK

MUSK

10

None

ROR

ROR1
ROR2

N/A
N/A

No Data
No Data

LMR1
LMR2
LMR3
STYK

N/A
N/A
N/A
N/A

No Data
No Data
No Data
No Data

PDGFR

TRK

353

B
Family

Members

# input
sequences

Preference

Family

Members

# input
sequences

Preference

SFK

SRC
LYN
FYN
LCK
YES
HCK
BRK
FGR
BLK
FRK
SRM

1278
234
366
240
32
56
38
28
12
10
N/A

High
High
Low
High
High
High
High
Low
Low
Low
No Data

JAK

JAK1
JAK2
JAK3
TYK2

16
136
40
26

Low
High
Low
None

FAK

FAK
PYK2

80
42

Low
Low

SYK

SYK
ZAP70

156
68

High
High

CSK
BTK
ETK
ITK
TXK
TEC

58
40
24
4
28

Low
Low
None
None
None

CSK
CTK

20
6

None
None

FER

FES
FER

18
38

None
Against

ACK
ABL
ARG

384
60

High
High

ACK
TNK1

20
N/A

Low
No Data

TEC

ABL
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Figure 53. Receptor (blue font) and non-receptor (red font) tyrosine kinase substrate motif
preferences.
Weblogos are reproduced from
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PhosphoSitePlus. Stars indicate a high

preference (dark green), low preference (light green), or selectivity against (orange) for Pro in the
+3 position relative to the site of tyrosine phosphorylation. Data are summarized in Table 19.
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Figure 54. Domain structure, YXXP Tyr positions, and statistics of four CRKL-SH2 interacting,
positive controls.
Site-specific experimental identifications of phosphorylated tyrosine residues in YXXP motifs are
shown within yellow circles for each site. Conservation of YXXP motifs was calculated across
representative vertebrates (H. sapiens, M. musculus, G. gallus, X. tropicalis, and D. rerio) and is
indicated for each motif position (black for 100% conservation, gray for < 100% conservation).
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Figure 55. Schematic of motif-based screening methodology.
Each step in the screen is indicated by a number next to the arrows. Dotted arrows, as in Steps 3
and 5, denote optional steps to further focus the screen. Step 1: Choose a motif and modification of
interest, then extract the motif count and modified motif count with Scansite and PhosphoSitePlus,
respectively. For the “Enriched” list, divide the number of motifs by the number of amino acids
and extract proteins two standard deviations above the mean. For the “Modified” list, extract
proteins above the mean number of modified-motif counts per protein. Step 2: Conduct a pathway
enrichment analysis of proteins in the “Enriched” and “Modified” lists to obtain the “Enriched
Pathways” list. Combine “Enriched” and “Modified” lists (2a) and remove duplicate entries (2b).
Using the Reactome Analysis tool (2c), extract pathways with a FDR < 0.05 (2d). For each enriched
pathway, obtain motif-containing proteins that participate in the pathway, but were not previously
found in the “Enriched” or “Modified” filters. Combine all motif-containing interactors as the
“Enriched Pathways” list of the tripartite bullseye (2e). Step 3: Identify secondary features of
interest for candidate prioritization (e.g. known or predicted substrates of kinases, ligases, or
transferases that prefer the motif of interest, known interactors of the motif-binding protein). Step
4: Apply weight using primary (tripartite bullseye) and secondary features to score proteins of
interest. Known interacting proteins will be expected to emerge with high priority scores. Step 5:
Assess motif conservation of proteins with high priority scores, and expression of proteins/genes in
a tissue of interest. Step 6: Test whether candidates reversibly bind the domain of interest in
modified vs unmodified states. Step 7: Test candidates in cell/organismal assays.
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Figure 56. Formation of the tripartite bullseye of high-priority RG-containing proteins.
A) Binary logarithmic distribution of the number of RG sites per AA. Proteins two standard
deviations above the mean were extracted as the “Enriched” group. B) Number of experimental
MeRG confirmations per protein (PhosphositePlus). All proteins above the mean were taken as the
“Modifed” list and contained 229 unique entries as parsed by Metascape. C) Metascape pathway
enrichment analysis shows the overlap of the enriched pathways within the “Enriched” and
“Modified” lists with all RG-containing proteins. Eight enriched parent pathways (FDR <0.05) of
A and B were obtained via Reactome. All RG-containing proteins in enriched pathways were
extracted as the “Enriched Pathways”. Populations of overlap are given in the subplots.
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